Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2623654,T4/T8 ratio,The T4/T8 ratio was 0.49.,[Pharmacokinetics of 3'-azido-3 deoxy-thymidine (AZT) in a patient undergoing hemodialysis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2623654/),,0.49,156,DB00495,Zidovudine
,2623654,peak,"The peak and the trough concentrations of zidovudine were 0.61 and 0.15 microgram per milliliter, respectively.",[Pharmacokinetics of 3'-azido-3 deoxy-thymidine (AZT) in a patient undergoing hemodialysis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2623654/),[μg] / [milliliter],0.61,157,DB00495,Zidovudine
,2623654,trough concentrations,"The peak and the trough concentrations of zidovudine were 0.61 and 0.15 microgram per milliliter, respectively.",[Pharmacokinetics of 3'-azido-3 deoxy-thymidine (AZT) in a patient undergoing hemodialysis]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2623654/),[μg] / [milliliter],0.15,158,DB00495,Zidovudine
,2623654,half-life,The half-life was 2.9 hours.,[Pharmacokinetics of 3'-azido-3 deoxy-thymidine (AZT) in a patient undergoing hemodialysis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2623654/),h,2.9,159,DB00495,Zidovudine
,2623654,clearance,"The hemodialysis clearance of zidovudine and its metabolite were 102 and 71 ml per minute, respectively.",[Pharmacokinetics of 3'-azido-3 deoxy-thymidine (AZT) in a patient undergoing hemodialysis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2623654/),[ml] / [min],102,160,DB00495,Zidovudine
,2623654,clearance,"The hemodialysis clearance of zidovudine and its metabolite were 102 and 71 ml per minute, respectively.",[Pharmacokinetics of 3'-azido-3 deoxy-thymidine (AZT) in a patient undergoing hemodialysis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2623654/),[ml] / [min],71,161,DB00495,Zidovudine
,1553347,concentrations,Plasma probenecid concentrations during low-dose and high-dose infusion were 56.9 +/- 12 and 248 +/- 42 micrograms/ml.,Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553347/),[μg] / [ml],56.9,427,DB00495,Zidovudine
,1553347,concentrations,Plasma probenecid concentrations during low-dose and high-dose infusion were 56.9 +/- 12 and 248 +/- 42 micrograms/ml.,Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553347/),[μg] / [ml],248,428,DB00495,Zidovudine
,1553347,terminal half-life,Postinfusion data showed that the zidovudine terminal half-life during high-dose probenecid treatment was longer than that with low-dose probenecid treatment (58.2 +/- 4.6 vs 39.0 +/- 9.1 min).,Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553347/),min,58.2,429,DB00495,Zidovudine
,1553347,terminal half-life,Postinfusion data showed that the zidovudine terminal half-life during high-dose probenecid treatment was longer than that with low-dose probenecid treatment (58.2 +/- 4.6 vs 39.0 +/- 9.1 min).,Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553347/),min,39.0,430,DB00495,Zidovudine
,1553347,volume of distribution,The volume of distribution of zidovudine also decreased (1.76 +/- 0.27 vs. 1.10 +/- 0.095 L/kg) as a result of probenecid coadministration.,Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553347/),[l] / [kg],1.76,431,DB00495,Zidovudine
,1553347,volume of distribution,The volume of distribution of zidovudine also decreased (1.76 +/- 0.27 vs. 1.10 +/- 0.095 L/kg) as a result of probenecid coadministration.,Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553347/),[l] / [kg],1.10,432,DB00495,Zidovudine
,1553347,Michaelis-type constants,"Michaelis-type constants for probenecid inhibition of zidovudine renal and nonrenal clearances were 73 and 55 micrograms/ml, respectively.",Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553347/),[μg] / [ml],73,433,DB00495,Zidovudine
,1553347,Michaelis-type constants,"Michaelis-type constants for probenecid inhibition of zidovudine renal and nonrenal clearances were 73 and 55 micrograms/ml, respectively.",Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553347/),[μg] / [ml],55,434,DB00495,Zidovudine
,16611002,transdermal flux,The optimized elastic liposomal formulation showed transdermal flux of 98.8+/-5.8 microg/cm2/hr across rat skin as compared to 5.72+/-0.3 microg/cm2/hr for free drug.,Sustained and targeted delivery of an anti-HIV agent using elastic liposomal formulation: mechanism of action. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16611002/),[μg] / [cm2·h],98.8,802,DB00495,Zidovudine
,16611002,transdermal flux,The optimized elastic liposomal formulation showed transdermal flux of 98.8+/-5.8 microg/cm2/hr across rat skin as compared to 5.72+/-0.3 microg/cm2/hr for free drug.,Sustained and targeted delivery of an anti-HIV agent using elastic liposomal formulation: mechanism of action. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16611002/),[μg] / [cm2·h],5.72,803,DB00495,Zidovudine
,16611002,AUC0-24h,"The AUC0-24h for elastic liposomal formulation was found to be (12.63+/-1.2 microg h/mL), nearly twelve fold higher than the control (0.83+/-0.2 microg h/mL).",Sustained and targeted delivery of an anti-HIV agent using elastic liposomal formulation: mechanism of action. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16611002/),[h·μg] / [ml],12.63,804,DB00495,Zidovudine
,16611002,AUC0-24h,"The AUC0-24h for elastic liposomal formulation was found to be (12.63+/-1.2 microg h/mL), nearly twelve fold higher than the control (0.83+/-0.2 microg h/mL).",Sustained and targeted delivery of an anti-HIV agent using elastic liposomal formulation: mechanism of action. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16611002/),[h·μg] / [ml],0.83,805,DB00495,Zidovudine
,26461917,bioavailability,"In spite of its higher bioavailability (50-75%) the most important reason of its cessation are bone marrow suppression, anemia, neutropenia and various organs related toxicities.","Improved Safety, Bioavailability and Pharmacokinetics of Zidovudine through Lactoferrin Nanoparticles during Oral Administration in Rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26461917/),%,50-75,1022,DB00495,Zidovudine
,9107545,steady-state plasma concentrations,Maternal steady-state plasma concentrations were 1.3-2.2 micrograms/ml for AZT and 2.3-8.0 micrograms/ml for AZTG.,"Transplacental pharmacokinetics and fetal distribution of azidothymidine, its glucuronide, and phosphorylated metabolites in late-term rhesus macaques after maternal infusion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9107545/),[μg] / [ml],1.3-2.2,1306,DB00495,Zidovudine
,9107545,steady-state plasma concentrations,Maternal steady-state plasma concentrations were 1.3-2.2 micrograms/ml for AZT and 2.3-8.0 micrograms/ml for AZTG.,"Transplacental pharmacokinetics and fetal distribution of azidothymidine, its glucuronide, and phosphorylated metabolites in late-term rhesus macaques after maternal infusion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9107545/),[μg] / [ml],2.3-8.0,1307,DB00495,Zidovudine
,9107545,fetal-to-maternal plasma ratios,"Fetal AZT and AZTG plasma concentrations were both lower (0.98-2.3 micrograms/ml and 1.3-5.4 micrograms/ml, respectively) than maternal concentrations, with fetal-to-maternal plasma ratios of 0.63-1.0 for AZT.","Transplacental pharmacokinetics and fetal distribution of azidothymidine, its glucuronide, and phosphorylated metabolites in late-term rhesus macaques after maternal infusion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9107545/),,0.63-1.0,1308,DB00495,Zidovudine
,9244142,brain ECF/plasma,"Its brain ECF/plasma and CSF/plasma steady-state concentration ratios were 0.33 +/- 0.06 and 0.49 +/- 0.12, respectively (n = 15).",Microdialysis studies of the distribution of stavudine into the central nervous system in the freely-moving rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244142/),,0.33,2594,DB00495,Zidovudine
,9244142,CSF/plasma steady-state concentration ratios,"Its brain ECF/plasma and CSF/plasma steady-state concentration ratios were 0.33 +/- 0.06 and 0.49 +/- 0.12, respectively (n = 15).",Microdialysis studies of the distribution of stavudine into the central nervous system in the freely-moving rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244142/),,0.49,2595,DB00495,Zidovudine
,11745755,peak concentrations,"The peak concentrations of AZT in plasma of G-20 and PND-20 rats were 92.2 microg/mL (0.345 micromol/mL) and 56.6 microg/mL (0.21 micromol/mL) at 15 and 30 min after intubation, respectively.",AZT distribution in the fetal and postnatal rat central nervous system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745755/),[μg] / [ml],92.2,4266,DB00495,Zidovudine
,11745755,peak concentrations,"The peak concentrations of AZT in plasma of G-20 and PND-20 rats were 92.2 microg/mL (0.345 micromol/mL) and 56.6 microg/mL (0.21 micromol/mL) at 15 and 30 min after intubation, respectively.",AZT distribution in the fetal and postnatal rat central nervous system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745755/),[μM] / [ml],0.345,4267,DB00495,Zidovudine
,11745755,peak concentrations,"The peak concentrations of AZT in plasma of G-20 and PND-20 rats were 92.2 microg/mL (0.345 micromol/mL) and 56.6 microg/mL (0.21 micromol/mL) at 15 and 30 min after intubation, respectively.",AZT distribution in the fetal and postnatal rat central nervous system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745755/),[μg] / [ml],56.6,4268,DB00495,Zidovudine
,11745755,peak concentrations,"The peak concentrations of AZT in plasma of G-20 and PND-20 rats were 92.2 microg/mL (0.345 micromol/mL) and 56.6 microg/mL (0.21 micromol/mL) at 15 and 30 min after intubation, respectively.",AZT distribution in the fetal and postnatal rat central nervous system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745755/),[μM] / [ml],0.21,4269,DB00495,Zidovudine
,11745755,peak concentration,The peak concentration of fetal tissue occurred in the colon at 60 min and was 205.8 microg/g tissue.,AZT distribution in the fetal and postnatal rat central nervous system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745755/),[μg] / [g·tissue],205.8,4270,DB00495,Zidovudine
,19106116,bioavailability,"Although bioavailability of AZT after oral administration of phosphonate 1 was lower than those of AZT H-phosphonate and AZT (8 against 14 and 49%), we expect that this reduction would not cause essential decrease of antiviral activity but noticeably decrease toxicity as a result of gradual accumulation of AZT in blood and the absence of sharp difference between C(max) and C(min).","5'-aminocarbonyl phosphonates as new zidovudine depot forms: antiviral properties, intracellular transformations, and pharmacokinetic parameters. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19106116/),%,8,4742,DB00495,Zidovudine
,19106116,bioavailability,"Although bioavailability of AZT after oral administration of phosphonate 1 was lower than those of AZT H-phosphonate and AZT (8 against 14 and 49%), we expect that this reduction would not cause essential decrease of antiviral activity but noticeably decrease toxicity as a result of gradual accumulation of AZT in blood and the absence of sharp difference between C(max) and C(min).","5'-aminocarbonyl phosphonates as new zidovudine depot forms: antiviral properties, intracellular transformations, and pharmacokinetic parameters. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19106116/),%,14,4743,DB00495,Zidovudine
,19106116,bioavailability,"Although bioavailability of AZT after oral administration of phosphonate 1 was lower than those of AZT H-phosphonate and AZT (8 against 14 and 49%), we expect that this reduction would not cause essential decrease of antiviral activity but noticeably decrease toxicity as a result of gradual accumulation of AZT in blood and the absence of sharp difference between C(max) and C(min).","5'-aminocarbonyl phosphonates as new zidovudine depot forms: antiviral properties, intracellular transformations, and pharmacokinetic parameters. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19106116/),%,49,4744,DB00495,Zidovudine
,7630678,absolute oral bioavailability,The absolute oral bioavailability of the drug ranged from 61% to 78%.,A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7630678/),%,61,5113,DB00495,Zidovudine
,7630678,absolute oral bioavailability,The absolute oral bioavailability of the drug ranged from 61% to 78%.,A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7630678/),%,78,5114,DB00495,Zidovudine
,9145885,peak,"After rectal administration of an aqueous ZDV solution (250 mg of ZDV), mean peak ZDV levels were 1.3 +/- 0.7 micromol/liter (mean +/- standard deviation) versus 5.0 +/- 2.2 micromol/liter (P < 0.0001) after oral intake of a 250-mg ZDV capsule.",Pharmacokinetics of zidovudine after rectal administration in human immunodeficiency virus-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145885/),[μM] / [l],1.3,5199,DB00495,Zidovudine
,9145885,peak,"After rectal administration of an aqueous ZDV solution (250 mg of ZDV), mean peak ZDV levels were 1.3 +/- 0.7 micromol/liter (mean +/- standard deviation) versus 5.0 +/- 2.2 micromol/liter (P < 0.0001) after oral intake of a 250-mg ZDV capsule.",Pharmacokinetics of zidovudine after rectal administration in human immunodeficiency virus-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145885/),[μM] / [l],5.0,5200,DB00495,Zidovudine
,9145885,half-life at beta phase,The half-life at beta phase was 87.8 +/- 39.6 min for rectally administered ZDV versus 55.8 +/- 20.1 min (P = 0.035) for orally administered ZDV.,Pharmacokinetics of zidovudine after rectal administration in human immunodeficiency virus-infected patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145885/),min,87.8,5201,DB00495,Zidovudine
,9145885,half-life at beta phase,The half-life at beta phase was 87.8 +/- 39.6 min for rectally administered ZDV versus 55.8 +/- 20.1 min (P = 0.035) for orally administered ZDV.,Pharmacokinetics of zidovudine after rectal administration in human immunodeficiency virus-infected patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145885/),min,55.8,5202,DB00495,Zidovudine
,9145885,area under the concentration-time curve from 0 min to infinity,The mean area under the concentration-time curve from 0 min to infinity was 232 +/- 181 micromol/liter x min after rectal administration versus 362 +/- 110 micromol/liter x min after oral intake.,Pharmacokinetics of zidovudine after rectal administration in human immunodeficiency virus-infected patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145885/),[μM] / [l·min],232,5203,DB00495,Zidovudine
,9145885,area under the concentration-time curve from 0 min to infinity,The mean area under the concentration-time curve from 0 min to infinity was 232 +/- 181 micromol/liter x min after rectal administration versus 362 +/- 110 micromol/liter x min after oral intake.,Pharmacokinetics of zidovudine after rectal administration in human immunodeficiency virus-infected patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145885/),[μM] / [l·min],362,5204,DB00495,Zidovudine
,8373716,AUC,"The mean AUC value for the glucuronidated metabolite, GZDV, was reduced from 26.6 +/- 11.7 mumol l-1 h in the presence of placebo to 20.9 +/- 8.3 mumol l-1 h (95% C.I. of the difference 1.39-9.98; P < 0.05) following treatment with naproxen 250 mg twice daily for 3 days.",The effects of indomethacin and naproxen on zidovudine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373716/),[h·μM] / [l],26.6,5535,DB00495,Zidovudine
,8373716,AUC,"The mean AUC value for the glucuronidated metabolite, GZDV, was reduced from 26.6 +/- 11.7 mumol l-1 h in the presence of placebo to 20.9 +/- 8.3 mumol l-1 h (95% C.I. of the difference 1.39-9.98; P < 0.05) following treatment with naproxen 250 mg twice daily for 3 days.",The effects of indomethacin and naproxen on zidovudine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8373716/),[h·μM] / [l],20.9,5536,DB00495,Zidovudine
,8787899,volume of the central compartment,"For didanosine, significant but clinically irrelevant decreases determined by standard hypothesis testing were seen for both the volume of the central compartment (1.91 to 1.86 liters) and the absorption rate constant (0.79 to 0.73 h-1) in the presence of alpha interferon.",Effects of cytokines on antiviral pharmacokinetics: an alternative approach to assessment of drug interactions using bioequivalence guidelines. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787899/),l,1.91 to 1.86,5637,DB00495,Zidovudine
,8787899,absorption rate constant,"For didanosine, significant but clinically irrelevant decreases determined by standard hypothesis testing were seen for both the volume of the central compartment (1.91 to 1.86 liters) and the absorption rate constant (0.79 to 0.73 h-1) in the presence of alpha interferon.",Effects of cytokines on antiviral pharmacokinetics: an alternative approach to assessment of drug interactions using bioequivalence guidelines. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787899/),1/[h],0.79 to 0.73,5638,DB00495,Zidovudine
,9535994,plasma steady-state concentration ratio,A fetal-maternal plasma steady-state concentration ratio of 0.76 +/- 0.06 suggested that the drug was transferred extensively to the fetal compartment.,In vivo maternal-fetal-amniotic fluid pharmacokinetics of zidovudine in the pigtailed macaque: comparison of steady-state and single-dose regimens. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9535994/),,0.76,6422,DB00495,Zidovudine
,9535994,plasma area under the curve (AUC) ratio,"Similarly, the mean fetal-maternal plasma area under the curve (AUC) ratio after administration of an i.v. bolus dose to the dam was 0.84 +/- 0. 09.",In vivo maternal-fetal-amniotic fluid pharmacokinetics of zidovudine in the pigtailed macaque: comparison of steady-state and single-dose regimens. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9535994/),,0.84,6423,DB00495,Zidovudine
,9535994,clearance,"The placental transfer of zidovudine was passive, with a clearance of approximately 2.0 ml/min/kg, about 35% of the rate of the placental blood flow marker antipyrine.",In vivo maternal-fetal-amniotic fluid pharmacokinetics of zidovudine in the pigtailed macaque: comparison of steady-state and single-dose regimens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9535994/),[ml] / [kg·min],2.0,6424,DB00495,Zidovudine
,9110063,bioavailability,The bioavailability of oral ganciclovir averages 6-9%.,Pharmacokinetics of oral ganciclovir capsules in HIV-infected persons. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9110063/),%,6-9,8164,DB00495,Zidovudine
,15910662,absorption rate constant,"For patients treated with indinavir alone, absorption rate constant was estimated to be 0.43/h, and oral clearance Cl/F was 33 L/h.",Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15910662/),1/[h],0.43,8254,DB00495,Zidovudine
,15910662,oral clearance Cl/F,"For patients treated with indinavir alone, absorption rate constant was estimated to be 0.43/h, and oral clearance Cl/F was 33 L/h.",Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15910662/),[l] / [h],33,8255,DB00495,Zidovudine
,15910662,Oral volume of distribution (V/F),Oral volume of distribution (V/F) was 24 L.,Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15910662/),l,24,8256,DB00495,Zidovudine
,10839658,plasma half-life,The plasma half-life was significantly longer (approximately 3.8 hours) than that of the parent drug ZDV.,"Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection: pharmacokinetics, tolerability, and efficacy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839658/),h,3.8,10080,DB00495,Zidovudine
,1762074,total clearance,"The respective values (mean +/- S.D.) for total clearance of AZT were 2.4 +/- 0.2, 2.3 +/- 0.3 and 1.8 +/- 0.4 l/hr/kg and for renal clearance were 1.7 +/- 0.2, 1.8 +/- 0.4 and 1.5 +/- 0.4 l/hr/kg.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),[l] / [h·kg],2.4,12876,DB00495,Zidovudine
,1762074,total clearance,"The respective values (mean +/- S.D.) for total clearance of AZT were 2.4 +/- 0.2, 2.3 +/- 0.3 and 1.8 +/- 0.4 l/hr/kg and for renal clearance were 1.7 +/- 0.2, 1.8 +/- 0.4 and 1.5 +/- 0.4 l/hr/kg.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),[l] / [h·kg],2.3,12877,DB00495,Zidovudine
,1762074,total clearance,"The respective values (mean +/- S.D.) for total clearance of AZT were 2.4 +/- 0.2, 2.3 +/- 0.3 and 1.8 +/- 0.4 l/hr/kg and for renal clearance were 1.7 +/- 0.2, 1.8 +/- 0.4 and 1.5 +/- 0.4 l/hr/kg.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),[l] / [h·kg],1.8,12878,DB00495,Zidovudine
,1762074,renal clearance,"The respective values (mean +/- S.D.) for total clearance of AZT were 2.4 +/- 0.2, 2.3 +/- 0.3 and 1.8 +/- 0.4 l/hr/kg and for renal clearance were 1.7 +/- 0.2, 1.8 +/- 0.4 and 1.5 +/- 0.4 l/hr/kg.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),[l] / [h·kg],1.7,12879,DB00495,Zidovudine
,1762074,renal clearance,"The respective values (mean +/- S.D.) for total clearance of AZT were 2.4 +/- 0.2, 2.3 +/- 0.3 and 1.8 +/- 0.4 l/hr/kg and for renal clearance were 1.7 +/- 0.2, 1.8 +/- 0.4 and 1.5 +/- 0.4 l/hr/kg.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),[l] / [h·kg],1.8,12880,DB00495,Zidovudine
,1762074,renal clearance,"The respective values (mean +/- S.D.) for total clearance of AZT were 2.4 +/- 0.2, 2.3 +/- 0.3 and 1.8 +/- 0.4 l/hr/kg and for renal clearance were 1.7 +/- 0.2, 1.8 +/- 0.4 and 1.5 +/- 0.4 l/hr/kg.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),[l] / [h·kg],1.5,12881,DB00495,Zidovudine
,1762074,renal clearance,"The renal clearance of AZT was approximately equal to renal plasma flow of rats (1.5 l/hr/kg), suggesting that in addition to filtration, AZT is also efficiently secreted in the kidney of the rat.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),[l] / [h·kg],1.5,12882,DB00495,Zidovudine
,1762074,volume of distribution at steady state,"The respective values for volume of distribution at steady state were 1.3 +/- 0.2, 1.0 +/- 0.2 and 0.84 +/- 0.19 l/kg (P less than .05) and elimination half-life were (harmonic mean) 0.55, 0.44 and 0.46 hr.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),[l] / [kg],1.3,12883,DB00495,Zidovudine
,1762074,volume of distribution at steady state,"The respective values for volume of distribution at steady state were 1.3 +/- 0.2, 1.0 +/- 0.2 and 0.84 +/- 0.19 l/kg (P less than .05) and elimination half-life were (harmonic mean) 0.55, 0.44 and 0.46 hr.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),[l] / [kg],1.0,12884,DB00495,Zidovudine
,1762074,volume of distribution at steady state,"The respective values for volume of distribution at steady state were 1.3 +/- 0.2, 1.0 +/- 0.2 and 0.84 +/- 0.19 l/kg (P less than .05) and elimination half-life were (harmonic mean) 0.55, 0.44 and 0.46 hr.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),[l] / [kg],0.84,12885,DB00495,Zidovudine
,1762074,elimination half-life,"The respective values for volume of distribution at steady state were 1.3 +/- 0.2, 1.0 +/- 0.2 and 0.84 +/- 0.19 l/kg (P less than .05) and elimination half-life were (harmonic mean) 0.55, 0.44 and 0.46 hr.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),h,0.55,12886,DB00495,Zidovudine
,1762074,elimination half-life,"The respective values for volume of distribution at steady state were 1.3 +/- 0.2, 1.0 +/- 0.2 and 0.84 +/- 0.19 l/kg (P less than .05) and elimination half-life were (harmonic mean) 0.55, 0.44 and 0.46 hr.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),h,0.44,12887,DB00495,Zidovudine
,1762074,elimination half-life,"The respective values for volume of distribution at steady state were 1.3 +/- 0.2, 1.0 +/- 0.2 and 0.84 +/- 0.19 l/kg (P less than .05) and elimination half-life were (harmonic mean) 0.55, 0.44 and 0.46 hr.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),h,0.46,12888,DB00495,Zidovudine
,1762074,Urinary excretion,"Urinary excretion of AZT as unchanged drug in intact rats accounted for 70 +/- 6, 79 +/- 6, and 83 +/- 12% of the dose, whereas only 0.7 to 0.8% of the dose was recovered in the urine as GAZT.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),%,70,12889,DB00495,Zidovudine
,1762074,Urinary excretion,"Urinary excretion of AZT as unchanged drug in intact rats accounted for 70 +/- 6, 79 +/- 6, and 83 +/- 12% of the dose, whereas only 0.7 to 0.8% of the dose was recovered in the urine as GAZT.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),%,79,12890,DB00495,Zidovudine
,1762074,Urinary excretion,"Urinary excretion of AZT as unchanged drug in intact rats accounted for 70 +/- 6, 79 +/- 6, and 83 +/- 12% of the dose, whereas only 0.7 to 0.8% of the dose was recovered in the urine as GAZT.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),%,83,12891,DB00495,Zidovudine
,1762074,Urinary excretion,"Urinary excretion of AZT as unchanged drug in intact rats accounted for 70 +/- 6, 79 +/- 6, and 83 +/- 12% of the dose, whereas only 0.7 to 0.8% of the dose was recovered in the urine as GAZT.",A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762074/),,0,12892,DB00495,Zidovudine
,17225002,oral clearance,"Final pharmacokinetic parameters, expressed as functions of the co-variates gender and creatinine clearance (CL CR), were: oral clearance (CL = 55.1 + 240 x CL CR + 16.6 L/h for males and CL = 55.1 + 240 x CL CR for females), central volume (V2 = 9.8 L), intercompartmental clearance (Q = 40.9 L/h), peripheral volume (V3 = 62.7 + 22.9 L for males and V3 = 62.7 L for females), absorption rate constant (Ka = 1.51/h), and dissolution time of the tablet (D = 0.43 h).",A new model for the population pharmacokinetics of didanosine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17225002/),,55,13246,DB00495,Zidovudine
,17225002,CL,"Final pharmacokinetic parameters, expressed as functions of the co-variates gender and creatinine clearance (CL CR), were: oral clearance (CL = 55.1 + 240 x CL CR + 16.6 L/h for males and CL = 55.1 + 240 x CL CR for females), central volume (V2 = 9.8 L), intercompartmental clearance (Q = 40.9 L/h), peripheral volume (V3 = 62.7 + 22.9 L for males and V3 = 62.7 L for females), absorption rate constant (Ka = 1.51/h), and dissolution time of the tablet (D = 0.43 h).",A new model for the population pharmacokinetics of didanosine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17225002/),,55,13247,DB00495,Zidovudine
,17225002,central volume (V2,"Final pharmacokinetic parameters, expressed as functions of the co-variates gender and creatinine clearance (CL CR), were: oral clearance (CL = 55.1 + 240 x CL CR + 16.6 L/h for males and CL = 55.1 + 240 x CL CR for females), central volume (V2 = 9.8 L), intercompartmental clearance (Q = 40.9 L/h), peripheral volume (V3 = 62.7 + 22.9 L for males and V3 = 62.7 L for females), absorption rate constant (Ka = 1.51/h), and dissolution time of the tablet (D = 0.43 h).",A new model for the population pharmacokinetics of didanosine in healthy subjects. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17225002/),l,9.8,13248,DB00495,Zidovudine
,17225002,intercompartmental clearance (Q,"Final pharmacokinetic parameters, expressed as functions of the co-variates gender and creatinine clearance (CL CR), were: oral clearance (CL = 55.1 + 240 x CL CR + 16.6 L/h for males and CL = 55.1 + 240 x CL CR for females), central volume (V2 = 9.8 L), intercompartmental clearance (Q = 40.9 L/h), peripheral volume (V3 = 62.7 + 22.9 L for males and V3 = 62.7 L for females), absorption rate constant (Ka = 1.51/h), and dissolution time of the tablet (D = 0.43 h).",A new model for the population pharmacokinetics of didanosine in healthy subjects. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17225002/),[l] / [h],40.9,13249,DB00495,Zidovudine
,17225002,peripheral volume (V3,"Final pharmacokinetic parameters, expressed as functions of the co-variates gender and creatinine clearance (CL CR), were: oral clearance (CL = 55.1 + 240 x CL CR + 16.6 L/h for males and CL = 55.1 + 240 x CL CR for females), central volume (V2 = 9.8 L), intercompartmental clearance (Q = 40.9 L/h), peripheral volume (V3 = 62.7 + 22.9 L for males and V3 = 62.7 L for females), absorption rate constant (Ka = 1.51/h), and dissolution time of the tablet (D = 0.43 h).",A new model for the population pharmacokinetics of didanosine in healthy subjects. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17225002/),l,62.7,13250,DB00495,Zidovudine
,17225002,V3,"Final pharmacokinetic parameters, expressed as functions of the co-variates gender and creatinine clearance (CL CR), were: oral clearance (CL = 55.1 + 240 x CL CR + 16.6 L/h for males and CL = 55.1 + 240 x CL CR for females), central volume (V2 = 9.8 L), intercompartmental clearance (Q = 40.9 L/h), peripheral volume (V3 = 62.7 + 22.9 L for males and V3 = 62.7 L for females), absorption rate constant (Ka = 1.51/h), and dissolution time of the tablet (D = 0.43 h).",A new model for the population pharmacokinetics of didanosine in healthy subjects. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17225002/),l,62.7,13251,DB00495,Zidovudine
,17225002,absorption rate constant (Ka,"Final pharmacokinetic parameters, expressed as functions of the co-variates gender and creatinine clearance (CL CR), were: oral clearance (CL = 55.1 + 240 x CL CR + 16.6 L/h for males and CL = 55.1 + 240 x CL CR for females), central volume (V2 = 9.8 L), intercompartmental clearance (Q = 40.9 L/h), peripheral volume (V3 = 62.7 + 22.9 L for males and V3 = 62.7 L for females), absorption rate constant (Ka = 1.51/h), and dissolution time of the tablet (D = 0.43 h).",A new model for the population pharmacokinetics of didanosine in healthy subjects. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17225002/),1/[h],1.51,13252,DB00495,Zidovudine
,17225002,dissolution time,"Final pharmacokinetic parameters, expressed as functions of the co-variates gender and creatinine clearance (CL CR), were: oral clearance (CL = 55.1 + 240 x CL CR + 16.6 L/h for males and CL = 55.1 + 240 x CL CR for females), central volume (V2 = 9.8 L), intercompartmental clearance (Q = 40.9 L/h), peripheral volume (V3 = 62.7 + 22.9 L for males and V3 = 62.7 L for females), absorption rate constant (Ka = 1.51/h), and dissolution time of the tablet (D = 0.43 h).",A new model for the population pharmacokinetics of didanosine in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17225002/),h,0.43,13253,DB00495,Zidovudine
,17225002,D,"Final pharmacokinetic parameters, expressed as functions of the co-variates gender and creatinine clearance (CL CR), were: oral clearance (CL = 55.1 + 240 x CL CR + 16.6 L/h for males and CL = 55.1 + 240 x CL CR for females), central volume (V2 = 9.8 L), intercompartmental clearance (Q = 40.9 L/h), peripheral volume (V3 = 62.7 + 22.9 L for males and V3 = 62.7 L for females), absorption rate constant (Ka = 1.51/h), and dissolution time of the tablet (D = 0.43 h).",A new model for the population pharmacokinetics of didanosine in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17225002/),h,0.43,13254,DB00495,Zidovudine
,27116047,C12h,"The most predictive PK thresholds for increased risk of unsuppressed viral load were C12h 1.12 mg/L [hazard ratio (HR): 6.14; 95% CI: 2.64 to 14.27], C24h 0.65 mg/L (HR: 6.57; 95% CI: 2.86 to 15.10), and AUC0-24 28 mg·h/L (HR: 5.77; 95% CI: 2.28 to 14.58).","Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116047/),[mg] / [l],1.12,13439,DB00495,Zidovudine
,27116047,C24h,"The most predictive PK thresholds for increased risk of unsuppressed viral load were C12h 1.12 mg/L [hazard ratio (HR): 6.14; 95% CI: 2.64 to 14.27], C24h 0.65 mg/L (HR: 6.57; 95% CI: 2.86 to 15.10), and AUC0-24 28 mg·h/L (HR: 5.77; 95% CI: 2.28 to 14.58).","Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116047/),[mg] / [l],0.65,13440,DB00495,Zidovudine
,27116047,AUC0-24,"The most predictive PK thresholds for increased risk of unsuppressed viral load were C12h 1.12 mg/L [hazard ratio (HR): 6.14; 95% CI: 2.64 to 14.27], C24h 0.65 mg/L (HR: 6.57; 95% CI: 2.86 to 15.10), and AUC0-24 28 mg·h/L (HR: 5.77; 95% CI: 2.28 to 14.58).","Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116047/),[h·mg] / [l],28,13441,DB00495,Zidovudine
,19628728,apparent oral clearance (CL/F),"Lamivudine, zidovudine, and stavudine apparent oral clearance (CL/F) values (mean +/- SD [% coefficient of variation [CV]) were 7.3 +/- 2.8 (39%), 31.9 +/- 33.6 (106%), and 16.4 +/- 5.8 (35%) mL/min/kg, respectively, whereas half-life values were 4.2 +/- 1.9 (46%), 8.1 +/- 7.9 (98%), and 1.5 +/- 1.0 (65%) hours, respectively.",Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628728/),[ml] / [kg·min],7.3,14601,DB00495,Zidovudine
,19628728,apparent oral clearance (CL/F),"Lamivudine, zidovudine, and stavudine apparent oral clearance (CL/F) values (mean +/- SD [% coefficient of variation [CV]) were 7.3 +/- 2.8 (39%), 31.9 +/- 33.6 (106%), and 16.4 +/- 5.8 (35%) mL/min/kg, respectively, whereas half-life values were 4.2 +/- 1.9 (46%), 8.1 +/- 7.9 (98%), and 1.5 +/- 1.0 (65%) hours, respectively.",Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628728/),[ml] / [kg·min],31.9,14602,DB00495,Zidovudine
,19628728,apparent oral clearance (CL/F),"Lamivudine, zidovudine, and stavudine apparent oral clearance (CL/F) values (mean +/- SD [% coefficient of variation [CV]) were 7.3 +/- 2.8 (39%), 31.9 +/- 33.6 (106%), and 16.4 +/- 5.8 (35%) mL/min/kg, respectively, whereas half-life values were 4.2 +/- 1.9 (46%), 8.1 +/- 7.9 (98%), and 1.5 +/- 1.0 (65%) hours, respectively.",Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628728/),[ml] / [kg·min],16.4,14603,DB00495,Zidovudine
,19628728,half-life,"Lamivudine, zidovudine, and stavudine apparent oral clearance (CL/F) values (mean +/- SD [% coefficient of variation [CV]) were 7.3 +/- 2.8 (39%), 31.9 +/- 33.6 (106%), and 16.4 +/- 5.8 (35%) mL/min/kg, respectively, whereas half-life values were 4.2 +/- 1.9 (46%), 8.1 +/- 7.9 (98%), and 1.5 +/- 1.0 (65%) hours, respectively.",Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628728/),h,4.2,14604,DB00495,Zidovudine
,19628728,half-life,"Lamivudine, zidovudine, and stavudine apparent oral clearance (CL/F) values (mean +/- SD [% coefficient of variation [CV]) were 7.3 +/- 2.8 (39%), 31.9 +/- 33.6 (106%), and 16.4 +/- 5.8 (35%) mL/min/kg, respectively, whereas half-life values were 4.2 +/- 1.9 (46%), 8.1 +/- 7.9 (98%), and 1.5 +/- 1.0 (65%) hours, respectively.",Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628728/),h,8.1,14605,DB00495,Zidovudine
,19628728,half-life,"Lamivudine, zidovudine, and stavudine apparent oral clearance (CL/F) values (mean +/- SD [% coefficient of variation [CV]) were 7.3 +/- 2.8 (39%), 31.9 +/- 33.6 (106%), and 16.4 +/- 5.8 (35%) mL/min/kg, respectively, whereas half-life values were 4.2 +/- 1.9 (46%), 8.1 +/- 7.9 (98%), and 1.5 +/- 1.0 (65%) hours, respectively.",Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628728/),h,1.5,14606,DB00495,Zidovudine
,9065170,clearance index,The clearance index of lamivudine at a maternal concentration of 1.39 micrograms/ml was 0.23 +/- 0.14.,The maternal-fetal transfer of lamivudine in the ex vivo human placenta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9065170/),,0.23,14683,DB00495,Zidovudine
,9065170,peak concentration,At a peak concentration of 14.68 micrograms/ml the clearance index was 0.14 +/- 0.06.,The maternal-fetal transfer of lamivudine in the ex vivo human placenta. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9065170/),[μg] / [ml],14.68,14684,DB00495,Zidovudine
,9065170,clearance index,At a peak concentration of 14.68 micrograms/ml the clearance index was 0.14 +/- 0.06.,The maternal-fetal transfer of lamivudine in the ex vivo human placenta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9065170/),,0.14,14685,DB00495,Zidovudine
,16724579,area under the curve from time 0 to the last measurable concentration (AUC(0-t)),"Mean area under the curve from time 0 to the last measurable concentration (AUC(0-t)), mean area under the curve from time 0 to infinity (AUC(0-infinity)) and peak plasma concentrations (C(max)) of zidovudine for the generic tablet formulation (2,220.6 ng x h/ml, 2,236.0 ng x h/ml and 1,087.9 ng/ml, respectively) were very similar to those observed for the innovator product (2,139.7 ng x h/ml, 2,158.6 ng x h/ml and 1,066.5 ng/ml, respectively).",Comparative bioavailability study of zidovudine administered as two different tablet formulations in healthy adult subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16724579/),[h·ng] / [ml],"2,220.6",15651,DB00495,Zidovudine
,16724579,area under the curve from time 0 to infinity (AUC(0-infinity)),"Mean area under the curve from time 0 to the last measurable concentration (AUC(0-t)), mean area under the curve from time 0 to infinity (AUC(0-infinity)) and peak plasma concentrations (C(max)) of zidovudine for the generic tablet formulation (2,220.6 ng x h/ml, 2,236.0 ng x h/ml and 1,087.9 ng/ml, respectively) were very similar to those observed for the innovator product (2,139.7 ng x h/ml, 2,158.6 ng x h/ml and 1,066.5 ng/ml, respectively).",Comparative bioavailability study of zidovudine administered as two different tablet formulations in healthy adult subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16724579/),[h·ng] / [ml],"2,236.0",15652,DB00495,Zidovudine
,16724579,area under the curve from time 0 to infinity (AUC(0-infinity)),"Mean area under the curve from time 0 to the last measurable concentration (AUC(0-t)), mean area under the curve from time 0 to infinity (AUC(0-infinity)) and peak plasma concentrations (C(max)) of zidovudine for the generic tablet formulation (2,220.6 ng x h/ml, 2,236.0 ng x h/ml and 1,087.9 ng/ml, respectively) were very similar to those observed for the innovator product (2,139.7 ng x h/ml, 2,158.6 ng x h/ml and 1,066.5 ng/ml, respectively).",Comparative bioavailability study of zidovudine administered as two different tablet formulations in healthy adult subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16724579/),[h·ng] / [ml],"2,158.6",15653,DB00495,Zidovudine
,16724579,peak plasma concentrations (C(max)),"Mean area under the curve from time 0 to the last measurable concentration (AUC(0-t)), mean area under the curve from time 0 to infinity (AUC(0-infinity)) and peak plasma concentrations (C(max)) of zidovudine for the generic tablet formulation (2,220.6 ng x h/ml, 2,236.0 ng x h/ml and 1,087.9 ng/ml, respectively) were very similar to those observed for the innovator product (2,139.7 ng x h/ml, 2,158.6 ng x h/ml and 1,066.5 ng/ml, respectively).",Comparative bioavailability study of zidovudine administered as two different tablet formulations in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16724579/),[ng] / [ml],"1,087.9",15654,DB00495,Zidovudine
,16724579,peak plasma concentrations (C(max)),"Mean area under the curve from time 0 to the last measurable concentration (AUC(0-t)), mean area under the curve from time 0 to infinity (AUC(0-infinity)) and peak plasma concentrations (C(max)) of zidovudine for the generic tablet formulation (2,220.6 ng x h/ml, 2,236.0 ng x h/ml and 1,087.9 ng/ml, respectively) were very similar to those observed for the innovator product (2,139.7 ng x h/ml, 2,158.6 ng x h/ml and 1,066.5 ng/ml, respectively).",Comparative bioavailability study of zidovudine administered as two different tablet formulations in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16724579/),[h·ng] / [ml],"2,158.6",15655,DB00495,Zidovudine
,16724579,peak plasma concentrations (C(max)),"Mean area under the curve from time 0 to the last measurable concentration (AUC(0-t)), mean area under the curve from time 0 to infinity (AUC(0-infinity)) and peak plasma concentrations (C(max)) of zidovudine for the generic tablet formulation (2,220.6 ng x h/ml, 2,236.0 ng x h/ml and 1,087.9 ng/ml, respectively) were very similar to those observed for the innovator product (2,139.7 ng x h/ml, 2,158.6 ng x h/ml and 1,066.5 ng/ml, respectively).",Comparative bioavailability study of zidovudine administered as two different tablet formulations in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16724579/),[ng] / [ml],"1,066.5",15656,DB00495,Zidovudine
,16724579,oral clearance (CL/F),"The oral clearance (CL/F) of zidovudine for the generic and innovator formulations were 2.11 1/h/kg and 2.16 1/h/kg, respectively.",Comparative bioavailability study of zidovudine administered as two different tablet formulations in healthy adult subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16724579/),[1] / [h·kg],2.11,15657,DB00495,Zidovudine
,16724579,oral clearance (CL/F),"The oral clearance (CL/F) of zidovudine for the generic and innovator formulations were 2.11 1/h/kg and 2.16 1/h/kg, respectively.",Comparative bioavailability study of zidovudine administered as two different tablet formulations in healthy adult subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16724579/),[1] / [h·kg],2.16,15658,DB00495,Zidovudine
,8787912,areas under the concentration-time curves,"ZDV areas under the concentration-time curves were (means +/- standard deviations) 1.80 +/- 0.70 and 1.69 +/- 0.64 micrograms.h/ml in the absence and presence of trimethoprim-sulfamethoxazole, respectively.",Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787912/),[h·μg] / [ml],1.80,16777,DB00495,Zidovudine
,8787912,areas under the concentration-time curves,"ZDV areas under the concentration-time curves were (means +/- standard deviations) 1.80 +/- 0.70 and 1.69 +/- 0.64 micrograms.h/ml in the absence and presence of trimethoprim-sulfamethoxazole, respectively.",Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787912/),[h·μg] / [ml],1.69,16778,DB00495,Zidovudine
,8787912,clearances,"ZDV clearances were 1.57 +/- 0.61 and 1.74 +/- 0.66 liters/h/kg, respectively.",Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787912/),[l] / [h·kg],1.57,16779,DB00495,Zidovudine
,8787912,clearances,"ZDV clearances were 1.57 +/- 0.61 and 1.74 +/- 0.66 liters/h/kg, respectively.",Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787912/),[l] / [h·kg],1.74,16780,DB00495,Zidovudine
,20578520,absolute recoveries,The absolute recoveries of both compounds ranged from 93.3 to 97.5%.,Simultaneous determination of stavudine and lamivudine in human plasma by high performance liquid chromatography and its application to a bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20578520/),%,93.3 to 97.5,16939,DB00495,Zidovudine
,1444306,total clearances,"The i.v. total clearances (means +/- standard deviations) were 14.9 +/- 7.3, 11.2 +/- 3.7, and 15.1 +/- 4.7 ml/min/kg of body weight.",Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444306/),[ml] / [kg·min],14.9,17662,DB00495,Zidovudine
,1444306,total clearances,"The i.v. total clearances (means +/- standard deviations) were 14.9 +/- 7.3, 11.2 +/- 3.7, and 15.1 +/- 4.7 ml/min/kg of body weight.",Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444306/),[ml] / [kg·min],11.2,17663,DB00495,Zidovudine
,1444306,total clearances,"The i.v. total clearances (means +/- standard deviations) were 14.9 +/- 7.3, 11.2 +/- 3.7, and 15.1 +/- 4.7 ml/min/kg of body weight.",Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444306/),[ml] / [kg·min],15.1,17664,DB00495,Zidovudine
,1444306,distribution volumes,"The i.v. distribution volumes were 1.08 +/- 0.5, 1.0 +/- 0.4, and 1.65 +/- 1.4 liters/kg.",Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444306/),[l] / [kg],1.08,17665,DB00495,Zidovudine
,1444306,distribution volumes,"The i.v. distribution volumes were 1.08 +/- 0.5, 1.0 +/- 0.4, and 1.65 +/- 1.4 liters/kg.",Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444306/),[l] / [kg],1.0,17666,DB00495,Zidovudine
,1444306,distribution volumes,"The i.v. distribution volumes were 1.08 +/- 0.5, 1.0 +/- 0.4, and 1.65 +/- 1.4 liters/kg.",Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444306/),[l] / [kg],1.65,17667,DB00495,Zidovudine
,1444306,bioavailabilities,"The bioavailabilities were 0.54 +/- 0.22, 0.46 +/- 0.19, and 0.59 +/- 0.13 at weeks 1, 6, and 12, respectively.",Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444306/),,0.54,17668,DB00495,Zidovudine
,1444306,bioavailabilities,"The bioavailabilities were 0.54 +/- 0.22, 0.46 +/- 0.19, and 0.59 +/- 0.13 at weeks 1, 6, and 12, respectively.",Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444306/),,0.46,17669,DB00495,Zidovudine
,1444306,bioavailabilities,"The bioavailabilities were 0.54 +/- 0.22, 0.46 +/- 0.19, and 0.59 +/- 0.13 at weeks 1, 6, and 12, respectively.",Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444306/),,0.59,17670,DB00495,Zidovudine
,11120972,steady-state concentrations,"The selected target concentrations were average steady-state concentrations of 0.19 mg/liter for zidovudine and 0.44 mg/liter for lamivudine and a trough concentration of 0.15 mg/liter for indinavir; mean concentrations achieved at week 28 in the concentration-controlled arm were 0.20, 0.54, and 0.19 mg/liter, respectively.","Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11120972/),[mg] / [l],0.19,18204,DB00495,Zidovudine
,11120972,steady-state concentrations,"The selected target concentrations were average steady-state concentrations of 0.19 mg/liter for zidovudine and 0.44 mg/liter for lamivudine and a trough concentration of 0.15 mg/liter for indinavir; mean concentrations achieved at week 28 in the concentration-controlled arm were 0.20, 0.54, and 0.19 mg/liter, respectively.","Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11120972/),[mg] / [l],0.44,18205,DB00495,Zidovudine
,11120972,trough concentration,"The selected target concentrations were average steady-state concentrations of 0.19 mg/liter for zidovudine and 0.44 mg/liter for lamivudine and a trough concentration of 0.15 mg/liter for indinavir; mean concentrations achieved at week 28 in the concentration-controlled arm were 0.20, 0.54, and 0.19 mg/liter, respectively.","Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11120972/),[mg] / [l],0.15,18206,DB00495,Zidovudine
,11120972,concentrations,"The selected target concentrations were average steady-state concentrations of 0.19 mg/liter for zidovudine and 0.44 mg/liter for lamivudine and a trough concentration of 0.15 mg/liter for indinavir; mean concentrations achieved at week 28 in the concentration-controlled arm were 0.20, 0.54, and 0.19 mg/liter, respectively.","Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11120972/),[mg] / [l],0.20,18207,DB00495,Zidovudine
,11120972,concentrations,"The selected target concentrations were average steady-state concentrations of 0.19 mg/liter for zidovudine and 0.44 mg/liter for lamivudine and a trough concentration of 0.15 mg/liter for indinavir; mean concentrations achieved at week 28 in the concentration-controlled arm were 0.20, 0.54, and 0.19 mg/liter, respectively.","Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11120972/),[mg] / [l],0.54,18208,DB00495,Zidovudine
,11120972,concentrations,"The selected target concentrations were average steady-state concentrations of 0.19 mg/liter for zidovudine and 0.44 mg/liter for lamivudine and a trough concentration of 0.15 mg/liter for indinavir; mean concentrations achieved at week 28 in the concentration-controlled arm were 0.20, 0.54, and 0.19 mg/liter, respectively.","Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11120972/),[mg] / [l],0.19,18209,DB00495,Zidovudine
,23864647,half-life,The GM (95% CI) half-life of nevirapine was 63.2 (52.8-75.7) versus 25.5 (21.6-30.1) h in the control group versus the intervention group (P < 0.001).,Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23864647/),h,63.2,19245,DB00495,Zidovudine
,23864647,half-life,The GM (95% CI) half-life of nevirapine was 63.2 (52.8-75.7) versus 25.5 (21.6-30.1) h in the control group versus the intervention group (P < 0.001).,Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23864647/),h,25.5,19246,DB00495,Zidovudine
,15150840,m/z,"The acquisition was performed in multiple reaction monitoring (MRM) mode, monitoring the transitions m/z 230.0 --> 111.8 for 3TC, m/z 268.1 --> 126.8 for AZT, and m/z 237.2 --> 136.8 for ddI.",A rapid and sensitive method for simultaneous determination of lamivudine and zidovudine in human serum by on-line solid-phase extraction coupled to liquid chromatography/tandem mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150840/),,230.0,20249,DB00495,Zidovudine
,15150840,m/z,"The acquisition was performed in multiple reaction monitoring (MRM) mode, monitoring the transitions m/z 230.0 --> 111.8 for 3TC, m/z 268.1 --> 126.8 for AZT, and m/z 237.2 --> 136.8 for ddI.",A rapid and sensitive method for simultaneous determination of lamivudine and zidovudine in human serum by on-line solid-phase extraction coupled to liquid chromatography/tandem mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150840/),,268.1,20250,DB00495,Zidovudine
,15150840,m/z,"The acquisition was performed in multiple reaction monitoring (MRM) mode, monitoring the transitions m/z 230.0 --> 111.8 for 3TC, m/z 268.1 --> 126.8 for AZT, and m/z 237.2 --> 136.8 for ddI.",A rapid and sensitive method for simultaneous determination of lamivudine and zidovudine in human serum by on-line solid-phase extraction coupled to liquid chromatography/tandem mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150840/),,126.8,20251,DB00495,Zidovudine
,15150840,m/z,"The acquisition was performed in multiple reaction monitoring (MRM) mode, monitoring the transitions m/z 230.0 --> 111.8 for 3TC, m/z 268.1 --> 126.8 for AZT, and m/z 237.2 --> 136.8 for ddI.",A rapid and sensitive method for simultaneous determination of lamivudine and zidovudine in human serum by on-line solid-phase extraction coupled to liquid chromatography/tandem mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150840/),,237.2,20252,DB00495,Zidovudine
,15150840,limits of detection,"The limits of detection and quantitation were 3 and 10 ng/mL for 3TC, and 5 and 15 ng/mL for AZT.",A rapid and sensitive method for simultaneous determination of lamivudine and zidovudine in human serum by on-line solid-phase extraction coupled to liquid chromatography/tandem mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150840/),[ng] / [ml],3,20253,DB00495,Zidovudine
,15150840,limits of detection,"The limits of detection and quantitation were 3 and 10 ng/mL for 3TC, and 5 and 15 ng/mL for AZT.",A rapid and sensitive method for simultaneous determination of lamivudine and zidovudine in human serum by on-line solid-phase extraction coupled to liquid chromatography/tandem mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150840/),[ng] / [ml],10,20254,DB00495,Zidovudine
,15150840,limits of detection,"The limits of detection and quantitation were 3 and 10 ng/mL for 3TC, and 5 and 15 ng/mL for AZT.",A rapid and sensitive method for simultaneous determination of lamivudine and zidovudine in human serum by on-line solid-phase extraction coupled to liquid chromatography/tandem mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150840/),[ng] / [ml],5,20255,DB00495,Zidovudine
,15150840,limits of detection,"The limits of detection and quantitation were 3 and 10 ng/mL for 3TC, and 5 and 15 ng/mL for AZT.",A rapid and sensitive method for simultaneous determination of lamivudine and zidovudine in human serum by on-line solid-phase extraction coupled to liquid chromatography/tandem mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150840/),[ng] / [ml],15,20256,DB00495,Zidovudine
,15150840,run time,"The method was linear in the studied ranges (10-1500 ng/mL for 3TC and 15-3000 ng/mL for AZT), with r(2) > 0.99 for each drug, and the run time was 4 min.",A rapid and sensitive method for simultaneous determination of lamivudine and zidovudine in human serum by on-line solid-phase extraction coupled to liquid chromatography/tandem mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150840/),min,4,20257,DB00495,Zidovudine
,15150840,absolute recoveries,"The absolute recoveries were 95-99% for 3TC (45, 600 and 1200 ng/mL) and 104-112% for AZT (45, 1000 and 2400 ng/mL).",A rapid and sensitive method for simultaneous determination of lamivudine and zidovudine in human serum by on-line solid-phase extraction coupled to liquid chromatography/tandem mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150840/),%,95-99,20258,DB00495,Zidovudine
,15150840,absolute recoveries,"The absolute recoveries were 95-99% for 3TC (45, 600 and 1200 ng/mL) and 104-112% for AZT (45, 1000 and 2400 ng/mL).",A rapid and sensitive method for simultaneous determination of lamivudine and zidovudine in human serum by on-line solid-phase extraction coupled to liquid chromatography/tandem mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150840/),[ng] / [ml],45,20259,DB00495,Zidovudine
,15150840,absolute recoveries,"The absolute recoveries were 95-99% for 3TC (45, 600 and 1200 ng/mL) and 104-112% for AZT (45, 1000 and 2400 ng/mL).",A rapid and sensitive method for simultaneous determination of lamivudine and zidovudine in human serum by on-line solid-phase extraction coupled to liquid chromatography/tandem mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150840/),[ng] / [ml],600,20260,DB00495,Zidovudine
,15150840,absolute recoveries,"The absolute recoveries were 95-99% for 3TC (45, 600 and 1200 ng/mL) and 104-112% for AZT (45, 1000 and 2400 ng/mL).",A rapid and sensitive method for simultaneous determination of lamivudine and zidovudine in human serum by on-line solid-phase extraction coupled to liquid chromatography/tandem mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150840/),[ng] / [ml],1200,20261,DB00495,Zidovudine
,15150840,absolute recoveries,"The absolute recoveries were 95-99% for 3TC (45, 600 and 1200 ng/mL) and 104-112% for AZT (45, 1000 and 2400 ng/mL).",A rapid and sensitive method for simultaneous determination of lamivudine and zidovudine in human serum by on-line solid-phase extraction coupled to liquid chromatography/tandem mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150840/),%,104-112,20262,DB00495,Zidovudine
,15150840,absolute recoveries,"The absolute recoveries were 95-99% for 3TC (45, 600 and 1200 ng/mL) and 104-112% for AZT (45, 1000 and 2400 ng/mL).",A rapid and sensitive method for simultaneous determination of lamivudine and zidovudine in human serum by on-line solid-phase extraction coupled to liquid chromatography/tandem mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150840/),[ng] / [ml],1000,20263,DB00495,Zidovudine
,15150840,absolute recoveries,"The absolute recoveries were 95-99% for 3TC (45, 600 and 1200 ng/mL) and 104-112% for AZT (45, 1000 and 2400 ng/mL).",A rapid and sensitive method for simultaneous determination of lamivudine and zidovudine in human serum by on-line solid-phase extraction coupled to liquid chromatography/tandem mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150840/),[ng] / [ml],2400,20264,DB00495,Zidovudine
higher,12039632,Extraction recoveries,Extraction recoveries of the analytes and IS from plasma were higher than 92%.,Determination of zidovudine/lamivudine/nevirapine in human plasma using ion-pair HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12039632/),%,92,20411,DB00495,Zidovudine
,10563709,intracellular half-life (t1/2),"The median lamivudine-TP intracellular half-life (t1/2) for the 150-mg and 300-mg regimens did not differ significantly (15.3 and 16.1 h, respectively).",The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10563709/),h,15.3,20970,DB00495,Zidovudine
,10563709,intracellular half-life (t1/2),"The median lamivudine-TP intracellular half-life (t1/2) for the 150-mg and 300-mg regimens did not differ significantly (15.3 and 16.1 h, respectively).",The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10563709/),h,16.1,20971,DB00495,Zidovudine
,8877888,k12,"Transfer rate constants (1/h) were as follows: k12, 0.58 +/- 0.41; k21, 47.64 +/- 46.61; k23, 67.50 +/- 42.03; k32, 13.09 +/- 8.80; k24, 0.62 +/- 0.03; k42, 0.32 +/- 0.06; k15, 5.75 +/- 7.00; k51, 4.12 +/- 1.01; and k10, 1.51 +/- 0.80.",Maternal-fetal pharmacokinetics of zidovudine in rats. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877888/),[1] / [h],0.58,28656,DB00495,Zidovudine
,8877888,k21,"Transfer rate constants (1/h) were as follows: k12, 0.58 +/- 0.41; k21, 47.64 +/- 46.61; k23, 67.50 +/- 42.03; k32, 13.09 +/- 8.80; k24, 0.62 +/- 0.03; k42, 0.32 +/- 0.06; k15, 5.75 +/- 7.00; k51, 4.12 +/- 1.01; and k10, 1.51 +/- 0.80.",Maternal-fetal pharmacokinetics of zidovudine in rats. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877888/),,47.64,28657,DB00495,Zidovudine
,8877888,k23,"Transfer rate constants (1/h) were as follows: k12, 0.58 +/- 0.41; k21, 47.64 +/- 46.61; k23, 67.50 +/- 42.03; k32, 13.09 +/- 8.80; k24, 0.62 +/- 0.03; k42, 0.32 +/- 0.06; k15, 5.75 +/- 7.00; k51, 4.12 +/- 1.01; and k10, 1.51 +/- 0.80.",Maternal-fetal pharmacokinetics of zidovudine in rats. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877888/),,67.50,28658,DB00495,Zidovudine
,8877888,k32,"Transfer rate constants (1/h) were as follows: k12, 0.58 +/- 0.41; k21, 47.64 +/- 46.61; k23, 67.50 +/- 42.03; k32, 13.09 +/- 8.80; k24, 0.62 +/- 0.03; k42, 0.32 +/- 0.06; k15, 5.75 +/- 7.00; k51, 4.12 +/- 1.01; and k10, 1.51 +/- 0.80.",Maternal-fetal pharmacokinetics of zidovudine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877888/),,13.09,28659,DB00495,Zidovudine
,8877888,k24,"Transfer rate constants (1/h) were as follows: k12, 0.58 +/- 0.41; k21, 47.64 +/- 46.61; k23, 67.50 +/- 42.03; k32, 13.09 +/- 8.80; k24, 0.62 +/- 0.03; k42, 0.32 +/- 0.06; k15, 5.75 +/- 7.00; k51, 4.12 +/- 1.01; and k10, 1.51 +/- 0.80.",Maternal-fetal pharmacokinetics of zidovudine in rats. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877888/),,0.62,28660,DB00495,Zidovudine
,8877888,k42,"Transfer rate constants (1/h) were as follows: k12, 0.58 +/- 0.41; k21, 47.64 +/- 46.61; k23, 67.50 +/- 42.03; k32, 13.09 +/- 8.80; k24, 0.62 +/- 0.03; k42, 0.32 +/- 0.06; k15, 5.75 +/- 7.00; k51, 4.12 +/- 1.01; and k10, 1.51 +/- 0.80.",Maternal-fetal pharmacokinetics of zidovudine in rats. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877888/),,0.32,28661,DB00495,Zidovudine
,8877888,k15,"Transfer rate constants (1/h) were as follows: k12, 0.58 +/- 0.41; k21, 47.64 +/- 46.61; k23, 67.50 +/- 42.03; k32, 13.09 +/- 8.80; k24, 0.62 +/- 0.03; k42, 0.32 +/- 0.06; k15, 5.75 +/- 7.00; k51, 4.12 +/- 1.01; and k10, 1.51 +/- 0.80.",Maternal-fetal pharmacokinetics of zidovudine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877888/),,5.75,28662,DB00495,Zidovudine
,8877888,k51,"Transfer rate constants (1/h) were as follows: k12, 0.58 +/- 0.41; k21, 47.64 +/- 46.61; k23, 67.50 +/- 42.03; k32, 13.09 +/- 8.80; k24, 0.62 +/- 0.03; k42, 0.32 +/- 0.06; k15, 5.75 +/- 7.00; k51, 4.12 +/- 1.01; and k10, 1.51 +/- 0.80.",Maternal-fetal pharmacokinetics of zidovudine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877888/),,4.12,28663,DB00495,Zidovudine
,8877888,k10,"Transfer rate constants (1/h) were as follows: k12, 0.58 +/- 0.41; k21, 47.64 +/- 46.61; k23, 67.50 +/- 42.03; k32, 13.09 +/- 8.80; k24, 0.62 +/- 0.03; k42, 0.32 +/- 0.06; k15, 5.75 +/- 7.00; k51, 4.12 +/- 1.01; and k10, 1.51 +/- 0.80.",Maternal-fetal pharmacokinetics of zidovudine in rats. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877888/),,1.51,28664,DB00495,Zidovudine
,2658792,50% effective dose (ED50),The 50% effective dose (ED50) of zidovudine (9.6 to 11.8 mg/kg of body weight) compared favorably with that of trimethoprim (19.4 to 22.2 mg/kg) in mice with systemic E. coli infection.,In vivo efficacy of zidovudine (3'-azido-3'-deoxythymidine) in experimental gram-negative-bacterial infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2658792/),[mg] / [kg],9.6 to 11.8,29577,DB00495,Zidovudine
,2658792,50% effective dose (ED50),The 50% effective dose (ED50) of zidovudine (9.6 to 11.8 mg/kg of body weight) compared favorably with that of trimethoprim (19.4 to 22.2 mg/kg) in mice with systemic E. coli infection.,In vivo efficacy of zidovudine (3'-azido-3'-deoxythymidine) in experimental gram-negative-bacterial infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2658792/),[mg] / [kg],19.4 to 22.2,29578,DB00495,Zidovudine
,29695616,total protein content,"The S9 total protein content was significantly lower in alcoholic or HCV cirrhotic versus control livers (i.e., 38.3 ± 8.3, 32.3 ± 12.8, vs. 51.1 ± 20.7 mg/g liver, respectively).",Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29695616/),[mg] / [g],38.3,29901,DB00495,Zidovudine
,29695616,total protein content,"The S9 total protein content was significantly lower in alcoholic or HCV cirrhotic versus control livers (i.e., 38.3 ± 8.3, 32.3 ± 12.8, vs. 51.1 ± 20.7 mg/g liver, respectively).",Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29695616/),[mg] / [g],32.3,29902,DB00495,Zidovudine
,29695616,total protein content,"The S9 total protein content was significantly lower in alcoholic or HCV cirrhotic versus control livers (i.e., 38.3 ± 8.3, 32.3 ± 12.8, vs. 51.1 ± 20.7 mg/g liver, respectively).",Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29695616/),[mg] / [g],51.1,29903,DB00495,Zidovudine
,8095218,maximum plasma concentrations (Cmax),"After oral administration, mean maximum plasma concentrations (Cmax) of 9.1, 18.9, and 40.3 mg/liter were observed at 18.3, 21.7, and 15.0 min (tmax) for the 15, 30, and 60 mg/kg doses, respectively.",Zidovudine bioavailability and linear pharmacokinetics in female B6C3F1 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095218/),[mg] / [l],9.1,29917,DB00495,Zidovudine
,8095218,maximum plasma concentrations (Cmax),"After oral administration, mean maximum plasma concentrations (Cmax) of 9.1, 18.9, and 40.3 mg/liter were observed at 18.3, 21.7, and 15.0 min (tmax) for the 15, 30, and 60 mg/kg doses, respectively.",Zidovudine bioavailability and linear pharmacokinetics in female B6C3F1 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095218/),[mg] / [l],18.9,29918,DB00495,Zidovudine
,8095218,maximum plasma concentrations (Cmax),"After oral administration, mean maximum plasma concentrations (Cmax) of 9.1, 18.9, and 40.3 mg/liter were observed at 18.3, 21.7, and 15.0 min (tmax) for the 15, 30, and 60 mg/kg doses, respectively.",Zidovudine bioavailability and linear pharmacokinetics in female B6C3F1 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095218/),[mg] / [l],40.3,29919,DB00495,Zidovudine
,8095218,tmax,"After oral administration, mean maximum plasma concentrations (Cmax) of 9.1, 18.9, and 40.3 mg/liter were observed at 18.3, 21.7, and 15.0 min (tmax) for the 15, 30, and 60 mg/kg doses, respectively.",Zidovudine bioavailability and linear pharmacokinetics in female B6C3F1 mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095218/),min,18.3,29920,DB00495,Zidovudine
,8095218,tmax,"After oral administration, mean maximum plasma concentrations (Cmax) of 9.1, 18.9, and 40.3 mg/liter were observed at 18.3, 21.7, and 15.0 min (tmax) for the 15, 30, and 60 mg/kg doses, respectively.",Zidovudine bioavailability and linear pharmacokinetics in female B6C3F1 mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095218/),min,21.7,29921,DB00495,Zidovudine
,8095218,tmax,"After oral administration, mean maximum plasma concentrations (Cmax) of 9.1, 18.9, and 40.3 mg/liter were observed at 18.3, 21.7, and 15.0 min (tmax) for the 15, 30, and 60 mg/kg doses, respectively.",Zidovudine bioavailability and linear pharmacokinetics in female B6C3F1 mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095218/),min,15.0,29922,DB00495,Zidovudine
,8095218,Cmax,"Following intravenous administration, mean Cmax values of 15.9, 41.8, and 76.0 mg/liter were observed for the 15, 30, and 60 mg/kg doses, respectively.",Zidovudine bioavailability and linear pharmacokinetics in female B6C3F1 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095218/),[mg] / [l],15.9,29923,DB00495,Zidovudine
,8095218,Cmax,"Following intravenous administration, mean Cmax values of 15.9, 41.8, and 76.0 mg/liter were observed for the 15, 30, and 60 mg/kg doses, respectively.",Zidovudine bioavailability and linear pharmacokinetics in female B6C3F1 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095218/),[mg] / [l],41.8,29924,DB00495,Zidovudine
,8095218,Cmax,"Following intravenous administration, mean Cmax values of 15.9, 41.8, and 76.0 mg/liter were observed for the 15, 30, and 60 mg/kg doses, respectively.",Zidovudine bioavailability and linear pharmacokinetics in female B6C3F1 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095218/),[mg] / [l],76.0,29925,DB00495,Zidovudine
,8095218,elimination half-life,The mean elimination half-life values ranged from 17.3 to 19.9 min for the three intravenous doses and from 16.5 to 21.9 min for the three oral doses.,Zidovudine bioavailability and linear pharmacokinetics in female B6C3F1 mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095218/),min,17.3 to 19.9,29926,DB00495,Zidovudine
,8095218,elimination half-life,The mean elimination half-life values ranged from 17.3 to 19.9 min for the three intravenous doses and from 16.5 to 21.9 min for the three oral doses.,Zidovudine bioavailability and linear pharmacokinetics in female B6C3F1 mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095218/),min,16.5 to 21.9,29927,DB00495,Zidovudine
,8095218,apparent volume of distribution (Vd),The mean values for the apparent volume of distribution (Vd) ranged from 0.8 to 1.0 liter/kg following oral and intravenous administration.,Zidovudine bioavailability and linear pharmacokinetics in female B6C3F1 mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095218/),[l] / [kg],0.8 to 1.0,29928,DB00495,Zidovudine
,8095218,total body clearance,The mean total body clearance values ranged from 28.9 to 34.3 ml/min/kg following intravenous administration.,Zidovudine bioavailability and linear pharmacokinetics in female B6C3F1 mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095218/),[ml] / [kg·min],28.9 to 34.3,29929,DB00495,Zidovudine
,9300934,half-life,"Administration of fluconazole resulted in a significant increase in the half-life of zidovudine and antipyrine (0.97 +/- 0.17 h prior to vs. 1.11 +/- 0. 14 h after fluconazole administration and 11.9 +/- 1.9 h prior to vs. 13.7 +/- 3.0 h after fluconazole, respectively) while the 6-beta-hydroxycortisol excretion decreased significantly (472.3 +/- 80.6 microg/24 h before and 340.6 +/- 82.1 microg/24 h after administration of fluconazole).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),h,0.97,31295,DB00495,Zidovudine
,9300934,half-life,"Administration of fluconazole resulted in a significant increase in the half-life of zidovudine and antipyrine (0.97 +/- 0.17 h prior to vs. 1.11 +/- 0. 14 h after fluconazole administration and 11.9 +/- 1.9 h prior to vs. 13.7 +/- 3.0 h after fluconazole, respectively) while the 6-beta-hydroxycortisol excretion decreased significantly (472.3 +/- 80.6 microg/24 h before and 340.6 +/- 82.1 microg/24 h after administration of fluconazole).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),h,1.11,31296,DB00495,Zidovudine
,9300934,half-life,"Administration of fluconazole resulted in a significant increase in the half-life of zidovudine and antipyrine (0.97 +/- 0.17 h prior to vs. 1.11 +/- 0. 14 h after fluconazole administration and 11.9 +/- 1.9 h prior to vs. 13.7 +/- 3.0 h after fluconazole, respectively) while the 6-beta-hydroxycortisol excretion decreased significantly (472.3 +/- 80.6 microg/24 h before and 340.6 +/- 82.1 microg/24 h after administration of fluconazole).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),h,11.9,31297,DB00495,Zidovudine
,9300934,half-life,"Administration of fluconazole resulted in a significant increase in the half-life of zidovudine and antipyrine (0.97 +/- 0.17 h prior to vs. 1.11 +/- 0. 14 h after fluconazole administration and 11.9 +/- 1.9 h prior to vs. 13.7 +/- 3.0 h after fluconazole, respectively) while the 6-beta-hydroxycortisol excretion decreased significantly (472.3 +/- 80.6 microg/24 h before and 340.6 +/- 82.1 microg/24 h after administration of fluconazole).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),h,13.7,31298,DB00495,Zidovudine
,9300934,excretion,"Administration of fluconazole resulted in a significant increase in the half-life of zidovudine and antipyrine (0.97 +/- 0.17 h prior to vs. 1.11 +/- 0. 14 h after fluconazole administration and 11.9 +/- 1.9 h prior to vs. 13.7 +/- 3.0 h after fluconazole, respectively) while the 6-beta-hydroxycortisol excretion decreased significantly (472.3 +/- 80.6 microg/24 h before and 340.6 +/- 82.1 microg/24 h after administration of fluconazole).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),[μg] / [24·h],472.3,31299,DB00495,Zidovudine
,9300934,excretion,"Administration of fluconazole resulted in a significant increase in the half-life of zidovudine and antipyrine (0.97 +/- 0.17 h prior to vs. 1.11 +/- 0. 14 h after fluconazole administration and 11.9 +/- 1.9 h prior to vs. 13.7 +/- 3.0 h after fluconazole, respectively) while the 6-beta-hydroxycortisol excretion decreased significantly (472.3 +/- 80.6 microg/24 h before and 340.6 +/- 82.1 microg/24 h after administration of fluconazole).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),[μg] / [24·h],340.6,31300,DB00495,Zidovudine
,9300934,half-life,"Administration of zidovudine did, however, result in a significant reduction in antipyrine half-life (11.7 +/- 2.0 h before vs. 9.9 +/- 2.3h after ZDV) and a significant increase in 6-beta-hydroxycortisol excretion (438,7 +/- 138.2 microg/24 h before and 684.6 +/- 157.3 microg/24 h after ZDV).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),h,11.7,31301,DB00495,Zidovudine
,9300934,half-life,"Administration of zidovudine did, however, result in a significant reduction in antipyrine half-life (11.7 +/- 2.0 h before vs. 9.9 +/- 2.3h after ZDV) and a significant increase in 6-beta-hydroxycortisol excretion (438,7 +/- 138.2 microg/24 h before and 684.6 +/- 157.3 microg/24 h after ZDV).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),h,9.9,31302,DB00495,Zidovudine
,9300934,excretion,"Administration of zidovudine did, however, result in a significant reduction in antipyrine half-life (11.7 +/- 2.0 h before vs. 9.9 +/- 2.3h after ZDV) and a significant increase in 6-beta-hydroxycortisol excretion (438,7 +/- 138.2 microg/24 h before and 684.6 +/- 157.3 microg/24 h after ZDV).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),[μg] / [24·h],"438,7",31303,DB00495,Zidovudine
,9300934,excretion,"Administration of zidovudine did, however, result in a significant reduction in antipyrine half-life (11.7 +/- 2.0 h before vs. 9.9 +/- 2.3h after ZDV) and a significant increase in 6-beta-hydroxycortisol excretion (438,7 +/- 138.2 microg/24 h before and 684.6 +/- 157.3 microg/24 h after ZDV).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),[μg] / [24·h],684.6,31304,DB00495,Zidovudine
above,19059324,similarity factors f2,"After 30min dissolution, AZT and 3TC released from Duovir and the novel tablets was above 95%, the similarity factors f2 were above 50 for both AZT and 3TC.",Development of fixed dose combination tablets containing zidovudine and lamivudine for paediatric applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19059324/),,50,31395,DB00495,Zidovudine
,19059324,breakability,"A tablet breakability test showed low weight variability (125.1+/-5mg, R.S.D.=4.4%), with limited weight loss (0.3%).",Development of fixed dose combination tablets containing zidovudine and lamivudine for paediatric applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19059324/),,125,31396,DB00495,Zidovudine
,9859956,first order elimination half-life,The first order elimination half-life of ZDV from both the mother and fetus was approximately 1.2 hours.,Implications of the kinetics of zidovudine in the pregnant baboon following oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9859956/),h,1.2,31917,DB00495,Zidovudine
,8419601,total body clearance,"The total body clearance of zidovudine increased significantly with age, from an average of 10.9 ml/min per kilogram in infants < or = 14 days of age to 19.0 ml/min per kilogram in older infants (p < 0.0001).",Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419601/),[ml] / [kg·min],10.9,32266,DB00495,Zidovudine
,8419601,total body clearance,"The total body clearance of zidovudine increased significantly with age, from an average of 10.9 ml/min per kilogram in infants < or = 14 days of age to 19.0 ml/min per kilogram in older infants (p < 0.0001).",Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419601/),[ml] / [kg·min],19.0,32267,DB00495,Zidovudine
,8419601,serum half-life,"Concurrently, there was a significant decrease in serum half-life from 3.12 hours in infants < or = 14 days to 1.87 hours in older infants (p = 0.0002).",Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419601/),h,3.12,32268,DB00495,Zidovudine
,8419601,serum half-life,"Concurrently, there was a significant decrease in serum half-life from 3.12 hours in infants < or = 14 days to 1.87 hours in older infants (p = 0.0002).",Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419601/),h,1.87,32269,DB00495,Zidovudine
,8419601,bioavailability,"Oral absorption was satisfactory and bioavailability decreased significantly with age, from 89% in infants < or = 14 days to 61% in those > 14 days of age (p = 0.0002).",Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419601/),%,89,32270,DB00495,Zidovudine
,8419601,bioavailability,"Oral absorption was satisfactory and bioavailability decreased significantly with age, from 89% in infants < or = 14 days to 61% in those > 14 days of age (p = 0.0002).",Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419601/),%,61,32271,DB00495,Zidovudine
excess of,8419601,Plasma concentrations,"Plasma concentrations of zidovudine were calculated to be in excess of 1 mumol/L (0.267 micrograms/ml) for 4.12 +/- 1.86 hours and 2.25 +/- 0.78 hours after oral doses of 2 mg/kg in infants younger than 2 weeks and 3 mg/kg in older infants, respectively.",Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419601/),[μM] / [l],1,32272,DB00495,Zidovudine
,8419601,Plasma concentrations,"Plasma concentrations of zidovudine were calculated to be in excess of 1 mumol/L (0.267 micrograms/ml) for 4.12 +/- 1.86 hours and 2.25 +/- 0.78 hours after oral doses of 2 mg/kg in infants younger than 2 weeks and 3 mg/kg in older infants, respectively.",Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419601/),[μg] / [ml],0.267,32273,DB00495,Zidovudine
,8851608,maximum concentration,Concurrent administration of didanosine and atevirdine significantly reduced the maximum concentration of atevirdine in serum from 3.45 +/- 2.8 to 0.854 +/- 0.33 microM (P = 0.004).,Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851608/),μM,3.45,32617,DB00495,Zidovudine
,8851608,maximum concentration,Concurrent administration of didanosine and atevirdine significantly reduced the maximum concentration of atevirdine in serum from 3.45 +/- 2.8 to 0.854 +/- 0.33 microM (P = 0.004).,Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851608/),μM,0.854,32618,DB00495,Zidovudine
,8851608,area under the concentration-time curve from 0 to 24 h,"Likewise, the mean atevirdine area under the concentration-time curve from 0 to 24 h after administration of the combination was reduced to 6.47 +/- 2.2 microM.h (P = 0.004) relative to a value of 11.3 +/- 4.8 microM.h for atevirdine alone.",Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851608/),h·μM,6.47,32619,DB00495,Zidovudine
,8851608,area under the concentration-time curve from 0 to 24 h,"Likewise, the mean atevirdine area under the concentration-time curve from 0 to 24 h after administration of the combination was reduced to 6.47 +/- 2.2 microM.h (P = 0.004) relative to a value of 11.3 +/- 4.8 microM.h for atevirdine alone.",Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8851608/),h·μM,11.3,32620,DB00495,Zidovudine
,8257138,Peak levels,"Peak levels in plasma were moderately reduced after administration of 100 mg AZT in the nonfasting group (1.79 mumol/liter in the fasting group [F], 1.12 mumol/liter in the group that received breakfast [B]) and were markedly reduced after administration of 250 mg AZT (6.51 mumol/liter [F], 1.79 mumol/liter [B]).",Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257138/),[μM] / [l],1.79,34006,DB00495,Zidovudine
,8257138,Peak levels,"Peak levels in plasma were moderately reduced after administration of 100 mg AZT in the nonfasting group (1.79 mumol/liter in the fasting group [F], 1.12 mumol/liter in the group that received breakfast [B]) and were markedly reduced after administration of 250 mg AZT (6.51 mumol/liter [F], 1.79 mumol/liter [B]).",Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257138/),[μM] / [l],1.12,34007,DB00495,Zidovudine
,8257138,Peak levels,"Peak levels in plasma were moderately reduced after administration of 100 mg AZT in the nonfasting group (1.79 mumol/liter in the fasting group [F], 1.12 mumol/liter in the group that received breakfast [B]) and were markedly reduced after administration of 250 mg AZT (6.51 mumol/liter [F], 1.79 mumol/liter [B]).",Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257138/),[μM] / [l],6.51,34008,DB00495,Zidovudine
,8257138,terminal half-life,"The terminal half-life in plasma was prolonged almost twofold after breakfast with 100 and 250 mg of AZT (100 mg, 36.4 min [F] and 51.6 min [B]; 250 mg, 35.3 min [F] and 63.6 min [B]).",Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257138/),min,36.4,34009,DB00495,Zidovudine
,8257138,terminal half-life,"The terminal half-life in plasma was prolonged almost twofold after breakfast with 100 and 250 mg of AZT (100 mg, 36.4 min [F] and 51.6 min [B]; 250 mg, 35.3 min [F] and 63.6 min [B]).",Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257138/),min,51.6,34010,DB00495,Zidovudine
,8257138,terminal half-life,"The terminal half-life in plasma was prolonged almost twofold after breakfast with 100 and 250 mg of AZT (100 mg, 36.4 min [F] and 51.6 min [B]; 250 mg, 35.3 min [F] and 63.6 min [B]).",Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257138/),min,35.3,34011,DB00495,Zidovudine
,8257138,terminal half-life,"The terminal half-life in plasma was prolonged almost twofold after breakfast with 100 and 250 mg of AZT (100 mg, 36.4 min [F] and 51.6 min [B]; 250 mg, 35.3 min [F] and 63.6 min [B]).",Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257138/),min,63.6,34012,DB00495,Zidovudine
,8257138,Recoveries,"Recoveries (AZT and GAZT) in urine varied with both dosages, reflecting more a problem of accounting for the metabolite GAZT in urine than a relevant difference (100 mg, 115% [F] and 76.5% [B]; 250 mg, 71% [F] and 99.4% [B]).",Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257138/),%,115,34013,DB00495,Zidovudine
,8257138,Recoveries,"Recoveries (AZT and GAZT) in urine varied with both dosages, reflecting more a problem of accounting for the metabolite GAZT in urine than a relevant difference (100 mg, 115% [F] and 76.5% [B]; 250 mg, 71% [F] and 99.4% [B]).",Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257138/),%,76.5,34014,DB00495,Zidovudine
,8257138,Recoveries,"Recoveries (AZT and GAZT) in urine varied with both dosages, reflecting more a problem of accounting for the metabolite GAZT in urine than a relevant difference (100 mg, 115% [F] and 76.5% [B]; 250 mg, 71% [F] and 99.4% [B]).",Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257138/),%,71,34015,DB00495,Zidovudine
,8257138,Recoveries,"Recoveries (AZT and GAZT) in urine varied with both dosages, reflecting more a problem of accounting for the metabolite GAZT in urine than a relevant difference (100 mg, 115% [F] and 76.5% [B]; 250 mg, 71% [F] and 99.4% [B]).",Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257138/),%,99.4,34016,DB00495,Zidovudine
,2715903,half-lives,"Zidovudine disappearance after intravenous administration was rapid and biexponential, with half-lives of 14 and 90 minutes and a total clearance of 641 +/- 161 ml/min/m2.",Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715903/),min,14,37762,DB00495,Zidovudine
,2715903,half-lives,"Zidovudine disappearance after intravenous administration was rapid and biexponential, with half-lives of 14 and 90 minutes and a total clearance of 641 +/- 161 ml/min/m2.",Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715903/),min,90,37763,DB00495,Zidovudine
,2715903,total clearance,"Zidovudine disappearance after intravenous administration was rapid and biexponential, with half-lives of 14 and 90 minutes and a total clearance of 641 +/- 161 ml/min/m2.",Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715903/),[ml] / [m2·min],641,37764,DB00495,Zidovudine
,2715903,volume of distribution at steady state,The volume of distribution at steady state was 45 +/- 28 L/m2.,Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715903/),[l] / [m2],45,37765,DB00495,Zidovudine
,2852679,Total body clearance,Total body clearance was 227 mL/min/m2 and did not change after 6 to 14 days of dosing.,"Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2852679/),[ml] / [m2·min],227,38536,DB00495,Zidovudine
,2852679,volume of distribution at steady state,The volume of distribution at steady state was 0.54 L/kg.,"Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2852679/),[l] / [kg],0.54,38537,DB00495,Zidovudine
,2852679,Plasma half-life,"Plasma half-life was 1.2 hours, and bioavailability was 88%.","Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2852679/),h,1.2,38538,DB00495,Zidovudine
,2852679,bioavailability,"Plasma half-life was 1.2 hours, and bioavailability was 88%.","Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2852679/),%,88,38539,DB00495,Zidovudine
,19362995,am,"Median maternal plasma concentrations for NFV, M8, 3TC, and ZDV were 456, 244, 176, and 794 ng/mL, respectively, while median amniotic fluid concentrations were 118, 21, 2537, and 1483 ng/mL, respectively.","Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19362995/),[ng] / [ml],118,39432,DB00495,Zidovudine
,19362995,am,"Median maternal plasma concentrations for NFV, M8, 3TC, and ZDV were 456, 244, 176, and 794 ng/mL, respectively, while median amniotic fluid concentrations were 118, 21, 2537, and 1483 ng/mL, respectively.","Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19362995/),[ng] / [ml],21,39433,DB00495,Zidovudine
,19362995,am,"Median maternal plasma concentrations for NFV, M8, 3TC, and ZDV were 456, 244, 176, and 794 ng/mL, respectively, while median amniotic fluid concentrations were 118, 21, 2537, and 1483 ng/mL, respectively.","Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19362995/),[ng] / [ml],2537,39434,DB00495,Zidovudine
,19362995,am,"Median maternal plasma concentrations for NFV, M8, 3TC, and ZDV were 456, 244, 176, and 794 ng/mL, respectively, while median amniotic fluid concentrations were 118, 21, 2537, and 1483 ng/mL, respectively.","Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19362995/),[ng] / [ml],1483,39435,DB00495,Zidovudine
,19362995,amniotic fluid to maternal plasma ratio,The median NFV amniotic fluid to maternal plasma ratio was 0.44; the median M8 ratio was 0.11.,"Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19362995/),,0.44,39436,DB00495,Zidovudine
,19362995,M8 ratio,The median NFV amniotic fluid to maternal plasma ratio was 0.44; the median M8 ratio was 0.11.,"Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19362995/),,0.11,39437,DB00495,Zidovudine
,19362995,amniotic fluid to plasma ratios,"Median 3TC and ZDV amniotic fluid to plasma ratios were 11.9 and 1.5, respectively.","Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19362995/),,11.9,39438,DB00495,Zidovudine
,19362995,amniotic fluid to plasma ratios,"Median 3TC and ZDV amniotic fluid to plasma ratios were 11.9 and 1.5, respectively.","Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19362995/),,1.5,39439,DB00495,Zidovudine
,8921318,AUC,"In an oral pharmacokinetics study, the AUC was 17 and 140 micrograms/ml.hr in female mice and rats given 40 or 300 mg/kg of ZDV, respectively.",Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8921318/),[μg] / [h·ml],17,39718,DB00495,Zidovudine
,8921318,AUC,"In an oral pharmacokinetics study, the AUC was 17 and 140 micrograms/ml.hr in female mice and rats given 40 or 300 mg/kg of ZDV, respectively.",Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8921318/),[μg] / [h·ml],140,39719,DB00495,Zidovudine
,8921318,steady-state concentration,"In contrast, the average steady-state concentration in humans at the recommended daily dose is 0.62 microgram/ml.",Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8921318/),[μg] / [ml],0.62,39720,DB00495,Zidovudine
,8921318,Twenty-four hour,"Twenty-four hour urine concentrations were 1245 and 4417 micrograms/ml in female mice and rats given 40 or 300 mg/kg of ZDV, respectively.",Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8921318/),[μg] / [ml],1245,39721,DB00495,Zidovudine
,8921318,Twenty-four hour,"Twenty-four hour urine concentrations were 1245 and 4417 micrograms/ml in female mice and rats given 40 or 300 mg/kg of ZDV, respectively.",Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8921318/),[μg] / [ml],4417,39722,DB00495,Zidovudine
,8921318,urine concentrations,"Twenty-four hour urine concentrations were 1245 and 4417 micrograms/ml in female mice and rats given 40 or 300 mg/kg of ZDV, respectively.",Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8921318/),[μg] / [ml],1245,39723,DB00495,Zidovudine
,8921318,urine concentrations,"Twenty-four hour urine concentrations were 1245 and 4417 micrograms/ml in female mice and rats given 40 or 300 mg/kg of ZDV, respectively.",Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8921318/),[μg] / [ml],4417,39724,DB00495,Zidovudine
,1316960,peak plasma,"Following bolus administration, the peak plasma ZDV concentration (30.5 mg/ml) was reached within 10 min, and elimination was rapid (mean half-life, 0.7 h).",Efficacy of continuous zidovudine infusion at early stages of retroviral infection in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1316960/),[mg] / [ml],30.5,40732,DB00495,Zidovudine
,1316960,half-life,"Following bolus administration, the peak plasma ZDV concentration (30.5 mg/ml) was reached within 10 min, and elimination was rapid (mean half-life, 0.7 h).",Efficacy of continuous zidovudine infusion at early stages of retroviral infection in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1316960/),h,0.7,40733,DB00495,Zidovudine
,8540705,half-life,"IsoddA was inefficiently phosphorylated in CEM cells; however, the half-life of the triphosphate was 9.4 h, and IsoddATP was a potent inhibitor of HIV-1 reverse transcriptase, with a Ki of 16 nM.","Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540705/),h,9.4,40839,DB00495,Zidovudine
,8540705,Ki,"IsoddA was inefficiently phosphorylated in CEM cells; however, the half-life of the triphosphate was 9.4 h, and IsoddATP was a potent inhibitor of HIV-1 reverse transcriptase, with a Ki of 16 nM.","Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540705/),nM,16,40840,DB00495,Zidovudine
greater,8540705,cytotoxicity 50% inhibitory concentrations,"The cytotoxicity 50% inhibitory concentrations of IsoddA were greater than 100 microM for CEM, MOLT-4, IM9, and the HepG2-derived HBV-infected 2.2.15 (subclone P5A) cell lines but were 12 and 11 microM for human granulocyte-macrophage (CFU-GM) and erythroid (BFU-E) progenitor cells, respectively.","Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540705/),μM,100,40841,DB00495,Zidovudine
,8540705,cytotoxicity 50% inhibitory concentrations,"The cytotoxicity 50% inhibitory concentrations of IsoddA were greater than 100 microM for CEM, MOLT-4, IM9, and the HepG2-derived HBV-infected 2.2.15 (subclone P5A) cell lines but were 12 and 11 microM for human granulocyte-macrophage (CFU-GM) and erythroid (BFU-E) progenitor cells, respectively.","Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540705/),μM,12,40842,DB00495,Zidovudine
,8540705,cytotoxicity 50% inhibitory concentrations,"The cytotoxicity 50% inhibitory concentrations of IsoddA were greater than 100 microM for CEM, MOLT-4, IM9, and the HepG2-derived HBV-infected 2.2.15 (subclone P5A) cell lines but were 12 and 11 microM for human granulocyte-macrophage (CFU-GM) and erythroid (BFU-E) progenitor cells, respectively.","Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8540705/),μM,11,40843,DB00495,Zidovudine
,1988507,peak zidovudine levels,"For the pregnant versus postpartum periods, peak zidovudine levels (mean +/- 1 SD) were 3.9 +/- 1.7 mumol/l versus 4.3 +/- 0.04 mumol/l (P = .56); elimination half-lives were 1.3 +/- 0.6 versus 1.0 +/- 0.3 h (P = .41); areas under the concentration curve were 4.5 +/- 1.0 mumol/l x h and 6.8 +/- 0.5 mumol/l x h (P = .02); apparent total body clearances were 2.5 +/- 0.6 l/h/kg and 1.7 +/- 0.4 l/h/kg (P = .05); and apparent steady state volumes of distribution were 3.9 +/- 1.0 l/kg and 2.6 +/- 0.8 l/kg (P = .07), respectively.",Pharmacokinetic disposition of zidovudine during pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988507/),[μM] / [l],3.9,41534,DB00495,Zidovudine
,1988507,peak zidovudine levels,"For the pregnant versus postpartum periods, peak zidovudine levels (mean +/- 1 SD) were 3.9 +/- 1.7 mumol/l versus 4.3 +/- 0.04 mumol/l (P = .56); elimination half-lives were 1.3 +/- 0.6 versus 1.0 +/- 0.3 h (P = .41); areas under the concentration curve were 4.5 +/- 1.0 mumol/l x h and 6.8 +/- 0.5 mumol/l x h (P = .02); apparent total body clearances were 2.5 +/- 0.6 l/h/kg and 1.7 +/- 0.4 l/h/kg (P = .05); and apparent steady state volumes of distribution were 3.9 +/- 1.0 l/kg and 2.6 +/- 0.8 l/kg (P = .07), respectively.",Pharmacokinetic disposition of zidovudine during pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988507/),[μM] / [l],4.3,41535,DB00495,Zidovudine
,1988507,elimination half-lives,"For the pregnant versus postpartum periods, peak zidovudine levels (mean +/- 1 SD) were 3.9 +/- 1.7 mumol/l versus 4.3 +/- 0.04 mumol/l (P = .56); elimination half-lives were 1.3 +/- 0.6 versus 1.0 +/- 0.3 h (P = .41); areas under the concentration curve were 4.5 +/- 1.0 mumol/l x h and 6.8 +/- 0.5 mumol/l x h (P = .02); apparent total body clearances were 2.5 +/- 0.6 l/h/kg and 1.7 +/- 0.4 l/h/kg (P = .05); and apparent steady state volumes of distribution were 3.9 +/- 1.0 l/kg and 2.6 +/- 0.8 l/kg (P = .07), respectively.",Pharmacokinetic disposition of zidovudine during pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988507/),h,1.3,41536,DB00495,Zidovudine
,1988507,elimination half-lives,"For the pregnant versus postpartum periods, peak zidovudine levels (mean +/- 1 SD) were 3.9 +/- 1.7 mumol/l versus 4.3 +/- 0.04 mumol/l (P = .56); elimination half-lives were 1.3 +/- 0.6 versus 1.0 +/- 0.3 h (P = .41); areas under the concentration curve were 4.5 +/- 1.0 mumol/l x h and 6.8 +/- 0.5 mumol/l x h (P = .02); apparent total body clearances were 2.5 +/- 0.6 l/h/kg and 1.7 +/- 0.4 l/h/kg (P = .05); and apparent steady state volumes of distribution were 3.9 +/- 1.0 l/kg and 2.6 +/- 0.8 l/kg (P = .07), respectively.",Pharmacokinetic disposition of zidovudine during pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988507/),h,1.0,41537,DB00495,Zidovudine
,1988507,areas under the concentration curve,"For the pregnant versus postpartum periods, peak zidovudine levels (mean +/- 1 SD) were 3.9 +/- 1.7 mumol/l versus 4.3 +/- 0.04 mumol/l (P = .56); elimination half-lives were 1.3 +/- 0.6 versus 1.0 +/- 0.3 h (P = .41); areas under the concentration curve were 4.5 +/- 1.0 mumol/l x h and 6.8 +/- 0.5 mumol/l x h (P = .02); apparent total body clearances were 2.5 +/- 0.6 l/h/kg and 1.7 +/- 0.4 l/h/kg (P = .05); and apparent steady state volumes of distribution were 3.9 +/- 1.0 l/kg and 2.6 +/- 0.8 l/kg (P = .07), respectively.",Pharmacokinetic disposition of zidovudine during pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988507/),[μM] / [h·l],4.5,41538,DB00495,Zidovudine
,1988507,areas under the concentration curve,"For the pregnant versus postpartum periods, peak zidovudine levels (mean +/- 1 SD) were 3.9 +/- 1.7 mumol/l versus 4.3 +/- 0.04 mumol/l (P = .56); elimination half-lives were 1.3 +/- 0.6 versus 1.0 +/- 0.3 h (P = .41); areas under the concentration curve were 4.5 +/- 1.0 mumol/l x h and 6.8 +/- 0.5 mumol/l x h (P = .02); apparent total body clearances were 2.5 +/- 0.6 l/h/kg and 1.7 +/- 0.4 l/h/kg (P = .05); and apparent steady state volumes of distribution were 3.9 +/- 1.0 l/kg and 2.6 +/- 0.8 l/kg (P = .07), respectively.",Pharmacokinetic disposition of zidovudine during pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988507/),[μM] / [h·l],6.8,41539,DB00495,Zidovudine
,1988507,apparent total body clearances,"For the pregnant versus postpartum periods, peak zidovudine levels (mean +/- 1 SD) were 3.9 +/- 1.7 mumol/l versus 4.3 +/- 0.04 mumol/l (P = .56); elimination half-lives were 1.3 +/- 0.6 versus 1.0 +/- 0.3 h (P = .41); areas under the concentration curve were 4.5 +/- 1.0 mumol/l x h and 6.8 +/- 0.5 mumol/l x h (P = .02); apparent total body clearances were 2.5 +/- 0.6 l/h/kg and 1.7 +/- 0.4 l/h/kg (P = .05); and apparent steady state volumes of distribution were 3.9 +/- 1.0 l/kg and 2.6 +/- 0.8 l/kg (P = .07), respectively.",Pharmacokinetic disposition of zidovudine during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988507/),[l] / [h·kg],2.5,41540,DB00495,Zidovudine
,1988507,apparent total body clearances,"For the pregnant versus postpartum periods, peak zidovudine levels (mean +/- 1 SD) were 3.9 +/- 1.7 mumol/l versus 4.3 +/- 0.04 mumol/l (P = .56); elimination half-lives were 1.3 +/- 0.6 versus 1.0 +/- 0.3 h (P = .41); areas under the concentration curve were 4.5 +/- 1.0 mumol/l x h and 6.8 +/- 0.5 mumol/l x h (P = .02); apparent total body clearances were 2.5 +/- 0.6 l/h/kg and 1.7 +/- 0.4 l/h/kg (P = .05); and apparent steady state volumes of distribution were 3.9 +/- 1.0 l/kg and 2.6 +/- 0.8 l/kg (P = .07), respectively.",Pharmacokinetic disposition of zidovudine during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988507/),[l] / [h·kg],1.7,41541,DB00495,Zidovudine
,1988507,apparent steady state volumes of distribution,"For the pregnant versus postpartum periods, peak zidovudine levels (mean +/- 1 SD) were 3.9 +/- 1.7 mumol/l versus 4.3 +/- 0.04 mumol/l (P = .56); elimination half-lives were 1.3 +/- 0.6 versus 1.0 +/- 0.3 h (P = .41); areas under the concentration curve were 4.5 +/- 1.0 mumol/l x h and 6.8 +/- 0.5 mumol/l x h (P = .02); apparent total body clearances were 2.5 +/- 0.6 l/h/kg and 1.7 +/- 0.4 l/h/kg (P = .05); and apparent steady state volumes of distribution were 3.9 +/- 1.0 l/kg and 2.6 +/- 0.8 l/kg (P = .07), respectively.",Pharmacokinetic disposition of zidovudine during pregnancy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988507/),[l] / [kg],3.9,41542,DB00495,Zidovudine
,1988507,apparent steady state volumes of distribution,"For the pregnant versus postpartum periods, peak zidovudine levels (mean +/- 1 SD) were 3.9 +/- 1.7 mumol/l versus 4.3 +/- 0.04 mumol/l (P = .56); elimination half-lives were 1.3 +/- 0.6 versus 1.0 +/- 0.3 h (P = .41); areas under the concentration curve were 4.5 +/- 1.0 mumol/l x h and 6.8 +/- 0.5 mumol/l x h (P = .02); apparent total body clearances were 2.5 +/- 0.6 l/h/kg and 1.7 +/- 0.4 l/h/kg (P = .05); and apparent steady state volumes of distribution were 3.9 +/- 1.0 l/kg and 2.6 +/- 0.8 l/kg (P = .07), respectively.",Pharmacokinetic disposition of zidovudine during pregnancy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988507/),[l] / [kg],2.6,41543,DB00495,Zidovudine
,2374145,Half-lives,"Half-lives in human serum, mouse serum, and mouse brain homogenate are 4.33, 0.56, 0.17 h, respectively, for AzddU and 7.70, 1.40, and 0.18 h, respectively, for AZT.","Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2374145/),h,4.33,42129,DB00495,Zidovudine
,2374145,Half-lives,"Half-lives in human serum, mouse serum, and mouse brain homogenate are 4.33, 0.56, 0.17 h, respectively, for AzddU and 7.70, 1.40, and 0.18 h, respectively, for AZT.","Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2374145/),h,0.56,42130,DB00495,Zidovudine
,2374145,Half-lives,"Half-lives in human serum, mouse serum, and mouse brain homogenate are 4.33, 0.56, 0.17 h, respectively, for AzddU and 7.70, 1.40, and 0.18 h, respectively, for AZT.","Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2374145/),h,0.17,42131,DB00495,Zidovudine
,2374145,Half-lives,"Half-lives in human serum, mouse serum, and mouse brain homogenate are 4.33, 0.56, 0.17 h, respectively, for AzddU and 7.70, 1.40, and 0.18 h, respectively, for AZT.","Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2374145/),h,7.70,42132,DB00495,Zidovudine
,2374145,Half-lives,"Half-lives in human serum, mouse serum, and mouse brain homogenate are 4.33, 0.56, 0.17 h, respectively, for AzddU and 7.70, 1.40, and 0.18 h, respectively, for AZT.","Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2374145/),h,1.40,42133,DB00495,Zidovudine
,2374145,Half-lives,"Half-lives in human serum, mouse serum, and mouse brain homogenate are 4.33, 0.56, 0.17 h, respectively, for AzddU and 7.70, 1.40, and 0.18 h, respectively, for AZT.","Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2374145/),h,0.18,42134,DB00495,Zidovudine
,2374145,AUC,"The AUC in serum for AzddU following prodrug administration is 25.79 micrograms h/mL, which is similar to the value of 25.83 micrograms h/mL when AzddU was administered.","Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2374145/),[h·μg] / [ml],25.79,42135,DB00495,Zidovudine
,2374145,AUC,"The AUC in serum for AzddU following prodrug administration is 25.79 micrograms h/mL, which is similar to the value of 25.83 micrograms h/mL when AzddU was administered.","Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2374145/),[h·μg] / [ml],25.83,42136,DB00495,Zidovudine
,2374145,serum AUCs,"Analogously, the serum AUCs for AZT when AZT-DHP and AZT were administered are 25.38 and 26.64 micrograms h/mL, respectively.","Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2374145/),[h·μg] / [ml],25.38,42137,DB00495,Zidovudine
,2374145,serum AUCs,"Analogously, the serum AUCs for AZT when AZT-DHP and AZT were administered are 25.38 and 26.64 micrograms h/mL, respectively.","Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2374145/),[h·μg] / [ml],26.64,42138,DB00495,Zidovudine
,2374145,brain,"However, the brain AUCs for both AzddU and AZT derived from prodrugs, being 11.43 and 11.28 micrograms h/mL, respectively, are greater than the brain AUCs for AzddU (2.09 micrograms h/mL) and AZT (1.21 micrograms h/mL) when the parent drugs were administered.","Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2374145/),[h·μg] / [ml],11.43,42139,DB00495,Zidovudine
,2374145,brain,"However, the brain AUCs for both AzddU and AZT derived from prodrugs, being 11.43 and 11.28 micrograms h/mL, respectively, are greater than the brain AUCs for AzddU (2.09 micrograms h/mL) and AZT (1.21 micrograms h/mL) when the parent drugs were administered.","Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2374145/),[h·μg] / [ml],11.28,42140,DB00495,Zidovudine
,2374145,AUCs,"However, the brain AUCs for both AzddU and AZT derived from prodrugs, being 11.43 and 11.28 micrograms h/mL, respectively, are greater than the brain AUCs for AzddU (2.09 micrograms h/mL) and AZT (1.21 micrograms h/mL) when the parent drugs were administered.","Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2374145/),[h·μg] / [ml],11.43,42141,DB00495,Zidovudine
,2374145,AUCs,"However, the brain AUCs for both AzddU and AZT derived from prodrugs, being 11.43 and 11.28 micrograms h/mL, respectively, are greater than the brain AUCs for AzddU (2.09 micrograms h/mL) and AZT (1.21 micrograms h/mL) when the parent drugs were administered.","Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2374145/),[h·μg] / [ml],11.28,42142,DB00495,Zidovudine
,2374145,AUCs,"However, the brain AUCs for both AzddU and AZT derived from prodrugs, being 11.43 and 11.28 micrograms h/mL, respectively, are greater than the brain AUCs for AzddU (2.09 micrograms h/mL) and AZT (1.21 micrograms h/mL) when the parent drugs were administered.","Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2374145/),[h·μg] / [ml],2.09,42143,DB00495,Zidovudine
,2374145,AUCs,"However, the brain AUCs for both AzddU and AZT derived from prodrugs, being 11.43 and 11.28 micrograms h/mL, respectively, are greater than the brain AUCs for AzddU (2.09 micrograms h/mL) and AZT (1.21 micrograms h/mL) when the parent drugs were administered.","Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2374145/),[h·μg] / [ml],1.21,42144,DB00495,Zidovudine
,31693190,AUC,"The following PK parameters were estimated for preterm neonates using simulated plasma profiles: AUC 2686.41 ± 123.49 μmol min/L, Cmax 6.46 ± 0.74 μmol/L, half-life 8.98 ± 2.36 hr, mean residence time 12.23 ± 3.43 hr, and total plasma clearance 1.48 ± 0.19 ml/min/kg in comparison with the observed PK parameters of a clinical study by Mirochknic et al. in preterm neonates with AUC 2020.04 μmol/min/L, Cmax 6.10 μmol/L, and total plasma clearance 1.62 ml/min/kg.",WB-PBPK approach in predicting zidovudine pharmacokinetics in preterm neonates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31693190/),[min·μM] / [l],2686.41,43772,DB00495,Zidovudine
,31693190,Cmax,"The following PK parameters were estimated for preterm neonates using simulated plasma profiles: AUC 2686.41 ± 123.49 μmol min/L, Cmax 6.46 ± 0.74 μmol/L, half-life 8.98 ± 2.36 hr, mean residence time 12.23 ± 3.43 hr, and total plasma clearance 1.48 ± 0.19 ml/min/kg in comparison with the observed PK parameters of a clinical study by Mirochknic et al. in preterm neonates with AUC 2020.04 μmol/min/L, Cmax 6.10 μmol/L, and total plasma clearance 1.62 ml/min/kg.",WB-PBPK approach in predicting zidovudine pharmacokinetics in preterm neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31693190/),[μM] / [l],6.46,43773,DB00495,Zidovudine
,31693190,half-life,"The following PK parameters were estimated for preterm neonates using simulated plasma profiles: AUC 2686.41 ± 123.49 μmol min/L, Cmax 6.46 ± 0.74 μmol/L, half-life 8.98 ± 2.36 hr, mean residence time 12.23 ± 3.43 hr, and total plasma clearance 1.48 ± 0.19 ml/min/kg in comparison with the observed PK parameters of a clinical study by Mirochknic et al. in preterm neonates with AUC 2020.04 μmol/min/L, Cmax 6.10 μmol/L, and total plasma clearance 1.62 ml/min/kg.",WB-PBPK approach in predicting zidovudine pharmacokinetics in preterm neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31693190/),h,8.98,43774,DB00495,Zidovudine
,31693190,mean residence time,"The following PK parameters were estimated for preterm neonates using simulated plasma profiles: AUC 2686.41 ± 123.49 μmol min/L, Cmax 6.46 ± 0.74 μmol/L, half-life 8.98 ± 2.36 hr, mean residence time 12.23 ± 3.43 hr, and total plasma clearance 1.48 ± 0.19 ml/min/kg in comparison with the observed PK parameters of a clinical study by Mirochknic et al. in preterm neonates with AUC 2020.04 μmol/min/L, Cmax 6.10 μmol/L, and total plasma clearance 1.62 ml/min/kg.",WB-PBPK approach in predicting zidovudine pharmacokinetics in preterm neonates. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31693190/),h,12.23,43775,DB00495,Zidovudine
,31693190,total plasma clearance,"The following PK parameters were estimated for preterm neonates using simulated plasma profiles: AUC 2686.41 ± 123.49 μmol min/L, Cmax 6.46 ± 0.74 μmol/L, half-life 8.98 ± 2.36 hr, mean residence time 12.23 ± 3.43 hr, and total plasma clearance 1.48 ± 0.19 ml/min/kg in comparison with the observed PK parameters of a clinical study by Mirochknic et al. in preterm neonates with AUC 2020.04 μmol/min/L, Cmax 6.10 μmol/L, and total plasma clearance 1.62 ml/min/kg.",WB-PBPK approach in predicting zidovudine pharmacokinetics in preterm neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31693190/),[ml] / [kg·min],1.48,43776,DB00495,Zidovudine
,31693190,AUC,"The following PK parameters were estimated for preterm neonates using simulated plasma profiles: AUC 2686.41 ± 123.49 μmol min/L, Cmax 6.46 ± 0.74 μmol/L, half-life 8.98 ± 2.36 hr, mean residence time 12.23 ± 3.43 hr, and total plasma clearance 1.48 ± 0.19 ml/min/kg in comparison with the observed PK parameters of a clinical study by Mirochknic et al. in preterm neonates with AUC 2020.04 μmol/min/L, Cmax 6.10 μmol/L, and total plasma clearance 1.62 ml/min/kg.",WB-PBPK approach in predicting zidovudine pharmacokinetics in preterm neonates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31693190/),[μM] / [l·min],2020.04,43777,DB00495,Zidovudine
,31693190,Cmax,"The following PK parameters were estimated for preterm neonates using simulated plasma profiles: AUC 2686.41 ± 123.49 μmol min/L, Cmax 6.46 ± 0.74 μmol/L, half-life 8.98 ± 2.36 hr, mean residence time 12.23 ± 3.43 hr, and total plasma clearance 1.48 ± 0.19 ml/min/kg in comparison with the observed PK parameters of a clinical study by Mirochknic et al. in preterm neonates with AUC 2020.04 μmol/min/L, Cmax 6.10 μmol/L, and total plasma clearance 1.62 ml/min/kg.",WB-PBPK approach in predicting zidovudine pharmacokinetics in preterm neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31693190/),[μM] / [l],6.10,43778,DB00495,Zidovudine
,31693190,total plasma clearance,"The following PK parameters were estimated for preterm neonates using simulated plasma profiles: AUC 2686.41 ± 123.49 μmol min/L, Cmax 6.46 ± 0.74 μmol/L, half-life 8.98 ± 2.36 hr, mean residence time 12.23 ± 3.43 hr, and total plasma clearance 1.48 ± 0.19 ml/min/kg in comparison with the observed PK parameters of a clinical study by Mirochknic et al. in preterm neonates with AUC 2020.04 μmol/min/L, Cmax 6.10 μmol/L, and total plasma clearance 1.62 ml/min/kg.",WB-PBPK approach in predicting zidovudine pharmacokinetics in preterm neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31693190/),[ml] / [kg·min],1.62,43779,DB00495,Zidovudine
,17604365,linear dynamic range,The method exhibited a linear dynamic range of 5-500 ng/mL for zidovudine in rat plasma.,Rapid and simple liquid chromatography tandem mass spectrometry method for the quantification of zidovudine in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17604365/),[ng] / [ml],5-500,45327,DB00495,Zidovudine
,17604365,run time,A run time of 1.5 min for each sample made it possible to analyze more than 400 plasma samples per day.,Rapid and simple liquid chromatography tandem mass spectrometry method for the quantification of zidovudine in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17604365/),min,1.5,45328,DB00495,Zidovudine
,8054247,AUC,"The mean AUC was 6.8 +/- 2.0 s.d. and 7.6 +/- 2.5 s.d. mumol l-1 h and oral clearance was 2766 +/- 686 and 2660 +/- 1297 ml min-1 in the presence and absence of ZDV, respectively.",Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054247/),[h·μM] / [l],6.8,45967,DB00495,Zidovudine
,8054247,AUC,"The mean AUC was 6.8 +/- 2.0 s.d. and 7.6 +/- 2.5 s.d. mumol l-1 h and oral clearance was 2766 +/- 686 and 2660 +/- 1297 ml min-1 in the presence and absence of ZDV, respectively.",Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054247/),[h·μM] / [l],7.6,45968,DB00495,Zidovudine
,8054247,oral clearance,"The mean AUC was 6.8 +/- 2.0 s.d. and 7.6 +/- 2.5 s.d. mumol l-1 h and oral clearance was 2766 +/- 686 and 2660 +/- 1297 ml min-1 in the presence and absence of ZDV, respectively.",Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054247/),[ml] / [min],2766,45969,DB00495,Zidovudine
,8054247,oral clearance,"The mean AUC was 6.8 +/- 2.0 s.d. and 7.6 +/- 2.5 s.d. mumol l-1 h and oral clearance was 2766 +/- 686 and 2660 +/- 1297 ml min-1 in the presence and absence of ZDV, respectively.",Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054247/),[ml] / [min],2660,45970,DB00495,Zidovudine
,8054247,elimination half-life,4. In the presence of ddI the elimination half-life of ZDV was increased significantly by 18% from 1.1 +/- 0.3 to 1.3 +/- 0.3 h (P < 0.05) and the mean AUC increased significantly by 35% from 4.8 +/- 1.5 to 6.5 +/- 1.5 mumol l-1 h (P < 0.05).,Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054247/),h,1.1,45971,DB00495,Zidovudine
,8054247,elimination half-life,4. In the presence of ddI the elimination half-life of ZDV was increased significantly by 18% from 1.1 +/- 0.3 to 1.3 +/- 0.3 h (P < 0.05) and the mean AUC increased significantly by 35% from 4.8 +/- 1.5 to 6.5 +/- 1.5 mumol l-1 h (P < 0.05).,Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054247/),h,1.3,45972,DB00495,Zidovudine
,8054247,AUC,4. In the presence of ddI the elimination half-life of ZDV was increased significantly by 18% from 1.1 +/- 0.3 to 1.3 +/- 0.3 h (P < 0.05) and the mean AUC increased significantly by 35% from 4.8 +/- 1.5 to 6.5 +/- 1.5 mumol l-1 h (P < 0.05).,Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054247/),[h·μM] / [l],4.8,45973,DB00495,Zidovudine
,8054247,AUC,4. In the presence of ddI the elimination half-life of ZDV was increased significantly by 18% from 1.1 +/- 0.3 to 1.3 +/- 0.3 h (P < 0.05) and the mean AUC increased significantly by 35% from 4.8 +/- 1.5 to 6.5 +/- 1.5 mumol l-1 h (P < 0.05).,Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054247/),[h·μM] / [l],6.5,45974,DB00495,Zidovudine
,8054247,clearance,"The clearance was decreased by 29% from 3518 +/- 1123 to 2505 +/- 575 ml min-1, but this difference was not significant.",Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054247/),[ml] / [min],3518,45975,DB00495,Zidovudine
,8054247,clearance,"The clearance was decreased by 29% from 3518 +/- 1123 to 2505 +/- 575 ml min-1, but this difference was not significant.",Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054247/),[ml] / [min],2505,45976,DB00495,Zidovudine
,8054247,AUC,"5. Administration of ddI also resulted in a significant 22% increase in the AUC of GZDV, from 28.5 +/- 15.7 to 34.9 +/- 12.8 mumol l-1 h (P < 0.05).",Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054247/),[h·μM] / [l],28.5,45977,DB00495,Zidovudine
,8054247,AUC,"5. Administration of ddI also resulted in a significant 22% increase in the AUC of GZDV, from 28.5 +/- 15.7 to 34.9 +/- 12.8 mumol l-1 h (P < 0.05).",Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054247/),[h·μM] / [l],34.9,45978,DB00495,Zidovudine
,14716748,steady state flux,"Ex vivo steady state flux of AZT across rat skin from gel was 2.26 mg cm(-2) h(-1), which is sufficient to achieve therapeutic plasma concentrations.","Transdermal delivery system for zidovudine: in vitro, ex vivo and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14716748/),[mg] / [(cm)^2·h],2.26,46606,DB00495,Zidovudine
,21502034,steady-state flux,"Among all gel formulations, gel containing cineole and menthol as penetration enhancers attained a steady-state flux of 5.9 mg/cm(2)/h and 5.4 mg/cm(2)/h of zidovudine, respectively, leading to plasma concentration in the therapeutic range.",Effect of penetration enhancers on gel formulation of Zidovudine: in vivo and ex vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21502034/),[mg] / [cm(2)·h],5.9,46662,DB00495,Zidovudine
,21502034,steady-state flux,"Among all gel formulations, gel containing cineole and menthol as penetration enhancers attained a steady-state flux of 5.9 mg/cm(2)/h and 5.4 mg/cm(2)/h of zidovudine, respectively, leading to plasma concentration in the therapeutic range.",Effect of penetration enhancers on gel formulation of Zidovudine: in vivo and ex vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21502034/),[mg] / [cm(2)·h],5.4,46663,DB00495,Zidovudine
,10875543,AUC,The mean AUC value for diclofenac was increased from 2.29 to 5.04 microg mL(-1) h in the presence of AZT.,"Zidovudine, diclofenac and ketoprofen pharmacokinetic interactions in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10875543/),[h·μg] / [ml],2.29,46732,DB00495,Zidovudine
,10875543,AUC,The mean AUC value for diclofenac was increased from 2.29 to 5.04 microg mL(-1) h in the presence of AZT.,"Zidovudine, diclofenac and ketoprofen pharmacokinetic interactions in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10875543/),[h·μg] / [ml],5.04,46733,DB00495,Zidovudine
below,11181346,area under the concentration-time curve (AUC),If patients had an indinavir area under the concentration-time curve (AUC) of below 10 or above 30 mg/liter.,Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181346/),[mg] / [l],10,48120,DB00495,Zidovudine
above,11181346,area under the concentration-time curve (AUC),If patients had an indinavir area under the concentration-time curve (AUC) of below 10 or above 30 mg/liter.,Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181346/),[mg] / [l],30,48121,DB00495,Zidovudine
,11181346,AUC,The median AUC (range) was 10.5 (2.8 to 51.0) mg/liter.,Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181346/),[mg] / [l],10.5,48122,DB00495,Zidovudine
,11181346,AUC,The median AUC (range) in 17 children treated with 50 mg/kg of MW q8h was 20.6 (4.1 to 38.7) mg/liter.,Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181346/),[mg] / [l],20.6,48123,DB00495,Zidovudine
,11181346,AUC,"Finally, five patients had a dose increase to 67 mg/kg of MW q8h, resulting in a median AUC (range) of 36.6 (27.2 to 80.0) mg/liter.",Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181346/),[mg] / [l],36.6,48124,DB00495,Zidovudine
below,11181346,AUC,"After 6 months of treatment, there were 11 children with an AUC of below 20 mg/liter.",Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181346/),[mg] / [l],20,48125,DB00495,Zidovudine
higher,11181346,AUC,"h, of whom 5 (45%) had a detectable viral load, while this was the case in none of the 11 children with an AUC of higher than 20 mg/liter.",Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181346/),[mg] / [l],20,48126,DB00495,Zidovudine
greater,11181346,AUC,It would even be better to adjust the indinavir dose based on an AUC of greater than 20 mg/liter.,Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181346/),[mg] / [l],20,48127,DB00495,Zidovudine
,9145378,MRT,Formulation I showed the longest MRT (4.4 h).,In vivo evaluation of zidovudine (AZT)-loaded ethylcellulose microspheres after oral administration in beagle dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145378/),h,4.4,48711,DB00495,Zidovudine
,9145378,relative bioavailability,The relative bioavailability of the microsphere formulations with respect to AZT powder was not significantly different from 1.,In vivo evaluation of zidovudine (AZT)-loaded ethylcellulose microspheres after oral administration in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145378/),,1,48712,DB00495,Zidovudine
,8913483,detection limit,"The detection limit is 0.02 pmol/10(6) cells, and this assay can measure a wide range of intracellular drug concentrations.",Quantitation of intracellular zidovudine phosphates by use of combined cartridge-radioimmunoassay methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8913483/),[pM] / [10],0.02,49498,DB00495,Zidovudine
,2362917,AUCAZT,Administration of 500 mg probenecid every 6 hr prior to and during AZT dosing resulted in an increase in the average AUCAZT from 89 micrograms.,Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362917/),μg,89,50481,DB00495,Zidovudine
,2362917,CLR,"Average CLR and CLTOT/F of AZT decreased from 4.76 and 28.7 to 2.98 and 14.1 ml/min/kg during control and probenecid treatment, respectively.",Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362917/),[ml] / [kg·min],4.76,50482,DB00495,Zidovudine
,2362917,CLR,"Average CLR and CLTOT/F of AZT decreased from 4.76 and 28.7 to 2.98 and 14.1 ml/min/kg during control and probenecid treatment, respectively.",Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362917/),[ml] / [kg·min],2.98,50483,DB00495,Zidovudine
,2362917,CLTOT/F,"Average CLR and CLTOT/F of AZT decreased from 4.76 and 28.7 to 2.98 and 14.1 ml/min/kg during control and probenecid treatment, respectively.",Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362917/),[ml] / [kg·min],28.7,50484,DB00495,Zidovudine
,2362917,CLTOT/F,"Average CLR and CLTOT/F of AZT decreased from 4.76 and 28.7 to 2.98 and 14.1 ml/min/kg during control and probenecid treatment, respectively.",Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362917/),[ml] / [kg·min],2.98,50485,DB00495,Zidovudine
,2362917,CLTOT/F,"Average CLR and CLTOT/F of AZT decreased from 4.76 and 28.7 to 2.98 and 14.1 ml/min/kg during control and probenecid treatment, respectively.",Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362917/),[ml] / [kg·min],14.1,50486,DB00495,Zidovudine
,2362917,CLR,"The CLR of GAZT decreased from an average of 11.3 ml/min/kg (control) to 2.63 ml/min/kg during probenecid treatment, resulting in a greater than 3.5-fold increase in AUCGAZT.",Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362917/),[ml] / [kg·min],11.3,50487,DB00495,Zidovudine
,2362917,CLR,"The CLR of GAZT decreased from an average of 11.3 ml/min/kg (control) to 2.63 ml/min/kg during probenecid treatment, resulting in a greater than 3.5-fold increase in AUCGAZT.",Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362917/),[ml] / [kg·min],2.63,50488,DB00495,Zidovudine
,16815761,recoveries,"The average recoveries of zidovudine and nevirapine from plasma were 95 and 94%, respectively.",A simple and rapid liquid chromatography method for simultaneous determination of zidovudine and nevirapine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815761/),%,95,52240,DB00495,Zidovudine
,16815761,recoveries,"The average recoveries of zidovudine and nevirapine from plasma were 95 and 94%, respectively.",A simple and rapid liquid chromatography method for simultaneous determination of zidovudine and nevirapine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815761/),%,94,52241,DB00495,Zidovudine
,8835201,total plasma clearance (Cl),"Zidovudine plasma pharmacokinetic parameters were in good agreement with previously reported data with a total plasma clearance (Cl) of 2.33 and 2.49 liters/hr/kg and an apparent elimination t1/2 of 1.14 and 1.20 hr at 100- and 500-mg doses, respectively.",Comparative pharmacokinetics of zidovudine and its toxic catabolite 3'-amino-3'-deoxythymidine in HIV-infected patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835201/),[l] / [h·kg],2.33,52715,DB00495,Zidovudine
,8835201,total plasma clearance (Cl),"Zidovudine plasma pharmacokinetic parameters were in good agreement with previously reported data with a total plasma clearance (Cl) of 2.33 and 2.49 liters/hr/kg and an apparent elimination t1/2 of 1.14 and 1.20 hr at 100- and 500-mg doses, respectively.",Comparative pharmacokinetics of zidovudine and its toxic catabolite 3'-amino-3'-deoxythymidine in HIV-infected patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835201/),[l] / [h·kg],2.49,52716,DB00495,Zidovudine
,8835201,apparent elimination t1/2,"Zidovudine plasma pharmacokinetic parameters were in good agreement with previously reported data with a total plasma clearance (Cl) of 2.33 and 2.49 liters/hr/kg and an apparent elimination t1/2 of 1.14 and 1.20 hr at 100- and 500-mg doses, respectively.",Comparative pharmacokinetics of zidovudine and its toxic catabolite 3'-amino-3'-deoxythymidine in HIV-infected patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835201/),h,1.14,52717,DB00495,Zidovudine
,8835201,apparent elimination t1/2,"Zidovudine plasma pharmacokinetic parameters were in good agreement with previously reported data with a total plasma clearance (Cl) of 2.33 and 2.49 liters/hr/kg and an apparent elimination t1/2 of 1.14 and 1.20 hr at 100- and 500-mg doses, respectively.",Comparative pharmacokinetics of zidovudine and its toxic catabolite 3'-amino-3'-deoxythymidine in HIV-infected patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835201/),h,1.20,52718,DB00495,Zidovudine
,8835201,AUCAMT,"The AUCAMT was 145.4 and 92.4 ng/ml.hr after administration of 100 and 500 mg of ZDV, respectively.",Comparative pharmacokinetics of zidovudine and its toxic catabolite 3'-amino-3'-deoxythymidine in HIV-infected patients. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835201/),[ng] / [h·ml],145.4,52719,DB00495,Zidovudine
,8835201,AUCAMT,"The AUCAMT was 145.4 and 92.4 ng/ml.hr after administration of 100 and 500 mg of ZDV, respectively.",Comparative pharmacokinetics of zidovudine and its toxic catabolite 3'-amino-3'-deoxythymidine in HIV-infected patients. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835201/),[ng] / [h·ml],92.4,52720,DB00495,Zidovudine
more,8860966,half lives,"Enzymatic degradation of ddNs in rat intestinal washing and in the intestinal homogenate showed them to be stable in the washing with half lives of more than 140 h, whereas degradation of DDI in the intestinal homogenate was more than ten times as rapid as those of AZT and D4T.","Intestinal absorption and first-pass elimination of 2', 3'-dideoxynucleosides following oral administration in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8860966/),h,140,52970,DB00495,Zidovudine
more,8860966,bioavailability,AZT and D4T were rapidly absorbed from the gastrointestinal tract and their bioavailability was more than 90%.,"Intestinal absorption and first-pass elimination of 2', 3'-dideoxynucleosides following oral administration in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8860966/),%,90,52971,DB00495,Zidovudine
,1588496,AUC,"The serum ZDV levels were significantly higher in the methadone patients, with a 43% increase (p less than 0.05) over the mean AUC of 7.68 microM h observed in the control patients.",Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1588496/),h·μM,7.68,54430,DB00495,Zidovudine
,11876585,area under the serum concentration-time curve (AUC(0-24h),"No significant differences in the mean area under the serum concentration-time curve (AUC(0-24h); 8,753 +/- 4,280 vs.",The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876585/),,"8,753",54939,DB00495,Zidovudine
,11876585,oralclearance(,"8,641 +/- 4,431 microg-h/L),oralclearance(CL/F;9.9 +/- 4.9vs.",The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876585/),vs,9.9,54940,DB00495,Zidovudine
,11876585,CL/F,"8,641 +/- 4,431 microg-h/L),oralclearance(CL/F;9.9 +/- 4.9vs.",The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876585/),vs,9.9,54941,DB00495,Zidovudine
,11876585,oral volume of distribution (Vd/F,"10.3 +/- 5.5 L/h),oral volume of distribution (Vd/F; 647 +/- 465 vs. 481 +/- 305 L), maximum serum concentration (Cmax; 514 +/- 223 vs. 5,510 +/- 237 microg/L), or terminal elimination half-life (t 1/2; 55.3 +/- 61.0 vs. 35.0 +/- 17.5 h) were detected.",The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876585/),l,647,54942,DB00495,Zidovudine
,11876585,oral volume of distribution (Vd/F,"10.3 +/- 5.5 L/h),oral volume of distribution (Vd/F; 647 +/- 465 vs. 481 +/- 305 L), maximum serum concentration (Cmax; 514 +/- 223 vs. 5,510 +/- 237 microg/L), or terminal elimination half-life (t 1/2; 55.3 +/- 61.0 vs. 35.0 +/- 17.5 h) were detected.",The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876585/),l,481,54943,DB00495,Zidovudine
,11876585,maximum serum concentration (Cmax,"10.3 +/- 5.5 L/h),oral volume of distribution (Vd/F; 647 +/- 465 vs. 481 +/- 305 L), maximum serum concentration (Cmax; 514 +/- 223 vs. 5,510 +/- 237 microg/L), or terminal elimination half-life (t 1/2; 55.3 +/- 61.0 vs. 35.0 +/- 17.5 h) were detected.",The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876585/),[μg] / [l],514,54944,DB00495,Zidovudine
,11876585,maximum serum concentration (Cmax,"10.3 +/- 5.5 L/h),oral volume of distribution (Vd/F; 647 +/- 465 vs. 481 +/- 305 L), maximum serum concentration (Cmax; 514 +/- 223 vs. 5,510 +/- 237 microg/L), or terminal elimination half-life (t 1/2; 55.3 +/- 61.0 vs. 35.0 +/- 17.5 h) were detected.",The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876585/),[μg] / [l],"5,510",54945,DB00495,Zidovudine
,11876585,terminal elimination half-life (t 1/2,"10.3 +/- 5.5 L/h),oral volume of distribution (Vd/F; 647 +/- 465 vs. 481 +/- 305 L), maximum serum concentration (Cmax; 514 +/- 223 vs. 5,510 +/- 237 microg/L), or terminal elimination half-life (t 1/2; 55.3 +/- 61.0 vs. 35.0 +/- 17.5 h) were detected.",The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876585/),h,55.3,54946,DB00495,Zidovudine
,11876585,terminal elimination half-life (t 1/2,"10.3 +/- 5.5 L/h),oral volume of distribution (Vd/F; 647 +/- 465 vs. 481 +/- 305 L), maximum serum concentration (Cmax; 514 +/- 223 vs. 5,510 +/- 237 microg/L), or terminal elimination half-life (t 1/2; 55.3 +/- 61.0 vs. 35.0 +/- 17.5 h) were detected.",The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876585/),h,35.0,54947,DB00495,Zidovudine
,1324635,maximum AZM concentrations,"After the first and fifth administrations, maximum AZM concentrations in serum were 0.6 +/- 0.1 and 0.8 +/- 0.2 microM (mean +/- standard error of the mean), respectively; times to peak concentration in serum were 3.7 +/- 0.2 and 2.9 +/- 0.4 h, respectively; areas under the plasma concentration-time curves were 9.2 +/- 1.6 and 9.3 +/- 2.0 micrograms.h/ml, respectively; and half-lives were 61.0 +/- 5.4 and 63.8 +/- 6.7 h, respectively.","Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1324635/),μM,0.6,55025,DB00495,Zidovudine
,1324635,maximum AZM concentrations,"After the first and fifth administrations, maximum AZM concentrations in serum were 0.6 +/- 0.1 and 0.8 +/- 0.2 microM (mean +/- standard error of the mean), respectively; times to peak concentration in serum were 3.7 +/- 0.2 and 2.9 +/- 0.4 h, respectively; areas under the plasma concentration-time curves were 9.2 +/- 1.6 and 9.3 +/- 2.0 micrograms.h/ml, respectively; and half-lives were 61.0 +/- 5.4 and 63.8 +/- 6.7 h, respectively.","Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1324635/),μM,0.8,55026,DB00495,Zidovudine
,1324635,times to peak concentration,"After the first and fifth administrations, maximum AZM concentrations in serum were 0.6 +/- 0.1 and 0.8 +/- 0.2 microM (mean +/- standard error of the mean), respectively; times to peak concentration in serum were 3.7 +/- 0.2 and 2.9 +/- 0.4 h, respectively; areas under the plasma concentration-time curves were 9.2 +/- 1.6 and 9.3 +/- 2.0 micrograms.h/ml, respectively; and half-lives were 61.0 +/- 5.4 and 63.8 +/- 6.7 h, respectively.","Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1324635/),h,3.7,55027,DB00495,Zidovudine
,1324635,times to peak concentration,"After the first and fifth administrations, maximum AZM concentrations in serum were 0.6 +/- 0.1 and 0.8 +/- 0.2 microM (mean +/- standard error of the mean), respectively; times to peak concentration in serum were 3.7 +/- 0.2 and 2.9 +/- 0.4 h, respectively; areas under the plasma concentration-time curves were 9.2 +/- 1.6 and 9.3 +/- 2.0 micrograms.h/ml, respectively; and half-lives were 61.0 +/- 5.4 and 63.8 +/- 6.7 h, respectively.","Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1324635/),h,2.9,55028,DB00495,Zidovudine
,1324635,areas under the plasma concentration-time curves,"After the first and fifth administrations, maximum AZM concentrations in serum were 0.6 +/- 0.1 and 0.8 +/- 0.2 microM (mean +/- standard error of the mean), respectively; times to peak concentration in serum were 3.7 +/- 0.2 and 2.9 +/- 0.4 h, respectively; areas under the plasma concentration-time curves were 9.2 +/- 1.6 and 9.3 +/- 2.0 micrograms.h/ml, respectively; and half-lives were 61.0 +/- 5.4 and 63.8 +/- 6.7 h, respectively.","Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1324635/),[h·μg] / [ml],9.2,55029,DB00495,Zidovudine
,1324635,areas under the plasma concentration-time curves,"After the first and fifth administrations, maximum AZM concentrations in serum were 0.6 +/- 0.1 and 0.8 +/- 0.2 microM (mean +/- standard error of the mean), respectively; times to peak concentration in serum were 3.7 +/- 0.2 and 2.9 +/- 0.4 h, respectively; areas under the plasma concentration-time curves were 9.2 +/- 1.6 and 9.3 +/- 2.0 micrograms.h/ml, respectively; and half-lives were 61.0 +/- 5.4 and 63.8 +/- 6.7 h, respectively.","Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1324635/),[h·μg] / [ml],9.3,55030,DB00495,Zidovudine
,1324635,half-lives,"After the first and fifth administrations, maximum AZM concentrations in serum were 0.6 +/- 0.1 and 0.8 +/- 0.2 microM (mean +/- standard error of the mean), respectively; times to peak concentration in serum were 3.7 +/- 0.2 and 2.9 +/- 0.4 h, respectively; areas under the plasma concentration-time curves were 9.2 +/- 1.6 and 9.3 +/- 2.0 micrograms.h/ml, respectively; and half-lives were 61.0 +/- 5.4 and 63.8 +/- 6.7 h, respectively.","Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1324635/),h,61.0,55031,DB00495,Zidovudine
,1324635,half-lives,"After the first and fifth administrations, maximum AZM concentrations in serum were 0.6 +/- 0.1 and 0.8 +/- 0.2 microM (mean +/- standard error of the mean), respectively; times to peak concentration in serum were 3.7 +/- 0.2 and 2.9 +/- 0.4 h, respectively; areas under the plasma concentration-time curves were 9.2 +/- 1.6 and 9.3 +/- 2.0 micrograms.h/ml, respectively; and half-lives were 61.0 +/- 5.4 and 63.8 +/- 6.7 h, respectively.","Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1324635/),h,63.8,55032,DB00495,Zidovudine
,1324635,maximum concentrations,"On days -1, 1, and 29, ZVD kinetic parameters were as follows: maximum concentrations in serum, 3.1+/- 0.6, 4.3 +/- 0.6, and 4.2 +/- 0.9 microM, respectively; times to maximum concentrations in serum, 1.1 +/- 0.4, 0.8 +/- 0.2, and 1.2 +/- 0.3 h, respectively: areas under the plasma concentration-time curves, 5.3 +/- 0.9, 5.9 +/- 0.6, and 5.7 +/- 0.8 microgram .","Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1324635/),μM,3.1,55033,DB00495,Zidovudine
,1324635,maximum concentrations,"On days -1, 1, and 29, ZVD kinetic parameters were as follows: maximum concentrations in serum, 3.1+/- 0.6, 4.3 +/- 0.6, and 4.2 +/- 0.9 microM, respectively; times to maximum concentrations in serum, 1.1 +/- 0.4, 0.8 +/- 0.2, and 1.2 +/- 0.3 h, respectively: areas under the plasma concentration-time curves, 5.3 +/- 0.9, 5.9 +/- 0.6, and 5.7 +/- 0.8 microgram .","Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1324635/),μM,4.3,55034,DB00495,Zidovudine
,1324635,maximum concentrations,"On days -1, 1, and 29, ZVD kinetic parameters were as follows: maximum concentrations in serum, 3.1+/- 0.6, 4.3 +/- 0.6, and 4.2 +/- 0.9 microM, respectively; times to maximum concentrations in serum, 1.1 +/- 0.4, 0.8 +/- 0.2, and 1.2 +/- 0.3 h, respectively: areas under the plasma concentration-time curves, 5.3 +/- 0.9, 5.9 +/- 0.6, and 5.7 +/- 0.8 microgram .","Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1324635/),μM,4.2,55035,DB00495,Zidovudine
,1324635,times to maximum concentrations,"On days -1, 1, and 29, ZVD kinetic parameters were as follows: maximum concentrations in serum, 3.1+/- 0.6, 4.3 +/- 0.6, and 4.2 +/- 0.9 microM, respectively; times to maximum concentrations in serum, 1.1 +/- 0.4, 0.8 +/- 0.2, and 1.2 +/- 0.3 h, respectively: areas under the plasma concentration-time curves, 5.3 +/- 0.9, 5.9 +/- 0.6, and 5.7 +/- 0.8 microgram .","Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1324635/),h,1.1,55036,DB00495,Zidovudine
,1324635,times to maximum concentrations,"On days -1, 1, and 29, ZVD kinetic parameters were as follows: maximum concentrations in serum, 3.1+/- 0.6, 4.3 +/- 0.6, and 4.2 +/- 0.9 microM, respectively; times to maximum concentrations in serum, 1.1 +/- 0.4, 0.8 +/- 0.2, and 1.2 +/- 0.3 h, respectively: areas under the plasma concentration-time curves, 5.3 +/- 0.9, 5.9 +/- 0.6, and 5.7 +/- 0.8 microgram .","Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1324635/),h,0.8,55037,DB00495,Zidovudine
,1324635,times to maximum concentrations,"On days -1, 1, and 29, ZVD kinetic parameters were as follows: maximum concentrations in serum, 3.1+/- 0.6, 4.3 +/- 0.6, and 4.2 +/- 0.9 microM, respectively; times to maximum concentrations in serum, 1.1 +/- 0.4, 0.8 +/- 0.2, and 1.2 +/- 0.3 h, respectively: areas under the plasma concentration-time curves, 5.3 +/- 0.9, 5.9 +/- 0.6, and 5.7 +/- 0.8 microgram .","Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1324635/),h,1.2,55038,DB00495,Zidovudine
,1324635,areas under the plasma concentration-time curves,"On days -1, 1, and 29, ZVD kinetic parameters were as follows: maximum concentrations in serum, 3.1+/- 0.6, 4.3 +/- 0.6, and 4.2 +/- 0.9 microM, respectively; times to maximum concentrations in serum, 1.1 +/- 0.4, 0.8 +/- 0.2, and 1.2 +/- 0.3 h, respectively: areas under the plasma concentration-time curves, 5.3 +/- 0.9, 5.9 +/- 0.6, and 5.7 +/- 0.8 microgram .","Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1324635/),μg,5.3,55039,DB00495,Zidovudine
,1324635,areas under the plasma concentration-time curves,"On days -1, 1, and 29, ZVD kinetic parameters were as follows: maximum concentrations in serum, 3.1+/- 0.6, 4.3 +/- 0.6, and 4.2 +/- 0.9 microM, respectively; times to maximum concentrations in serum, 1.1 +/- 0.4, 0.8 +/- 0.2, and 1.2 +/- 0.3 h, respectively: areas under the plasma concentration-time curves, 5.3 +/- 0.9, 5.9 +/- 0.6, and 5.7 +/- 0.8 microgram .","Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1324635/),μg,5.9,55040,DB00495,Zidovudine
,1324635,areas under the plasma concentration-time curves,"On days -1, 1, and 29, ZVD kinetic parameters were as follows: maximum concentrations in serum, 3.1+/- 0.6, 4.3 +/- 0.6, and 4.2 +/- 0.9 microM, respectively; times to maximum concentrations in serum, 1.1 +/- 0.4, 0.8 +/- 0.2, and 1.2 +/- 0.3 h, respectively: areas under the plasma concentration-time curves, 5.3 +/- 0.9, 5.9 +/- 0.6, and 5.7 +/- 0.8 microgram .","Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1324635/),μg,5.7,55041,DB00495,Zidovudine
,1324635,half-lives,"h/ml, respectively; and half-lives, 1.3 +/- 0.08, 1.4 +/- 0.04, and 1.3 +/- 0.04 h, respectively.","Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1324635/),h,1.3,55042,DB00495,Zidovudine
,1324635,half-lives,"h/ml, respectively; and half-lives, 1.3 +/- 0.08, 1.4 +/- 0.04, and 1.3 +/- 0.04 h, respectively.","Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1324635/),h,1.4,55043,DB00495,Zidovudine
,1324635,half-lives,"h/ml, respectively; and half-lives, 1.3 +/- 0.08, 1.4 +/- 0.04, and 1.3 +/- 0.04 h, respectively.","Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1324635/),h,1.3,55044,DB00495,Zidovudine
,3165603,half-life,"The mean half-life was 1.1 hours over this dose range and the total body clearance was approximately 1,900 ml/minute/70 kg, up to doses of 5 mg/kg.",Pharmacokinetics and bioavailability of zidovudine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3165603/),h,1.1,56364,DB00495,Zidovudine
,3165603,total body clearance,"The mean half-life was 1.1 hours over this dose range and the total body clearance was approximately 1,900 ml/minute/70 kg, up to doses of 5 mg/kg.",Pharmacokinetics and bioavailability of zidovudine in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3165603/),[ml] / [70·kg·min],"1,900",56365,DB00495,Zidovudine
,3165603,Renal clearance,Renal clearance of zidovudine was estimated at 350 ml/minute/70 kg.,Pharmacokinetics and bioavailability of zidovudine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3165603/),[ml] / [70·kg·min],350,56366,DB00495,Zidovudine
,3165603,cerebrospinal fluid:plasma ratio,"Zidovudine penetrated the blood brain barrier as indicated by a cerebrospinal fluid:plasma ratio averaging 0.5, determined two to four hours after dosing.",Pharmacokinetics and bioavailability of zidovudine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3165603/),,0.5,56367,DB00495,Zidovudine
,3165603,bioavailability,"Following oral administration of zidovudine at doses from 2.0 mg/kg every eight hours to 10 mg/kg every four hours, peak plasma levels increased proportionately with dose; the average bioavailability was 65 percent.",Pharmacokinetics and bioavailability of zidovudine in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3165603/),%,65,56368,DB00495,Zidovudine
,2398459,steady-state plasma concentration,ZDV was administered to five dams at a rate predicted to produce a steady-state plasma concentration of about 1 microgram/ml.,Pharmacokinetics of zidovudine (azidothymidine). I. Transplacental transfer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2398459/),[μg] / [ml],1,56616,DB00495,Zidovudine
,20499831,half-life,An increased half-life of 202 minutes and mean residence time of 212.1 minutes was observed in Tween 80 formulation.,"Tissue distribution, pharmacokinetics and stability studies of zidovudine delivered by niosomes and proniosomes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20499831/),min,202,56644,DB00495,Zidovudine
,20499831,mean residence time,An increased half-life of 202 minutes and mean residence time of 212.1 minutes was observed in Tween 80 formulation.,"Tissue distribution, pharmacokinetics and stability studies of zidovudine delivered by niosomes and proniosomes. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20499831/),min,212.1,56645,DB00495,Zidovudine
,9515187,peak drug plasma concentrations (Cmax),"Significant inhibition of tumour growth was obtained in mice bearing human colon cancer xenografts and given intraperitoneal zidovudine 300 to 600 mg/kg weekly in combination with methotrexate 87.5 mg/kg or intraperitoneal fluorouracil 85 mg/kg, and in pharmacokinetic studies high peak drug plasma concentrations (Cmax) of zidovudine were obtained, ranging from 610.3 to 1698.8 mumol/L.",Pharmacokinetic optimisation of the treatment of cancer with high dose zidovudine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9515187/),[μM] / [l],610.3 to 1698.8,57087,DB00495,Zidovudine
,2329572,IC50,The IC50 for AZT in this system was 0.12 microM whereas for prodrugs it ranged from 0.05 to 0.2 microM.,Synthesis and biological evaluation of prodrugs of zidovudine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2329572/),μM,0.12,57298,DB00495,Zidovudine
,2329572,IC50,The IC50 for AZT in this system was 0.12 microM whereas for prodrugs it ranged from 0.05 to 0.2 microM.,Synthesis and biological evaluation of prodrugs of zidovudine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2329572/),μM,0.05 to 0.2,57299,DB00495,Zidovudine
,2329572,t1/2,In vitro hydrolysis of the various esters in human plasma indicated that these agents were relatively stable toward plasma esterases with t1/2 ranging from 10 to 240 min.,Synthesis and biological evaluation of prodrugs of zidovudine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2329572/),min,10 to 240,57300,DB00495,Zidovudine
,7562916,IC50,"We prepared a series of 5-aryl-substituted analogues of 5-benzylacyclouridine (BAU), a good inhibitor of UrdPase (IC50 of 0.46 microM), to develop a compound with enhanced potency and improved pharmacokinetics.",Inhibition of uridine phosphorylase: synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7562916/),μM,0.46,58228,DB00495,Zidovudine
,7562916,IC50s,"The two most potent compounds, 10y (3-propoxy) and 10dd (3-sec-butoxy), were inhibitors of UrdPase with IC50s of 0.047 and 0.027 microM, respectively.",Inhibition of uridine phosphorylase: synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7562916/),μM,0.047,58229,DB00495,Zidovudine
,7562916,IC50s,"The two most potent compounds, 10y (3-propoxy) and 10dd (3-sec-butoxy), were inhibitors of UrdPase with IC50s of 0.047 and 0.027 microM, respectively.",Inhibition of uridine phosphorylase: synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7562916/),μM,0.027,58230,DB00495,Zidovudine
,2178336,peak concentrations,"Subcutaneous injection of 1.6 x 10(6) U of human recombinant IFN-alpha 2b per kg delivered peak concentrations in plasma of 3,600 U/ml at 2 h postadministration with a half-life of elimination of 2.9 h.",Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178336/),[u] / [ml],"3,600",59946,DB00495,Zidovudine
,2178336,half-life of elimination,"Subcutaneous injection of 1.6 x 10(6) U of human recombinant IFN-alpha 2b per kg delivered peak concentrations in plasma of 3,600 U/ml at 2 h postadministration with a half-life of elimination of 2.9 h.",Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178336/),h,2.9,59947,DB00495,Zidovudine
,2178336,peak concentrations,Oral administration of AZT (20 mg/kg three times daily) resulted in peak concentrations in plasma of 3 micrograms/ml at 2 h with a half-life of elimination of approximately 1.60 h.,Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178336/),[μg] / [ml],3,59948,DB00495,Zidovudine
,2178336,half-life of elimination,Oral administration of AZT (20 mg/kg three times daily) resulted in peak concentrations in plasma of 3 micrograms/ml at 2 h with a half-life of elimination of approximately 1.60 h.,Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178336/),h,1.60,59949,DB00495,Zidovudine
,10516944,maximum (Cmax),"However, both the maximum (Cmax) and minimum (Cmin) concentrations of IDV were significantly reduced, from a mean of 7514 +/- 1636 and 146 +/- 81 mcg/L to 4725 +/- 2494 mcg/L and 54 +/- 24 mcg/L (p < .05) after addition of HBY.",Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516944/),[mcg] / [l],7514,60482,DB00495,Zidovudine
,10516944,maximum (Cmax),"However, both the maximum (Cmax) and minimum (Cmin) concentrations of IDV were significantly reduced, from a mean of 7514 +/- 1636 and 146 +/- 81 mcg/L to 4725 +/- 2494 mcg/L and 54 +/- 24 mcg/L (p < .05) after addition of HBY.",Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516944/),[mcg] / [l],4725,60483,DB00495,Zidovudine
,10516944,minimum (Cmin) concentrations,"However, both the maximum (Cmax) and minimum (Cmin) concentrations of IDV were significantly reduced, from a mean of 7514 +/- 1636 and 146 +/- 81 mcg/L to 4725 +/- 2494 mcg/L and 54 +/- 24 mcg/L (p < .05) after addition of HBY.",Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516944/),[mcg] / [l],146,60484,DB00495,Zidovudine
,10516944,minimum (Cmin) concentrations,"However, both the maximum (Cmax) and minimum (Cmin) concentrations of IDV were significantly reduced, from a mean of 7514 +/- 1636 and 146 +/- 81 mcg/L to 4725 +/- 2494 mcg/L and 54 +/- 24 mcg/L (p < .05) after addition of HBY.",Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516944/),[mcg] / [l],54,60485,DB00495,Zidovudine
,10516944,apparent clearance (CL/F),"Furthermore, apparent clearance (CL/F) of IDV before and after 11 days of concomitant HBY administration was significantly higher, from 0.69 +/- 0.14 to 1.94 +/- 0.63 L/h/kg (p < .05) with an associated reduction in area under the curve (AUC0-8) from 16,034 +/- 4903 to 6134 +/- 2701 mg/L/h (p < .05).",Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516944/),[l] / [h·kg],0.69,60486,DB00495,Zidovudine
,10516944,apparent clearance (CL/F),"Furthermore, apparent clearance (CL/F) of IDV before and after 11 days of concomitant HBY administration was significantly higher, from 0.69 +/- 0.14 to 1.94 +/- 0.63 L/h/kg (p < .05) with an associated reduction in area under the curve (AUC0-8) from 16,034 +/- 4903 to 6134 +/- 2701 mg/L/h (p < .05).",Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516944/),[l] / [h·kg],1.94,60487,DB00495,Zidovudine
,10516944,area under the curve (AUC0-8),"Furthermore, apparent clearance (CL/F) of IDV before and after 11 days of concomitant HBY administration was significantly higher, from 0.69 +/- 0.14 to 1.94 +/- 0.63 L/h/kg (p < .05) with an associated reduction in area under the curve (AUC0-8) from 16,034 +/- 4903 to 6134 +/- 2701 mg/L/h (p < .05).",Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516944/),[mg] / [h·l],"16,034",60488,DB00495,Zidovudine
,10516944,area under the curve (AUC0-8),"Furthermore, apparent clearance (CL/F) of IDV before and after 11 days of concomitant HBY administration was significantly higher, from 0.69 +/- 0.14 to 1.94 +/- 0.63 L/h/kg (p < .05) with an associated reduction in area under the curve (AUC0-8) from 16,034 +/- 4903 to 6134 +/- 2701 mg/L/h (p < .05).",Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516944/),[mg] / [h·l],6134,60489,DB00495,Zidovudine
,1418779,peak plasma concentrations,"The peak plasma concentrations of ZDV and G-ZDV after drug administration between haemodialysis sessions were 0.57 and 10.01 micrograms/ml, respectively.",Pharmacokinetics of zidovudine in end-stage renal disease: influence of haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418779/),[μg] / [ml],0.57,60868,DB00495,Zidovudine
,1418779,peak plasma concentrations,"The peak plasma concentrations of ZDV and G-ZDV after drug administration between haemodialysis sessions were 0.57 and 10.01 micrograms/ml, respectively.",Pharmacokinetics of zidovudine in end-stage renal disease: influence of haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418779/),[μg] / [ml],10.01,60869,DB00495,Zidovudine
,1418779,half-lives,"The half-lives of ZDV and G-ZDV rose to 3.2 and 14.2 h, respectively.",Pharmacokinetics of zidovudine in end-stage renal disease: influence of haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418779/),h,3.2,60870,DB00495,Zidovudine
,1418779,half-lives,"The half-lives of ZDV and G-ZDV rose to 3.2 and 14.2 h, respectively.",Pharmacokinetics of zidovudine in end-stage renal disease: influence of haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418779/),h,14.2,60871,DB00495,Zidovudine
,1418779,total body clearance,The total body clearance for ZDV in the period between haemodialysis sessions (0.44 l/kg/h) was 66% lower than normal values.,Pharmacokinetics of zidovudine in end-stage renal disease: influence of haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418779/),[l] / [h·kg],0.44,60872,DB00495,Zidovudine
,1418779,total body clearance,"The ZDV half-life was normalized by haemodialysis, the total body clearance of ZDV increased (1.12 l/kg/h) and the G-ZDV half-life shortened (5.9-7.9 h).",Pharmacokinetics of zidovudine in end-stage renal disease: influence of haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418779/),[l] / [h·kg],1.12,60873,DB00495,Zidovudine
,1418779,half-life,"The ZDV half-life was normalized by haemodialysis, the total body clearance of ZDV increased (1.12 l/kg/h) and the G-ZDV half-life shortened (5.9-7.9 h).",Pharmacokinetics of zidovudine in end-stage renal disease: influence of haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418779/),h,5.9-7.9,60874,DB00495,Zidovudine
,7979286,area under the concentration-time curve (AUC),"Although ZDV phosphorylation occurred readily upon initiation of therapy, it declined with time; the area under the concentration-time curve (AUC) at week 4 (mean +/- standard deviation, 3.41 +/- 0.93 pmol.h/10(6) cells) was significantly greater than that at week 24 (2.19 +/- 1.10 pmol.h/10(6) cells).",Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7979286/),[h·pM] / [10(6)·cells],3.41,63278,DB00495,Zidovudine
,7979286,area under the concentration-time curve (AUC),"Although ZDV phosphorylation occurred readily upon initiation of therapy, it declined with time; the area under the concentration-time curve (AUC) at week 4 (mean +/- standard deviation, 3.41 +/- 0.93 pmol.h/10(6) cells) was significantly greater than that at week 24 (2.19 +/- 1.10 pmol.h/10(6) cells).",Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7979286/),[h·pM] / [10(6)·cells],2.19,63279,DB00495,Zidovudine
,7979286,half-life,"The half-life of intracellular ZDVPt was twice that of plasma ZDV (4 versus 2 h), suggesting that an every-8-h dosing regimen is justifiable.",Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7979286/),h,4,63280,DB00495,Zidovudine
,7979286,half-life,"The half-life of intracellular ZDVPt was twice that of plasma ZDV (4 versus 2 h), suggesting that an every-8-h dosing regimen is justifiable.",Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7979286/),h,2,63281,DB00495,Zidovudine
,2915139,half-life,The mean half-life is approximately 1 h.,A review of the pharmacokinetics of zidovudine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2915139/),h,1,64501,DB00495,Zidovudine
,15198225,t(1/2),"Plasma concentrations of zidovudine declined rapidly with t(1/2) of 1.4 +/- 0.19 hours, 1.4 +/- 0.16 hours, and 1.5 +/- 0.28 hours after i.v., i.g., and p.o. administration, respectively.",Pharmacokinetics of zidovudine in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198225/),h,1.4,64820,DB00495,Zidovudine
,15198225,t(1/2),"Plasma concentrations of zidovudine declined rapidly with t(1/2) of 1.4 +/- 0.19 hours, 1.4 +/- 0.16 hours, and 1.5 +/- 0.28 hours after i.v., i.g., and p.o. administration, respectively.",Pharmacokinetics of zidovudine in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198225/),h,1.4,64821,DB00495,Zidovudine
,15198225,t(1/2),"Plasma concentrations of zidovudine declined rapidly with t(1/2) of 1.4 +/- 0.19 hours, 1.4 +/- 0.16 hours, and 1.5 +/- 0.28 hours after i.v., i.g., and p.o. administration, respectively.",Pharmacokinetics of zidovudine in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198225/),h,1.5,64822,DB00495,Zidovudine
,15198225,Total body clearance,"Total body clearance and steady-state volume of distribution were 0.41 +/- 0.10 L/h/kg and 0.82 +/- 0.15 L/kg, respectively.",Pharmacokinetics of zidovudine in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198225/),[l] / [h·kg],0.41,64823,DB00495,Zidovudine
,15198225,steady-state volume of distribution,"Total body clearance and steady-state volume of distribution were 0.41 +/- 0.10 L/h/kg and 0.82 +/- 0.15 L/kg, respectively.",Pharmacokinetics of zidovudine in cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198225/),[l] / [kg],0.82,64824,DB00495,Zidovudine
,15198225,Tmax,Mean Tmax for i.g. administration (0.22 hours) was significantly shorter than Tmax for p.o. administration (0.67 hours).,Pharmacokinetics of zidovudine in cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198225/),h,0.22,64825,DB00495,Zidovudine
,15198225,Tmax,Mean Tmax for i.g. administration (0.22 hours) was significantly shorter than Tmax for p.o. administration (0.67 hours).,Pharmacokinetics of zidovudine in cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198225/),h,0.67,64826,DB00495,Zidovudine
,15198225,AUC,"The AUC after i.v. and p.o. administration was 64.7 +/- 16.6 mg x h/L and 60.5 +/- 17.0 mg x h/L, respectively, whereas AUC for the i.g. route was significantly less at 42.5 +/- 9.41 mg x h/L.",Pharmacokinetics of zidovudine in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198225/),[h·mg] / [l],64.7,64827,DB00495,Zidovudine
,15198225,AUC,"The AUC after i.v. and p.o. administration was 64.7 +/- 16.6 mg x h/L and 60.5 +/- 17.0 mg x h/L, respectively, whereas AUC for the i.g. route was significantly less at 42.5 +/- 9.41 mg x h/L.",Pharmacokinetics of zidovudine in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198225/),[h·mg] / [l],60.5,64828,DB00495,Zidovudine
,15198225,AUC,"The AUC after i.v. and p.o. administration was 64.7 +/- 16.6 mg x h/L and 60.5 +/- 17.0 mg x h/L, respectively, whereas AUC for the i.g. route was significantly less at 42.5 +/- 9.41 mg x h/L.",Pharmacokinetics of zidovudine in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198225/),[h·mg] / [l],42.5,64829,DB00495,Zidovudine
,15198225,bioavailability,"Zidovudine was well absorbed after i.g. and p.o. administration with bioavailability values of 70 +/- 24% and 95 +/- 23%, respectively.",Pharmacokinetics of zidovudine in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198225/),%,70,64830,DB00495,Zidovudine
,15198225,bioavailability,"Zidovudine was well absorbed after i.g. and p.o. administration with bioavailability values of 70 +/- 24% and 95 +/- 23%, respectively.",Pharmacokinetics of zidovudine in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198225/),%,95,64831,DB00495,Zidovudine
,15198225,minimum effective concentration,"Plasma concentrations of zidovudine were maintained above the minimum effective concentration for inhibiting FIV replication by 50% (0.07 microM [0.019 microg/mL] for wild-type FIV clinical isolate) for at least 12 hours after i.v., i.g., or p.o. administration.",Pharmacokinetics of zidovudine in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198225/),μM,0.07,64832,DB00495,Zidovudine
,15198225,minimum effective concentration,"Plasma concentrations of zidovudine were maintained above the minimum effective concentration for inhibiting FIV replication by 50% (0.07 microM [0.019 microg/mL] for wild-type FIV clinical isolate) for at least 12 hours after i.v., i.g., or p.o. administration.",Pharmacokinetics of zidovudine in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198225/),μg,0.019,64833,DB00495,Zidovudine
,2729955,peak serum concentrations,ZDV was rapidly absorbed with a wide range of peak serum concentrations (2052 +/- 970 ng/ml) at 0.5 h.,Pharmacokinetics of orally administered zidovudine among patients with hemophilia and asymptomatic human immunodeficiency virus (HIV) infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729955/),[ng] / [ml],2052,65960,DB00495,Zidovudine
,2729955,serum concentrations,Peak GZDV serum concentrations were 4751 +/- 2269 ng/ml at 1 h.,Pharmacokinetics of orally administered zidovudine among patients with hemophilia and asymptomatic human immunodeficiency virus (HIV) infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729955/),[ng] / [ml],4751,65961,DB00495,Zidovudine
,2729955,terminal elimination half-life,"After 4 h, the ZDV serum concentration decay in three patients continued a log-linear decline, while five patients demonstrated a tri-exponential curve which had a mean terminal elimination half-life of 4.8 +/- 2.8 h.",Pharmacokinetics of orally administered zidovudine among patients with hemophilia and asymptomatic human immunodeficiency virus (HIV) infection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729955/),h,4.8,65962,DB00495,Zidovudine
,26565115,EC90,Nanogel conjugate of lamivudine was the most effective single nanodrug (EC90 2 μM).,Nanogel-Conjugated Reverse Transcriptase Inhibitors and Their Combinations as Novel Antiviral Agents with Increased Efficacy against HIV-1 Infection. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26565115/),μM,2,68955,DB00495,Zidovudine
,9257653,terminal elimination half-life (t 1/2),"ZDV was cleared rapidly from plasma, with a mean terminal elimination half-life (t 1/2) of 75.5 +/- 4.9 minutes.",Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257653/),min,75.5,69151,DB00495,Zidovudine
,9257653,t 1/2,ZDV was cleared from the CSF with a mean t 1/2 of 187.6 +/- 69.3 minutes.,Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257653/),min,187.6,69152,DB00495,Zidovudine
,9257653,Cmax,"Mean Cmax in the CSF was 1.3 +/- 1.2 micromol/l (17% of that of plasma), and mean area under the concentration time curve (AUC) was 358 +/- 200 micromol x minutes/l (75% of that of plasma).",Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257653/),[μM] / [l],1.3,69153,DB00495,Zidovudine
,9257653,area under the concentration time curve (AUC),"Mean Cmax in the CSF was 1.3 +/- 1.2 micromol/l (17% of that of plasma), and mean area under the concentration time curve (AUC) was 358 +/- 200 micromol x minutes/l (75% of that of plasma).",Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257653/),[min·μM] / [l],358,69154,DB00495,Zidovudine
,9257653,trough levels,Calculated trough levels in CSF for a 12-hour dosing interval were 0.090 +/- 0.065 micromol/l and thus about twice the 50% inhibitory concentration (IC50) of susceptible HIV strains.,Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257653/),[μM] / [l],0.090,69155,DB00495,Zidovudine
,1283384,clearance,The antipyrine clearance showed a significant decrease from 57.9 ml min-1 to 45.0 ml min-1.,Endogenous interferon plasma levels and antipyrine pharmacokinetics in patients with viral infections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1283384/),[ml] / [min],57.9,69663,DB00495,Zidovudine
,1283384,clearance,The antipyrine clearance showed a significant decrease from 57.9 ml min-1 to 45.0 ml min-1.,Endogenous interferon plasma levels and antipyrine pharmacokinetics in patients with viral infections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1283384/),[ml] / [min],45.0,69664,DB00495,Zidovudine
,15905735,24-hour,"Two cohort 1 infants at week 1 and none at week 6 exceeded the target 24-hour area under the curve (AUC) of 30 mug.h/mL, equal to the 10th percentile of the AUC for adults receiving standard nelfinavir dosing.",Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905735/),[h·μg] / [ml],30,70111,DB00495,Zidovudine
,15905735,area under the curve (AUC),"Two cohort 1 infants at week 1 and none at week 6 exceeded the target 24-hour area under the curve (AUC) of 30 mug.h/mL, equal to the 10th percentile of the AUC for adults receiving standard nelfinavir dosing.",Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905735/),[h·μg] / [ml],30,70112,DB00495,Zidovudine
,15905735,24-hour AUC,"In cohort 2, the median 24-hour AUC was 38 mug.h/mL at both time points, with considerable variability among the infants.",Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905735/),[h·μg] / [ml],38,70113,DB00495,Zidovudine
,15905735,oral clearance,Median nelfinavir oral clearance was 2.1 L/h/kg at weeks 1 and 6.,Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905735/),[l] / [h·kg],2.1,70114,DB00495,Zidovudine
,19549583,plasma half-life (t(1/2)),"In vivo studies demonstrated that AZT plasma half-life (t(1/2)) is extended after administration of AZT-Ac compared to AZT (2.16 and 0.96h, respectively), while after administering AZT-Iso the t(1/2) of the regenerated AZT was shorter (0.38h).",In vitro and in vivo pharmacokinetic characterization of two novel prodrugs of zidovudine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19549583/),h,2.16,70694,DB00495,Zidovudine
,19549583,plasma half-life (t(1/2)),"In vivo studies demonstrated that AZT plasma half-life (t(1/2)) is extended after administration of AZT-Ac compared to AZT (2.16 and 0.96h, respectively), while after administering AZT-Iso the t(1/2) of the regenerated AZT was shorter (0.38h).",In vitro and in vivo pharmacokinetic characterization of two novel prodrugs of zidovudine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19549583/),h,0.96,70695,DB00495,Zidovudine
,19549583,t(1/2),"In vivo studies demonstrated that AZT plasma half-life (t(1/2)) is extended after administration of AZT-Ac compared to AZT (2.16 and 0.96h, respectively), while after administering AZT-Iso the t(1/2) of the regenerated AZT was shorter (0.38h).",In vitro and in vivo pharmacokinetic characterization of two novel prodrugs of zidovudine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19549583/),h,0.38,70696,DB00495,Zidovudine
,19915744,recovery from plasma,"mL(-1) (r(2) > or = 0.9995), and zidovudine had a mean recovery from plasma of 92.8%.",Reversed phase HPLC determination of zidovudine in rat plasma and its pharmacokinetics after a single intranasal dose administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915744/),%,92.8,72175,DB00495,Zidovudine
,1389940,Cmax,"A protein meal significantly decreased Cmax [532 (228 s.d.) vs 802 (452 s.d.) ng ml-1, P = 0.004] and increased mean residence time (138 (26 s.d.) vs 114 (26 s.d.) min, corrected for lag times, P = 0.001).",The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389940/),[ng] / [ml],532,72286,DB00495,Zidovudine
,1389940,Cmax,"A protein meal significantly decreased Cmax [532 (228 s.d.) vs 802 (452 s.d.) ng ml-1, P = 0.004] and increased mean residence time (138 (26 s.d.) vs 114 (26 s.d.) min, corrected for lag times, P = 0.001).",The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389940/),[ng] / [ml],802,72287,DB00495,Zidovudine
,1389940,mean residence time,"A protein meal significantly decreased Cmax [532 (228 s.d.) vs 802 (452 s.d.) ng ml-1, P = 0.004] and increased mean residence time (138 (26 s.d.) vs 114 (26 s.d.) min, corrected for lag times, P = 0.001).",The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389940/),min,138,72288,DB00495,Zidovudine
,1389940,mean residence time,"A protein meal significantly decreased Cmax [532 (228 s.d.) vs 802 (452 s.d.) ng ml-1, P = 0.004] and increased mean residence time (138 (26 s.d.) vs 114 (26 s.d.) min, corrected for lag times, P = 0.001).",The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389940/),min,114,72289,DB00495,Zidovudine
,9342503,absolute oral bioavailability,"The absolute oral bioavailability is high, approaching 100%.",Clinical pharmacokinetics of stavudine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342503/),%,100,73643,DB00495,Zidovudine
,11310515,area under the serum concentration-time curve,"Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),[h·μg] / [ml],6.08,75768,DB00495,Zidovudine
,11310515,area under the serum concentration-time curve,"Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),[h·μg] / [ml],5.87,75769,DB00495,Zidovudine
,11310515,area under the serum concentration-time curve,"Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),[h·μg] / [ml],5.51,75770,DB00495,Zidovudine
,11310515,area under the serum concentration-time curve,"Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),[h·μg] / [ml],5.53,75771,DB00495,Zidovudine
,11310515,area under the serum concentration-time curve,"Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),[h·μg] / [ml],1.38,75772,DB00495,Zidovudine
,11310515,area under the serum concentration-time curve,"Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),[h·μg] / [ml],1.46,75773,DB00495,Zidovudine
,11310515,maximum serum concentration (Cmax-ss),"Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),[μg] / [ml],3.09,75774,DB00495,Zidovudine
,11310515,maximum serum concentration (Cmax-ss),"Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),[μg] / [ml],3.19,75775,DB00495,Zidovudine
,11310515,maximum serum concentration (Cmax-ss),"Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),[μg] / [ml],1.26,75776,DB00495,Zidovudine
,11310515,maximum serum concentration (Cmax-ss),"Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),[μg] / [ml],1.40,75777,DB00495,Zidovudine
,11310515,maximum serum concentration (Cmax-ss),"Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),[μg] / [ml],1.19,75778,DB00495,Zidovudine
,11310515,maximum serum concentration (Cmax-ss),"Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),[μg] / [ml],1.15,75779,DB00495,Zidovudine
,11310515,time to Cmax-ss,"Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),h,0.75,75780,DB00495,Zidovudine
,11310515,time to Cmax-ss,"Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),h,1.50,75781,DB00495,Zidovudine
,11310515,time to Cmax-ss,"Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),h,1.24,75782,DB00495,Zidovudine
,11310515,oral clearance,"Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),[l] / [h],51,75783,DB00495,Zidovudine
,11310515,oral clearance,"Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),[l] / [h],49,75784,DB00495,Zidovudine
,11310515,oral clearance,"Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),[l] / [h],27,75785,DB00495,Zidovudine
,11310515,oral clearance,"Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),[l] / [h],217,75786,DB00495,Zidovudine
,11310515,oral clearance,"Steady-state pharmacokinetics of ABC, 3TC, and ZDV were similar for the triple combination tablet versus ABC-COM for the following: geometric mean (GM) area under the serum concentration-time curve, ABC 6.08 versus 5.87, 3TC 5.51 versus 5.53, and ZDV 1.38 versus 1.46 microg x hr/ml; GM maximum serum concentration (Cmax-ss), ABC 3.09 versus 3.19, 3TC 1.26 versus 1.40, and ZDV 1.19 versus 1.15 microg/ml; median time to Cmax-ss, ABC 0.75 versus 0.75, 3TC 1.50 versus 1.24, and ZDV 0.75 versus 0.75 hours; and GM oral clearance, ABC 51 versus 49, 3TC 27 versus 27, and ZDV 217 versus 206 L/hour.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),[l] / [h],206,75787,DB00495,Zidovudine
,11310515,half-lives,"The GM half-lives of ABC and ZDV were similar for both treatments, 1.69 versus 1.58 and 2.30 versus 2.08 hours, respectively.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),h,1.69,75788,DB00495,Zidovudine
,11310515,half-lives,"The GM half-lives of ABC and ZDV were similar for both treatments, 1.69 versus 1.58 and 2.30 versus 2.08 hours, respectively.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),h,1.58,75789,DB00495,Zidovudine
,11310515,half-lives,"The GM half-lives of ABC and ZDV were similar for both treatments, 1.69 versus 1.58 and 2.30 versus 2.08 hours, respectively.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),h,2.30,75790,DB00495,Zidovudine
,11310515,half-lives,"The GM half-lives of ABC and ZDV were similar for both treatments, 1.69 versus 1.58 and 2.30 versus 2.08 hours, respectively.","A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11310515/),h,2.08,75791,DB00495,Zidovudine
,18319359,Total g,Total ginsenoside content was 8.5 +/- 0.5%.,"Possible differential induction of phase 2 enzyme and antioxidant pathways by american ginseng, Panax quinquefolius. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18319359/),%,8.5,76338,DB00495,Zidovudine
,12602459,apparent volume of distribution,"The mean (+/- SD) apparent volume of distribution and clearance were 151 L (+/- 94) and 184 L/h (+/- 72), respectively.",Relationship between exposure to zidovudine and decrease of P24 antigenemia in HIV-infected patients in monotherapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602459/),l,151,77619,DB00495,Zidovudine
,12602459,clearance,"The mean (+/- SD) apparent volume of distribution and clearance were 151 L (+/- 94) and 184 L/h (+/- 72), respectively.",Relationship between exposure to zidovudine and decrease of P24 antigenemia in HIV-infected patients in monotherapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602459/),[l] / [h],184,77620,DB00495,Zidovudine
,12602459,initial antigen level,"The mean initial antigen level was 472 pg/mL (+/- 409), the coefficient of reduction of antigenemia was 0.27 (+/- 0.21) and the rate of decrease was 0.27/day (+/- 0.16).",Relationship between exposure to zidovudine and decrease of P24 antigenemia in HIV-infected patients in monotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602459/),[pg] / [ml],472,77621,DB00495,Zidovudine
,12602459,coefficient of,"The mean initial antigen level was 472 pg/mL (+/- 409), the coefficient of reduction of antigenemia was 0.27 (+/- 0.21) and the rate of decrease was 0.27/day (+/- 0.16).",Relationship between exposure to zidovudine and decrease of P24 antigenemia in HIV-infected patients in monotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602459/),,0.27,77622,DB00495,Zidovudine
,12602459,rate of decrease,"The mean initial antigen level was 472 pg/mL (+/- 409), the coefficient of reduction of antigenemia was 0.27 (+/- 0.21) and the rate of decrease was 0.27/day (+/- 0.16).",Relationship between exposure to zidovudine and decrease of P24 antigenemia in HIV-infected patients in monotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602459/),1/[d],0.27,77623,DB00495,Zidovudine
,12602459,area under the curve,"This relationship was adequately described by an Imax model and the daily area under the curve, leading to 50% of antigenemia decrease, was estimated to be 2.32 mg x h/L (+/- 0.33).",Relationship between exposure to zidovudine and decrease of P24 antigenemia in HIV-infected patients in monotherapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602459/),[h·mg] / [l],2.32,77624,DB00495,Zidovudine
,12602459,steady-state concentration,"It was estimated that the average steady-state concentration, which corresponds to 70% of maximal efficacy, was 0.22 mg/L.",Relationship between exposure to zidovudine and decrease of P24 antigenemia in HIV-infected patients in monotherapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602459/),[mg] / [l],0.22,77625,DB00495,Zidovudine
,2613387,elimination half-life,"It has a short elimination half-life (1 h) in patients with normal hepatic and renal functions, and it is extensively metabolized to a glucuronide derivative (GAZT).",Influence of hemodialysis on zidovudine (AZT) and its glucuronide (GAZT) pharmacokinetics: two case reports. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2613387/),h,1,78313,DB00495,Zidovudine
,2613387,elimination half-life,"In patients with end stage renal disease, the AZT elimination half-life is slightly increased (1.9 h) while for GAZT the very important increase of this parameter results in a major risk of accumulation.",Influence of hemodialysis on zidovudine (AZT) and its glucuronide (GAZT) pharmacokinetics: two case reports. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2613387/),h,1.9,78314,DB00495,Zidovudine
,17962426,oral clearance (CL/F),"Mean oral clearance (CL/F) values of lamivudine, zidovudine, and nevirapine for the fixed-dose combination were 23.7, 127, and 1.65 L/h, respectively.","Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17962426/),[l] / [h],23.7,78393,DB00495,Zidovudine
,17962426,oral clearance (CL/F),"Mean oral clearance (CL/F) values of lamivudine, zidovudine, and nevirapine for the fixed-dose combination were 23.7, 127, and 1.65 L/h, respectively.","Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17962426/),[l] / [h],127,78394,DB00495,Zidovudine
,17962426,oral clearance (CL/F),"Mean oral clearance (CL/F) values of lamivudine, zidovudine, and nevirapine for the fixed-dose combination were 23.7, 127, and 1.65 L/h, respectively.","Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17962426/),[l] / [h],1.65,78395,DB00495,Zidovudine
,11153668,oral clearance (CL),"Mean individual Bayesian estimates for oral clearance (CL) and volume of distribution (V) by the final model that incorporated interoccasion variability were 0.75 l/h per kg [coefficient of variation (CV) 54.8%] and 1.74 l/kg (CV 82.7%), respectively.",Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11153668/),[l] / [h·kg],0.75,80493,DB00495,Zidovudine
,11153668,volume of distribution (V),"Mean individual Bayesian estimates for oral clearance (CL) and volume of distribution (V) by the final model that incorporated interoccasion variability were 0.75 l/h per kg [coefficient of variation (CV) 54.8%] and 1.74 l/kg (CV 82.7%), respectively.",Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11153668/),[l] / [kg],1.74,80494,DB00495,Zidovudine
,11153668,plasma half-life,"Mean model-predicted plasma IDV level at 8 h, maximal level, area under the plasma level-time curve up to 8 h and plasma half-life were 0.42 micromol/l (CV 57.5%), 9.51 micromol/l (CV 47.3%), 29.56 micromol/l x h (CV 46.9%) and 1.50 h (CV 20.9%), respectively.",Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11153668/),[μM] / [h·l],29.56,80495,DB00495,Zidovudine
,11153668,plasma half-life,"Mean model-predicted plasma IDV level at 8 h, maximal level, area under the plasma level-time curve up to 8 h and plasma half-life were 0.42 micromol/l (CV 57.5%), 9.51 micromol/l (CV 47.3%), 29.56 micromol/l x h (CV 46.9%) and 1.50 h (CV 20.9%), respectively.",Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11153668/),h,1.50,80496,DB00495,Zidovudine
,11153668,CSF level,The mean IDV CSF level was 0.11 micromol/l (CV 49.7%) and the mean CSF:plasma concentration ratio was 0.017.,Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11153668/),[μM] / [l],0.11,80497,DB00495,Zidovudine
,11153668,CSF:plasma concentration ratio,The mean IDV CSF level was 0.11 micromol/l (CV 49.7%) and the mean CSF:plasma concentration ratio was 0.017.,Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11153668/),,0.017,80498,DB00495,Zidovudine
,18360288,AUC0-12h ratios,"Intracellular median (IQR) SP/BP AUC0-12h ratios for ZDV-TP and 3TC-TP were 0.36 (0.30 to 0.37) and 1.0 (0.62 to 1.30), respectively, whereas individual SP/BP concentration ratios ranged from 0.11 to 2.9.",Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18360288/),,0.36,81107,DB00495,Zidovudine
,18360288,AUC0-12h ratios,"Intracellular median (IQR) SP/BP AUC0-12h ratios for ZDV-TP and 3TC-TP were 0.36 (0.30 to 0.37) and 1.0 (0.62 to 1.30), respectively, whereas individual SP/BP concentration ratios ranged from 0.11 to 2.9.",Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18360288/),,1.0,81108,DB00495,Zidovudine
,18360288,concentration ratios,"Intracellular median (IQR) SP/BP AUC0-12h ratios for ZDV-TP and 3TC-TP were 0.36 (0.30 to 0.37) and 1.0 (0.62 to 1.30), respectively, whereas individual SP/BP concentration ratios ranged from 0.11 to 2.9.",Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18360288/),,0.11,81109,DB00495,Zidovudine
,2016843,half-life,"The half-life of antipyrine decreased (patient 1 from 11.3 to 8.4 h and patient 2 from 10.7 to 7.6 h after rifampin, patient 3 from 12.2 to 8.6 h after fucidic acid, and patient 4 from 10.6 to 8.6 h after zidovudine).",Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2016843/),h,11.3 to 8.4,81404,DB00495,Zidovudine
,2016843,half-life,"The half-life of antipyrine decreased (patient 1 from 11.3 to 8.4 h and patient 2 from 10.7 to 7.6 h after rifampin, patient 3 from 12.2 to 8.6 h after fucidic acid, and patient 4 from 10.6 to 8.6 h after zidovudine).",Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2016843/),h,10.7 to 7.6,81405,DB00495,Zidovudine
,2016843,half-life,"The half-life of antipyrine decreased (patient 1 from 11.3 to 8.4 h and patient 2 from 10.7 to 7.6 h after rifampin, patient 3 from 12.2 to 8.6 h after fucidic acid, and patient 4 from 10.6 to 8.6 h after zidovudine).",Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2016843/),h,12.2 to 8.6,81406,DB00495,Zidovudine
,2016843,half-life,"The half-life of antipyrine decreased (patient 1 from 11.3 to 8.4 h and patient 2 from 10.7 to 7.6 h after rifampin, patient 3 from 12.2 to 8.6 h after fucidic acid, and patient 4 from 10.6 to 8.6 h after zidovudine).",Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2016843/),h,10.6 to 8.6,81407,DB00495,Zidovudine
,10432717,IC50,"dT-N4-pamddC was the most active (IC50 = 40 microM, EC50 = 80 nM) and least toxic (TI = 524) dimer and it exhibited also strong antiviral effects against eight AZT-resistant HIV strains.","Synthesis, in vitro anti-HIV and anti-hepatitis B activities and pharmacokinetic properties of amphiphilic heterodinucleoside phosphates containing ddC and AZT. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10432717/),μM,40,83095,DB00495,Zidovudine
,10432717,EC50,"dT-N4-pamddC was the most active (IC50 = 40 microM, EC50 = 80 nM) and least toxic (TI = 524) dimer and it exhibited also strong antiviral effects against eight AZT-resistant HIV strains.","Synthesis, in vitro anti-HIV and anti-hepatitis B activities and pharmacokinetic properties of amphiphilic heterodinucleoside phosphates containing ddC and AZT. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10432717/),nM,80,83096,DB00495,Zidovudine
,10432717,TI,"dT-N4-pamddC was the most active (IC50 = 40 microM, EC50 = 80 nM) and least toxic (TI = 524) dimer and it exhibited also strong antiviral effects against eight AZT-resistant HIV strains.","Synthesis, in vitro anti-HIV and anti-hepatitis B activities and pharmacokinetic properties of amphiphilic heterodinucleoside phosphates containing ddC and AZT. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10432717/),,524,83097,DB00495,Zidovudine
,2357867,oral clearance,"As a consequence of a marked drop in oral clearance (10 +/- 4 versus 38 +/- 15 ml/min/kg), zidovudine concentrations, half-life, and mean residence time were increased in patients with cirrhosis.",Pharmacokinetics of zidovudine in patients with liver cirrhosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357867/),[ml] / [kg·min],10,84187,DB00495,Zidovudine
,2357867,oral clearance,"As a consequence of a marked drop in oral clearance (10 +/- 4 versus 38 +/- 15 ml/min/kg), zidovudine concentrations, half-life, and mean residence time were increased in patients with cirrhosis.",Pharmacokinetics of zidovudine in patients with liver cirrhosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357867/),[ml] / [kg·min],38,84188,DB00495,Zidovudine
,2357867,formation clearance,"The reason for such a decrease in oral clearance of zidovudine was the reduction in the GAZT formation clearance (236 +/- 73 versus 1540 +/- 540 ml/min); this led to a decrease in the AUC ratio of GAZT and zidovudine (1.3 +/- 0.6 versus 4.6 +/- 0.7), which was directly related to the severity of the cirrhosis.",Pharmacokinetics of zidovudine in patients with liver cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357867/),[ml] / [min],236,84189,DB00495,Zidovudine
,2357867,formation clearance,"The reason for such a decrease in oral clearance of zidovudine was the reduction in the GAZT formation clearance (236 +/- 73 versus 1540 +/- 540 ml/min); this led to a decrease in the AUC ratio of GAZT and zidovudine (1.3 +/- 0.6 versus 4.6 +/- 0.7), which was directly related to the severity of the cirrhosis.",Pharmacokinetics of zidovudine in patients with liver cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357867/),[ml] / [min],1540,84190,DB00495,Zidovudine
,2357867,AUC ratio,"The reason for such a decrease in oral clearance of zidovudine was the reduction in the GAZT formation clearance (236 +/- 73 versus 1540 +/- 540 ml/min); this led to a decrease in the AUC ratio of GAZT and zidovudine (1.3 +/- 0.6 versus 4.6 +/- 0.7), which was directly related to the severity of the cirrhosis.",Pharmacokinetics of zidovudine in patients with liver cirrhosis. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357867/),,1.3,84191,DB00495,Zidovudine
,2357867,AUC ratio,"The reason for such a decrease in oral clearance of zidovudine was the reduction in the GAZT formation clearance (236 +/- 73 versus 1540 +/- 540 ml/min); this led to a decrease in the AUC ratio of GAZT and zidovudine (1.3 +/- 0.6 versus 4.6 +/- 0.7), which was directly related to the severity of the cirrhosis.",Pharmacokinetics of zidovudine in patients with liver cirrhosis. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357867/),,4.6,84192,DB00495,Zidovudine
,8112367,volume of distribution,"On Day 1, the mean (coefficient of variation) volume of distribution of zidovudine was 94.41 (90%), its mean half-life was 0.81 h (107%) and its mean oral clearance was 117 l.h-1 (57%) and on Day 35, these values were, respectively, 1121 (139%), 0.75 h (181%) and 295 l.h-1 (196%).",Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112367/),,94.41,84452,DB00495,Zidovudine
,8112367,half-life,"On Day 1, the mean (coefficient of variation) volume of distribution of zidovudine was 94.41 (90%), its mean half-life was 0.81 h (107%) and its mean oral clearance was 117 l.h-1 (57%) and on Day 35, these values were, respectively, 1121 (139%), 0.75 h (181%) and 295 l.h-1 (196%).",Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112367/),h,0.81,84453,DB00495,Zidovudine
,8112367,oral clearance,"On Day 1, the mean (coefficient of variation) volume of distribution of zidovudine was 94.41 (90%), its mean half-life was 0.81 h (107%) and its mean oral clearance was 117 l.h-1 (57%) and on Day 35, these values were, respectively, 1121 (139%), 0.75 h (181%) and 295 l.h-1 (196%).",Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112367/),[l] / [h],117,84454,DB00495,Zidovudine
,8112367,oral clearance,"On Day 1, the mean (coefficient of variation) volume of distribution of zidovudine was 94.41 (90%), its mean half-life was 0.81 h (107%) and its mean oral clearance was 117 l.h-1 (57%) and on Day 35, these values were, respectively, 1121 (139%), 0.75 h (181%) and 295 l.h-1 (196%).",Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112367/),,1121,84455,DB00495,Zidovudine
,8112367,oral clearance,"On Day 1, the mean (coefficient of variation) volume of distribution of zidovudine was 94.41 (90%), its mean half-life was 0.81 h (107%) and its mean oral clearance was 117 l.h-1 (57%) and on Day 35, these values were, respectively, 1121 (139%), 0.75 h (181%) and 295 l.h-1 (196%).",Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112367/),h,0.75,84456,DB00495,Zidovudine
,8112367,oral clearance,"On Day 1, the mean (coefficient of variation) volume of distribution of zidovudine was 94.41 (90%), its mean half-life was 0.81 h (107%) and its mean oral clearance was 117 l.h-1 (57%) and on Day 35, these values were, respectively, 1121 (139%), 0.75 h (181%) and 295 l.h-1 (196%).",Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112367/),[l] / [h],295,84457,DB00495,Zidovudine
,8112367,steady stade concentration,"A significant relationship between mean daily concentration and toxicity was found, with an hazard of occurrence of toxicity 4.3-times larger when the mean steady stade concentration was 0.8 mg.l-1 than 0.6.",Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112367/),[mg] / [l],0.8,84458,DB00495,Zidovudine
>,18474496,AUC0-24,The pharmacokinetic (PK) target was an extrapolated NFV AUC0-24 > 30 mug .,Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474496/),μg,30,84697,DB00495,Zidovudine
,18474496,Cmax,"When Cohort 2 NFV PK parameters AP and PP were compared, median Cmax (3.90 microg/mL vs. 5.01 microg/mL, p < .05) and AUC0-24 (56.6 vs. 86.8 microg . h/mL, p < .05) were increased PP and oral clearance (Cl/F; 44.2 vs. 28.8 L/h, p < .05) was decreased PP.",Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474496/),[μg] / [ml],3.90,84698,DB00495,Zidovudine
,18474496,Cmax,"When Cohort 2 NFV PK parameters AP and PP were compared, median Cmax (3.90 microg/mL vs. 5.01 microg/mL, p < .05) and AUC0-24 (56.6 vs. 86.8 microg . h/mL, p < .05) were increased PP and oral clearance (Cl/F; 44.2 vs. 28.8 L/h, p < .05) was decreased PP.",Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474496/),[μg] / [ml],5.01,84699,DB00495,Zidovudine
,18474496,AUC0-24,"When Cohort 2 NFV PK parameters AP and PP were compared, median Cmax (3.90 microg/mL vs. 5.01 microg/mL, p < .05) and AUC0-24 (56.6 vs. 86.8 microg . h/mL, p < .05) were increased PP and oral clearance (Cl/F; 44.2 vs. 28.8 L/h, p < .05) was decreased PP.",Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474496/),[h·μg] / [ml],56.6,84700,DB00495,Zidovudine
,18474496,AUC0-24,"When Cohort 2 NFV PK parameters AP and PP were compared, median Cmax (3.90 microg/mL vs. 5.01 microg/mL, p < .05) and AUC0-24 (56.6 vs. 86.8 microg . h/mL, p < .05) were increased PP and oral clearance (Cl/F; 44.2 vs. 28.8 L/h, p < .05) was decreased PP.",Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474496/),[h·μg] / [ml],86.8,84701,DB00495,Zidovudine
,18474496,oral clearance (Cl/F,"When Cohort 2 NFV PK parameters AP and PP were compared, median Cmax (3.90 microg/mL vs. 5.01 microg/mL, p < .05) and AUC0-24 (56.6 vs. 86.8 microg . h/mL, p < .05) were increased PP and oral clearance (Cl/F; 44.2 vs. 28.8 L/h, p < .05) was decreased PP.",Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474496/),[l] / [h],44.2,84702,DB00495,Zidovudine
,18474496,oral clearance (Cl/F,"When Cohort 2 NFV PK parameters AP and PP were compared, median Cmax (3.90 microg/mL vs. 5.01 microg/mL, p < .05) and AUC0-24 (56.6 vs. 86.8 microg . h/mL, p < .05) were increased PP and oral clearance (Cl/F; 44.2 vs. 28.8 L/h, p < .05) was decreased PP.",Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474496/),[l] / [h],28.8,84703,DB00495,Zidovudine
,18474496,cord blood:maternal plasma ratio,Placental transfer of NFV was low with a median cord blood:maternal plasma ratio at delivery of 0.05.,Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18474496/),,0.05,84704,DB00495,Zidovudine
,1501232,half-life,The results demonstrated the promising qualities of the prodrug 3 which gave AZT-5'-phosphate as the main metabolite: the total concentration of AZT derivatives detected in brain presented a peak of 156 nmol/g (5 nmol/g for AZT) at 1 h; the half-life was about 24 h (1 h for AZT) with an AUC of 4366 nmol h/g as compared to 4 nmol h/g for AZT.,Improved brain delivery of AZT using a glycosyl phosphotriester prodrug. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501232/),h,24,86766,DB00495,Zidovudine
,1501232,half-life,The results demonstrated the promising qualities of the prodrug 3 which gave AZT-5'-phosphate as the main metabolite: the total concentration of AZT derivatives detected in brain presented a peak of 156 nmol/g (5 nmol/g for AZT) at 1 h; the half-life was about 24 h (1 h for AZT) with an AUC of 4366 nmol h/g as compared to 4 nmol h/g for AZT.,Improved brain delivery of AZT using a glycosyl phosphotriester prodrug. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501232/),h,1,86767,DB00495,Zidovudine
,1501232,AUC,The results demonstrated the promising qualities of the prodrug 3 which gave AZT-5'-phosphate as the main metabolite: the total concentration of AZT derivatives detected in brain presented a peak of 156 nmol/g (5 nmol/g for AZT) at 1 h; the half-life was about 24 h (1 h for AZT) with an AUC of 4366 nmol h/g as compared to 4 nmol h/g for AZT.,Improved brain delivery of AZT using a glycosyl phosphotriester prodrug. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501232/),[h·nM] / [g],4366,86768,DB00495,Zidovudine
,1501232,AUC,The results demonstrated the promising qualities of the prodrug 3 which gave AZT-5'-phosphate as the main metabolite: the total concentration of AZT derivatives detected in brain presented a peak of 156 nmol/g (5 nmol/g for AZT) at 1 h; the half-life was about 24 h (1 h for AZT) with an AUC of 4366 nmol h/g as compared to 4 nmol h/g for AZT.,Improved brain delivery of AZT using a glycosyl phosphotriester prodrug. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501232/),[h·nM] / [g],4,86769,DB00495,Zidovudine
,9241112,concentrations,"AMT can be detected in the CSF after oral administration of ZDV; concentrations of AMT in CSF ranged from 0.75 to 4.8 ng/ml (median, 1.7 ng/ml).","Penetration of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241112/),,0.75 to 4.8,88251,DB00495,Zidovudine
,9241112,concentrations,"AMT can be detected in the CSF after oral administration of ZDV; concentrations of AMT in CSF ranged from 0.75 to 4.8 ng/ml (median, 1.7 ng/ml).","Penetration of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241112/),ng,1.7,88252,DB00495,Zidovudine
,9241112,CSF-plasma concentration ratio,"The median CSF-plasma concentration ratio was 1, and equaled that for ZDV.","Penetration of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241112/),,1,88253,DB00495,Zidovudine
,2469710,half-life,"AZT levels on day 14 were significantly higher than the corresponding levels on day 7, resulting in a 2-fold increase of the area under the serum concentration-time curve (AUC) and a prolongation of the mean half-life of AZT (44 to 70 min) during the INPX treatment.",Pharmacokinetics of zidovudine and concomitant inosine-pranobex in AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469710/),min,44 to 70,88342,DB00495,Zidovudine
,1503443,50% effective concentration,"3'-Fluoro-3'-deoxythymidine (FLT), a candidate anti-AIDS compound in clinical trials, showed anti-human immunodeficiency virus type 1 (HIV-1) potency (50% effective concentration, 0.0052 microM) slightly better than or equal to that of 3'-azido-3'-deoxythymidine (AZT) in MT4 cells and was threefold more potent in H9 cells.","Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503443/),μM,0.0052,88533,DB00495,Zidovudine
greater,1503443,selectivity indices (efficacy/toxicity ratio),"Both FLT and AZT showed low cytotoxicity for MT4 cells, with selectivity indices (efficacy/toxicity ratio) of greater than 47,000 and greater than 33,000, respectively.","Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503443/),,"47,000",88534,DB00495,Zidovudine
greater,1503443,selectivity indices (efficacy/toxicity ratio),"Both FLT and AZT showed low cytotoxicity for MT4 cells, with selectivity indices (efficacy/toxicity ratio) of greater than 47,000 and greater than 33,000, respectively.","Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503443/),,"33,000",88535,DB00495,Zidovudine
,1503443,initial half-lives,"The elimination kinetics of FLTTP and AZTTP in HIV-1-infected MT4 cells in fresh medium showed biphasic patterns, with initial half-lives of 1.03 and 1.09 h, respectively.","Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503443/),h,1.03,88536,DB00495,Zidovudine
,1503443,initial half-lives,"The elimination kinetics of FLTTP and AZTTP in HIV-1-infected MT4 cells in fresh medium showed biphasic patterns, with initial half-lives of 1.03 and 1.09 h, respectively.","Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503443/),h,1.09,88537,DB00495,Zidovudine
,1503443,half-life,"Pharmacokinetics of FLT in plasma of monkeys after intravenous (i.v.) administration showed that the FLT concentration in plasma declined, with a half-life of 1.19 +/- 0.1 h; the steady-state volume of distribution was 0.93 +/- 0.2 liter/kg of body weight, and total clearance was 0.56 +/- 0.15 liter/kg.","Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503443/),h,1.19,88538,DB00495,Zidovudine
,1503443,steady-state volume of distribution,"Pharmacokinetics of FLT in plasma of monkeys after intravenous (i.v.) administration showed that the FLT concentration in plasma declined, with a half-life of 1.19 +/- 0.1 h; the steady-state volume of distribution was 0.93 +/- 0.2 liter/kg of body weight, and total clearance was 0.56 +/- 0.15 liter/kg.","Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503443/),[l] / [kg],0.93,88539,DB00495,Zidovudine
,1503443,total clearance,"Pharmacokinetics of FLT in plasma of monkeys after intravenous (i.v.) administration showed that the FLT concentration in plasma declined, with a half-life of 1.19 +/- 0.1 h; the steady-state volume of distribution was 0.93 +/- 0.2 liter/kg of body weight, and total clearance was 0.56 +/- 0.15 liter/kg.","Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503443/),[l] / [kg],0.56,88540,DB00495,Zidovudine
,24446424,AUC₀₋₂₄,"Exposures to both amodiaquine and DEAQ were significantly lower in the nevirapine-based ART group compared with the control group (amodiaquine AUC₀₋₂₄ 145 versus 204 ng·h/mL, P = 0.02; DEAQ AUC₀₋₉₆ 14,571 versus 21,648 ng·h/mL, P < 0.01).",Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24446424/),[h·ng] / [ml],145,88723,DB00495,Zidovudine
,24446424,AUC₀₋₂₄,"Exposures to both amodiaquine and DEAQ were significantly lower in the nevirapine-based ART group compared with the control group (amodiaquine AUC₀₋₂₄ 145 versus 204 ng·h/mL, P = 0.02; DEAQ AUC₀₋₉₆ 14,571 versus 21,648 ng·h/mL, P < 0.01).",Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24446424/),[h·ng] / [ml],204,88724,DB00495,Zidovudine
,24446424,AUC₀₋₉₆,"Exposures to both amodiaquine and DEAQ were significantly lower in the nevirapine-based ART group compared with the control group (amodiaquine AUC₀₋₂₄ 145 versus 204 ng·h/mL, P = 0.02; DEAQ AUC₀₋₉₆ 14,571 versus 21,648 ng·h/mL, P < 0.01).",Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24446424/),[h·ng] / [ml],"14,571",88725,DB00495,Zidovudine
,24446424,AUC₀₋₉₆,"Exposures to both amodiaquine and DEAQ were significantly lower in the nevirapine-based ART group compared with the control group (amodiaquine AUC₀₋₂₄ 145 versus 204 ng·h/mL, P = 0.02; DEAQ AUC₀₋₉₆ 14,571 versus 21,648 ng·h/mL, P < 0.01).",Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24446424/),[h·ng] / [ml],"21,648",88726,DB00495,Zidovudine
,24446424,AUCDEAQ/AUC,"The AUCDEAQ/AUC(amodiaquine) ratio was not different between groups (ART group 116 versus control group 102, P = 0.67).",Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24446424/),,116,88727,DB00495,Zidovudine
,24446424,AUCDEAQ/AUC,"The AUCDEAQ/AUC(amodiaquine) ratio was not different between groups (ART group 116 versus control group 102, P = 0.67).",Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24446424/),,102,88728,DB00495,Zidovudine
,7574530,maximum concentrations,"The maximum concentrations of zidovudine in plasma were significantly different in phases 1 and 2 (616.6 and 949.0 ng/ml, respectively), as were the times to the maximum concentrations of zidovudine (2.1 and 1.0 h, respectively).",Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574530/),[ng] / [ml],616.6,89181,DB00495,Zidovudine
,7574530,maximum concentrations,"The maximum concentrations of zidovudine in plasma were significantly different in phases 1 and 2 (616.6 and 949.0 ng/ml, respectively), as were the times to the maximum concentrations of zidovudine (2.1 and 1.0 h, respectively).",Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574530/),[ng] / [ml],949.0,89182,DB00495,Zidovudine
,7574530,times to the maximum concentrations,"The maximum concentrations of zidovudine in plasma were significantly different in phases 1 and 2 (616.6 and 949.0 ng/ml, respectively), as were the times to the maximum concentrations of zidovudine (2.1 and 1.0 h, respectively).",Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574530/),h,2.1,89183,DB00495,Zidovudine
,7574530,times to the maximum concentrations,"The maximum concentrations of zidovudine in plasma were significantly different in phases 1 and 2 (616.6 and 949.0 ng/ml, respectively), as were the times to the maximum concentrations of zidovudine (2.1 and 1.0 h, respectively).",Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574530/),h,1.0,89184,DB00495,Zidovudine
,8655204,Time to reach peak concentrations,"Time to reach peak concentrations and mean terminal elimination half-life times (t1/2 beta = 63.4 +/- 47.6, 74.9 +/- 54.9 and 56.9 +/- 16.4 min in group 1, 2 and 3, respectively, mean +/- SD) were not significantly different between the three groups.",Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8655204/),min,63.4,89216,DB00495,Zidovudine
,8655204,terminal elimination half-life times (t1/2 beta,"Time to reach peak concentrations and mean terminal elimination half-life times (t1/2 beta = 63.4 +/- 47.6, 74.9 +/- 54.9 and 56.9 +/- 16.4 min in group 1, 2 and 3, respectively, mean +/- SD) were not significantly different between the three groups.",Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8655204/),min,74.9,89217,DB00495,Zidovudine
,8655204,terminal elimination half-life times (t1/2 beta,"Time to reach peak concentrations and mean terminal elimination half-life times (t1/2 beta = 63.4 +/- 47.6, 74.9 +/- 54.9 and 56.9 +/- 16.4 min in group 1, 2 and 3, respectively, mean +/- SD) were not significantly different between the three groups.",Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8655204/),min,56.9,89218,DB00495,Zidovudine
,8655204,Cmax,"With normalization to dose/bw young children in comparison to adults had significantly lower Cmax (2.7 +/- 1.3 vs. 4.6 +/- 2.4 mumol/l, p = 0.016) and AUC (226 +/- 108 vs. 373 +/- 224 mumol.min/l, p = 0.038).",Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8655204/),[μM] / [l],2.7,89219,DB00495,Zidovudine
,8655204,Cmax,"With normalization to dose/bw young children in comparison to adults had significantly lower Cmax (2.7 +/- 1.3 vs. 4.6 +/- 2.4 mumol/l, p = 0.016) and AUC (226 +/- 108 vs. 373 +/- 224 mumol.min/l, p = 0.038).",Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8655204/),[μM] / [l],4.6,89220,DB00495,Zidovudine
,8655204,AUC,"With normalization to dose/bw young children in comparison to adults had significantly lower Cmax (2.7 +/- 1.3 vs. 4.6 +/- 2.4 mumol/l, p = 0.016) and AUC (226 +/- 108 vs. 373 +/- 224 mumol.min/l, p = 0.038).",Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8655204/),[min·μM] / [l],226,89221,DB00495,Zidovudine
,8655204,AUC,"With normalization to dose/bw young children in comparison to adults had significantly lower Cmax (2.7 +/- 1.3 vs. 4.6 +/- 2.4 mumol/l, p = 0.016) and AUC (226 +/- 108 vs. 373 +/- 224 mumol.min/l, p = 0.038).",Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8655204/),[min·μM] / [l],373,89222,DB00495,Zidovudine
,8655204,Cmax,"However, with normalization to dose/bs differences in Cmax (6.5 +/- 3.3, 7.3 +/- 4.2 and 6.8 +/- 3.6 mumol/l, in group 1, 2, and 3, respectively) and AUC (563 +/- 313, 691 +/- 351 and 555 +/- 342 mumol.min/l, in group 1, 2 and 3) were not significant between the three groups.",Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8655204/),[μM] / [l],6.5,89223,DB00495,Zidovudine
,8655204,Cmax,"However, with normalization to dose/bs differences in Cmax (6.5 +/- 3.3, 7.3 +/- 4.2 and 6.8 +/- 3.6 mumol/l, in group 1, 2, and 3, respectively) and AUC (563 +/- 313, 691 +/- 351 and 555 +/- 342 mumol.min/l, in group 1, 2 and 3) were not significant between the three groups.",Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8655204/),[μM] / [l],7.3,89224,DB00495,Zidovudine
,8655204,Cmax,"However, with normalization to dose/bs differences in Cmax (6.5 +/- 3.3, 7.3 +/- 4.2 and 6.8 +/- 3.6 mumol/l, in group 1, 2, and 3, respectively) and AUC (563 +/- 313, 691 +/- 351 and 555 +/- 342 mumol.min/l, in group 1, 2 and 3) were not significant between the three groups.",Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8655204/),[μM] / [l],6.8,89225,DB00495,Zidovudine
,8655204,AUC,"However, with normalization to dose/bs differences in Cmax (6.5 +/- 3.3, 7.3 +/- 4.2 and 6.8 +/- 3.6 mumol/l, in group 1, 2, and 3, respectively) and AUC (563 +/- 313, 691 +/- 351 and 555 +/- 342 mumol.min/l, in group 1, 2 and 3) were not significant between the three groups.",Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8655204/),[min·μM] / [l],563,89226,DB00495,Zidovudine
,8655204,AUC,"However, with normalization to dose/bs differences in Cmax (6.5 +/- 3.3, 7.3 +/- 4.2 and 6.8 +/- 3.6 mumol/l, in group 1, 2, and 3, respectively) and AUC (563 +/- 313, 691 +/- 351 and 555 +/- 342 mumol.min/l, in group 1, 2 and 3) were not significant between the three groups.",Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8655204/),[min·μM] / [l],691,89227,DB00495,Zidovudine
,8655204,AUC,"However, with normalization to dose/bs differences in Cmax (6.5 +/- 3.3, 7.3 +/- 4.2 and 6.8 +/- 3.6 mumol/l, in group 1, 2, and 3, respectively) and AUC (563 +/- 313, 691 +/- 351 and 555 +/- 342 mumol.min/l, in group 1, 2 and 3) were not significant between the three groups.",Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8655204/),[min·μM] / [l],555,89228,DB00495,Zidovudine
,1740749,serum half-lives,ZDV serum half-lives on day 1 were 7.9 h (patient 1) and 2.6 h (patient 2).,Pharmacokinetics of single and chronic dose zidovudine in two HIV positive patients undergoing continuous ambulatory peritoneal dialysis (CAPD). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740749/),h,7.9,89497,DB00495,Zidovudine
,1740749,serum half-lives,ZDV serum half-lives on day 1 were 7.9 h (patient 1) and 2.6 h (patient 2).,Pharmacokinetics of single and chronic dose zidovudine in two HIV positive patients undergoing continuous ambulatory peritoneal dialysis (CAPD). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740749/),h,2.6,89498,DB00495,Zidovudine
,1740749,half-lives,"The apparent GZDV half-lives on day 1 were 19.9 h (patient 1) and 7.1 h (patient 2), with resultant accumulation of metabolite (up to 36 micrograms/ml) during chronic therapy.",Pharmacokinetics of single and chronic dose zidovudine in two HIV positive patients undergoing continuous ambulatory peritoneal dialysis (CAPD). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740749/),h,19.9,89499,DB00495,Zidovudine
,1740749,half-lives,"The apparent GZDV half-lives on day 1 were 19.9 h (patient 1) and 7.1 h (patient 2), with resultant accumulation of metabolite (up to 36 micrograms/ml) during chronic therapy.",Pharmacokinetics of single and chronic dose zidovudine in two HIV positive patients undergoing continuous ambulatory peritoneal dialysis (CAPD). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740749/),h,7.1,89500,DB00495,Zidovudine
,1740749,peritoneal clearances,"After the initial dwell (tau) following single dose, peritoneal clearances of ZDV were 4.3 ml/min (tau = 4 h, patient 1) and 5.9 ml/min (tau = 5 h, patient 2), and GZDV clearances were 6.7 and 5.1 ml/min, respectively.",Pharmacokinetics of single and chronic dose zidovudine in two HIV positive patients undergoing continuous ambulatory peritoneal dialysis (CAPD). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740749/),[ml] / [min],4.3,89501,DB00495,Zidovudine
,1740749,peritoneal clearances,"After the initial dwell (tau) following single dose, peritoneal clearances of ZDV were 4.3 ml/min (tau = 4 h, patient 1) and 5.9 ml/min (tau = 5 h, patient 2), and GZDV clearances were 6.7 and 5.1 ml/min, respectively.",Pharmacokinetics of single and chronic dose zidovudine in two HIV positive patients undergoing continuous ambulatory peritoneal dialysis (CAPD). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740749/),[ml] / [min],5.9,89502,DB00495,Zidovudine
,1740749,tau,"After the initial dwell (tau) following single dose, peritoneal clearances of ZDV were 4.3 ml/min (tau = 4 h, patient 1) and 5.9 ml/min (tau = 5 h, patient 2), and GZDV clearances were 6.7 and 5.1 ml/min, respectively.",Pharmacokinetics of single and chronic dose zidovudine in two HIV positive patients undergoing continuous ambulatory peritoneal dialysis (CAPD). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740749/),h,4,89503,DB00495,Zidovudine
,1740749,tau,"After the initial dwell (tau) following single dose, peritoneal clearances of ZDV were 4.3 ml/min (tau = 4 h, patient 1) and 5.9 ml/min (tau = 5 h, patient 2), and GZDV clearances were 6.7 and 5.1 ml/min, respectively.",Pharmacokinetics of single and chronic dose zidovudine in two HIV positive patients undergoing continuous ambulatory peritoneal dialysis (CAPD). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740749/),[ml] / [min],5.9,89504,DB00495,Zidovudine
,1740749,tau,"After the initial dwell (tau) following single dose, peritoneal clearances of ZDV were 4.3 ml/min (tau = 4 h, patient 1) and 5.9 ml/min (tau = 5 h, patient 2), and GZDV clearances were 6.7 and 5.1 ml/min, respectively.",Pharmacokinetics of single and chronic dose zidovudine in two HIV positive patients undergoing continuous ambulatory peritoneal dialysis (CAPD). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740749/),h,5,89505,DB00495,Zidovudine
,1740749,clearances,"After the initial dwell (tau) following single dose, peritoneal clearances of ZDV were 4.3 ml/min (tau = 4 h, patient 1) and 5.9 ml/min (tau = 5 h, patient 2), and GZDV clearances were 6.7 and 5.1 ml/min, respectively.",Pharmacokinetics of single and chronic dose zidovudine in two HIV positive patients undergoing continuous ambulatory peritoneal dialysis (CAPD). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740749/),[ml] / [min],6.7,89506,DB00495,Zidovudine
,1740749,clearances,"After the initial dwell (tau) following single dose, peritoneal clearances of ZDV were 4.3 ml/min (tau = 4 h, patient 1) and 5.9 ml/min (tau = 5 h, patient 2), and GZDV clearances were 6.7 and 5.1 ml/min, respectively.",Pharmacokinetics of single and chronic dose zidovudine in two HIV positive patients undergoing continuous ambulatory peritoneal dialysis (CAPD). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740749/),[ml] / [min],5.1,89507,DB00495,Zidovudine
less,1740749,serum protein binding,ZDV serum protein binding was less than 10%.,Pharmacokinetics of single and chronic dose zidovudine in two HIV positive patients undergoing continuous ambulatory peritoneal dialysis (CAPD). ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740749/),%,10,89508,DB00495,Zidovudine
,11978144,half-life,"Following intravitreal administration, fomivirsen is slowly cleared from vitreous with a half-life of approximately 55 hours in humans.",Fomivirsen: clinical pharmacology and potential drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11978144/),h,55,90169,DB00495,Zidovudine
,11978144,half-life for clearance,The estimated half-life for clearance of fomivirsen from retina was 78 hours in monkeys following a 115-microg dose.,Fomivirsen: clinical pharmacology and potential drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11978144/),h,78,90170,DB00495,Zidovudine
,8193419,tmax,"The results showed extremely rapid absorption of both drugs (tmax the time to reach maximum concentration, 10-15 minutes for acetaminophen and 15-20 minutes for zidovudine) and, consequently, relatively high maximum plasma concentration (Cmax).",Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193419/),min,10-15,91599,DB00495,Zidovudine
,8193419,tmax,"The results showed extremely rapid absorption of both drugs (tmax the time to reach maximum concentration, 10-15 minutes for acetaminophen and 15-20 minutes for zidovudine) and, consequently, relatively high maximum plasma concentration (Cmax).",Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193419/),min,15-20,91600,DB00495,Zidovudine
,8193419,time to reach maximum concentration,"The results showed extremely rapid absorption of both drugs (tmax the time to reach maximum concentration, 10-15 minutes for acetaminophen and 15-20 minutes for zidovudine) and, consequently, relatively high maximum plasma concentration (Cmax).",Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193419/),min,10-15,91601,DB00495,Zidovudine
,8193419,time to reach maximum concentration,"The results showed extremely rapid absorption of both drugs (tmax the time to reach maximum concentration, 10-15 minutes for acetaminophen and 15-20 minutes for zidovudine) and, consequently, relatively high maximum plasma concentration (Cmax).",Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8193419/),min,15-20,91602,DB00495,Zidovudine
,7479197,total clearance,"The mean (SD) ZDV pharmacokinetic values were total clearance 1.44 (1.09) L/hr/kg, volume of distribution 2.72 (2.97) L/kg, and half-life 1.2 (0.6) hours.",Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479197/),[l] / [h·kg],1.44,91924,DB00495,Zidovudine
,7479197,volume of distribution,"The mean (SD) ZDV pharmacokinetic values were total clearance 1.44 (1.09) L/hr/kg, volume of distribution 2.72 (2.97) L/kg, and half-life 1.2 (0.6) hours.",Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479197/),[l] / [kg],2.72,91925,DB00495,Zidovudine
,7479197,half-life,"The mean (SD) ZDV pharmacokinetic values were total clearance 1.44 (1.09) L/hr/kg, volume of distribution 2.72 (2.97) L/kg, and half-life 1.2 (0.6) hours.",Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479197/),h,1.2,91926,DB00495,Zidovudine
,32481459,run-time,"The chromatographic separation was achieved with a run-time of 3.0 minutes and 3-μL injection on an ethylene bridged hybrid C18 column (2.1 μm × 50 mm, 1.7 μm), under gradient conditions using acetonitrile and formic acid (0.1%).","Assessment of lamivudine, zidovudine, lopinavir, and ritonavir plasma levels in HIV-positive pregnant women: Drug monitoring application to improve patient safety. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32481459/),min,3.0,91946,DB00495,Zidovudine
,32481459,Minimum absolute recovery percentages,"Minimum absolute recovery percentages (%CV) were 90.5 (5.4), 90.8 (5.0), 95.4 (3.5), and 93.7 (6.9), for LMV, ZDV, LPV, and RTV, respectively.","Assessment of lamivudine, zidovudine, lopinavir, and ritonavir plasma levels in HIV-positive pregnant women: Drug monitoring application to improve patient safety. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32481459/),%,90.5,91947,DB00495,Zidovudine
,32481459,Minimum absolute recovery percentages,"Minimum absolute recovery percentages (%CV) were 90.5 (5.4), 90.8 (5.0), 95.4 (3.5), and 93.7 (6.9), for LMV, ZDV, LPV, and RTV, respectively.","Assessment of lamivudine, zidovudine, lopinavir, and ritonavir plasma levels in HIV-positive pregnant women: Drug monitoring application to improve patient safety. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32481459/),%,90.8,91948,DB00495,Zidovudine
,32481459,Minimum absolute recovery percentages,"Minimum absolute recovery percentages (%CV) were 90.5 (5.4), 90.8 (5.0), 95.4 (3.5), and 93.7 (6.9), for LMV, ZDV, LPV, and RTV, respectively.","Assessment of lamivudine, zidovudine, lopinavir, and ritonavir plasma levels in HIV-positive pregnant women: Drug monitoring application to improve patient safety. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32481459/),%,95.4,91949,DB00495,Zidovudine
,32481459,Minimum absolute recovery percentages,"Minimum absolute recovery percentages (%CV) were 90.5 (5.4), 90.8 (5.0), 95.4 (3.5), and 93.7 (6.9), for LMV, ZDV, LPV, and RTV, respectively.","Assessment of lamivudine, zidovudine, lopinavir, and ritonavir plasma levels in HIV-positive pregnant women: Drug monitoring application to improve patient safety. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32481459/),%,93.7,91950,DB00495,Zidovudine
,8947989,concentrations,Predicted concentrations 1 hour after 100 mg was administered fell in the range of 0.52-5.18 microM; measured values in 30 patients were 0.54-3.07 microM.,Variability in zidovudine serum concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8947989/),μM,0.52-5.18,94444,DB00495,Zidovudine
,8947989,concentrations,Predicted concentrations 1 hour after 100 mg was administered fell in the range of 0.52-5.18 microM; measured values in 30 patients were 0.54-3.07 microM.,Variability in zidovudine serum concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8947989/),μM,0.54-3.07,94445,DB00495,Zidovudine
less,8739595,Oral bioavailability,"Oral bioavailability was poor, estimated to be less than 5%.","Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739595/),%,5,94863,DB00495,Zidovudine
,25393417,Ki,"Consistent with its inhibitory effects on UGT2B7 activity, warfarin inhibited AZT glucuronidation in HLM (Ki = 74.9-96.3 μM) and RLM (Ki = 190-230 μM).",Warfarin is an effective modifier of multiple UDP-glucuronosyltransferase enzymes: evaluation of its potential to alter the pharmacokinetics of zidovudine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25393417/),μM,74.9-96.3,96091,DB00495,Zidovudine
,25393417,Ki,"Consistent with its inhibitory effects on UGT2B7 activity, warfarin inhibited AZT glucuronidation in HLM (Ki = 74.9-96.3 μM) and RLM (Ki = 190-230 μM).",Warfarin is an effective modifier of multiple UDP-glucuronosyltransferase enzymes: evaluation of its potential to alter the pharmacokinetics of zidovudine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25393417/),μM,190-230,96092,DB00495,Zidovudine
,11689002,bound fraction of,"Binding assays of studied compounds to purified 1% (w/v) HSA at 0 degrees C, indicate that bound fraction of 2-7 ranges from 13 to 47%, exhibiting a higher affinity to HSA than AZT (12%), which would introduce some interesting improvements in their pharmacokinetic properties.",Human serum albumin binding of novel antiretroviral nucleoside derivatives of AZT. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11689002/),%,13 to 47,96817,DB00495,Zidovudine
,11689002,DeltaS,"In addition, by means of displacement studies using HSA site specific drugs such as diazepam and salicylate, it was determined that AZT binds to site I of the HSA molecule, by a mainly entropy driven process (DeltaS = 10.834 cal/mol degrees K), being these observations extensive to 2-7.",Human serum albumin binding of novel antiretroviral nucleoside derivatives of AZT. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11689002/),[cal] / [degrees·k·mol],10.834,96818,DB00495,Zidovudine
,8645788,terminal half-life,"Except for a statistically significant decrease (28%) in the terminal half-life of zidovudine from 1.5 to 1.1 hours (P = .005) after coadministration of both agents for 14 days, concurrent administration of rifabutin for 7 or 14 days had no statistically significant effects on zidovudine plasma and urine pharmacokinetic parameters (the difference among treatment means was < 25%).",Effect of rifabutin on the pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8645788/),h,1.5,97070,DB00495,Zidovudine
,8645788,terminal half-life,"Except for a statistically significant decrease (28%) in the terminal half-life of zidovudine from 1.5 to 1.1 hours (P = .005) after coadministration of both agents for 14 days, concurrent administration of rifabutin for 7 or 14 days had no statistically significant effects on zidovudine plasma and urine pharmacokinetic parameters (the difference among treatment means was < 25%).",Effect of rifabutin on the pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8645788/),h,1.1,97071,DB00495,Zidovudine
,8556393,Plasma clearance,"Plasma clearance in the pregnant animals was 51 +/- 10 ml/min/kg compared with 37 +/- 2 ml/min/kg in the nonpregnant animals, and steady state volume of distribution was 3.7 +/- 1.21/kg compared with 2.2 +/- 0.61/kg.",Zidovudine kinetics in the pregnant baboon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556393/),[ml] / [kg·min],51,97652,DB00495,Zidovudine
,8556393,Plasma clearance,"Plasma clearance in the pregnant animals was 51 +/- 10 ml/min/kg compared with 37 +/- 2 ml/min/kg in the nonpregnant animals, and steady state volume of distribution was 3.7 +/- 1.21/kg compared with 2.2 +/- 0.61/kg.",Zidovudine kinetics in the pregnant baboon. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556393/),[ml] / [kg·min],37,97653,DB00495,Zidovudine
,8556393,steady state volume of distribution,"Plasma clearance in the pregnant animals was 51 +/- 10 ml/min/kg compared with 37 +/- 2 ml/min/kg in the nonpregnant animals, and steady state volume of distribution was 3.7 +/- 1.21/kg compared with 2.2 +/- 0.61/kg.",Zidovudine kinetics in the pregnant baboon. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556393/),1/[kg],3.7,97654,DB00495,Zidovudine
,8556393,steady state volume of distribution,"Plasma clearance in the pregnant animals was 51 +/- 10 ml/min/kg compared with 37 +/- 2 ml/min/kg in the nonpregnant animals, and steady state volume of distribution was 3.7 +/- 1.21/kg compared with 2.2 +/- 0.61/kg.",Zidovudine kinetics in the pregnant baboon. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556393/),1/[kg],2.2,97655,DB00495,Zidovudine
,21920159,maximum concentration (Cmax),"Median (range) maximum concentration (Cmax), time to reach maximum concentration (Tmax), area under the plasma concentration-time curve (AUC) and half-life (T½) were 1 438 (350 - 3 832) ng/ml, 25h50 (9h40 - 83h45), 174 134 (22 308 - 546 408) ng/h/ml and 59.0 (15.4 - 532.6) hours for group I and 1 535 (635 - 4 218) ng/ml, 17h35 (7h40 - 29h), 168 576 (20 268 - 476 712) ng/h/ml and 69.0 (22.12 - 172.3) hours for group II.",Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21920159/),[ng] / [ml],1 438,98172,DB00495,Zidovudine
,21920159,half-life (T½),"Median (range) maximum concentration (Cmax), time to reach maximum concentration (Tmax), area under the plasma concentration-time curve (AUC) and half-life (T½) were 1 438 (350 - 3 832) ng/ml, 25h50 (9h40 - 83h45), 174 134 (22 308 - 546 408) ng/h/ml and 59.0 (15.4 - 532.6) hours for group I and 1 535 (635 - 4 218) ng/ml, 17h35 (7h40 - 29h), 168 576 (20 268 - 476 712) ng/h/ml and 69.0 (22.12 - 172.3) hours for group II.",Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21920159/),h,59.0,98173,DB00495,Zidovudine
,21920159,volume of distribution (Vd),"For group II, the median (range) volume of distribution (Vd) and body clearance (Cl) were 1 702.6 (623.7 - 6 189.8) ml and 34.9 (6.2 - 163.8) ml/h.",Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21920159/),ml,1 702.6,98174,DB00495,Zidovudine
,21920159,body clearance (Cl),"For group II, the median (range) volume of distribution (Vd) and body clearance (Cl) were 1 702.6 (623.7 - 6 189.8) ml and 34.9 (6.2 - 163.8) ml/h.",Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21920159/),[ml] / [h],34.9,98175,DB00495,Zidovudine
exceeding,21920159,Plasma concentrations,Plasma concentrations exceeding 100ng/ml were achieved over 8 days in 78% infants in group I and 70.0% in group II.,Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21920159/),[ng] / [ml],100,98176,DB00495,Zidovudine
,21920159,MTCT rate,The MTCT rate was 4.8%.,Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21920159/),%,4.8,98177,DB00495,Zidovudine
,10103214,bioavailability,"The bioavailability of zidovudine nanospheres at 50 mg/kg of body weight was 76%, and this dose achieved prolonged exposure to zidovudine compared to standard formulations without an increase in the drug's peak concentration.",Pharmacokinetics of oral zidovudine entrapped in biodegradable nanospheres in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10103214/),%,76,100062,DB00495,Zidovudine
,2277865,half-lives,"Kinetic interpretation of the terminal linear phase of the urinary excretion rate vs. time data yielded mean (+/- SD) half-lives of 4.35 +/- 2.1 hr for NF and 3.42 +/- 0.86 hr for P, which were significantly greater than the mean 1.58 +/- 0.63 hr half-life observed for F.",Existence of a flip-flop kinetic model for zidovudine (AZT) after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2277865/),h,4.35,100200,DB00495,Zidovudine
,2277865,half-lives,"Kinetic interpretation of the terminal linear phase of the urinary excretion rate vs. time data yielded mean (+/- SD) half-lives of 4.35 +/- 2.1 hr for NF and 3.42 +/- 0.86 hr for P, which were significantly greater than the mean 1.58 +/- 0.63 hr half-life observed for F.",Existence of a flip-flop kinetic model for zidovudine (AZT) after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2277865/),h,3.42,100201,DB00495,Zidovudine
,2277865,half-lives,"Kinetic interpretation of the terminal linear phase of the urinary excretion rate vs. time data yielded mean (+/- SD) half-lives of 4.35 +/- 2.1 hr for NF and 3.42 +/- 0.86 hr for P, which were significantly greater than the mean 1.58 +/- 0.63 hr half-life observed for F.",Existence of a flip-flop kinetic model for zidovudine (AZT) after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2277865/),h,1.58,100202,DB00495,Zidovudine
,2277865,half-life,"Kinetic interpretation of the terminal linear phase of the urinary excretion rate vs. time data yielded mean (+/- SD) half-lives of 4.35 +/- 2.1 hr for NF and 3.42 +/- 0.86 hr for P, which were significantly greater than the mean 1.58 +/- 0.63 hr half-life observed for F.",Existence of a flip-flop kinetic model for zidovudine (AZT) after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2277865/),h,1.58,100203,DB00495,Zidovudine
,2277865,biological half-life,The reported mean biological half-life of AZT after a 10 mg/kg intravenous dose to the same strain of rats is 0.76 +/- 0.35 hr (n = 6).,Existence of a flip-flop kinetic model for zidovudine (AZT) after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2277865/),h,0.76,100204,DB00495,Zidovudine
,18475334,terminal half-life (T1/2),"In monkeys who received ZDV, the terminal half-life (T1/2) for ZDV was 37+/-15 and 33 +/- 13 min in the maternal and fetal compartments, respectively.",Placental transport of Zidovudine in the rhesus monkey. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18475334/),min,37,103047,DB00495,Zidovudine
,18475334,terminal half-life (T1/2),"In monkeys who received ZDV, the terminal half-life (T1/2) for ZDV was 37+/-15 and 33 +/- 13 min in the maternal and fetal compartments, respectively.",Placental transport of Zidovudine in the rhesus monkey. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18475334/),min,33,103048,DB00495,Zidovudine
,18475334,apparent T1/2,"The apparent T1/2 for maternal ZDVG was 124 +/- 44 and 142 +/- 50 min in the maternal and fetal compartments, respectively.",Placental transport of Zidovudine in the rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18475334/),min,124,103049,DB00495,Zidovudine
,18475334,apparent T1/2,"The apparent T1/2 for maternal ZDVG was 124 +/- 44 and 142 +/- 50 min in the maternal and fetal compartments, respectively.",Placental transport of Zidovudine in the rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18475334/),min,142,103050,DB00495,Zidovudine
,18475334,concentration ratios,"The mean fetal/maternal concentration ratios for ZDV and ZDVG ranged from 0.20 +/- 0.20 at 20 min to a maximum of 0.74 +/- 1.0 at 120 min and from 0.28 +/- 0.08 at 20 min to 1.4 +/- 1.3 at 180 min, respectively.",Placental transport of Zidovudine in the rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18475334/),,0.20,103051,DB00495,Zidovudine
,18475334,concentration ratios,"The mean fetal/maternal concentration ratios for ZDV and ZDVG ranged from 0.20 +/- 0.20 at 20 min to a maximum of 0.74 +/- 1.0 at 120 min and from 0.28 +/- 0.08 at 20 min to 1.4 +/- 1.3 at 180 min, respectively.",Placental transport of Zidovudine in the rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18475334/),,0,103052,DB00495,Zidovudine
,18475334,concentration ratios,"The mean fetal/maternal concentration ratios for ZDV and ZDVG ranged from 0.20 +/- 0.20 at 20 min to a maximum of 0.74 +/- 1.0 at 120 min and from 0.28 +/- 0.08 at 20 min to 1.4 +/- 1.3 at 180 min, respectively.",Placental transport of Zidovudine in the rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18475334/),,0.28,103053,DB00495,Zidovudine
,18475334,concentration ratios,"The mean fetal/maternal concentration ratios for ZDV and ZDVG ranged from 0.20 +/- 0.20 at 20 min to a maximum of 0.74 +/- 1.0 at 120 min and from 0.28 +/- 0.08 at 20 min to 1.4 +/- 1.3 at 180 min, respectively.",Placental transport of Zidovudine in the rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18475334/),,1.4,103054,DB00495,Zidovudine
,18475334,T1/2,"In monkeys who received ZDVG, the T1/2 for ZDWG in the maternal and fetal compartments was 47 +/- 26 and 119 +/- 164 min, respectively.",Placental transport of Zidovudine in the rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18475334/),min,47,103055,DB00495,Zidovudine
,18475334,T1/2,"In monkeys who received ZDVG, the T1/2 for ZDWG in the maternal and fetal compartments was 47 +/- 26 and 119 +/- 164 min, respectively.",Placental transport of Zidovudine in the rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18475334/),min,119,103056,DB00495,Zidovudine
,18475334,rafio,The fetal/maternal rafio ranged from 0.08 +/- 0.11 at 20 min to 4.2 +/- 4.2 at 180 min post-injection.,Placental transport of Zidovudine in the rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18475334/),,0.08,103057,DB00495,Zidovudine
,18475334,rafio,The fetal/maternal rafio ranged from 0.08 +/- 0.11 at 20 min to 4.2 +/- 4.2 at 180 min post-injection.,Placental transport of Zidovudine in the rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18475334/),,4.2,103058,DB00495,Zidovudine
,19729375,AUC(0-12),Median (IQR) AUC(0-12) and C(trough) of lopinavir were 117.6 mg.h/L (74.0-128.5) and 4.9 mg/L (2.7-8.0) for the standard arm and 83.8 mg.h/L (56.0-112.9) and 3.4 mg/L (2.7-5.4) for the low-dose arm.,Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19729375/),[h·mg] / [l],117.6,103835,DB00495,Zidovudine
,19729375,AUC(0-12),Median (IQR) AUC(0-12) and C(trough) of lopinavir were 117.6 mg.h/L (74.0-128.5) and 4.9 mg/L (2.7-8.0) for the standard arm and 83.8 mg.h/L (56.0-112.9) and 3.4 mg/L (2.7-5.4) for the low-dose arm.,Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19729375/),[h·mg] / [l],83.8,103836,DB00495,Zidovudine
,19729375,C(trough),Median (IQR) AUC(0-12) and C(trough) of lopinavir were 117.6 mg.h/L (74.0-128.5) and 4.9 mg/L (2.7-8.0) for the standard arm and 83.8 mg.h/L (56.0-112.9) and 3.4 mg/L (2.7-5.4) for the low-dose arm.,Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19729375/),[mg] / [l],4.9,103837,DB00495,Zidovudine
,19729375,C(trough),Median (IQR) AUC(0-12) and C(trough) of lopinavir were 117.6 mg.h/L (74.0-128.5) and 4.9 mg/L (2.7-8.0) for the standard arm and 83.8 mg.h/L (56.0-112.9) and 3.4 mg/L (2.7-5.4) for the low-dose arm.,Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19729375/),[mg] / [l],3.4,103838,DB00495,Zidovudine
,9869576,oral clearance (CL),"Individual oral clearance (CL) and volume of distribution (V) averaged 0.0533 liters/h/kg of body weight and 1.17 liters/kg, respectively.","Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869576/),[l] / [h·kg],0.0533,104997,DB00495,Zidovudine
,9869576,volume of distribution (V),"Individual oral clearance (CL) and volume of distribution (V) averaged 0.0533 liters/h/kg of body weight and 1.17 liters/kg, respectively.","Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869576/),[l] / [kg],1.17,104998,DB00495,Zidovudine
,9869576,oral CL,"Individual mean oral CL, VSS (volume of distribution at steady state), and V of ZDV were 1.84 liters/h/kg and 6.68 and 2.67 liters/kg, respectively, with body weight and age as correlates of CL and body weight as a correlate of VSS.","Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869576/),[l] / [h·kg],1.84,104999,DB00495,Zidovudine
,9869576,VSS (volume of distribution at steady state),"Individual mean oral CL, VSS (volume of distribution at steady state), and V of ZDV were 1.84 liters/h/kg and 6.68 and 2.67 liters/kg, respectively, with body weight and age as correlates of CL and body weight as a correlate of VSS.","Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869576/),[l] / [kg],6.68,105000,DB00495,Zidovudine
,9869576,VSS (volume of distribution at steady state),"Individual mean oral CL, VSS (volume of distribution at steady state), and V of ZDV were 1.84 liters/h/kg and 6.68 and 2.67 liters/kg, respectively, with body weight and age as correlates of CL and body weight as a correlate of VSS.","Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869576/),[l] / [kg],2.67,105001,DB00495,Zidovudine
,9869576,V,"Individual mean oral CL, VSS (volume of distribution at steady state), and V of ZDV were 1.84 liters/h/kg and 6.68 and 2.67 liters/kg, respectively, with body weight and age as correlates of CL and body weight as a correlate of VSS.","Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869576/),[l] / [kg],2.67,105002,DB00495,Zidovudine
,9869576,oral CL,"The average individual oral CL, VSS, and V of ddI were 1.64 liters/h/kg and 3.56 and 2.74 liters/kg, respectively, with body weight as a significant correlate of both CL and VSS.","Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869576/),[l] / [h·kg],1.64,105003,DB00495,Zidovudine
,9869576,VSS,"The average individual oral CL, VSS, and V of ddI were 1.64 liters/h/kg and 3.56 and 2.74 liters/kg, respectively, with body weight as a significant correlate of both CL and VSS.","Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869576/),[l] / [kg],3.56,105004,DB00495,Zidovudine
,9869576,VSS,"The average individual oral CL, VSS, and V of ddI were 1.64 liters/h/kg and 3.56 and 2.74 liters/kg, respectively, with body weight as a significant correlate of both CL and VSS.","Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869576/),[l] / [kg],2.74,105005,DB00495,Zidovudine
,9869576,V,"The average individual oral CL, VSS, and V of ddI were 1.64 liters/h/kg and 3.56 and 2.74 liters/kg, respectively, with body weight as a significant correlate of both CL and VSS.","Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869576/),[l] / [kg],2.74,105006,DB00495,Zidovudine
,2757312,Peak serum levels,Peak serum levels of interferon-alpha (32 to 250 U/mL) and zidovudine (0.40 to 3.85 microM) were in the ranges previously shown to be synergistic against HIV.,Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS) ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2757312/),[u] / [ml],32 to 250,107035,DB00495,Zidovudine
,2757312,Peak serum levels,Peak serum levels of interferon-alpha (32 to 250 U/mL) and zidovudine (0.40 to 3.85 microM) were in the ranges previously shown to be synergistic against HIV.,Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS) ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2757312/),μM,0.40 to 3.85,107036,DB00495,Zidovudine
,15933559,area under the concentration-time curve (AUC),The target area under the concentration-time curve (AUC) was between 2.5 and 5.0 microM . hour.,Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933559/),h·μM,2.5 and 5.0,107993,DB00495,Zidovudine
,15933559,AUC0-infinity,The initial ddI pharmacokinetic dosing of 50 mg/m for infants >28 days of age achieved a median AUC0-infinity of 2.8 microM . hour.,Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933559/),h·μM,2.8,107994,DB00495,Zidovudine
,15933559,AUC0-infinity,"For infants < or =28 days of age, the target AUC was achieved after dose escalation from 25 mg/m (median AUC0-infinity, 1.4 microM . hour) to 50 mg/m (median AUC0-infinity, 5.40 microM . hour).",Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933559/),h·μM,1.4,107995,DB00495,Zidovudine
,15933559,AUC0-infinity,"For infants < or =28 days of age, the target AUC was achieved after dose escalation from 25 mg/m (median AUC0-infinity, 1.4 microM . hour) to 50 mg/m (median AUC0-infinity, 5.40 microM . hour).",Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15933559/),h·μM,5.40,107996,DB00495,Zidovudine
,15302139,concentration in blood,"Administration of 180 nmol of [3H]-HpAZT resulted in an AZT concentration in blood of 1-3 microM after 5 min, which remained practically constant during the next 25 min and did not depend on the route of administration.","Intracellular metabolism and pharmacokinetics of 5'-hydrogenphosphonate of 3'-azido-2',3'-dideoxythymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15302139/),μM,1-3,108806,DB00495,Zidovudine
,18626772,drug content,The drug content of the conjugate was 18.9 wt.%.,A novel anti-HIV dextrin-zidovudine conjugate improving the pharmacokinetics of zidovudine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18626772/),w,18.9,109619,DB00495,Zidovudine
,18626772,release,"AZT and succinoylated AZT release from the conjugate was 1.4% (pH 5.5), 41.7% (pH 7.4) and 78.4% in human plasma after 24 h.",A novel anti-HIV dextrin-zidovudine conjugate improving the pharmacokinetics of zidovudine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18626772/),%,1.4,109620,DB00495,Zidovudine
,18626772,release,"AZT and succinoylated AZT release from the conjugate was 1.4% (pH 5.5), 41.7% (pH 7.4) and 78.4% in human plasma after 24 h.",A novel anti-HIV dextrin-zidovudine conjugate improving the pharmacokinetics of zidovudine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18626772/),%,41.7,109621,DB00495,Zidovudine
,18626772,release,"AZT and succinoylated AZT release from the conjugate was 1.4% (pH 5.5), 41.7% (pH 7.4) and 78.4% in human plasma after 24 h.",A novel anti-HIV dextrin-zidovudine conjugate improving the pharmacokinetics of zidovudine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18626772/),%,78.4,109622,DB00495,Zidovudine
,18626772,plasma half-life,The use of the conjugate extended the plasma half-life of AZT from 1.3 to 19.3 h and the mean residence time from 0.4 to 23.6 h.,A novel anti-HIV dextrin-zidovudine conjugate improving the pharmacokinetics of zidovudine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18626772/),h,1.3 to 19.3,109623,DB00495,Zidovudine
,18626772,mean residence time,The use of the conjugate extended the plasma half-life of AZT from 1.3 to 19.3 h and the mean residence time from 0.4 to 23.6 h.,A novel anti-HIV dextrin-zidovudine conjugate improving the pharmacokinetics of zidovudine in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18626772/),h,0.4 to 23.6,109624,DB00495,Zidovudine
over,7511360,recoveries,"ZDV-TP recoveries were over 90%, and the limit of quantitation of ZDV-TP by this method was 20 to 50 fmol.",Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7511360/),%,90,109823,DB00495,Zidovudine
,7511360,Systemic oral clearance rates,"Systemic oral clearance rates were similar to those in previous studies with adults but were highly variable (range, 0.86 to 2.75 liters/h/kg of body weight).",Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7511360/),[l] / [h·kg],0.86 to 2.75,109824,DB00495,Zidovudine
,7511360,area under the plasma concentration versus time curve,The area under the plasma concentration versus time curve increased significantly (P < 0.0005) with the dose from a median value of 1.2 mg.h/liter at the lower dose to 4.2 mg.h/liter at the higher dose.,Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7511360/),[h·mg] / [l],1.2,109825,DB00495,Zidovudine
,7511360,area under the plasma concentration versus time curve,The area under the plasma concentration versus time curve increased significantly (P < 0.0005) with the dose from a median value of 1.2 mg.h/liter at the lower dose to 4.2 mg.h/liter at the higher dose.,Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7511360/),[h·mg] / [l],4.2,109826,DB00495,Zidovudine
,17413694,plasma concentration,"Geometric mean plasma concentration when nevirapine was stopped in the remaining 19 patients was 6421 ng/ml (range, 3724-9473).",Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17413694/),[ng] / [ml],6421,111149,DB00495,Zidovudine
,17413694,times to reach threshold,"The median times to reach thresholds of 200, 100 and 20 ng/ml (limit of detection) were estimated to be 7.6 [interquartile range (IQR), 7.0-10.1], 9.3 (IQR, 8.7-13.0) and 13.2 (IQR, 12.3-18.4) days, respectively, with 3/19 (16%) and 14/19 (74%) estimated to have reached < 20 ng/ml by 7 and 14 days, respectively.",Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17413694/),d,20,111150,DB00495,Zidovudine
,17413694,times to reach threshold,"The median times to reach thresholds of 200, 100 and 20 ng/ml (limit of detection) were estimated to be 7.6 [interquartile range (IQR), 7.0-10.1], 9.3 (IQR, 8.7-13.0) and 13.2 (IQR, 12.3-18.4) days, respectively, with 3/19 (16%) and 14/19 (74%) estimated to have reached < 20 ng/ml by 7 and 14 days, respectively.",Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17413694/),d,7.6,111151,DB00495,Zidovudine
,17413694,times to reach threshold,"The median times to reach thresholds of 200, 100 and 20 ng/ml (limit of detection) were estimated to be 7.6 [interquartile range (IQR), 7.0-10.1], 9.3 (IQR, 8.7-13.0) and 13.2 (IQR, 12.3-18.4) days, respectively, with 3/19 (16%) and 14/19 (74%) estimated to have reached < 20 ng/ml by 7 and 14 days, respectively.",Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17413694/),d,9.3,111152,DB00495,Zidovudine
,17413694,times to reach threshold,"The median times to reach thresholds of 200, 100 and 20 ng/ml (limit of detection) were estimated to be 7.6 [interquartile range (IQR), 7.0-10.1], 9.3 (IQR, 8.7-13.0) and 13.2 (IQR, 12.3-18.4) days, respectively, with 3/19 (16%) and 14/19 (74%) estimated to have reached < 20 ng/ml by 7 and 14 days, respectively.",Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17413694/),d,13.2,111153,DB00495,Zidovudine
,21576446,half-lives,"The half-lives of AZT and 3TC were 0.81 h (94.8%) and 2.97 h (39.2%), respectively, whereas the intracellular half-lives of AZT-TP and 3TC-TP were 10.73 h (69%) and 21.16 h (44%), respectively.","Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21576446/),h,0.81,111665,DB00495,Zidovudine
,21576446,half-lives,"The half-lives of AZT and 3TC were 0.81 h (94.8%) and 2.97 h (39.2%), respectively, whereas the intracellular half-lives of AZT-TP and 3TC-TP were 10.73 h (69%) and 21.16 h (44%), respectively.","Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21576446/),h,2.97,111666,DB00495,Zidovudine
,21576446,intracellular half-lives,"The half-lives of AZT and 3TC were 0.81 h (94.8%) and 2.97 h (39.2%), respectively, whereas the intracellular half-lives of AZT-TP and 3TC-TP were 10.73 h (69%) and 21.16 h (44%), respectively.","Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21576446/),h,10.73,111667,DB00495,Zidovudine
,21576446,intracellular half-lives,"The half-lives of AZT and 3TC were 0.81 h (94.8%) and 2.97 h (39.2%), respectively, whereas the intracellular half-lives of AZT-TP and 3TC-TP were 10.73 h (69%) and 21.16 h (44%), respectively.","Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21576446/),h,21.16,111668,DB00495,Zidovudine
,10428900,half-lives,"Intracellular metabolism studies showed that dOTC is phosphorylated within cells via the deoxycytidine kinase pathway and that approximately 2 to 5% of dOTC is converted into the racemic triphosphate derivatives, which had measurable half-lives (2 to 3 hours) within cells.","Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428900/),h,2 to 3,113344,DB00495,Zidovudine
,10428900,K(i),"The K(i) values for dOTC-TP obtained against human DNA polymerases alpha, beta, and gamma were 5,000-, 78-, and 571-fold greater, respectively, than those for HIV RT (28 nM), indicating a good selectivity for the viral enzyme.","Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428900/),nM,28,113345,DB00495,Zidovudine
,10428900,50% inhibitory concentration,"The mean 50% inhibitory concentration of dOTC for drug-naive isolates was 1.76 microM, rising to only 2.53 and 2.5 microM for viruses resistant to 3TC and viruses resistant to 3TC and AZT, respectively.","Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428900/),μM,1.76,113346,DB00495,Zidovudine
,10428900,50% inhibitory concentration,"The mean 50% inhibitory concentration of dOTC for drug-naive isolates was 1.76 microM, rising to only 2.53 and 2.5 microM for viruses resistant to 3TC and viruses resistant to 3TC and AZT, respectively.","Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428900/),μM,2.53,113347,DB00495,Zidovudine
,10428900,50% inhibitory concentration,"The mean 50% inhibitory concentration of dOTC for drug-naive isolates was 1.76 microM, rising to only 2.53 and 2.5 microM for viruses resistant to 3TC and viruses resistant to 3TC and AZT, respectively.","Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428900/),μM,2.5,113348,DB00495,Zidovudine
greater,10428900,50% toxicity levels,"In tissue culture studies, the 50% toxicity levels for dOTC, which were determined by using [(3)H]thymidine uptake as a measure of logarithmic-phase cell proliferation, was greater than 100 microM for all cell lines tested.","Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428900/),μM,100,113349,DB00495,Zidovudine
,10428900,bioavailability,"When administered orally to rats, dOTC was well absorbed, with a bioavailability of approximately 77%, with a high proportion (approximately 16.5% of the levels in serum) found in the cerebrospinal fluid.","Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10428900/),%,77,113350,DB00495,Zidovudine
,8067734,free/total dipyridamole ratio,"Dipyridamole was highly protein bound, with a median free/total dipyridamole ratio of 0.7%; the percent free/total dipyridamole ratio was inversely correlated with alpha 1 acid glycoprotein concentrations (r2 =0.66).",Effect of dipyridamole on zidovudine pharmacokinetics and short-term tolerance in asymptomatic human immunodeficiency virus-infected subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067734/),%,0.7,114476,DB00495,Zidovudine
,33839311,Cmin,"Of the 53 participants, the median (range) Cmin was 3.3 (0.0-14.0) mg/L and AUC0-12h was 56.0 (16.7-202.6) mg.hr/L.",Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33839311/),[mg] / [l],3.3,120219,DB00495,Zidovudine
,33839311,AUC0-12h,"Of the 53 participants, the median (range) Cmin was 3.3 (0.0-14.0) mg/L and AUC0-12h was 56.0 (16.7-202.6) mg.hr/L.",Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33839311/),[h·mg] / [l],56.0,120220,DB00495,Zidovudine
<,9165548,minimum gastric pH,"They were stratified into two groups according to fasting gastric pH: those without and with gastric hypoacidity (minimum gastric pH < 3 and > or = 3, respectively).",Effects of spontaneous gastric hypoacidity on the pharmacokinetics of zidovudine and didanosine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165548/),,3,120828,DB00495,Zidovudine
,7959316,clearance index,The clearance index of d4T was 0.24 +/- 0.07 at 1.0 micrograms/ml and 0.235 +/- 0.045 at 10.0 micrograms/ml.,The ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7959316/),,0.24,122016,DB00495,Zidovudine
,7959316,clearance index,The clearance index of d4T was 0.24 +/- 0.07 at 1.0 micrograms/ml and 0.235 +/- 0.045 at 10.0 micrograms/ml.,The ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7959316/),,0.235,122017,DB00495,Zidovudine
,1492005,absorption rate constant,The absorption rate constant (4.05 vs 2.11 hr-1) and time to maximum concentration (0.61 vs 1.03 hr) were significantly different in healthy volunteers versus patients with AIDS without hepatic disease.,Comparative pharmacokinetics of zidovudine in healthy volunteers and in patients with AIDS with and without hepatic disease. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492005/),1/[h],4.05,122245,DB00495,Zidovudine
,1492005,absorption rate constant,The absorption rate constant (4.05 vs 2.11 hr-1) and time to maximum concentration (0.61 vs 1.03 hr) were significantly different in healthy volunteers versus patients with AIDS without hepatic disease.,Comparative pharmacokinetics of zidovudine in healthy volunteers and in patients with AIDS with and without hepatic disease. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492005/),1/[h],2.11,122246,DB00495,Zidovudine
,1492005,time to maximum concentration,The absorption rate constant (4.05 vs 2.11 hr-1) and time to maximum concentration (0.61 vs 1.03 hr) were significantly different in healthy volunteers versus patients with AIDS without hepatic disease.,Comparative pharmacokinetics of zidovudine in healthy volunteers and in patients with AIDS with and without hepatic disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492005/),h,0.61,122247,DB00495,Zidovudine
,1492005,time to maximum concentration,The absorption rate constant (4.05 vs 2.11 hr-1) and time to maximum concentration (0.61 vs 1.03 hr) were significantly different in healthy volunteers versus patients with AIDS without hepatic disease.,Comparative pharmacokinetics of zidovudine in healthy volunteers and in patients with AIDS with and without hepatic disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492005/),h,1.03,122248,DB00495,Zidovudine
,2215081,initial,The drug kinetics in plasma followed biexponential disposition with an initial distribution half-life of approximately 11 minutes and an elimination half-life of 40 minutes.,Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2215081/),min,11,124805,DB00495,Zidovudine
,2215081,distribution half-life,The drug kinetics in plasma followed biexponential disposition with an initial distribution half-life of approximately 11 minutes and an elimination half-life of 40 minutes.,Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2215081/),min,11,124806,DB00495,Zidovudine
,2215081,elimination half-life,The drug kinetics in plasma followed biexponential disposition with an initial distribution half-life of approximately 11 minutes and an elimination half-life of 40 minutes.,Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2215081/),min,40,124807,DB00495,Zidovudine
,2215081,cerebrospinal fluid to plasma ratio,"Over the plasma concentration range of 0.2 to 10 micrograms/ml, the cerebrospinal fluid to plasma ratio averaged 14.8 +/- 1.9% whereas the mean brain tissue to plasma ratio was 8.2 +/- 1.2% (uncorrected) or 2.3 +/- 1.8% (corrected) for the brain vascular space contribution.",Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2215081/),%,14.8,124808,DB00495,Zidovudine
,2215081,brain tissue to plasma ratio,"Over the plasma concentration range of 0.2 to 10 micrograms/ml, the cerebrospinal fluid to plasma ratio averaged 14.8 +/- 1.9% whereas the mean brain tissue to plasma ratio was 8.2 +/- 1.2% (uncorrected) or 2.3 +/- 1.8% (corrected) for the brain vascular space contribution.",Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2215081/),%,8.2,124809,DB00495,Zidovudine
,2215081,brain tissue to plasma ratio,"Over the plasma concentration range of 0.2 to 10 micrograms/ml, the cerebrospinal fluid to plasma ratio averaged 14.8 +/- 1.9% whereas the mean brain tissue to plasma ratio was 8.2 +/- 1.2% (uncorrected) or 2.3 +/- 1.8% (corrected) for the brain vascular space contribution.",Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2215081/),%,2.3,124810,DB00495,Zidovudine
>,8086134,intracellular AUC,"Patients who responded to ZDV therapy, as measured by these variables, demonstrated significantly higher intracellular AUC (> 3 pmol x h/10(6) cells) than those who did not (approximately 2 pmol x h/10(6) cells).",Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8086134/),[h·pM] / [10(6)·cells],3,124872,DB00495,Zidovudine
,8086134,intracellular AUC,"Patients who responded to ZDV therapy, as measured by these variables, demonstrated significantly higher intracellular AUC (> 3 pmol x h/10(6) cells) than those who did not (approximately 2 pmol x h/10(6) cells).",Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8086134/),[h·pM] / [10(6)·cells],2,124873,DB00495,Zidovudine
,17722305,peak (,The results found that the mean peak (X+/- SD) plasma concentration (Cmax) of Antivir was 3.34 +/- 0.15 ng/mL and of Retrovir was 3.32 +/- 0.21 ng/mL.,Evaluation of the bioequivalence of zidovudine 100 mg capsules in healthy Thai male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17722305/),[ng] / [ml],3.34,125410,DB00495,Zidovudine
,17722305,peak (,The results found that the mean peak (X+/- SD) plasma concentration (Cmax) of Antivir was 3.34 +/- 0.15 ng/mL and of Retrovir was 3.32 +/- 0.21 ng/mL.,Evaluation of the bioequivalence of zidovudine 100 mg capsules in healthy Thai male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17722305/),[ng] / [ml],3.32,125411,DB00495,Zidovudine
,17722305,plasma concentration (Cmax),The results found that the mean peak (X+/- SD) plasma concentration (Cmax) of Antivir was 3.34 +/- 0.15 ng/mL and of Retrovir was 3.32 +/- 0.21 ng/mL.,Evaluation of the bioequivalence of zidovudine 100 mg capsules in healthy Thai male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17722305/),[ng] / [ml],3.34,125412,DB00495,Zidovudine
,17722305,plasma concentration (Cmax),The results found that the mean peak (X+/- SD) plasma concentration (Cmax) of Antivir was 3.34 +/- 0.15 ng/mL and of Retrovir was 3.32 +/- 0.21 ng/mL.,Evaluation of the bioequivalence of zidovudine 100 mg capsules in healthy Thai male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17722305/),[ng] / [ml],3.32,125413,DB00495,Zidovudine
,17722305,time to peak plasma concentration (Tmax),The time to peak plasma concentration (Tmax) of Antivir was 0.49 +/- 0.16 hours and for Retrovir was 0.62 +/- 0.35 hours with a difference time to peak of 20.96%.,Evaluation of the bioequivalence of zidovudine 100 mg capsules in healthy Thai male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17722305/),h,0.49,125414,DB00495,Zidovudine
,17722305,time to peak plasma concentration (Tmax),The time to peak plasma concentration (Tmax) of Antivir was 0.49 +/- 0.16 hours and for Retrovir was 0.62 +/- 0.35 hours with a difference time to peak of 20.96%.,Evaluation of the bioequivalence of zidovudine 100 mg capsules in healthy Thai male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17722305/),h,0.62,125415,DB00495,Zidovudine
,17722305,half life (t1/2),The half life (t1/2) of Antivir was 1.16 +/- 0.28 hours and t1/2 of Retrovir was 1.05 +/- 0.25 hours.,Evaluation of the bioequivalence of zidovudine 100 mg capsules in healthy Thai male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17722305/),h,1.16,125416,DB00495,Zidovudine
,17722305,t1/2,The half life (t1/2) of Antivir was 1.16 +/- 0.28 hours and t1/2 of Retrovir was 1.05 +/- 0.25 hours.,Evaluation of the bioequivalence of zidovudine 100 mg capsules in healthy Thai male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17722305/),h,1.05,125417,DB00495,Zidovudine
,17722305,area under the curve (AUC0-->t),The mean area under the curve (AUC0-->t) of Antivir was 3.34 +/- 0.12 ng.hr/mL and of Retrovir was 3.35 +/- 0.15 ng.hr/mL.,Evaluation of the bioequivalence of zidovudine 100 mg capsules in healthy Thai male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17722305/),[h·ng] / [ml],3.34,125418,DB00495,Zidovudine
,17722305,area under the curve (AUC0-->t),The mean area under the curve (AUC0-->t) of Antivir was 3.34 +/- 0.12 ng.hr/mL and of Retrovir was 3.35 +/- 0.15 ng.hr/mL.,Evaluation of the bioequivalence of zidovudine 100 mg capsules in healthy Thai male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17722305/),[h·ng] / [ml],3.35,125419,DB00495,Zidovudine
,17722305,AUC0-->infinity,The mean AUC0-->infinity of Antivir was 3.37 +/- 0.12 nghr/mL and for and Retrovir was 3.38 +/- 0.14 ng.hr/mL.,Evaluation of the bioequivalence of zidovudine 100 mg capsules in healthy Thai male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17722305/),[nghr] / [ml],3.37,125420,DB00495,Zidovudine
,17722305,AUC0-->infinity,The mean AUC0-->infinity of Antivir was 3.37 +/- 0.12 nghr/mL and for and Retrovir was 3.38 +/- 0.14 ng.hr/mL.,Evaluation of the bioequivalence of zidovudine 100 mg capsules in healthy Thai male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17722305/),[h·ng] / [ml],3.38,125421,DB00495,Zidovudine
,1803995,half-lives,"Zidovudine concentrations in serum declined in a biphasic manner, with half-lives ranging from 1 to 2 h, and were independent of acyclovir administration or length of zidovudine therapy.",Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803995/),h,1 to 2,125522,DB00495,Zidovudine
,1803995,time of peak concentrations,"The median time of peak concentrations in serum following oral doses was 0.75 h (range, 0.25 to 3 h).",Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803995/),h,0.75,125523,DB00495,Zidovudine
,1803995,oral Cmax,"Mean day 7 oral Cmax values were 0.20 +/- 0.12, 0.55 +/- 0.33, and 1.0 +/- 0.5 micrograms/ml for 17 patients receiving total daily doses of, respectively, 300, 600, and 1,500 mg of zidovudine alone, whereas Cmax values were, respectively, 0.27 +/- 0.18, 0.43 +/- 0.33, and 1.2 +/- 0.80 micrograms/ml for 15 comparably treated recipients of zidovudine plus acyclovir (P was not significant).",Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803995/),[μg] / [ml],0.20,125524,DB00495,Zidovudine
,1803995,oral Cmax,"Mean day 7 oral Cmax values were 0.20 +/- 0.12, 0.55 +/- 0.33, and 1.0 +/- 0.5 micrograms/ml for 17 patients receiving total daily doses of, respectively, 300, 600, and 1,500 mg of zidovudine alone, whereas Cmax values were, respectively, 0.27 +/- 0.18, 0.43 +/- 0.33, and 1.2 +/- 0.80 micrograms/ml for 15 comparably treated recipients of zidovudine plus acyclovir (P was not significant).",Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803995/),[μg] / [ml],0.55,125525,DB00495,Zidovudine
,1803995,oral Cmax,"Mean day 7 oral Cmax values were 0.20 +/- 0.12, 0.55 +/- 0.33, and 1.0 +/- 0.5 micrograms/ml for 17 patients receiving total daily doses of, respectively, 300, 600, and 1,500 mg of zidovudine alone, whereas Cmax values were, respectively, 0.27 +/- 0.18, 0.43 +/- 0.33, and 1.2 +/- 0.80 micrograms/ml for 15 comparably treated recipients of zidovudine plus acyclovir (P was not significant).",Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803995/),[μg] / [ml],1.0,125526,DB00495,Zidovudine
,1803995,Cmax,"Mean day 7 oral Cmax values were 0.20 +/- 0.12, 0.55 +/- 0.33, and 1.0 +/- 0.5 micrograms/ml for 17 patients receiving total daily doses of, respectively, 300, 600, and 1,500 mg of zidovudine alone, whereas Cmax values were, respectively, 0.27 +/- 0.18, 0.43 +/- 0.33, and 1.2 +/- 0.80 micrograms/ml for 15 comparably treated recipients of zidovudine plus acyclovir (P was not significant).",Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803995/),[μg] / [ml],0.27,125527,DB00495,Zidovudine
,1803995,Cmax,"Mean day 7 oral Cmax values were 0.20 +/- 0.12, 0.55 +/- 0.33, and 1.0 +/- 0.5 micrograms/ml for 17 patients receiving total daily doses of, respectively, 300, 600, and 1,500 mg of zidovudine alone, whereas Cmax values were, respectively, 0.27 +/- 0.18, 0.43 +/- 0.33, and 1.2 +/- 0.80 micrograms/ml for 15 comparably treated recipients of zidovudine plus acyclovir (P was not significant).",Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803995/),[μg] / [ml],0.43,125528,DB00495,Zidovudine
,1803995,Cmax,"Mean day 7 oral Cmax values were 0.20 +/- 0.12, 0.55 +/- 0.33, and 1.0 +/- 0.5 micrograms/ml for 17 patients receiving total daily doses of, respectively, 300, 600, and 1,500 mg of zidovudine alone, whereas Cmax values were, respectively, 0.27 +/- 0.18, 0.43 +/- 0.33, and 1.2 +/- 0.80 micrograms/ml for 15 comparably treated recipients of zidovudine plus acyclovir (P was not significant).",Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803995/),[μg] / [ml],1.2,125529,DB00495,Zidovudine
,1803995,bioavailability,The median bioavailability of oral zidovudine was 67% (42 to 120%) and did not vary with dosage.,Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1803995/),%,67,125530,DB00495,Zidovudine
,2758728,AUC,"In healthy subjects, GAZT concentrations were higher than those of AZT; AUC values were 23.7 +/- 1.9 and 5.2 +/- 0.6 mumol.hr/L, respectively.",Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758728/),[h·μM] / [l],23.7,125531,DB00495,Zidovudine
,2758728,AUC,"In healthy subjects, GAZT concentrations were higher than those of AZT; AUC values were 23.7 +/- 1.9 and 5.2 +/- 0.6 mumol.hr/L, respectively.",Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758728/),[h·μM] / [l],5.2,125532,DB00495,Zidovudine
,2758728,half-life (t 1/2),"Formation of GAZT rate-limits its elimination: GAZT half-life (t 1/2) parallels that of AZT, which is around 1 hour.",Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758728/),h,1,125533,DB00495,Zidovudine
,2758728,AUC,"In uremic patients, AZT concentrations were moderately increased (AUC = 11.7 +/- 1.1 mumol.hr/L), whereas t 1/2 and mean residence time (MRT) remain unchanged despite the decreased renal clearance (16 +/- 2 versus 220 +/- 58 ml/min) and decreased urinary excretion (1.6 +/- 0.3 versus 8.1 +/- 1.0% of the dose).",Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758728/),[h·μM] / [l],11.7,125534,DB00495,Zidovudine
,2758728,renal clearance,"In uremic patients, AZT concentrations were moderately increased (AUC = 11.7 +/- 1.1 mumol.hr/L), whereas t 1/2 and mean residence time (MRT) remain unchanged despite the decreased renal clearance (16 +/- 2 versus 220 +/- 58 ml/min) and decreased urinary excretion (1.6 +/- 0.3 versus 8.1 +/- 1.0% of the dose).",Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758728/),[ml] / [min],16,125535,DB00495,Zidovudine
,2758728,renal clearance,"In uremic patients, AZT concentrations were moderately increased (AUC = 11.7 +/- 1.1 mumol.hr/L), whereas t 1/2 and mean residence time (MRT) remain unchanged despite the decreased renal clearance (16 +/- 2 versus 220 +/- 58 ml/min) and decreased urinary excretion (1.6 +/- 0.3 versus 8.1 +/- 1.0% of the dose).",Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758728/),[ml] / [min],220,125536,DB00495,Zidovudine
,2758728,AUC,"In contrast, GAZT concentrations are markedly increased (AUC = 402.9 +/- 88.6 mumol.hr/L).",Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758728/),[h·μM] / [l],402.9,125537,DB00495,Zidovudine
,2758728,renal clearance,"As a consequence of the decreased renal clearance (27 +/- 3 versus 331 +/- 42 ml/min), elimination is the rate-limiting step and t 1/2 is increased (8 +/- 2 versus 0.9 +/- 0.1 hr).",Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758728/),[ml] / [min],27,125538,DB00495,Zidovudine
,2758728,renal clearance,"As a consequence of the decreased renal clearance (27 +/- 3 versus 331 +/- 42 ml/min), elimination is the rate-limiting step and t 1/2 is increased (8 +/- 2 versus 0.9 +/- 0.1 hr).",Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758728/),[ml] / [min],331,125539,DB00495,Zidovudine
,2758728,t 1/2,"As a consequence of the decreased renal clearance (27 +/- 3 versus 331 +/- 42 ml/min), elimination is the rate-limiting step and t 1/2 is increased (8 +/- 2 versus 0.9 +/- 0.1 hr).",Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758728/),h,8,125540,DB00495,Zidovudine
,2758728,t 1/2,"As a consequence of the decreased renal clearance (27 +/- 3 versus 331 +/- 42 ml/min), elimination is the rate-limiting step and t 1/2 is increased (8 +/- 2 versus 0.9 +/- 0.1 hr).",Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758728/),h,0.9,125541,DB00495,Zidovudine
,11327444,AUC,"After normalization for a dose of 100 mg/patient, the mean AUC was 8.6 mg x h/l and the mean Cmax was 1.13 mg/l; t1/2 was 3.78 h.","Single dose, dose-escalating trial with fozivudine tidoxil (BM 21.1290). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327444/),[h·mg] / [l],8.6,125972,DB00495,Zidovudine
,11327444,Cmax,"After normalization for a dose of 100 mg/patient, the mean AUC was 8.6 mg x h/l and the mean Cmax was 1.13 mg/l; t1/2 was 3.78 h.","Single dose, dose-escalating trial with fozivudine tidoxil (BM 21.1290). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327444/),[mg] / [l],1.13,125973,DB00495,Zidovudine
,11327444,t1/2,"After normalization for a dose of 100 mg/patient, the mean AUC was 8.6 mg x h/l and the mean Cmax was 1.13 mg/l; t1/2 was 3.78 h.","Single dose, dose-escalating trial with fozivudine tidoxil (BM 21.1290). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327444/),h,3.78,125974,DB00495,Zidovudine
,8633656,transfer clearance,The maternal-fetal transfer clearance of zalcitabine (0.41 +/- 0.16 ml/min/kg) was not significantly different from the fetal-maternal transfer clearance of the drug (0.66 +/ 0.30 ml/min/kg).,"Mechanism and rate of placental transfer of zalcitabine (2',3'-dideoxycytidine) in Macaca nemestrina. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8633656/),[ml] / [kg·min],0.41,126263,DB00495,Zidovudine
,8633656,transfer clearance,The maternal-fetal transfer clearance of zalcitabine (0.41 +/- 0.16 ml/min/kg) was not significantly different from the fetal-maternal transfer clearance of the drug (0.66 +/ 0.30 ml/min/kg).,"Mechanism and rate of placental transfer of zalcitabine (2',3'-dideoxycytidine) in Macaca nemestrina. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8633656/),[ml] / [kg·min],0.66,126264,DB00495,Zidovudine
,8633656,placental transfer rate,The placental transfer rate of zalcitabine was 11% (+/-4%) that of antipyrine.,"Mechanism and rate of placental transfer of zalcitabine (2',3'-dideoxycytidine) in Macaca nemestrina. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8633656/),%,11,126265,DB00495,Zidovudine
,22374835,flow rate,"Chromatographic separation was carried out in a Hypersil BDS, C(18) column (250 mm × 4.6 mm; 5 µm particle size) with simple mobile phase composition of 0.1 M ammonium acetate buffer in 0.5% acetic acid, v/v and methanol (40:60, v/v) at a flow rate of 0.85 ml min(-1) where detector was set at 270 nm with a total run time of 10 min which is very short for simultaneous estimation of three analytes in plasma.","Development and validation of an HPLC-UV method for simultaneous determination of zidovudine, lamivudine, and nevirapine in human plasma and its application to pharmacokinetic study in human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22374835/),[ml] / [min],0.85,126713,DB00495,Zidovudine
,22374835,total run time,"Chromatographic separation was carried out in a Hypersil BDS, C(18) column (250 mm × 4.6 mm; 5 µm particle size) with simple mobile phase composition of 0.1 M ammonium acetate buffer in 0.5% acetic acid, v/v and methanol (40:60, v/v) at a flow rate of 0.85 ml min(-1) where detector was set at 270 nm with a total run time of 10 min which is very short for simultaneous estimation of three analytes in plasma.","Development and validation of an HPLC-UV method for simultaneous determination of zidovudine, lamivudine, and nevirapine in human plasma and its application to pharmacokinetic study in human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22374835/),min,10,126714,DB00495,Zidovudine
above,22374835,Extraction recovery,Extraction recovery of analytes in plasma samples was above 90.16%.,"Development and validation of an HPLC-UV method for simultaneous determination of zidovudine, lamivudine, and nevirapine in human plasma and its application to pharmacokinetic study in human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22374835/),%,90.16,126715,DB00495,Zidovudine
greater,20054854,f(2),The f(2) values for 3TC and AZT in both products were found to be greater than 51.,Postmarketing in vitro/in vivo assessment of fixed dose combination products of first line antiretrovirals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20054854/),,51,128064,DB00495,Zidovudine
,23641955,total body metabolic clearance,The total body metabolic clearance of laropiprant determined using this approach (5.0 L/hr) agreed well with the value determined in vivo following intravenous administration to healthy human volunteers (5.1 L/hr).,Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23641955/),[l] / [h],5.0,129817,DB00495,Zidovudine
,23641955,total body metabolic clearance,The total body metabolic clearance of laropiprant determined using this approach (5.0 L/hr) agreed well with the value determined in vivo following intravenous administration to healthy human volunteers (5.1 L/hr).,Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23641955/),[l] / [h],5.1,129818,DB00495,Zidovudine
,9559787,clearance,"The values of the pharmacokinetic parameters were as follows: clearance, 2.53 +/- 0.44 ml/min/kg; volume of distribution, 1.59 +/- 0.51 liters/kg; and half-life, 7.2 +/- 1.5 h.",Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559787/),[ml] / [kg·min],2.53,130033,DB00495,Zidovudine
,9559787,volume of distribution,"The values of the pharmacokinetic parameters were as follows: clearance, 2.53 +/- 0.44 ml/min/kg; volume of distribution, 1.59 +/- 0.51 liters/kg; and half-life, 7.2 +/- 1.5 h.",Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559787/),[l] / [kg],1.59,130034,DB00495,Zidovudine
,9559787,half-life,"The values of the pharmacokinetic parameters were as follows: clearance, 2.53 +/- 0.44 ml/min/kg; volume of distribution, 1.59 +/- 0.51 liters/kg; and half-life, 7.2 +/- 1.5 h.",Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559787/),h,7.2,130035,DB00495,Zidovudine
,9559787,clearance,"For seven infants studied a second time, at a mean age of 17.7 days, an increase in the mean clearance (2.33 versus 4.35 ml/min/kg; P = 0.024) and a decrease in the half-life (7.3 versus 4.4 h; P = 0.003) were found.",Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559787/),[ml] / [kg·min],2.33,130036,DB00495,Zidovudine
,9559787,clearance,"For seven infants studied a second time, at a mean age of 17.7 days, an increase in the mean clearance (2.33 versus 4.35 ml/min/kg; P = 0.024) and a decrease in the half-life (7.3 versus 4.4 h; P = 0.003) were found.",Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559787/),[ml] / [kg·min],4.35,130037,DB00495,Zidovudine
,9559787,half-life,"For seven infants studied a second time, at a mean age of 17.7 days, an increase in the mean clearance (2.33 versus 4.35 ml/min/kg; P = 0.024) and a decrease in the half-life (7.3 versus 4.4 h; P = 0.003) were found.",Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559787/),h,7.3,130038,DB00495,Zidovudine
,9559787,half-life,"For seven infants studied a second time, at a mean age of 17.7 days, an increase in the mean clearance (2.33 versus 4.35 ml/min/kg; P = 0.024) and a decrease in the half-life (7.3 versus 4.4 h; P = 0.003) were found.",Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559787/),h,4.4,130039,DB00495,Zidovudine
,20580792,relative bioavailability,"The relative bioavailability of zidovudine-loaded PLA-PEG blend nanoparticles was 2.7, relative to zidovudine-loaded PLA nanoparticles and 1.3 relative to aqueous solution formulation.",Intranasal delivery of zidovudine by PLA and PLA-PEG blend nanoparticles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20580792/),,2.7,130831,DB00495,Zidovudine
,20580792,relative bioavailability,"The relative bioavailability of zidovudine-loaded PLA-PEG blend nanoparticles was 2.7, relative to zidovudine-loaded PLA nanoparticles and 1.3 relative to aqueous solution formulation.",Intranasal delivery of zidovudine by PLA and PLA-PEG blend nanoparticles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20580792/),,1.3,130832,DB00495,Zidovudine
,8257128,Ki,The compound inhibited recombinant HIV-1 protease with a Ki of 0.2 nM.,"CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257128/),nM,0.2,133025,DB00495,Zidovudine
,8257128,inhibition constant,The inhibition constant versus human cathepsin D and human cathepsin E was 4 nM.,"CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257128/),nM,4,133026,DB00495,Zidovudine
,8257128,Kis,"Human pepsin and gastricsin were inhibited with Kis of 8 and 500 nM, respectively, and human renin was inhibited with a Ki of 190 microM.","CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257128/),nM,8,133027,DB00495,Zidovudine
,8257128,Kis,"Human pepsin and gastricsin were inhibited with Kis of 8 and 500 nM, respectively, and human renin was inhibited with a Ki of 190 microM.","CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257128/),nM,500,133028,DB00495,Zidovudine
,8257128,Ki,"Human pepsin and gastricsin were inhibited with Kis of 8 and 500 nM, respectively, and human renin was inhibited with a Ki of 190 microM.","CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257128/),μM,190,133029,DB00495,Zidovudine
,8257128,90% effective dose,"The replication of HIV-1/LAV, HIV-1/Z-84, and HIV-1/pLAI was inhibited with a 90% effective dose of 0.1 microM in acutely infected MT-2 cells.","CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257128/),μM,0.1,133030,DB00495,Zidovudine
,8257128,50% cytotoxic dose,The 50% cytotoxic dose was 100 microM.,"CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257128/),μM,100,133031,DB00495,Zidovudine
,10774589,plasma trough atevirdine concentrations,ACTG 199; 12 weeks of therapy with atevirdine (dose-adjusted to achieve plasma trough atevirdine concentrations of 5-10 microM) and zidovudine (200 mg every 8 h).,Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774589/),μM,5-10,133113,DB00495,Zidovudine
,10774589,trough plasma concentration,"ACTG 187: 12 weeks of atevirdine monotherapy with atevirdine doses adjusted to achieve escalating, targeted trough plasma concentration ranges (5-13, 14-22, and 23-31 microM).",Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774589/),μM,5-13,133114,DB00495,Zidovudine
,10774589,trough plasma concentration,"ACTG 187: 12 weeks of atevirdine monotherapy with atevirdine doses adjusted to achieve escalating, targeted trough plasma concentration ranges (5-13, 14-22, and 23-31 microM).",Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774589/),μM,14-22,133115,DB00495,Zidovudine
,10774589,trough plasma concentration,"ACTG 187: 12 weeks of atevirdine monotherapy with atevirdine doses adjusted to achieve escalating, targeted trough plasma concentration ranges (5-13, 14-22, and 23-31 microM).",Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774589/),μM,23-31,133116,DB00495,Zidovudine
,10774589,trough,In ACTG 199 it was 3.2+/-5.2 weeks (95%) to achieve a 5-10 microM trough.,Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774589/),μ,5,133117,DB00495,Zidovudine
>,10774589,Cmax to Cmin ratios,"During multiple-dosing a number of patterns of atevirdine disposition were observed including; rapid absorption with Cmax at 0.5-1 h, delayed absorption with Cmax at 3-4 h; minimal Cmax to Cmin fluctuation and Cmax to Cmin ratios of > 4.",Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774589/),,4,133118,DB00495,Zidovudine
,1540413,apparent total clearance,"Statistical analysis indicated no differences in AZT's apparent total clearance, apparent volume of distribution at steady-state, and elimination half-life due to ddI, however, the mean apparent total clearance decreased from 2.92 to 1.67 L/h/kg, and the mean apparent volume of distribution at steady-state decreased from 5.79 to 3.43 L/kg in the presence of ddI.","Pharmacokinetic evaluation of drug interactions with anti-HIV drugs, II: Effect of 2',3'-dideoxyinosine (ddI) on zidovudine kinetics in monkeys. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540413/),[l] / [h·kg],2,133159,DB00495,Zidovudine
,1540413,apparent volume of distribution at steady-state,"Statistical analysis indicated no differences in AZT's apparent total clearance, apparent volume of distribution at steady-state, and elimination half-life due to ddI, however, the mean apparent total clearance decreased from 2.92 to 1.67 L/h/kg, and the mean apparent volume of distribution at steady-state decreased from 5.79 to 3.43 L/kg in the presence of ddI.","Pharmacokinetic evaluation of drug interactions with anti-HIV drugs, II: Effect of 2',3'-dideoxyinosine (ddI) on zidovudine kinetics in monkeys. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540413/),[l] / [kg],5.79,133160,DB00495,Zidovudine
below,20625263,area under the concentration-time curve (AUC),Rules were defined a priori for a LPV/r dose escalation based on the proportion of women with an LPV area under the concentration-time curve (AUC) below 52 microg h/ml (10th percentile for LPV AUC in nonpregnant adults).,Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20625263/),[h·μg] / [ml],52,134389,DB00495,Zidovudine
,20625263,AUC,"Geometric mean (90% confidence interval) LPV AUC, Cmax and Cmin were 64.6 (59.7-69.8) microg h/ml, 8.1 (7.5-8.7) microg/ml and 2.7 (2.4-3.0) microg/ml, respectively.",Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20625263/),[h·μg] / [ml],64.6,134390,DB00495,Zidovudine
,20625263,Cmax,"Geometric mean (90% confidence interval) LPV AUC, Cmax and Cmin were 64.6 (59.7-69.8) microg h/ml, 8.1 (7.5-8.7) microg/ml and 2.7 (2.4-3.0) microg/ml, respectively.",Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20625263/),[μg] / [ml],8.1,134391,DB00495,Zidovudine
,20625263,Cmin,"Geometric mean (90% confidence interval) LPV AUC, Cmax and Cmin were 64.6 (59.7-69.8) microg h/ml, 8.1 (7.5-8.7) microg/ml and 2.7 (2.4-3.0) microg/ml, respectively.",Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20625263/),[μg] / [ml],2.7,134392,DB00495,Zidovudine
,31696528,plasma unbound fraction,The plasma unbound fraction of the drug (0.09 vs 0.06) and the umbilical cord vein/maternal plasma ratio (0.47 vs 0.39) were higher for the R-bupivacaine enantiomer than the S-bupivacaine enantiomer (P < .05).,Pharmacokinetics and Placental Transfer of Bupivacaine Enantiomers in HIV-Infected Parturient Women on Antiretroviral Therapy. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31696528/),,0.09,135973,DB00495,Zidovudine
,31696528,plasma unbound fraction,The plasma unbound fraction of the drug (0.09 vs 0.06) and the umbilical cord vein/maternal plasma ratio (0.47 vs 0.39) were higher for the R-bupivacaine enantiomer than the S-bupivacaine enantiomer (P < .05).,Pharmacokinetics and Placental Transfer of Bupivacaine Enantiomers in HIV-Infected Parturient Women on Antiretroviral Therapy. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31696528/),,0.06,135974,DB00495,Zidovudine
,31696528,plasma ratio,The plasma unbound fraction of the drug (0.09 vs 0.06) and the umbilical cord vein/maternal plasma ratio (0.47 vs 0.39) were higher for the R-bupivacaine enantiomer than the S-bupivacaine enantiomer (P < .05).,Pharmacokinetics and Placental Transfer of Bupivacaine Enantiomers in HIV-Infected Parturient Women on Antiretroviral Therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31696528/),,0.47,135975,DB00495,Zidovudine
,31696528,plasma ratio,The plasma unbound fraction of the drug (0.09 vs 0.06) and the umbilical cord vein/maternal plasma ratio (0.47 vs 0.39) were higher for the R-bupivacaine enantiomer than the S-bupivacaine enantiomer (P < .05).,Pharmacokinetics and Placental Transfer of Bupivacaine Enantiomers in HIV-Infected Parturient Women on Antiretroviral Therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31696528/),,0.39,135976,DB00495,Zidovudine
,1416864,clearance,Foscarnet clearance in plasma averaged (+/- standard deviation) 0.16 +/- 0.03 and 0.13 +/- 0.05 liter/h/kg of body weight in the absence and presence of ZDV.,Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1416864/),[l] / [h·kg],0.16,138092,DB00495,Zidovudine
,1416864,clearance,Foscarnet clearance in plasma averaged (+/- standard deviation) 0.16 +/- 0.03 and 0.13 +/- 0.05 liter/h/kg of body weight in the absence and presence of ZDV.,Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1416864/),[l] / [h·kg],0.13,138093,DB00495,Zidovudine
,1416864,oral clearance,"ZDV parameters were also not significantly altered, with a mean (+/- standard deviation) oral clearance of 2.7 +/- 1.0 and 2.6 +/- 0.8 liter/h/kg for the 2 study days, respectively.",Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1416864/),[l] / [h·kg],2.7,138094,DB00495,Zidovudine
,1416864,oral clearance,"ZDV parameters were also not significantly altered, with a mean (+/- standard deviation) oral clearance of 2.7 +/- 1.0 and 2.6 +/- 0.8 liter/h/kg for the 2 study days, respectively.",Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1416864/),[l] / [h·kg],2.6,138095,DB00495,Zidovudine
,26239974,drug concentration ratios,"Despite higher zidovudine (ZDV) and lamivudine (3TC) concentrations in seminal plasma (SP) than in blood plasma (BP) (SP/BP drug concentration ratios of 2.3 and 6.7, respectively), we have previously reported lower relative intracellular concentrations of their active metabolites, zidovudine triphosphate (ZDV-TP) and lamivudine triphosphate (3TC-TP), in seminal mononuclear cells (SMCs) than in peripheral blood mononuclear cells (PBMCs) (SMC/PBMC drug concentration ratios of 0.36 and 1.0, respectively).",Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26239974/),,2,139382,DB00495,Zidovudine
,26239974,drug concentration ratios,"Despite higher zidovudine (ZDV) and lamivudine (3TC) concentrations in seminal plasma (SP) than in blood plasma (BP) (SP/BP drug concentration ratios of 2.3 and 6.7, respectively), we have previously reported lower relative intracellular concentrations of their active metabolites, zidovudine triphosphate (ZDV-TP) and lamivudine triphosphate (3TC-TP), in seminal mononuclear cells (SMCs) than in peripheral blood mononuclear cells (PBMCs) (SMC/PBMC drug concentration ratios of 0.36 and 1.0, respectively).",Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26239974/),,0,139383,DB00495,Zidovudine
,26239974,drug concentration ratios,"Despite higher zidovudine (ZDV) and lamivudine (3TC) concentrations in seminal plasma (SP) than in blood plasma (BP) (SP/BP drug concentration ratios of 2.3 and 6.7, respectively), we have previously reported lower relative intracellular concentrations of their active metabolites, zidovudine triphosphate (ZDV-TP) and lamivudine triphosphate (3TC-TP), in seminal mononuclear cells (SMCs) than in peripheral blood mononuclear cells (PBMCs) (SMC/PBMC drug concentration ratios of 0.36 and 1.0, respectively).",Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26239974/),,1,139384,DB00495,Zidovudine
,8622018,peak AZT plasma concentration,The peak AZT plasma concentration increased from 21.9 to 995.6 micromol/L.,Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622018/),[μM] / [l],21.9,139452,DB00495,Zidovudine
,8622018,peak AZT plasma concentration,The peak AZT plasma concentration increased from 21.9 to 995.6 micromol/L.,Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622018/),[μM] / [l],995.6,139453,DB00495,Zidovudine
,8622018,area under the concentration/time curve (AUC),"The area under the concentration/time curve (AUC) also showed a progressive, but not linear increase from 40.34 to 3,108 h x micromol/L.",Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622018/),[h·μM] / [l],40.34,139454,DB00495,Zidovudine
,8622018,area under the concentration/time curve (AUC),"The area under the concentration/time curve (AUC) also showed a progressive, but not linear increase from 40.34 to 3,108 h x micromol/L.",Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622018/),[h·μM] / [l],"3,108",139455,DB00495,Zidovudine
greater,11956511,C(max),"At week 80, subjects with a C(max) greater than the overall group median value of 7 microg/ml had an increase in CD4 count of 358 cells/microl versus 197 cells/microl for those with a C(max) less than 7 microg/ml (P =.006).",CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11956511/),[μg] / [ml],7,139733,DB00495,Zidovudine
less,11956511,C(max),"At week 80, subjects with a C(max) greater than the overall group median value of 7 microg/ml had an increase in CD4 count of 358 cells/microl versus 197 cells/microl for those with a C(max) less than 7 microg/ml (P =.006).",CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11956511/),[μg] / [ml],7,139734,DB00495,Zidovudine
,22390847,EC(50),"All conjugates showed good stability in vitro release experiments, and good anti-HIV activity and low cytotoxicity in MT-4 cells, in which, mPEG(750)-succinyl-AZT exhibited good inhibition to wild-type viruses (strains IIIB and ROD) with EC(50) values of 0.11 and 0.090 μmol/L, respectively, and it showed no cytotoxicity up to 110 μmol/L.","Synthesis, drug release and anti-HIV activity of a series of PEGylated zidovudine conjugates. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22390847/),[μM] / [l],0.11,141920,DB00495,Zidovudine
,22390847,EC(50),"All conjugates showed good stability in vitro release experiments, and good anti-HIV activity and low cytotoxicity in MT-4 cells, in which, mPEG(750)-succinyl-AZT exhibited good inhibition to wild-type viruses (strains IIIB and ROD) with EC(50) values of 0.11 and 0.090 μmol/L, respectively, and it showed no cytotoxicity up to 110 μmol/L.","Synthesis, drug release and anti-HIV activity of a series of PEGylated zidovudine conjugates. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22390847/),[μM] / [l],0.090,141921,DB00495,Zidovudine
<,12520254,troughs,"Population pharmacokinetics were evaluated at 1, 2, and 4 weeks' postnatal age; zidovudine doses were adjusted to maintain troughs <3 microM.",Pharmacokinetics and tolerance of zidovudine in preterm infants. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520254/),μM,3,142484,DB00495,Zidovudine
,7902243,apparent Ki,Their estimated apparent Ki values ranged from 0.3 mM for navelbine to 9.8 mM for methotrexate.,Effect of anticancer drugs on the glucuronidation of 3'-azido-3'-deoxythymidine in human liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902243/),mM,0.3,142868,DB00495,Zidovudine
,7902243,apparent Ki,Their estimated apparent Ki values ranged from 0.3 mM for navelbine to 9.8 mM for methotrexate.,Effect of anticancer drugs on the glucuronidation of 3'-azido-3'-deoxythymidine in human liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902243/),mM,9.8,142869,DB00495,Zidovudine
,2623653,AUC,"In healthy subjects, G. AZT concentrations are higher than those of AZT; AUC were 23.7 +/- 1.9 and 5.2 +/- 0.6 mumol.h/l respectively.",[Pharmacokinetics of zidovudine (AZT) and its metabolite (G-AZT) in healthy subjects and in patients with kidney failure]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2623653/),[h·μM] / [l],23.7,144740,DB00495,Zidovudine
,2623653,AUC,"In healthy subjects, G. AZT concentrations are higher than those of AZT; AUC were 23.7 +/- 1.9 and 5.2 +/- 0.6 mumol.h/l respectively.",[Pharmacokinetics of zidovudine (AZT) and its metabolite (G-AZT) in healthy subjects and in patients with kidney failure]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2623653/),[h·μM] / [l],5.2,144741,DB00495,Zidovudine
,2623653,half-life,Formation of G. AZT rate-limits its elimination: G. AZT half-life parallels that of AZT which is around 1 hour.,[Pharmacokinetics of zidovudine (AZT) and its metabolite (G-AZT) in healthy subjects and in patients with kidney failure]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2623653/),h,1,144742,DB00495,Zidovudine
,2623653,AUC,"In uremic patients AZT concentrations are moderately increased (AUC = 11.7 +/- 1.1 mumol.h/l), whereas half-life and MRT remains unchanged, despite the decreased renal clearance (16 +/- 2 vs 220 +/- 58 ml/min).",[Pharmacokinetics of zidovudine (AZT) and its metabolite (G-AZT) in healthy subjects and in patients with kidney failure]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2623653/),[h·μM] / [l],11.7,144743,DB00495,Zidovudine
,2623653,renal clearance,"In uremic patients AZT concentrations are moderately increased (AUC = 11.7 +/- 1.1 mumol.h/l), whereas half-life and MRT remains unchanged, despite the decreased renal clearance (16 +/- 2 vs 220 +/- 58 ml/min).",[Pharmacokinetics of zidovudine (AZT) and its metabolite (G-AZT) in healthy subjects and in patients with kidney failure]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2623653/),[ml] / [min],16,144744,DB00495,Zidovudine
,2623653,renal clearance,"In uremic patients AZT concentrations are moderately increased (AUC = 11.7 +/- 1.1 mumol.h/l), whereas half-life and MRT remains unchanged, despite the decreased renal clearance (16 +/- 2 vs 220 +/- 58 ml/min).",[Pharmacokinetics of zidovudine (AZT) and its metabolite (G-AZT) in healthy subjects and in patients with kidney failure]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2623653/),[ml] / [min],220,144745,DB00495,Zidovudine
,2623653,AUC,In contrast G. AZT concentrations are markedly increased (AUC = 403 +/- 89 mumol.h/l).,[Pharmacokinetics of zidovudine (AZT) and its metabolite (G-AZT) in healthy subjects and in patients with kidney failure]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2623653/),[h·μM] / [l],403,144746,DB00495,Zidovudine
,2623653,renal clearance,"As a consequence of the decreased renal clearance (27 +/- 3 vs 331 +/- 42 ml/min), elimination is the rate limiting step and half-life is increased (8 +/- 2 vs 0.9 +/- 0.1 h).",[Pharmacokinetics of zidovudine (AZT) and its metabolite (G-AZT) in healthy subjects and in patients with kidney failure]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2623653/),[ml] / [min],27,144747,DB00495,Zidovudine
,2623653,renal clearance,"As a consequence of the decreased renal clearance (27 +/- 3 vs 331 +/- 42 ml/min), elimination is the rate limiting step and half-life is increased (8 +/- 2 vs 0.9 +/- 0.1 h).",[Pharmacokinetics of zidovudine (AZT) and its metabolite (G-AZT) in healthy subjects and in patients with kidney failure]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2623653/),[ml] / [min],331,144748,DB00495,Zidovudine
,2623653,half-life,"As a consequence of the decreased renal clearance (27 +/- 3 vs 331 +/- 42 ml/min), elimination is the rate limiting step and half-life is increased (8 +/- 2 vs 0.9 +/- 0.1 h).",[Pharmacokinetics of zidovudine (AZT) and its metabolite (G-AZT) in healthy subjects and in patients with kidney failure]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2623653/),h,8,144749,DB00495,Zidovudine
,2623653,half-life,"As a consequence of the decreased renal clearance (27 +/- 3 vs 331 +/- 42 ml/min), elimination is the rate limiting step and half-life is increased (8 +/- 2 vs 0.9 +/- 0.1 h).",[Pharmacokinetics of zidovudine (AZT) and its metabolite (G-AZT) in healthy subjects and in patients with kidney failure]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2623653/),h,0.9,144750,DB00495,Zidovudine
,7587948,oral bioavailability,"Maximum concentration, half-life, and area under the serum concentration vs. time curve (AUC) obtained from the serum concentration data were similar for both compounds after intravenous and intraperitoneal administrations; however, a difference in oral bioavailability for AZT and AZdU (49% and 76%, respectively) was noted.","Lymphatic distribution of 3'-azido-3'-deoxythymidine and 3'-azido-2',3'-dideoxyuridine in mice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587948/),%,49,145386,DB00495,Zidovudine
,7587948,oral bioavailability,"Maximum concentration, half-life, and area under the serum concentration vs. time curve (AUC) obtained from the serum concentration data were similar for both compounds after intravenous and intraperitoneal administrations; however, a difference in oral bioavailability for AZT and AZdU (49% and 76%, respectively) was noted.","Lymphatic distribution of 3'-azido-3'-deoxythymidine and 3'-azido-2',3'-dideoxyuridine in mice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587948/),%,76,145387,DB00495,Zidovudine
,8483107,Cmax,"The concentrations attained in blood and muscle were similar for each drug, with a Cmax of 57 microM (blood) and 54 microM (muscle) for alovudine and 38 and 46 microM, respectively, for zidovudine.","Pharmacokinetics and extracellular distribution to blood, brain, and muscle of alovudine (3'-fluorothymidine) and zidovudine in the rat studied by microdialysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8483107/),μM,57,146518,DB00495,Zidovudine
,8483107,Cmax,"The concentrations attained in blood and muscle were similar for each drug, with a Cmax of 57 microM (blood) and 54 microM (muscle) for alovudine and 38 and 46 microM, respectively, for zidovudine.","Pharmacokinetics and extracellular distribution to blood, brain, and muscle of alovudine (3'-fluorothymidine) and zidovudine in the rat studied by microdialysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8483107/),μM,54,146519,DB00495,Zidovudine
,8483107,Cmax,"The concentrations attained in blood and muscle were similar for each drug, with a Cmax of 57 microM (blood) and 54 microM (muscle) for alovudine and 38 and 46 microM, respectively, for zidovudine.","Pharmacokinetics and extracellular distribution to blood, brain, and muscle of alovudine (3'-fluorothymidine) and zidovudine in the rat studied by microdialysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8483107/),μM,38,146520,DB00495,Zidovudine
,8483107,Cmax,"The concentrations attained in blood and muscle were similar for each drug, with a Cmax of 57 microM (blood) and 54 microM (muscle) for alovudine and 38 and 46 microM, respectively, for zidovudine.","Pharmacokinetics and extracellular distribution to blood, brain, and muscle of alovudine (3'-fluorothymidine) and zidovudine in the rat studied by microdialysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8483107/),μM,46,146521,DB00495,Zidovudine
,8483107,Cmax,In contrast the Cmax in brain was 8 microM for alovudine and 4 microM for zidovudine.,"Pharmacokinetics and extracellular distribution to blood, brain, and muscle of alovudine (3'-fluorothymidine) and zidovudine in the rat studied by microdialysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8483107/),μM,8,146522,DB00495,Zidovudine
,8483107,Cmax,In contrast the Cmax in brain was 8 microM for alovudine and 4 microM for zidovudine.,"Pharmacokinetics and extracellular distribution to blood, brain, and muscle of alovudine (3'-fluorothymidine) and zidovudine in the rat studied by microdialysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8483107/),μM,4,146523,DB00495,Zidovudine
,8483107,half-lives,The half-lives of zidovudine in both blood and muscle were 37 min and in brain 69 min.,"Pharmacokinetics and extracellular distribution to blood, brain, and muscle of alovudine (3'-fluorothymidine) and zidovudine in the rat studied by microdialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8483107/),min,37,146524,DB00495,Zidovudine
,8483107,half-lives,The half-lives of zidovudine in both blood and muscle were 37 min and in brain 69 min.,"Pharmacokinetics and extracellular distribution to blood, brain, and muscle of alovudine (3'-fluorothymidine) and zidovudine in the rat studied by microdialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8483107/),min,69,146525,DB00495,Zidovudine
,8483107,half-lives,"For alovudine the corresponding half-lives were significantly longer: 61, 58, and 105 min, respectively.","Pharmacokinetics and extracellular distribution to blood, brain, and muscle of alovudine (3'-fluorothymidine) and zidovudine in the rat studied by microdialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8483107/),min,61,146526,DB00495,Zidovudine
,8483107,half-lives,"For alovudine the corresponding half-lives were significantly longer: 61, 58, and 105 min, respectively.","Pharmacokinetics and extracellular distribution to blood, brain, and muscle of alovudine (3'-fluorothymidine) and zidovudine in the rat studied by microdialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8483107/),min,58,146527,DB00495,Zidovudine
,8483107,half-lives,"For alovudine the corresponding half-lives were significantly longer: 61, 58, and 105 min, respectively.","Pharmacokinetics and extracellular distribution to blood, brain, and muscle of alovudine (3'-fluorothymidine) and zidovudine in the rat studied by microdialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8483107/),min,105,146528,DB00495,Zidovudine
,8483107,ratio of the AUC0-180,The ratio of the AUC0-180 brain/blood was 0.257 for alovudine and 0.186 for zidovudine.,"Pharmacokinetics and extracellular distribution to blood, brain, and muscle of alovudine (3'-fluorothymidine) and zidovudine in the rat studied by microdialysis. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8483107/),,0,146529,DB00495,Zidovudine
,8483107,plasma protein binding,"The plasma protein binding of zidovudine was 10%, while alovudine was virtually unbound.","Pharmacokinetics and extracellular distribution to blood, brain, and muscle of alovudine (3'-fluorothymidine) and zidovudine in the rat studied by microdialysis. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8483107/),%,10,146530,DB00495,Zidovudine
,9089422,area under the concentration-time curve (AUC) ratio,"The formation of AZT and ddI metabolites was increased after oral administration of AZT-P-ddI compared with the intravenous infusion, with an area under the concentration-time curve (AUC) ratio of metabolite to AZT and metabolite to ddI being 7.7 and 5.7 (oral) and 3.8 and 1.1 (intravenous), respectively.",Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089422/),,7.7,146639,DB00495,Zidovudine
,9089422,area under the concentration-time curve (AUC) ratio,"The formation of AZT and ddI metabolites was increased after oral administration of AZT-P-ddI compared with the intravenous infusion, with an area under the concentration-time curve (AUC) ratio of metabolite to AZT and metabolite to ddI being 7.7 and 5.7 (oral) and 3.8 and 1.1 (intravenous), respectively.",Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089422/),,5.7,146640,DB00495,Zidovudine
,9089422,area under the concentration-time curve (AUC) ratio,"The formation of AZT and ddI metabolites was increased after oral administration of AZT-P-ddI compared with the intravenous infusion, with an area under the concentration-time curve (AUC) ratio of metabolite to AZT and metabolite to ddI being 7.7 and 5.7 (oral) and 3.8 and 1.1 (intravenous), respectively.",Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089422/),,3.8,146641,DB00495,Zidovudine
,9089422,area under the concentration-time curve (AUC) ratio,"The formation of AZT and ddI metabolites was increased after oral administration of AZT-P-ddI compared with the intravenous infusion, with an area under the concentration-time curve (AUC) ratio of metabolite to AZT and metabolite to ddI being 7.7 and 5.7 (oral) and 3.8 and 1.1 (intravenous), respectively.",Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089422/),,1.1,146642,DB00495,Zidovudine
,9089422,apparent elimination half-life (t1/2),The newly identified ddI-M exhibited sustained plasma levels for extended time periods with an apparent elimination half-life (t1/2) of approximately 10 hours after oral administration of AZT-P-ddI.,Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089422/),h,10,146643,DB00495,Zidovudine
,9089422,oral bioavailability,The oral bioavailability of AZT (64.7-67.3%) and ddI (33.6-42.9%) and the other pharmacokinetic parameters were consistent with previous data reported with each nucleoside analog alone or in combination therapy.,Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089422/),%,64.7-67.3,146644,DB00495,Zidovudine
,9089422,oral bioavailability,The oral bioavailability of AZT (64.7-67.3%) and ddI (33.6-42.9%) and the other pharmacokinetic parameters were consistent with previous data reported with each nucleoside analog alone or in combination therapy.,Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089422/),%,33.6-42.9,146645,DB00495,Zidovudine
,12695856,MTD,The MTD of AZT was 8135 mg/m(2) per day when administered on this schedule.,Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12695856/),[mg] / [d·m(2)],8135,147114,DB00495,Zidovudine
,12695856,steady-state level,The mean steady-state level of AZT at the MTD was 44 microM (range 35-51 microM).,Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12695856/),μM,44,147115,DB00495,Zidovudine
,1611806,apparent plasma elimination half-life,The AMT apparent plasma elimination half-life (2.70 +/- 0.7 hours) was longer than that of zidovudine (1.20 +/- 0.30 hours) and zidovudine glucuronide (1.60 +/- 0.5 hours).,"Clinical pharmacokinetics of 3'-azido-3'-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3'-amino-3'-deoxythymidine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611806/),h,2.70,147901,DB00495,Zidovudine
,1611806,apparent plasma elimination half-life,The AMT apparent plasma elimination half-life (2.70 +/- 0.7 hours) was longer than that of zidovudine (1.20 +/- 0.30 hours) and zidovudine glucuronide (1.60 +/- 0.5 hours).,"Clinical pharmacokinetics of 3'-azido-3'-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3'-amino-3'-deoxythymidine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611806/),h,1.20,147902,DB00495,Zidovudine
,1611806,apparent plasma elimination half-life,The AMT apparent plasma elimination half-life (2.70 +/- 0.7 hours) was longer than that of zidovudine (1.20 +/- 0.30 hours) and zidovudine glucuronide (1.60 +/- 0.5 hours).,"Clinical pharmacokinetics of 3'-azido-3'-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3'-amino-3'-deoxythymidine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611806/),h,1.60,147903,DB00495,Zidovudine
,1611806,plasma peak concentration,"The zidovudine/AMT plasma peak concentration and area under the concentration-time curve ratios were approximately 8 and 5, respectively.","Clinical pharmacokinetics of 3'-azido-3'-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3'-amino-3'-deoxythymidine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611806/),,8,147904,DB00495,Zidovudine
,1611806,area under the concentration-time curve ratios,"The zidovudine/AMT plasma peak concentration and area under the concentration-time curve ratios were approximately 8 and 5, respectively.","Clinical pharmacokinetics of 3'-azido-3'-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3'-amino-3'-deoxythymidine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1611806/),,5,147905,DB00495,Zidovudine
,9989342,absolute bioavailability,"The absolute bioavailability is approximately 82 and 68% in adults and children, respectively.",Clinical pharmacokinetics of lamivudine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989342/),%,82,148539,DB00495,Zidovudine
,9989342,absolute bioavailability,"The absolute bioavailability is approximately 82 and 68% in adults and children, respectively.",Clinical pharmacokinetics of lamivudine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989342/),%,68,148540,DB00495,Zidovudine
,9989342,apparent volume of distribution (Vd),"Lamivudine is widely distributed into total body fluid, the mean apparent volume of distribution (Vd) being approximately 1.3 L/kg following intravenous administration.",Clinical pharmacokinetics of lamivudine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989342/),[l] / [kg],1.3,148541,DB00495,Zidovudine
,9989342,Systemic clearance,Systemic clearance following single intravenous doses averages 20 to 25 L/h (approximately 0.3 L/h/kg).,Clinical pharmacokinetics of lamivudine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989342/),[l] / [h],20 to 25,148542,DB00495,Zidovudine
,9989342,Systemic clearance,Systemic clearance following single intravenous doses averages 20 to 25 L/h (approximately 0.3 L/h/kg).,Clinical pharmacokinetics of lamivudine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989342/),[l] / [h·kg],0.3,148543,DB00495,Zidovudine
,9989342,elimination half-life,"The dominant elimination half-life of lamivudine is approximately 5 to 7 hours, and the in vitro intracellular half-life of its active 5'-triphosphate anabolite is 10.5 to 15.5 hours and 17 to 19 hours in HIV-1 and HBV cell lines, respectively.",Clinical pharmacokinetics of lamivudine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989342/),h,5 to 7,148544,DB00495,Zidovudine
,9989342,intracellular half-life,"The dominant elimination half-life of lamivudine is approximately 5 to 7 hours, and the in vitro intracellular half-life of its active 5'-triphosphate anabolite is 10.5 to 15.5 hours and 17 to 19 hours in HIV-1 and HBV cell lines, respectively.",Clinical pharmacokinetics of lamivudine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989342/),h,10.5 to 15.5,148545,DB00495,Zidovudine
,9989342,intracellular half-life,"The dominant elimination half-life of lamivudine is approximately 5 to 7 hours, and the in vitro intracellular half-life of its active 5'-triphosphate anabolite is 10.5 to 15.5 hours and 17 to 19 hours in HIV-1 and HBV cell lines, respectively.",Clinical pharmacokinetics of lamivudine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989342/),h,17 to 19,148546,DB00495,Zidovudine
,8619573,50% effective concentration,"The mean 50% effective concentration for lymphotropic, monocytotropic strains and field isolates of HIV type 1 (HIV-1), HIV-2, and simian immunodeficiency virus is 26 ng/ml (43 nM).","SC-52151, a novel inhibitor of the human immunodeficiency virus protease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619573/),[ng] / [ml],26,149044,DB00495,Zidovudine
,8619573,oral bioavailability,"The oral bioavailability of [14C]SC-52151 is 17% when it is administered as an elixir to the rat, dog, or monkey.","SC-52151, a novel inhibitor of the human immunodeficiency virus protease. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619573/),%,17,149045,DB00495,Zidovudine
,8619573,systemic bioavailability,"Pharmacokinetic and metabolism studies in multiple animal species predict 20 to 30% systemic bioavailability, an elimination half-life of 1 to 2 h, and a volume of distribution of greater than 3 liters/kg in humans.","SC-52151, a novel inhibitor of the human immunodeficiency virus protease. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619573/),%,20 to 30,149046,DB00495,Zidovudine
,8619573,elimination half-life,"Pharmacokinetic and metabolism studies in multiple animal species predict 20 to 30% systemic bioavailability, an elimination half-life of 1 to 2 h, and a volume of distribution of greater than 3 liters/kg in humans.","SC-52151, a novel inhibitor of the human immunodeficiency virus protease. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619573/),h,1 to 2,149047,DB00495,Zidovudine
greater,8619573,volume of distribution,"Pharmacokinetic and metabolism studies in multiple animal species predict 20 to 30% systemic bioavailability, an elimination half-life of 1 to 2 h, and a volume of distribution of greater than 3 liters/kg in humans.","SC-52151, a novel inhibitor of the human immunodeficiency virus protease. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619573/),[l] / [kg],3,149048,DB00495,Zidovudine
,17664328,half-lives,The typical population estimated half-lives (+/- the standard error of the mean) were 9.1 +/- 0.859 h for ZDV-TP and 17.7 +/- 2.8 h for 3TC-TP.,Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17664328/),h,9.1,151735,DB00495,Zidovudine
,17664328,half-lives,The typical population estimated half-lives (+/- the standard error of the mean) were 9.1 +/- 0.859 h for ZDV-TP and 17.7 +/- 2.8 h for 3TC-TP.,Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17664328/),h,17.7,151736,DB00495,Zidovudine
,9257757,time to maximum plasma concentration,"Levofloxacin was rapidly absorbed (time to maximum plasma concentration, approximately 1.0 h) and extensively distributed in the body with an apparent volume of distribution of approximately 104 liters (approximately 1.34 liters/kg).",Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257757/),h,1.0,152520,DB00495,Zidovudine
,9257757,apparent volume of distribution,"Levofloxacin was rapidly absorbed (time to maximum plasma concentration, approximately 1.0 h) and extensively distributed in the body with an apparent volume of distribution of approximately 104 liters (approximately 1.34 liters/kg).",Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257757/),l,104,152521,DB00495,Zidovudine
,9257757,apparent volume of distribution,"Levofloxacin was rapidly absorbed (time to maximum plasma concentration, approximately 1.0 h) and extensively distributed in the body with an apparent volume of distribution of approximately 104 liters (approximately 1.34 liters/kg).",Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257757/),[l] / [kg],1.34,152522,DB00495,Zidovudine
,9257757,steady-state peak plasma concentration,"Mean average steady-state peak plasma concentration, plasma levofloxacin concentration at the end of the dosing interval, AUC(0-8), terminal half-life, and total body clearance were 7.06 microg/ml, 3.62 microg/ml, 37.4 microg x h/ml, 7.2 h, and 9.4 liters/h (0.12 liters/h/kg), respectively.",Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257757/),[μg] / [ml],7.06,152523,DB00495,Zidovudine
,9257757,total body clearance,"Mean average steady-state peak plasma concentration, plasma levofloxacin concentration at the end of the dosing interval, AUC(0-8), terminal half-life, and total body clearance were 7.06 microg/ml, 3.62 microg/ml, 37.4 microg x h/ml, 7.2 h, and 9.4 liters/h (0.12 liters/h/kg), respectively.",Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257757/),[l] / [h],9.4,152524,DB00495,Zidovudine
,9257757,total body clearance,"Mean average steady-state peak plasma concentration, plasma levofloxacin concentration at the end of the dosing interval, AUC(0-8), terminal half-life, and total body clearance were 7.06 microg/ml, 3.62 microg/ml, 37.4 microg x h/ml, 7.2 h, and 9.4 liters/h (0.12 liters/h/kg), respectively.",Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257757/),[l] / [h·kg],0.12,152525,DB00495,Zidovudine
,12023531,steady-state blood,"Mean (+/-S.D.) steady-state blood, muscle, and brain zidovudine concentrations by microdialysis were 112 +/- 63.8, 105 +/- 51.1, and 13.8 +/- 10.4 microM, respectively; and steady-state serum ultrafiltrate and CSF concentrations were 81.2 +/- 40.2 and 14.1 +/- 8.0 microM, respectively.",Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12023531/),μM,112,160484,DB00495,Zidovudine
,12023531,muscle,"Mean (+/-S.D.) steady-state blood, muscle, and brain zidovudine concentrations by microdialysis were 112 +/- 63.8, 105 +/- 51.1, and 13.8 +/- 10.4 microM, respectively; and steady-state serum ultrafiltrate and CSF concentrations were 81.2 +/- 40.2 and 14.1 +/- 8.0 microM, respectively.",Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12023531/),μM,112,160485,DB00495,Zidovudine
,12023531,muscle,"Mean (+/-S.D.) steady-state blood, muscle, and brain zidovudine concentrations by microdialysis were 112 +/- 63.8, 105 +/- 51.1, and 13.8 +/- 10.4 microM, respectively; and steady-state serum ultrafiltrate and CSF concentrations were 81.2 +/- 40.2 and 14.1 +/- 8.0 microM, respectively.",Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12023531/),μM,105,160486,DB00495,Zidovudine
,12023531,muscle,"Mean (+/-S.D.) steady-state blood, muscle, and brain zidovudine concentrations by microdialysis were 112 +/- 63.8, 105 +/- 51.1, and 13.8 +/- 10.4 microM, respectively; and steady-state serum ultrafiltrate and CSF concentrations were 81.2 +/- 40.2 and 14.1 +/- 8.0 microM, respectively.",Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12023531/),μM,13.8,160487,DB00495,Zidovudine
,12023531,concentrations,"Mean (+/-S.D.) steady-state blood, muscle, and brain zidovudine concentrations by microdialysis were 112 +/- 63.8, 105 +/- 51.1, and 13.8 +/- 10.4 microM, respectively; and steady-state serum ultrafiltrate and CSF concentrations were 81.2 +/- 40.2 and 14.1 +/- 8.0 microM, respectively.",Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12023531/),μM,112,160488,DB00495,Zidovudine
,12023531,concentrations,"Mean (+/-S.D.) steady-state blood, muscle, and brain zidovudine concentrations by microdialysis were 112 +/- 63.8, 105 +/- 51.1, and 13.8 +/- 10.4 microM, respectively; and steady-state serum ultrafiltrate and CSF concentrations were 81.2 +/- 40.2 and 14.1 +/- 8.0 microM, respectively.",Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12023531/),μM,105,160489,DB00495,Zidovudine
,12023531,concentrations,"Mean (+/-S.D.) steady-state blood, muscle, and brain zidovudine concentrations by microdialysis were 112 +/- 63.8, 105 +/- 51.1, and 13.8 +/- 10.4 microM, respectively; and steady-state serum ultrafiltrate and CSF concentrations were 81.2 +/- 40.2 and 14.1 +/- 8.0 microM, respectively.",Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12023531/),μM,13.8,160490,DB00495,Zidovudine
,12023531,steady-state serum ultrafiltrate,"Mean (+/-S.D.) steady-state blood, muscle, and brain zidovudine concentrations by microdialysis were 112 +/- 63.8, 105 +/- 51.1, and 13.8 +/- 10.4 microM, respectively; and steady-state serum ultrafiltrate and CSF concentrations were 81.2 +/- 40.2 and 14.1 +/- 8.0 microM, respectively.",Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12023531/),μM,81.2,160491,DB00495,Zidovudine
,12023531,CSF,"Mean (+/-S.D.) steady-state blood, muscle, and brain zidovudine concentrations by microdialysis were 112 +/- 63.8, 105 +/- 51.1, and 13.8 +/- 10.4 microM, respectively; and steady-state serum ultrafiltrate and CSF concentrations were 81.2 +/- 40.2 and 14.1 +/- 8.0 microM, respectively.",Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12023531/),μM,81.2,160492,DB00495,Zidovudine
,12023531,CSF,"Mean (+/-S.D.) steady-state blood, muscle, and brain zidovudine concentrations by microdialysis were 112 +/- 63.8, 105 +/- 51.1, and 13.8 +/- 10.4 microM, respectively; and steady-state serum ultrafiltrate and CSF concentrations were 81.2 +/- 40.2 and 14.1 +/- 8.0 microM, respectively.",Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12023531/),μM,14.1,160493,DB00495,Zidovudine
,12023531,concentrations,"Mean (+/-S.D.) steady-state blood, muscle, and brain zidovudine concentrations by microdialysis were 112 +/- 63.8, 105 +/- 51.1, and 13.8 +/- 10.4 microM, respectively; and steady-state serum ultrafiltrate and CSF concentrations were 81.2 +/- 40.2 and 14.1 +/- 8.0 microM, respectively.",Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12023531/),μM,81.2,160494,DB00495,Zidovudine
,12023531,concentrations,"Mean (+/-S.D.) steady-state blood, muscle, and brain zidovudine concentrations by microdialysis were 112 +/- 63.8, 105 +/- 51.1, and 13.8 +/- 10.4 microM, respectively; and steady-state serum ultrafiltrate and CSF concentrations were 81.2 +/- 40.2 and 14.1 +/- 8.0 microM, respectively.",Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12023531/),μM,14.1,160495,DB00495,Zidovudine
,12023531,penetration,"Brain ECF penetration (microdialysis brain/blood ratio) and CSF penetration (standard sampling CSF/serum ratio) at steady state were 0.13 +/- 0.06 and 0.17 +/- 0.02, respectively.",Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12023531/),,0.13,160496,DB00495,Zidovudine
,12023531,area under concentration-time curve (AUC),"With bolus dosing the mean (+/-S.D.) zidovudine area under concentration-time curve (AUC) normalized to a dose of 80 mg/kg was 577 +/- 103 microM. h in blood, 528 +/- 202 microM. h in muscle, and 108 +/- 74 microM. h in brain (brain/blood ratio of 0.18 +/- 0.10) by microdialysis.",Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12023531/),h·μM,577,160497,DB00495,Zidovudine
,12023531,area under concentration-time curve (AUC),"With bolus dosing the mean (+/-S.D.) zidovudine area under concentration-time curve (AUC) normalized to a dose of 80 mg/kg was 577 +/- 103 microM. h in blood, 528 +/- 202 microM. h in muscle, and 108 +/- 74 microM. h in brain (brain/blood ratio of 0.18 +/- 0.10) by microdialysis.",Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12023531/),h·μM,528,160498,DB00495,Zidovudine
,12023531,area under concentration-time curve (AUC),"With bolus dosing the mean (+/-S.D.) zidovudine area under concentration-time curve (AUC) normalized to a dose of 80 mg/kg was 577 +/- 103 microM. h in blood, 528 +/- 202 microM. h in muscle, and 108 +/- 74 microM. h in brain (brain/blood ratio of 0.18 +/- 0.10) by microdialysis.",Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12023531/),h·μM,108,160499,DB00495,Zidovudine
,12023531,brain/blood ratio,"With bolus dosing the mean (+/-S.D.) zidovudine area under concentration-time curve (AUC) normalized to a dose of 80 mg/kg was 577 +/- 103 microM. h in blood, 528 +/- 202 microM. h in muscle, and 108 +/- 74 microM. h in brain (brain/blood ratio of 0.18 +/- 0.10) by microdialysis.",Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12023531/),,0.18,160500,DB00495,Zidovudine
,12023531,AUC,Serum ultrafiltrate AUC was 446 +/- 72 microM. h and the CSF AUC was 123 +/- 4.7 microM. h (CSF/serum ratio of 0.28 +/- 0.06).,Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12023531/),h·μM,446,160501,DB00495,Zidovudine
,12023531,AUC,Serum ultrafiltrate AUC was 446 +/- 72 microM. h and the CSF AUC was 123 +/- 4.7 microM. h (CSF/serum ratio of 0.28 +/- 0.06).,Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12023531/),h·μM,123,160502,DB00495,Zidovudine
,12023531,CSF/serum ratio,Serum ultrafiltrate AUC was 446 +/- 72 microM. h and the CSF AUC was 123 +/- 4.7 microM. h (CSF/serum ratio of 0.28 +/- 0.06).,Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12023531/),,0.28,160503,DB00495,Zidovudine
,10858368,area under the concentration-time curve from 0 to 6 h (AUC(0-6)),The plasma ZDV area under the concentration-time curve from 0 to 6 h (AUC(0-6)) was similar in patients and healthy volunteers (32.77 and 22.77 micromol/liter.,Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive thai patients and healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10858368/),[μM] / [l],32.77,160748,DB00495,Zidovudine
,10858368,area under the concentration-time curve from 0 to 6 h (AUC(0-6)),The plasma ZDV area under the concentration-time curve from 0 to 6 h (AUC(0-6)) was similar in patients and healthy volunteers (32.77 and 22.77 micromol/liter.,Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive thai patients and healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10858368/),[μM] / [l],22.77,160749,DB00495,Zidovudine
,10858368,AUC(0-6),"Although the concentration of ZDV triphosphate (ZDVTP) was similar in the two groups, the ZDV monophosphate (ZDVMP) AUC(0-6) was significantly greater in HIV patients (1.12 pmol/10(6) cells) than in healthy volunteers (0.15 pmol/10(6) cells).",Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive thai patients and healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10858368/),[pM] / [10(6)·cells],1.12,160750,DB00495,Zidovudine
,10858368,AUC(0-6),"Although the concentration of ZDV triphosphate (ZDVTP) was similar in the two groups, the ZDV monophosphate (ZDVMP) AUC(0-6) was significantly greater in HIV patients (1.12 pmol/10(6) cells) than in healthy volunteers (0.15 pmol/10(6) cells).",Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive thai patients and healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10858368/),[pM] / [10(6)·cells],0.15,160751,DB00495,Zidovudine
,8398581,Cmax,"The following mean (+/- s.d.) pharmacokinetic parameters were determined on day 1 and during chronic therapy, respectively: Cmax (4.09 +/- 2.54 vs 3.82 +/- 1.03 mumol l-1), oral clearance (40.7 +/- 12.9 vs 41.1 +/- 8.4 ml min-1 kg-1) and terminal half-life (68.4 +/- 29.4 vs 65.1 +/- 13.1 min).",Pharmacokinetics of zidovudine after the initial single dose and during chronic-dose therapy in HIV-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398581/),[μM] / [l],4.09,161172,DB00495,Zidovudine
,8398581,Cmax,"The following mean (+/- s.d.) pharmacokinetic parameters were determined on day 1 and during chronic therapy, respectively: Cmax (4.09 +/- 2.54 vs 3.82 +/- 1.03 mumol l-1), oral clearance (40.7 +/- 12.9 vs 41.1 +/- 8.4 ml min-1 kg-1) and terminal half-life (68.4 +/- 29.4 vs 65.1 +/- 13.1 min).",Pharmacokinetics of zidovudine after the initial single dose and during chronic-dose therapy in HIV-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398581/),[μM] / [l],3.82,161173,DB00495,Zidovudine
,8398581,oral clearance,"The following mean (+/- s.d.) pharmacokinetic parameters were determined on day 1 and during chronic therapy, respectively: Cmax (4.09 +/- 2.54 vs 3.82 +/- 1.03 mumol l-1), oral clearance (40.7 +/- 12.9 vs 41.1 +/- 8.4 ml min-1 kg-1) and terminal half-life (68.4 +/- 29.4 vs 65.1 +/- 13.1 min).",Pharmacokinetics of zidovudine after the initial single dose and during chronic-dose therapy in HIV-infected patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398581/),[ml] / [kg·min],40.7,161174,DB00495,Zidovudine
,8398581,oral clearance,"The following mean (+/- s.d.) pharmacokinetic parameters were determined on day 1 and during chronic therapy, respectively: Cmax (4.09 +/- 2.54 vs 3.82 +/- 1.03 mumol l-1), oral clearance (40.7 +/- 12.9 vs 41.1 +/- 8.4 ml min-1 kg-1) and terminal half-life (68.4 +/- 29.4 vs 65.1 +/- 13.1 min).",Pharmacokinetics of zidovudine after the initial single dose and during chronic-dose therapy in HIV-infected patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398581/),[ml] / [kg·min],41.1,161175,DB00495,Zidovudine
,8398581,terminal half-life,"The following mean (+/- s.d.) pharmacokinetic parameters were determined on day 1 and during chronic therapy, respectively: Cmax (4.09 +/- 2.54 vs 3.82 +/- 1.03 mumol l-1), oral clearance (40.7 +/- 12.9 vs 41.1 +/- 8.4 ml min-1 kg-1) and terminal half-life (68.4 +/- 29.4 vs 65.1 +/- 13.1 min).",Pharmacokinetics of zidovudine after the initial single dose and during chronic-dose therapy in HIV-infected patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398581/),min,68.4,161176,DB00495,Zidovudine
,8398581,terminal half-life,"The following mean (+/- s.d.) pharmacokinetic parameters were determined on day 1 and during chronic therapy, respectively: Cmax (4.09 +/- 2.54 vs 3.82 +/- 1.03 mumol l-1), oral clearance (40.7 +/- 12.9 vs 41.1 +/- 8.4 ml min-1 kg-1) and terminal half-life (68.4 +/- 29.4 vs 65.1 +/- 13.1 min).",Pharmacokinetics of zidovudine after the initial single dose and during chronic-dose therapy in HIV-infected patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398581/),min,65.1,161177,DB00495,Zidovudine
,9316866,distribution volume,"The distribution volume of AZT and DDI in brain tissue (V(br)) was found to be 1.07 +/- 0.09 and 0.727 +/- 0.030 ml/g brain, respectively, in an in vitro brain slice uptake study.","Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316866/),[ml] / [brain·g],1.07,162357,DB00495,Zidovudine
,9316866,distribution volume,"The distribution volume of AZT and DDI in brain tissue (V(br)) was found to be 1.07 +/- 0.09 and 0.727 +/- 0.030 ml/g brain, respectively, in an in vitro brain slice uptake study.","Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316866/),[ml] / [brain·g],0.727,162358,DB00495,Zidovudine
,9316866,bulk flow rate,"The pharmacokinetic parameters were obtained by fitting the concentration-time profiles of AZT and DDI in brain tissue and CSF after i.v. or i.c.v. administration taking the value of V(br), the CSF bulk flow rate (2.9 microl/min), and the surface area of the cerebroventricular ependyma (2.0 cm2), using a nonlinear least squares program combined with a fast inverse Laplace transform.","Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316866/),[μl] / [min],2.9,162359,DB00495,Zidovudine
,9316866,surface area,"The pharmacokinetic parameters were obtained by fitting the concentration-time profiles of AZT and DDI in brain tissue and CSF after i.v. or i.c.v. administration taking the value of V(br), the CSF bulk flow rate (2.9 microl/min), and the surface area of the cerebroventricular ependyma (2.0 cm2), using a nonlinear least squares program combined with a fast inverse Laplace transform.","Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316866/),cm,2.0,162360,DB00495,Zidovudine
,9316866,"efflux transport clearance (PS(BBB,eff))","The efflux transport clearance (PS(BBB,eff)) across the blood-brain barrier (BBB) and the symmetrical permeability clearance (PS(BBB)) across the BBB for AZT were calculated as 179 and 10.3 microl/min/g brain, respectively.","Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316866/),[μl] / [brain·g·min],179,162361,DB00495,Zidovudine
,9316866,permeability clearance (PS(BBB)),"The efflux transport clearance (PS(BBB,eff)) across the blood-brain barrier (BBB) and the symmetrical permeability clearance (PS(BBB)) across the BBB for AZT were calculated as 179 and 10.3 microl/min/g brain, respectively.","Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316866/),[μl] / [brain·g·min],10.3,162362,DB00495,Zidovudine
,9316866,"efflux transport clearance (PS(CSF,eff))","The efflux transport clearance (PS(CSF,eff)) across the blood-cerebrospinal fluid barrier (BCSFB) and the symmetrical permeability clearance (PS(CSF)) across the BCSFB for AZT were calculated as 227 and 28.3 microl/min/ml CSF, respectively.","Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316866/),[μl] / [csf·min·ml],227,162363,DB00495,Zidovudine
,9316866,"efflux transport clearance (PS(CSF,eff))","The efflux transport clearance (PS(CSF,eff)) across the blood-cerebrospinal fluid barrier (BCSFB) and the symmetrical permeability clearance (PS(CSF)) across the BCSFB for AZT were calculated as 227 and 28.3 microl/min/ml CSF, respectively.","Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316866/),[μl] / [csf·min·ml],28.3,162364,DB00495,Zidovudine
,9316866,permeability clearance (PS(CSF)),"The efflux transport clearance (PS(CSF,eff)) across the blood-cerebrospinal fluid barrier (BCSFB) and the symmetrical permeability clearance (PS(CSF)) across the BCSFB for AZT were calculated as 227 and 28.3 microl/min/ml CSF, respectively.","Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316866/),[μl] / [csf·min·ml],28.3,162365,DB00495,Zidovudine
,9316866,"BBB,eff","For the distribution of DDI, the PS(BBB,eff) and PS(BBB) were 79.2 and 2.03 microl/min/g brain, respectively, while the PS(CSF,eff) and PS(CSF) for DDI were 196 and 5.88 microl/min/ml CSF, respectively.","Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316866/),[μl] / [g·min],79.2,162366,DB00495,Zidovudine
,9316866,"BBB,eff","For the distribution of DDI, the PS(BBB,eff) and PS(BBB) were 79.2 and 2.03 microl/min/g brain, respectively, while the PS(CSF,eff) and PS(CSF) for DDI were 196 and 5.88 microl/min/ml CSF, respectively.","Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316866/),[μl] / [g·min],2.03,162367,DB00495,Zidovudine
,9316866,"CSF,eff","For the distribution of DDI, the PS(BBB,eff) and PS(BBB) were 79.2 and 2.03 microl/min/g brain, respectively, while the PS(CSF,eff) and PS(CSF) for DDI were 196 and 5.88 microl/min/ml CSF, respectively.","Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316866/),[μl] / [min·ml],196,162368,DB00495,Zidovudine
,9316866,"CSF,eff","For the distribution of DDI, the PS(BBB,eff) and PS(BBB) were 79.2 and 2.03 microl/min/g brain, respectively, while the PS(CSF,eff) and PS(CSF) for DDI were 196 and 5.88 microl/min/ml CSF, respectively.","Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316866/),[μl] / [min·ml],5.88,162369,DB00495,Zidovudine
,8723455,maximal effect,"If both drugs were to be administered simultaneously, the model predicts a mean maximal effect of a steady-state interval (12 h) of 67%.",Modeling combinations of antiretroviral agents in vitro with integration of pharmacokinetics: guidance in regimen choice for clinical trial evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723455/),%,67,164142,DB00495,Zidovudine
>,28489732,trough concentrations,Simulations were performed to estimate the probability of achieving target NVP trough concentrations for prophylaxis (>0.10 mg/L) and for therapeutic efficacy (>3.0 mg/L) using different infant dosing strategies.,Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28489732/),[mg] / [l],0.10,165542,DB00495,Zidovudine
>,28489732,trough concentrations,Simulations were performed to estimate the probability of achieving target NVP trough concentrations for prophylaxis (>0.10 mg/L) and for therapeutic efficacy (>3.0 mg/L) using different infant dosing strategies.,Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28489732/),[mg] / [l],3.0,165543,DB00495,Zidovudine
>,28489732,trough,"Based on simulations for a 3-kg infant, ≥92% would have an NVP trough >0.1 mg/L after 48 hours through 2 weeks using the PHPT-5 and WHO-dosing regimens.",Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28489732/),[mg] / [l],0.1,165544,DB00495,Zidovudine
>,28489732,trough,"For NVP-based therapy, a 6-mg/kg twice daily dose produced a trough >3.0 mg/L in 87% of infants at 48 hours and 80% at 2 weeks.",Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28489732/),[mg] / [l],3.0,165545,DB00495,Zidovudine
,2197818,Bioavailability,"Bioavailability ranges from 50 to 70 percent, and values for half-life, total body clearance, and volume of distribution are 1-2 h, 20-40 mL/min/kg, and 1-2 L/kg, respectively.",Zidovudine update: 1990. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197818/),%,50 to 70,166086,DB00495,Zidovudine
,2197818,half-life,"Bioavailability ranges from 50 to 70 percent, and values for half-life, total body clearance, and volume of distribution are 1-2 h, 20-40 mL/min/kg, and 1-2 L/kg, respectively.",Zidovudine update: 1990. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197818/),h,1-2,166087,DB00495,Zidovudine
,2197818,total body clearance,"Bioavailability ranges from 50 to 70 percent, and values for half-life, total body clearance, and volume of distribution are 1-2 h, 20-40 mL/min/kg, and 1-2 L/kg, respectively.",Zidovudine update: 1990. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197818/),[ml] / [kg·min],20-40,166088,DB00495,Zidovudine
,2197818,volume of distribution,"Bioavailability ranges from 50 to 70 percent, and values for half-life, total body clearance, and volume of distribution are 1-2 h, 20-40 mL/min/kg, and 1-2 L/kg, respectively.",Zidovudine update: 1990. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197818/),[l] / [kg],1-2,166089,DB00495,Zidovudine
,16187971,apparent volume of distribution (V/F ),"For nelfinavir, the apparent volume of distribution (V/F ) (95% confidence interval for the mean), was 309 l (185, 516), the absorption rate constant (k(a)) was 0.4 h(-1) (0.2, 0.8), and the apparent clearance (CL/F ) was 37.3 l h(-1) (32, 44).",Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187971/),l,309,166183,DB00495,Zidovudine
,16187971,absorption rate constant (k(a)),"For nelfinavir, the apparent volume of distribution (V/F ) (95% confidence interval for the mean), was 309 l (185, 516), the absorption rate constant (k(a)) was 0.4 h(-1) (0.2, 0.8), and the apparent clearance (CL/F ) was 37.3 l h(-1) (32, 44).",Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187971/),1/[h],0.4,166184,DB00495,Zidovudine
,16187971,apparent clearance (CL/F ),"For nelfinavir, the apparent volume of distribution (V/F ) (95% confidence interval for the mean), was 309 l (185, 516), the absorption rate constant (k(a)) was 0.4 h(-1) (0.2, 0.8), and the apparent clearance (CL/F ) was 37.3 l h(-1) (32, 44).",Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187971/),[l] / [h],37.3,166185,DB00495,Zidovudine
,16187971,V(m) /(Fk(m)),"For M8, V(m) /(Fk(m)) and CL(m)/(Fk(m)) were 866 l h(-1) (351, 2161) and 1670 l (965, 2894), respectively.",Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187971/),[l] / [h],866,166186,DB00495,Zidovudine
,16187971,CL(m)/(Fk(m)),"For M8, V(m) /(Fk(m)) and CL(m)/(Fk(m)) were 866 l h(-1) (351, 2161) and 1670 l (965, 2894), respectively.",Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187971/),l,1670,166187,DB00495,Zidovudine
,16187971,half-lives,"The mean half-lives were 05.38 h and 00.44 h for nelfinavir and M8, respectively.",Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187971/),h,05.38,166188,DB00495,Zidovudine
,16187971,half-lives,"The mean half-lives were 05.38 h and 00.44 h for nelfinavir and M8, respectively.",Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187971/),h,00.44,166189,DB00495,Zidovudine
,2778651,terminal half-life,Plasma AZT concentrations declined rapidly with a terminal half-life ranging from 0.76 h at a dose of 10 mg/kg to 1.58 h at 250 mg/kg.,Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778651/),h,0.76,167716,DB00495,Zidovudine
,2778651,terminal half-life,Plasma AZT concentrations declined rapidly with a terminal half-life ranging from 0.76 h at a dose of 10 mg/kg to 1.58 h at 250 mg/kg.,Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778651/),h,1.58,167717,DB00495,Zidovudine
,2778651,Total clearance (CLT),"Total clearance (CLT) was similar at the doses of 10 and 50 mg/kg, with values of 2.80 and 2.73 L/h/kg, respectively.",Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778651/),[l] / [h·kg],2.80,167718,DB00495,Zidovudine
,2778651,Total clearance (CLT),"Total clearance (CLT) was similar at the doses of 10 and 50 mg/kg, with values of 2.80 and 2.73 L/h/kg, respectively.",Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778651/),[l] / [h·kg],2.73,167719,DB00495,Zidovudine
,2778651,CLT,"However, there was a trend toward nonlinearity at the dose of 100 mg/kg (CLT = 2.13 L/h/kg) and a significant decrease in CLT (1.22 L/h/kg) at the dose of 250 mg/kg.",Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778651/),[l] / [h·kg],2.13,167720,DB00495,Zidovudine
,2778651,CLT,"However, there was a trend toward nonlinearity at the dose of 100 mg/kg (CLT = 2.13 L/h/kg) and a significant decrease in CLT (1.22 L/h/kg) at the dose of 250 mg/kg.",Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778651/),[l] / [h·kg],1.22,167721,DB00495,Zidovudine
,2778651,Nonrenal clearance,Nonrenal clearance remained unaffected by dose with a mean value of 0.98 L/h/kg.,Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778651/),[l] / [h·kg],0.98,167722,DB00495,Zidovudine
,2778651,Renal clearance (CLR),"Renal clearance (CLR) was similar at the doses of 10 and 50 mg/kg, with values of 1.89 and 1.37 L/h/kg, respectively.",Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778651/),[l] / [h·kg],1.89,167723,DB00495,Zidovudine
,2778651,Renal clearance (CLR),"Renal clearance (CLR) was similar at the doses of 10 and 50 mg/kg, with values of 1.89 and 1.37 L/h/kg, respectively.",Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778651/),[l] / [h·kg],1.37,167724,DB00495,Zidovudine
,2778651,CLR,"However, significant decreases in CLR were observed at the doses of 100 (CLR = 1.30 L/h/kg) and 250 mg/kg (CLR = 0.57 L/h/kg).",Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778651/),[l] / [h·kg],1.30,167725,DB00495,Zidovudine
,2778651,CLR,"However, significant decreases in CLR were observed at the doses of 100 (CLR = 1.30 L/h/kg) and 250 mg/kg (CLR = 0.57 L/h/kg).",Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778651/),[l] / [h·kg],0.57,167726,DB00495,Zidovudine
,2778651,maximum transport capacity (Tmax),"The maximum transport capacity (Tmax) and the Michaelis-Menten constant (Km) for renal tubular secretion obtained after simultaneously fitting plasma concentration-time profiles at the four doses to a renal clearance model were 215.5 +/- 82.1 mg/h and 119.3 +/- 80.5 mg/L, respectively, thereby yielding an unbound secretory intrinsic clearance (CLus,int) of 1.81 L/h.",Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778651/),[mg] / [h],215.5,167727,DB00495,Zidovudine
,2778651,Michaelis-Menten constant (Km),"The maximum transport capacity (Tmax) and the Michaelis-Menten constant (Km) for renal tubular secretion obtained after simultaneously fitting plasma concentration-time profiles at the four doses to a renal clearance model were 215.5 +/- 82.1 mg/h and 119.3 +/- 80.5 mg/L, respectively, thereby yielding an unbound secretory intrinsic clearance (CLus,int) of 1.81 L/h.",Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778651/),[mg] / [l],119.3,167728,DB00495,Zidovudine
,2778651,"unbound secretory intrinsic clearance (CLus,int)","The maximum transport capacity (Tmax) and the Michaelis-Menten constant (Km) for renal tubular secretion obtained after simultaneously fitting plasma concentration-time profiles at the four doses to a renal clearance model were 215.5 +/- 82.1 mg/h and 119.3 +/- 80.5 mg/L, respectively, thereby yielding an unbound secretory intrinsic clearance (CLus,int) of 1.81 L/h.",Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778651/),[l] / [h],1.81,167729,DB00495,Zidovudine
,8549029,area under the zidovudine concentration-time curve (AUC),Atovaquone significantly increased the area under the zidovudine concentration-time curve (AUC) (1.82 +/- 0.62 micrograms.hr/ml versus 2.39 +/- 0.68 micrograms.hr/ml; p < 0.05) and decreased the oral clearance of zidovudine (2029 +/- 666 ml/min versus 1512 +/- 464 ml/min; p < 0.05).,Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549029/),[h·μg] / [ml],1.82,168099,DB00495,Zidovudine
,8549029,area under the zidovudine concentration-time curve (AUC),Atovaquone significantly increased the area under the zidovudine concentration-time curve (AUC) (1.82 +/- 0.62 micrograms.hr/ml versus 2.39 +/- 0.68 micrograms.hr/ml; p < 0.05) and decreased the oral clearance of zidovudine (2029 +/- 666 ml/min versus 1512 +/- 464 ml/min; p < 0.05).,Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549029/),[h·μg] / [ml],2.39,168100,DB00495,Zidovudine
,8549029,oral clearance,Atovaquone significantly increased the area under the zidovudine concentration-time curve (AUC) (1.82 +/- 0.62 micrograms.hr/ml versus 2.39 +/- 0.68 micrograms.hr/ml; p < 0.05) and decreased the oral clearance of zidovudine (2029 +/- 666 ml/min versus 1512 +/- 464 ml/min; p < 0.05).,Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549029/),[ml] / [min],2029,168101,DB00495,Zidovudine
,8549029,oral clearance,Atovaquone significantly increased the area under the zidovudine concentration-time curve (AUC) (1.82 +/- 0.62 micrograms.hr/ml versus 2.39 +/- 0.68 micrograms.hr/ml; p < 0.05) and decreased the oral clearance of zidovudine (2029 +/- 666 ml/min versus 1512 +/- 464 ml/min; p < 0.05).,Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549029/),[ml] / [min],1512,168102,DB00495,Zidovudine
,8549029,AUC,"In contrast, atovaquone tended to decrease the AUC of zidovudine-glucuronide (7.31 +/- 1.51 micrograms.hr/ml versus 6.89 +/- 1.42 micrograms.hr/ml; p < 0.1) and significantly decreased the ratio of AUC zidovudine-glucuronide/AUC zidovudine (4.48 +/- 1.94 versus 3.12 +/- 1.1; p < 0.05).",Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549029/),[h·μg] / [ml],7.31,168103,DB00495,Zidovudine
,8549029,AUC,"In contrast, atovaquone tended to decrease the AUC of zidovudine-glucuronide (7.31 +/- 1.51 micrograms.hr/ml versus 6.89 +/- 1.42 micrograms.hr/ml; p < 0.1) and significantly decreased the ratio of AUC zidovudine-glucuronide/AUC zidovudine (4.48 +/- 1.94 versus 3.12 +/- 1.1; p < 0.05).",Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549029/),[h·μg] / [ml],6.89,168104,DB00495,Zidovudine
,8549029,ratio of AUC,"In contrast, atovaquone tended to decrease the AUC of zidovudine-glucuronide (7.31 +/- 1.51 micrograms.hr/ml versus 6.89 +/- 1.42 micrograms.hr/ml; p < 0.1) and significantly decreased the ratio of AUC zidovudine-glucuronide/AUC zidovudine (4.48 +/- 1.94 versus 3.12 +/- 1.1; p < 0.05).",Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549029/),,4.48,168105,DB00495,Zidovudine
,8549029,ratio of AUC,"In contrast, atovaquone tended to decrease the AUC of zidovudine-glucuronide (7.31 +/- 1.51 micrograms.hr/ml versus 6.89 +/- 1.42 micrograms.hr/ml; p < 0.1) and significantly decreased the ratio of AUC zidovudine-glucuronide/AUC zidovudine (4.48 +/- 1.94 versus 3.12 +/- 1.1; p < 0.05).",Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549029/),,3.12,168106,DB00495,Zidovudine
,8549029,maximum concentration,The maximum concentration of zidovudine-glucuronide was significantly lowered by atovaquone (5.7 +/- 1.5 versus 4.57 +/- 0.97 micrograms/ml; p < 0.05).,Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549029/),[μg] / [ml],5.7,168107,DB00495,Zidovudine
,8549029,maximum concentration,The maximum concentration of zidovudine-glucuronide was significantly lowered by atovaquone (5.7 +/- 1.5 versus 4.57 +/- 0.97 micrograms/ml; p < 0.05).,Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549029/),[μg] / [ml],4.57,168108,DB00495,Zidovudine
,7885970,maximum plasma concentration (Cmax),"The high-fat breakfast significantly reduced the mean (coefficient of variation) maximum plasma concentration (Cmax) from 806 (55%) ng/ml with treatment A to 341 (47%) and 424 (42%) ng/ml with treatments B and C, respectively.","Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7885970/),[ng] / [ml],806,168828,DB00495,Zidovudine
,7885970,maximum plasma concentration (Cmax),"The high-fat breakfast significantly reduced the mean (coefficient of variation) maximum plasma concentration (Cmax) from 806 (55%) ng/ml with treatment A to 341 (47%) and 424 (42%) ng/ml with treatments B and C, respectively.","Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7885970/),[ng] / [ml],341,168829,DB00495,Zidovudine
,7885970,maximum plasma concentration (Cmax),"The high-fat breakfast significantly reduced the mean (coefficient of variation) maximum plasma concentration (Cmax) from 806 (55%) ng/ml with treatment A to 341 (47%) and 424 (42%) ng/ml with treatments B and C, respectively.","Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7885970/),[ng] / [ml],424,168830,DB00495,Zidovudine
,7885970,time to Cmax,"The time to Cmax was significantly prolonged from 0.68 (30%) hours with treatment A to 1.7 (54%) and 1.3 (42%) hours with treatments B and C, respectively.","Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7885970/),,0.68,168831,DB00495,Zidovudine
,7885970,time to Cmax,"The time to Cmax was significantly prolonged from 0.68 (30%) hours with treatment A to 1.7 (54%) and 1.3 (42%) hours with treatments B and C, respectively.","Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7885970/),h,1.7,168832,DB00495,Zidovudine
,7885970,time to Cmax,"The time to Cmax was significantly prolonged from 0.68 (30%) hours with treatment A to 1.7 (54%) and 1.3 (42%) hours with treatments B and C, respectively.","Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7885970/),h,1.3,168833,DB00495,Zidovudine
,2120418,total plasma clearance,"The mean ZDV total plasma clearance, renal clearance, and the metabolic clearance of ZDV to the glucuronide (ZDVG) were significantly (p less than 0.05) smaller during the first week of life (6.15 +/- 1.03, 4.25 +/- 0.36, and 1.19 +/- 0.67 ml/min/kg, respectively) than the corresponding estimates at the age of 4 months (19.62 +/- 3.5, 8.28 +/- 1.90, and 8.28 +/- 2.24 ml/min/kg, respectively).",Pharmacokinetics of zidovudine (azidothymidine). Development of metabolic and renal clearance pathways in the neonate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120418/),[ml] / [kg·min],6.15,169736,DB00495,Zidovudine
,2120418,total plasma clearance,"The mean ZDV total plasma clearance, renal clearance, and the metabolic clearance of ZDV to the glucuronide (ZDVG) were significantly (p less than 0.05) smaller during the first week of life (6.15 +/- 1.03, 4.25 +/- 0.36, and 1.19 +/- 0.67 ml/min/kg, respectively) than the corresponding estimates at the age of 4 months (19.62 +/- 3.5, 8.28 +/- 1.90, and 8.28 +/- 2.24 ml/min/kg, respectively).",Pharmacokinetics of zidovudine (azidothymidine). Development of metabolic and renal clearance pathways in the neonate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120418/),[ml] / [kg·min],19.62,169737,DB00495,Zidovudine
,2120418,renal clearance,"The mean ZDV total plasma clearance, renal clearance, and the metabolic clearance of ZDV to the glucuronide (ZDVG) were significantly (p less than 0.05) smaller during the first week of life (6.15 +/- 1.03, 4.25 +/- 0.36, and 1.19 +/- 0.67 ml/min/kg, respectively) than the corresponding estimates at the age of 4 months (19.62 +/- 3.5, 8.28 +/- 1.90, and 8.28 +/- 2.24 ml/min/kg, respectively).",Pharmacokinetics of zidovudine (azidothymidine). Development of metabolic and renal clearance pathways in the neonate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120418/),[ml] / [kg·min],4.25,169738,DB00495,Zidovudine
,2120418,renal clearance,"The mean ZDV total plasma clearance, renal clearance, and the metabolic clearance of ZDV to the glucuronide (ZDVG) were significantly (p less than 0.05) smaller during the first week of life (6.15 +/- 1.03, 4.25 +/- 0.36, and 1.19 +/- 0.67 ml/min/kg, respectively) than the corresponding estimates at the age of 4 months (19.62 +/- 3.5, 8.28 +/- 1.90, and 8.28 +/- 2.24 ml/min/kg, respectively).",Pharmacokinetics of zidovudine (azidothymidine). Development of metabolic and renal clearance pathways in the neonate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120418/),[ml] / [kg·min],1.19,169739,DB00495,Zidovudine
,2120418,renal clearance,"The mean ZDV total plasma clearance, renal clearance, and the metabolic clearance of ZDV to the glucuronide (ZDVG) were significantly (p less than 0.05) smaller during the first week of life (6.15 +/- 1.03, 4.25 +/- 0.36, and 1.19 +/- 0.67 ml/min/kg, respectively) than the corresponding estimates at the age of 4 months (19.62 +/- 3.5, 8.28 +/- 1.90, and 8.28 +/- 2.24 ml/min/kg, respectively).",Pharmacokinetics of zidovudine (azidothymidine). Development of metabolic and renal clearance pathways in the neonate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120418/),[ml] / [kg·min],19.62,169740,DB00495,Zidovudine
,2120418,renal clearance,"The mean ZDV total plasma clearance, renal clearance, and the metabolic clearance of ZDV to the glucuronide (ZDVG) were significantly (p less than 0.05) smaller during the first week of life (6.15 +/- 1.03, 4.25 +/- 0.36, and 1.19 +/- 0.67 ml/min/kg, respectively) than the corresponding estimates at the age of 4 months (19.62 +/- 3.5, 8.28 +/- 1.90, and 8.28 +/- 2.24 ml/min/kg, respectively).",Pharmacokinetics of zidovudine (azidothymidine). Development of metabolic and renal clearance pathways in the neonate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120418/),[ml] / [kg·min],8.28,169741,DB00495,Zidovudine
,2120418,metabolic clearance,"The mean ZDV total plasma clearance, renal clearance, and the metabolic clearance of ZDV to the glucuronide (ZDVG) were significantly (p less than 0.05) smaller during the first week of life (6.15 +/- 1.03, 4.25 +/- 0.36, and 1.19 +/- 0.67 ml/min/kg, respectively) than the corresponding estimates at the age of 4 months (19.62 +/- 3.5, 8.28 +/- 1.90, and 8.28 +/- 2.24 ml/min/kg, respectively).",Pharmacokinetics of zidovudine (azidothymidine). Development of metabolic and renal clearance pathways in the neonate. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120418/),[ml] / [kg·min],1.19,169742,DB00495,Zidovudine
,2120418,metabolic clearance,"The mean ZDV total plasma clearance, renal clearance, and the metabolic clearance of ZDV to the glucuronide (ZDVG) were significantly (p less than 0.05) smaller during the first week of life (6.15 +/- 1.03, 4.25 +/- 0.36, and 1.19 +/- 0.67 ml/min/kg, respectively) than the corresponding estimates at the age of 4 months (19.62 +/- 3.5, 8.28 +/- 1.90, and 8.28 +/- 2.24 ml/min/kg, respectively).",Pharmacokinetics of zidovudine (azidothymidine). Development of metabolic and renal clearance pathways in the neonate. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120418/),[ml] / [kg·min],19.62,169743,DB00495,Zidovudine
,2120418,metabolic clearance,"The mean ZDV total plasma clearance, renal clearance, and the metabolic clearance of ZDV to the glucuronide (ZDVG) were significantly (p less than 0.05) smaller during the first week of life (6.15 +/- 1.03, 4.25 +/- 0.36, and 1.19 +/- 0.67 ml/min/kg, respectively) than the corresponding estimates at the age of 4 months (19.62 +/- 3.5, 8.28 +/- 1.90, and 8.28 +/- 2.24 ml/min/kg, respectively).",Pharmacokinetics of zidovudine (azidothymidine). Development of metabolic and renal clearance pathways in the neonate. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120418/),[ml] / [kg·min],8.28,169744,DB00495,Zidovudine
,2120418,metabolic clearance,"The mean ZDV total plasma clearance, renal clearance, and the metabolic clearance of ZDV to the glucuronide (ZDVG) were significantly (p less than 0.05) smaller during the first week of life (6.15 +/- 1.03, 4.25 +/- 0.36, and 1.19 +/- 0.67 ml/min/kg, respectively) than the corresponding estimates at the age of 4 months (19.62 +/- 3.5, 8.28 +/- 1.90, and 8.28 +/- 2.24 ml/min/kg, respectively).",Pharmacokinetics of zidovudine (azidothymidine). Development of metabolic and renal clearance pathways in the neonate. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2120418/),[ml] / [kg·min],8.28,169745,DB00495,Zidovudine
,8417175,bioavailability,The calculated bioavailability was 0.61 for zidovudine alone and 0.75 when administered in combination with oxazepam (p = 0.16).,Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),,0.61,170391,DB00495,Zidovudine
,8417175,bioavailability,The calculated bioavailability was 0.61 for zidovudine alone and 0.75 when administered in combination with oxazepam (p = 0.16).,Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),,0.75,170392,DB00495,Zidovudine
,8417175,Plasma half-life,"Plasma half-life for oral zidovudine alone and in combination with oxazepam was 1.17 h versus 0.99 h, respectively (p = 0.25), and 1.38 h versus 1.15 h (p = 0.38) for intravenous zidovudine during single and combination therapy, respectively.",Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),h,1.17,170393,DB00495,Zidovudine
,8417175,Plasma half-life,"Plasma half-life for oral zidovudine alone and in combination with oxazepam was 1.17 h versus 0.99 h, respectively (p = 0.25), and 1.38 h versus 1.15 h (p = 0.38) for intravenous zidovudine during single and combination therapy, respectively.",Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),h,0.99,170394,DB00495,Zidovudine
,8417175,Plasma half-life,"Plasma half-life for oral zidovudine alone and in combination with oxazepam was 1.17 h versus 0.99 h, respectively (p = 0.25), and 1.38 h versus 1.15 h (p = 0.38) for intravenous zidovudine during single and combination therapy, respectively.",Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),h,1.38,170395,DB00495,Zidovudine
,8417175,Plasma half-life,"Plasma half-life for oral zidovudine alone and in combination with oxazepam was 1.17 h versus 0.99 h, respectively (p = 0.25), and 1.38 h versus 1.15 h (p = 0.38) for intravenous zidovudine during single and combination therapy, respectively.",Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),h,1.15,170396,DB00495,Zidovudine
,8417175,Total body clearance,"Total body clearance of zidovudine was not significantly altered by oxazepam (93 L/h vs. 109 L/h, p = 0.16).",Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),[l] / [h],93,170397,DB00495,Zidovudine
,8417175,Total body clearance,"Total body clearance of zidovudine was not significantly altered by oxazepam (93 L/h vs. 109 L/h, p = 0.16).",Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),[l] / [h],109,170398,DB00495,Zidovudine
,8417175,oral clearance,"The mean pharmacokinetic parameters determined for a single 30-mg dose of oxazepam for oral clearance, apparent volume of distribution, and plasma half-life were 9.8 L/h, 65.7 L, and 5.1 h, respectively.",Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),[l] / [h],9.8,170399,DB00495,Zidovudine
,8417175,apparent volume of distribution,"The mean pharmacokinetic parameters determined for a single 30-mg dose of oxazepam for oral clearance, apparent volume of distribution, and plasma half-life were 9.8 L/h, 65.7 L, and 5.1 h, respectively.",Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),l,65.7,170400,DB00495,Zidovudine
,8417175,plasma half-life,"The mean pharmacokinetic parameters determined for a single 30-mg dose of oxazepam for oral clearance, apparent volume of distribution, and plasma half-life were 9.8 L/h, 65.7 L, and 5.1 h, respectively.",Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),h,5.1,170401,DB00495,Zidovudine
,19114673,concentrations,"The median concentrations in breast milk of zidovudine, lamivudine, and nevirapine during the study period were 14 ng/ml, 1,214 ng/ml, and 4,546 ng/ml, respectively.",Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114673/),[ng] / [ml],14,171674,DB00495,Zidovudine
,19114673,concentrations,"The median concentrations in breast milk of zidovudine, lamivudine, and nevirapine during the study period were 14 ng/ml, 1,214 ng/ml, and 4,546 ng/ml, respectively.",Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114673/),[ng] / [ml],"1,214",171675,DB00495,Zidovudine
,19114673,concentrations,"The median concentrations in breast milk of zidovudine, lamivudine, and nevirapine during the study period were 14 ng/ml, 1,214 ng/ml, and 4,546 ng/ml, respectively.",Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114673/),[ng] / [ml],"4,546",171676,DB00495,Zidovudine
,19114673,concentrations,"Zidovudine was not detectable in any infant plasma samples obtained after the day of delivery, while the median concentrations in infant plasma samples from postpartum weeks 2, 6, and 14 were 67 ng/ml, 32 ng/ml, and 24 ng/ml for lamivudine and 987 ng/ml, 1,032 ng/ml, and 734 ng/ml for nevirapine, respectively.",Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114673/),[ng] / [ml],67,171677,DB00495,Zidovudine
,19114673,concentrations,"Zidovudine was not detectable in any infant plasma samples obtained after the day of delivery, while the median concentrations in infant plasma samples from postpartum weeks 2, 6, and 14 were 67 ng/ml, 32 ng/ml, and 24 ng/ml for lamivudine and 987 ng/ml, 1,032 ng/ml, and 734 ng/ml for nevirapine, respectively.",Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114673/),[ng] / [ml],32,171678,DB00495,Zidovudine
,19114673,concentrations,"Zidovudine was not detectable in any infant plasma samples obtained after the day of delivery, while the median concentrations in infant plasma samples from postpartum weeks 2, 6, and 14 were 67 ng/ml, 32 ng/ml, and 24 ng/ml for lamivudine and 987 ng/ml, 1,032 ng/ml, and 734 ng/ml for nevirapine, respectively.",Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114673/),[ng] / [ml],24,171679,DB00495,Zidovudine
,19114673,concentrations,"Zidovudine was not detectable in any infant plasma samples obtained after the day of delivery, while the median concentrations in infant plasma samples from postpartum weeks 2, 6, and 14 were 67 ng/ml, 32 ng/ml, and 24 ng/ml for lamivudine and 987 ng/ml, 1,032 ng/ml, and 734 ng/ml for nevirapine, respectively.",Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114673/),[ng] / [ml],987,171680,DB00495,Zidovudine
,19114673,concentrations,"Zidovudine was not detectable in any infant plasma samples obtained after the day of delivery, while the median concentrations in infant plasma samples from postpartum weeks 2, 6, and 14 were 67 ng/ml, 32 ng/ml, and 24 ng/ml for lamivudine and 987 ng/ml, 1,032 ng/ml, and 734 ng/ml for nevirapine, respectively.",Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114673/),[ng] / [ml],"1,032",171681,DB00495,Zidovudine
,19114673,concentrations,"Zidovudine was not detectable in any infant plasma samples obtained after the day of delivery, while the median concentrations in infant plasma samples from postpartum weeks 2, 6, and 14 were 67 ng/ml, 32 ng/ml, and 24 ng/ml for lamivudine and 987 ng/ml, 1,032 ng/ml, and 734 ng/ml for nevirapine, respectively.",Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114673/),[ng] / [ml],734,171682,DB00495,Zidovudine
,1313173,steady-state ddC plasma concentration,The regimen was designed to produce steady-state ddC plasma concentration of 1.77 micrograms/ml for 30 min.,"Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) Drugs. III. 2',3'-Dideoxycytidine (ddC) and zidovudine in monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1313173/),[μg] / [ml],1.77,172818,DB00495,Zidovudine
,1313173,apparent clearance,"The mean apparent clearance of AZT was 1.40 and 1.78 L/hr/kg in the absence and presence of ddC, respectively.","Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) Drugs. III. 2',3'-Dideoxycytidine (ddC) and zidovudine in monkeys. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1313173/),[l] / [h·kg],1.40,172819,DB00495,Zidovudine
,1313173,apparent clearance,"The mean apparent clearance of AZT was 1.40 and 1.78 L/hr/kg in the absence and presence of ddC, respectively.","Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) Drugs. III. 2',3'-Dideoxycytidine (ddC) and zidovudine in monkeys. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1313173/),[l] / [h·kg],1.78,172820,DB00495,Zidovudine
,1313173,AUC,The mean AUC for GAZT was 36.39 micrograms-hr/ml in the absence of ddC and 28.81 micrograms-hr/ml in the presence of ddC.,"Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) Drugs. III. 2',3'-Dideoxycytidine (ddC) and zidovudine in monkeys. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1313173/),[μgrams-hr] / [ml],36.39,172821,DB00495,Zidovudine
,1313173,AUC,The mean AUC for GAZT was 36.39 micrograms-hr/ml in the absence of ddC and 28.81 micrograms-hr/ml in the presence of ddC.,"Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) Drugs. III. 2',3'-Dideoxycytidine (ddC) and zidovudine in monkeys. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1313173/),[μgrams-hr] / [ml],28.81,172822,DB00495,Zidovudine
,16320946,AUC0_infinity,"AZT levels in plasma were significantly higher following application of AZT-M liposomes compared with AZT solution, and AUC0_infinity increased from 5.0 +/- 0.7 micromol x min x ml(-1) to 8.2 +/- 1.7 micromol x min x ml(-1) accordingly.",Pharmacokinetics and tissue distribution of zidovudine in rats following intravenous administration of zidovudine myristate loaded liposomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320946/),[min·μM] / [ml],5.0,173404,DB00495,Zidovudine
,16320946,AUC0_infinity,"AZT levels in plasma were significantly higher following application of AZT-M liposomes compared with AZT solution, and AUC0_infinity increased from 5.0 +/- 0.7 micromol x min x ml(-1) to 8.2 +/- 1.7 micromol x min x ml(-1) accordingly.",Pharmacokinetics and tissue distribution of zidovudine in rats following intravenous administration of zidovudine myristate loaded liposomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320946/),[min·μM] / [ml],8.2,173405,DB00495,Zidovudine
,2231760,alpha half-life,"A dose-related increase in peak plasma levels of AZT was observed, and the alpha half-life of AZT in plasma (75 min) was unaffected by these high doses.","Oral zidovudine, continuous-infusion fluorouracil, and oral leucovorin calcium: a phase I study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231760/),min,75,175020,DB00495,Zidovudine
,14694989,bioavailability,The bioavailability of AZDU after oral administration was approximately 53%.,"Pharmacokinetic evaluation of 3'-azido-2', 3'-dideoxyuridine-5'-O-valinate-hydrochloride as a prodrug of the anti-HIV nucleoside 3'-azido-2', 3'-dideoxyuridine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14694989/),%,53,175103,DB00495,Zidovudine
,14694989,terminal phase half-life,The terminal phase half-life of the nucleoside analogue ranged between 0.6 h after intravenous administration and 1 h following oral administration.,"Pharmacokinetic evaluation of 3'-azido-2', 3'-dideoxyuridine-5'-O-valinate-hydrochloride as a prodrug of the anti-HIV nucleoside 3'-azido-2', 3'-dideoxyuridine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14694989/),h,0.6,175104,DB00495,Zidovudine
,14694989,terminal phase half-life,The terminal phase half-life of the nucleoside analogue ranged between 0.6 h after intravenous administration and 1 h following oral administration.,"Pharmacokinetic evaluation of 3'-azido-2', 3'-dideoxyuridine-5'-O-valinate-hydrochloride as a prodrug of the anti-HIV nucleoside 3'-azido-2', 3'-dideoxyuridine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14694989/),h,1,175105,DB00495,Zidovudine
,14694989,apparent availability,The apparent availability of AZDU was virtually complete following oral administration of prodrug AZDU-VAL averaging 101%.,"Pharmacokinetic evaluation of 3'-azido-2', 3'-dideoxyuridine-5'-O-valinate-hydrochloride as a prodrug of the anti-HIV nucleoside 3'-azido-2', 3'-dideoxyuridine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14694989/),%,101,175106,DB00495,Zidovudine
,14694989,bioavailability,The bioavailability of AZDU following intravenous administration of AZDU-VAL averaged 106%.,"Pharmacokinetic evaluation of 3'-azido-2', 3'-dideoxyuridine-5'-O-valinate-hydrochloride as a prodrug of the anti-HIV nucleoside 3'-azido-2', 3'-dideoxyuridine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14694989/),%,106,175107,DB00495,Zidovudine
,7834398,peak serum rCD4-IgG concentrations,"Mean calculated peak serum rCD4-IgG concentrations were 5.47 micrograms/ml with ZDV and 8.28 micrograms/ml without ZDV, with serum half-lives of 34.2 and 32.0 h, respectively.",Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834398/),[μg] / [ml],5.47,175343,DB00495,Zidovudine
,7834398,peak serum rCD4-IgG concentrations,"Mean calculated peak serum rCD4-IgG concentrations were 5.47 micrograms/ml with ZDV and 8.28 micrograms/ml without ZDV, with serum half-lives of 34.2 and 32.0 h, respectively.",Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834398/),[μg] / [ml],8.28,175344,DB00495,Zidovudine
,7834398,serum half-lives,"Mean calculated peak serum rCD4-IgG concentrations were 5.47 micrograms/ml with ZDV and 8.28 micrograms/ml without ZDV, with serum half-lives of 34.2 and 32.0 h, respectively.",Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834398/),h,34.2,175345,DB00495,Zidovudine
,7834398,serum half-lives,"Mean calculated peak serum rCD4-IgG concentrations were 5.47 micrograms/ml with ZDV and 8.28 micrograms/ml without ZDV, with serum half-lives of 34.2 and 32.0 h, respectively.",Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834398/),h,32.0,175346,DB00495,Zidovudine
,1670591,CD4 cell count,The median CD4 cell count in 38 patients with paired counts increased from 0.218 x 10(9) per liter (218 per cubic millimeter) at base line to 0.327 x 10(9) per liter (327 per cubic millimeter) after 20 to 24 weeks (P = 0.001).,Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1670591/),1/[l],0.218,177263,DB00495,Zidovudine
,1670591,CD4 cell count,The median CD4 cell count in 38 patients with paired counts increased from 0.218 x 10(9) per liter (218 per cubic millimeter) at base line to 0.327 x 10(9) per liter (327 per cubic millimeter) after 20 to 24 weeks (P = 0.001).,Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1670591/),1/[l],0.327 x,177264,DB00495,Zidovudine
,1670591,p24 antigen,The median levels of p24 antigen (in 27 patients with detectable levels at entry) declined from 272 pg per milliliter at base line to 77 pg per milliliter at 20 to 24 weeks (P = 0.005).,Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1670591/),[pg] / [milliliter],272,177265,DB00495,Zidovudine
,1670591,p24 antigen,The median levels of p24 antigen (in 27 patients with detectable levels at entry) declined from 272 pg per milliliter at base line to 77 pg per milliliter at 20 to 24 weeks (P = 0.005).,Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1670591/),[pg] / [milliliter],77,177266,DB00495,Zidovudine
,1854160,elimination half-life,"GAZT exhibited a kinetic profile similar to that of AZT, with an elimination half-life of approximately 1 h, while AMT was more variable, with an apparent half-life of 1.6 +/- 1.5 h.",Pharmacokinetics of 3'-azido-3'-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854160/),h,1,179563,DB00495,Zidovudine
,1854160,apparent half-life,"GAZT exhibited a kinetic profile similar to that of AZT, with an elimination half-life of approximately 1 h, while AMT was more variable, with an apparent half-life of 1.6 +/- 1.5 h.",Pharmacokinetics of 3'-azido-3'-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854160/),h,1.6,179564,DB00495,Zidovudine
,1919075,rate of metabolism,"The rate of metabolism of AZT was diminished from 1.43 h-1 prior to IFN-beta therapy, to 0.4 h-1 and 0.05 h-1 at days 3 and 15, respectively.",Metabolic interaction of recombinant interferon-beta and zidovudine in AIDS patients. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1919075/),1/[h],1.43,180946,DB00495,Zidovudine
,1919075,rate of metabolism,"The rate of metabolism of AZT was diminished from 1.43 h-1 prior to IFN-beta therapy, to 0.4 h-1 and 0.05 h-1 at days 3 and 15, respectively.",Metabolic interaction of recombinant interferon-beta and zidovudine in AIDS patients. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1919075/),1/[h],0.4,180947,DB00495,Zidovudine
,1919075,rate of metabolism,"The rate of metabolism of AZT was diminished from 1.43 h-1 prior to IFN-beta therapy, to 0.4 h-1 and 0.05 h-1 at days 3 and 15, respectively.",Metabolic interaction of recombinant interferon-beta and zidovudine in AIDS patients. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1919075/),1/[h],0.05,180948,DB00495,Zidovudine
,1919075,volume of distribution,"The volume of distribution of AZT was 2 l/kg at day 0 and increased to 3.2 and 3.5 l/kg on days 3 and 15, respectively.",Metabolic interaction of recombinant interferon-beta and zidovudine in AIDS patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1919075/),[l] / [kg],2,180949,DB00495,Zidovudine
,1919075,volume of distribution,"The volume of distribution of AZT was 2 l/kg at day 0 and increased to 3.2 and 3.5 l/kg on days 3 and 15, respectively.",Metabolic interaction of recombinant interferon-beta and zidovudine in AIDS patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1919075/),[l] / [kg],3.2,180950,DB00495,Zidovudine
,1919075,volume of distribution,"The volume of distribution of AZT was 2 l/kg at day 0 and increased to 3.2 and 3.5 l/kg on days 3 and 15, respectively.",Metabolic interaction of recombinant interferon-beta and zidovudine in AIDS patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1919075/),[l] / [kg],3.5,180951,DB00495,Zidovudine
,9811159,"beta t1/2 (elimination, or beta-phase, half-life)","The pharmacokinetics of AZT (beta t1/2 (elimination, or beta-phase, half-life) = 112.5 min; AUC (area under the plot of concentration against time) = 29.1 +/- 2.9 micromol g(-1) min; CL (blood clearance) = 10.5 +/- 1.1 mL min(-1) kg(-1)) and its ester prodrug (3, beta t1/2 = 428.5 min; AUC = 17.3 +/- 4.7 micromol g(-1) min; CL = 17.6 +/- 4.8 mL min(-1) kg(-1) were compared after intravenous injection of equimolar doses (0.3 mmol kg(-1)) via the tail vein of Balb/c mice (25-30 g).","Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811159/),min,112.5,181900,DB00495,Zidovudine
,9811159,AUC (area under the plot of concentration against time),"The pharmacokinetics of AZT (beta t1/2 (elimination, or beta-phase, half-life) = 112.5 min; AUC (area under the plot of concentration against time) = 29.1 +/- 2.9 micromol g(-1) min; CL (blood clearance) = 10.5 +/- 1.1 mL min(-1) kg(-1)) and its ester prodrug (3, beta t1/2 = 428.5 min; AUC = 17.3 +/- 4.7 micromol g(-1) min; CL = 17.6 +/- 4.8 mL min(-1) kg(-1) were compared after intravenous injection of equimolar doses (0.3 mmol kg(-1)) via the tail vein of Balb/c mice (25-30 g).","Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811159/),[min·μM] / [g],29.1,181901,DB00495,Zidovudine
,9811159,CL (blood clearance),"The pharmacokinetics of AZT (beta t1/2 (elimination, or beta-phase, half-life) = 112.5 min; AUC (area under the plot of concentration against time) = 29.1 +/- 2.9 micromol g(-1) min; CL (blood clearance) = 10.5 +/- 1.1 mL min(-1) kg(-1)) and its ester prodrug (3, beta t1/2 = 428.5 min; AUC = 17.3 +/- 4.7 micromol g(-1) min; CL = 17.6 +/- 4.8 mL min(-1) kg(-1) were compared after intravenous injection of equimolar doses (0.3 mmol kg(-1)) via the tail vein of Balb/c mice (25-30 g).","Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811159/),[ml] / [kg·min],10.5,181902,DB00495,Zidovudine
,9811159,beta t1/2,"The pharmacokinetics of AZT (beta t1/2 (elimination, or beta-phase, half-life) = 112.5 min; AUC (area under the plot of concentration against time) = 29.1 +/- 2.9 micromol g(-1) min; CL (blood clearance) = 10.5 +/- 1.1 mL min(-1) kg(-1)) and its ester prodrug (3, beta t1/2 = 428.5 min; AUC = 17.3 +/- 4.7 micromol g(-1) min; CL = 17.6 +/- 4.8 mL min(-1) kg(-1) were compared after intravenous injection of equimolar doses (0.3 mmol kg(-1)) via the tail vein of Balb/c mice (25-30 g).","Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811159/),min,428.5,181903,DB00495,Zidovudine
,9811159,AUC,"The pharmacokinetics of AZT (beta t1/2 (elimination, or beta-phase, half-life) = 112.5 min; AUC (area under the plot of concentration against time) = 29.1 +/- 2.9 micromol g(-1) min; CL (blood clearance) = 10.5 +/- 1.1 mL min(-1) kg(-1)) and its ester prodrug (3, beta t1/2 = 428.5 min; AUC = 17.3 +/- 4.7 micromol g(-1) min; CL = 17.6 +/- 4.8 mL min(-1) kg(-1) were compared after intravenous injection of equimolar doses (0.3 mmol kg(-1)) via the tail vein of Balb/c mice (25-30 g).","Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811159/),[min·μM] / [g],17.3,181904,DB00495,Zidovudine
,9811159,CL,"The pharmacokinetics of AZT (beta t1/2 (elimination, or beta-phase, half-life) = 112.5 min; AUC (area under the plot of concentration against time) = 29.1 +/- 2.9 micromol g(-1) min; CL (blood clearance) = 10.5 +/- 1.1 mL min(-1) kg(-1)) and its ester prodrug (3, beta t1/2 = 428.5 min; AUC = 17.3 +/- 4.7 micromol g(-1) min; CL = 17.6 +/- 4.8 mL min(-1) kg(-1) were compared after intravenous injection of equimolar doses (0.3 mmol kg(-1)) via the tail vein of Balb/c mice (25-30 g).","Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811159/),[ml] / [kg·min],17.6,181905,DB00495,Zidovudine
,9811159,peak concentration,"The prodrug was rapidly converted to AZT in-vivo, but plasma levels of AZT (peak concentration 0.17 micromol g(-1)) and AUC (12.3 micromol min g(-1)) were lower than observed after AZT administration (peak concentration 0.36 micromol g(-1); AUC 29.1 micromol min g(-1).","Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811159/),[μM] / [g],0.17,181906,DB00495,Zidovudine
,9811159,AUC,"The prodrug was rapidly converted to AZT in-vivo, but plasma levels of AZT (peak concentration 0.17 micromol g(-1)) and AUC (12.3 micromol min g(-1)) were lower than observed after AZT administration (peak concentration 0.36 micromol g(-1); AUC 29.1 micromol min g(-1).","Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811159/),[min·μM] / [g],12.3,181907,DB00495,Zidovudine
,9811159,peak concentration,"The prodrug was rapidly converted to AZT in-vivo, but plasma levels of AZT (peak concentration 0.17 micromol g(-1)) and AUC (12.3 micromol min g(-1)) were lower than observed after AZT administration (peak concentration 0.36 micromol g(-1); AUC 29.1 micromol min g(-1).","Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811159/),[μM] / [g],0.36,181908,DB00495,Zidovudine
,9811159,AUC,"The prodrug was rapidly converted to AZT in-vivo, but plasma levels of AZT (peak concentration 0.17 micromol g(-1)) and AUC (12.3 micromol min g(-1)) were lower than observed after AZT administration (peak concentration 0.36 micromol g(-1); AUC 29.1 micromol min g(-1).","Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811159/),[min·μM] / [g],29.1,181909,DB00495,Zidovudine
,9811159,peak concentrations,"The prodrug also accumulated rapidly in the liver immediately after injection, resulting in higher concentrations of AZT than observed after administration of AZT itself (respective peak concentrations 1.11 and 0.81 micromol g(-1); respective AUCs 42.5 and 12.7 micromol min g(-1)).","Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811159/),[μM] / [g],1.11,181910,DB00495,Zidovudine
,9811159,peak concentrations,"The prodrug also accumulated rapidly in the liver immediately after injection, resulting in higher concentrations of AZT than observed after administration of AZT itself (respective peak concentrations 1.11 and 0.81 micromol g(-1); respective AUCs 42.5 and 12.7 micromol min g(-1)).","Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811159/),[μM] / [g],0.81,181911,DB00495,Zidovudine
,9811159,AUCs,"The prodrug also accumulated rapidly in the liver immediately after injection, resulting in higher concentrations of AZT than observed after administration of AZT itself (respective peak concentrations 1.11 and 0.81 micromol g(-1); respective AUCs 42.5 and 12.7 micromol min g(-1)).","Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811159/),[min·μM] / [g],42.5,181912,DB00495,Zidovudine
,9811159,AUCs,"The prodrug also accumulated rapidly in the liver immediately after injection, resulting in higher concentrations of AZT than observed after administration of AZT itself (respective peak concentrations 1.11 and 0.81 micromol g(-1); respective AUCs 42.5 and 12.7 micromol min g(-1)).","Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811159/),[min·μM] / [g],12.7,181913,DB00495,Zidovudine
,9811159,brain concentration,"Compared with doses of AZT itself, 3 also led to significantly higher brain concentration of AZT (25.7 compared with 9.8 nmol g(-1)) and AUCs (2.8 compared with 1.4 micromol min g(-1)).","Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811159/),[nM] / [g],25.7,181914,DB00495,Zidovudine
,9811159,brain concentration,"Compared with doses of AZT itself, 3 also led to significantly higher brain concentration of AZT (25.7 compared with 9.8 nmol g(-1)) and AUCs (2.8 compared with 1.4 micromol min g(-1)).","Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811159/),[nM] / [g],9.8,181915,DB00495,Zidovudine
,9811159,AUCs,"Compared with doses of AZT itself, 3 also led to significantly higher brain concentration of AZT (25.7 compared with 9.8 nmol g(-1)) and AUCs (2.8 compared with 1.4 micromol min g(-1)).","Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811159/),[min·μM] / [g],2.8,181916,DB00495,Zidovudine
,9811159,AUCs,"Compared with doses of AZT itself, 3 also led to significantly higher brain concentration of AZT (25.7 compared with 9.8 nmol g(-1)) and AUCs (2.8 compared with 1.4 micromol min g(-1)).","Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811159/),[min·μM] / [g],1.4,181917,DB00495,Zidovudine
,1364018,peak plasma concentrations,"In the concentration range comprising usual peak plasma concentrations during AZT therapy (0.1-20 mumol/l, i.e. 0.026-5.34 micrograms/ml) mean efficiency of the extraction procedure reached as high as 75.3% of original AZT concentrations in standard unextracted aqueous solutions.",HPLC-monitoring of AZT in HIV-infected patient's plasma: a critical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1364018/),[μM] / [l],0.1-20,182745,DB00495,Zidovudine
,1364018,detection limit,"The detection limit in plasma was 2 mumol/l, i.e. 5.3 ng per a 20 microliter of sample injected to the HPLC column.",HPLC-monitoring of AZT in HIV-infected patient's plasma: a critical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1364018/),[μM] / [l],2,182746,DB00495,Zidovudine
,1364018,detection limit,"The detection limit in plasma was 2 mumol/l, i.e. 5.3 ng per a 20 microliter of sample injected to the HPLC column.",HPLC-monitoring of AZT in HIV-infected patient's plasma: a critical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1364018/),[ng] / [a],5.3,182747,DB00495,Zidovudine
,2362907,CSF/plasma steady-state AZT concentration ratio,The CSF/plasma steady-state AZT concentration ratio was 0.192 +/- 0.003.,Modeling the enhanced uptake of zidovudine (AZT) into cerebrospinal fluid. 1. Effect of probenecid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2362907/),,0.192,183518,DB00495,Zidovudine
<,15612614,tmax,"Maximum ala-AZT-MP concentrations were reached almost immediately (tmax < 5 min), while 50.4 min and 143.5 min were required to reach maximum AZT concentrations after intravenous and oral administration, respectively.",In vitro and in vivo pharmacokinetic features and metabolism of the novel cytotoxic nucleoside analog 3'-azidothymidine 5'-[p-methoxyphenyl methoxyalaninyl phosphate] (Compound 003). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15612614/),min,5,184054,DB00495,Zidovudine
,3166511,CD4/CD8 ratio,The mean CD4/CD8 ratio was 0.18; 11 patients had CD4 counts below 0.2 x 10(9) per liter.,Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3166511/),,0.18,185222,DB00495,Zidovudine
,3166511,plasma drug concentrations,"The plasma drug concentrations achieved at the respective dose levels were 1.9 +/- 0.3, 2.8 +/- 1.4, 3.1 +/- 1.1, and 4.5 +/- 1.0 microM.",Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3166511/),μM,1.9,185223,DB00495,Zidovudine
,3166511,plasma drug concentrations,"The plasma drug concentrations achieved at the respective dose levels were 1.9 +/- 0.3, 2.8 +/- 1.4, 3.1 +/- 1.1, and 4.5 +/- 1.0 microM.",Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3166511/),μM,2.8,185224,DB00495,Zidovudine
,3166511,plasma drug concentrations,"The plasma drug concentrations achieved at the respective dose levels were 1.9 +/- 0.3, 2.8 +/- 1.4, 3.1 +/- 1.1, and 4.5 +/- 1.0 microM.",Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3166511/),μM,3.1,185225,DB00495,Zidovudine
,3166511,plasma drug concentrations,"The plasma drug concentrations achieved at the respective dose levels were 1.9 +/- 0.3, 2.8 +/- 1.4, 3.1 +/- 1.1, and 4.5 +/- 1.0 microM.",Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3166511/),μM,4.5,185226,DB00495,Zidovudine
,3166511,steady-state cerebrospinal fluid:plasma ratio,The steady-state cerebrospinal fluid:plasma ratio was 0.24 +/- 0.07.,Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3166511/),,0.24,185227,DB00495,Zidovudine
,8723472,renal clearance,Trimethoprim significantly decreased the renal clearance of zidovudine by 58% (5.0 +/- 1.8 versus 2.1 +/- 0.5 ml/min/kg of body weight [P < 0.05]).,"Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723472/),[ml] / [kg·min],5.0,185465,DB00495,Zidovudine
,8723472,renal clearance,Trimethoprim significantly decreased the renal clearance of zidovudine by 58% (5.0 +/- 1.8 versus 2.1 +/- 0.5 ml/min/kg of body weight [P < 0.05]).,"Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723472/),[ml] / [kg·min],2.1,185466,DB00495,Zidovudine
,8723472,urinary recovery,"There was a concurrent 54% decrease in the mean urinary recovery of zidovudine (11.7 +/- 3.5 versus 5.4 +/- 3.0 [P < 0.05]), and the metabolic ratio was decreased by 78% (0.32 +/- 0.4 versus 0.07 +/- 0.05 [P < 0.05]).","Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723472/),,11.7,185467,DB00495,Zidovudine
,8723472,urinary recovery,"There was a concurrent 54% decrease in the mean urinary recovery of zidovudine (11.7 +/- 3.5 versus 5.4 +/- 3.0 [P < 0.05]), and the metabolic ratio was decreased by 78% (0.32 +/- 0.4 versus 0.07 +/- 0.05 [P < 0.05]).","Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723472/),,5.4,185468,DB00495,Zidovudine
,8723472,metabolic,"There was a concurrent 54% decrease in the mean urinary recovery of zidovudine (11.7 +/- 3.5 versus 5.4 +/- 3.0 [P < 0.05]), and the metabolic ratio was decreased by 78% (0.32 +/- 0.4 versus 0.07 +/- 0.05 [P < 0.05]).","Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723472/),,0,185469,DB00495,Zidovudine
,1519301,terminal half-life,"Plasma pharmacokinetics followed expected patterns, with considerable interpatient variability in area under the concentration-versus-time curve (AUC), and a terminal half-life of 1.5 h.",Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1519301/),h,1.5,188070,DB00495,Zidovudine
,1519301,intracellular half-life,"The intracellular half-life of 3.5 h was consistently longer than the plasma half-life, and varied little between patients.",Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1519301/),h,3.5,188071,DB00495,Zidovudine
,3549120,plasma half-life,The plasma half-life of N3TdR was 1.1 hour.,Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549120/),h,1.1,188147,DB00495,Zidovudine
,3549120,total body clearance,The total body clearance was 1.3 L/kg/hr.,Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549120/),[l] / [h·kg],1.3,188148,DB00495,Zidovudine
,3549120,Oral bioavailability,"At intravenous doses of 5 mg/kg or oral doses of 10 mg/kg, plasma levels were continuously maintained above the target level of 1 mumol/L. Oral bioavailability was 63% +/- 13%.",Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549120/),%,63,188149,DB00495,Zidovudine
,3549120,Renal clearance,Renal clearance was 0.23 L/kg/hr.,Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549120/),[l] / [h·kg],0.23,188150,DB00495,Zidovudine
,2575492,CIt,"At the 50 mg/kg doses, the CIt of AZddU and AZT was 1.27 liters/hr/kg and 1.38 liters/hr/kg, respectively, which is analogous to the clearance value of AZT observed in humans.","Comparative pharmacokinetics of 3'-azido-3'-deoxythymidine (AZT) and 3'-azido-2',3'-dideoxyuridine (AZddU) in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575492/),[l] / [h·kg],1.27,188262,DB00495,Zidovudine
,2575492,CIt,"At the 50 mg/kg doses, the CIt of AZddU and AZT was 1.27 liters/hr/kg and 1.38 liters/hr/kg, respectively, which is analogous to the clearance value of AZT observed in humans.","Comparative pharmacokinetics of 3'-azido-3'-deoxythymidine (AZT) and 3'-azido-2',3'-dideoxyuridine (AZddU) in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575492/),[l] / [h·kg],1.38,188263,DB00495,Zidovudine
,2575492,Brain/serum concentration ratios,"Brain/serum concentration ratios for AZddU tended to be greater than those obtained for AZT and were significantly different at the 50 mg/kg dose, being 0.234 +/- 0.282 for AZddU and 0.064 +/- 0.025 for AZT.","Comparative pharmacokinetics of 3'-azido-3'-deoxythymidine (AZT) and 3'-azido-2',3'-dideoxyuridine (AZddU) in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575492/),,0.234,188264,DB00495,Zidovudine
,2575492,Brain/serum concentration ratios,"Brain/serum concentration ratios for AZddU tended to be greater than those obtained for AZT and were significantly different at the 50 mg/kg dose, being 0.234 +/- 0.282 for AZddU and 0.064 +/- 0.025 for AZT.","Comparative pharmacokinetics of 3'-azido-3'-deoxythymidine (AZT) and 3'-azido-2',3'-dideoxyuridine (AZddU) in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575492/),,0.064,188265,DB00495,Zidovudine
,18479171,absolute bioavailability,The absolute bioavailability of abacavir is approximately 83%.,A review of the pharmacokinetics of abacavir. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),%,83,188444,DB00495,Zidovudine
,18479171,peak concentration,"To date, one study has assessed the steady-state pharmacokinetics of abacavir following a 600-mg once-daily regimen, and reported a geometric mean steady-state abacavir peak concentration of 3.85 microg/mL.",A review of the pharmacokinetics of abacavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),[μg] / [ml],3.85,188445,DB00495,Zidovudine
,18479171,peak concentration,"Although this concentration is higher than the steady-state abacavir peak concentration reported following a 300-mg twice-daily regimen (0.88-3.19 microg/mL, depending on the study), the geometric mean steady-state abacavir exposure over 24 hours was similar following these regimens.",A review of the pharmacokinetics of abacavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),[μg] / [ml],0.88-3.19,188446,DB00495,Zidovudine
,18479171,apparent volume of distribution,"The apparent volume of distribution of abacavir after intravenous administration is approximately 0.86 +/- 0.15 L/kg, suggesting that abacavir is distributed to extravascular spaces.",A review of the pharmacokinetics of abacavir. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),[l] / [kg],0.86,188447,DB00495,Zidovudine
,18479171,Binding,Binding to plasma proteins is about 50% and is independent of the plasma abacavir concentration.,A review of the pharmacokinetics of abacavir. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),%,50,188448,DB00495,Zidovudine
,18479171,terminal elimination half-life,The terminal elimination half-life of abacavir is approximately 1.5 hours.,A review of the pharmacokinetics of abacavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),h,1.5,188449,DB00495,Zidovudine
>,18479171,elimination half-life,"When assessed by validated high-performance liquid chromatography electrospray ionization tandem mass spectrometry, CBV-TP has been shown to have a long elimination half-life (>20 hours), supporting once-daily dosing.",A review of the pharmacokinetics of abacavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),h,20,188450,DB00495,Zidovudine
,8215300,free fraction,"The free fraction of zidovudine at a concentration of 500 ng/ml (1.7 microM) was 0.77 +/- 0.05 in plasma, 0.78 +/- 0.03 in serum, 0.88 +/- 0.03 in 4 g/dl albumin solution, and 1.0 in 100 mg/dl alpha 1-acid glycoprotein solution.",Intravascular distribution of zidovudine: role of plasma proteins and whole blood components. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8215300/),,0.77,189781,DB00495,Zidovudine
,8215300,free fraction,"The free fraction of zidovudine at a concentration of 500 ng/ml (1.7 microM) was 0.77 +/- 0.05 in plasma, 0.78 +/- 0.03 in serum, 0.88 +/- 0.03 in 4 g/dl albumin solution, and 1.0 in 100 mg/dl alpha 1-acid glycoprotein solution.",Intravascular distribution of zidovudine: role of plasma proteins and whole blood components. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8215300/),,0.78,189782,DB00495,Zidovudine
,8215300,free fraction,"The free fraction of zidovudine at a concentration of 500 ng/ml (1.7 microM) was 0.77 +/- 0.05 in plasma, 0.78 +/- 0.03 in serum, 0.88 +/- 0.03 in 4 g/dl albumin solution, and 1.0 in 100 mg/dl alpha 1-acid glycoprotein solution.",Intravascular distribution of zidovudine: role of plasma proteins and whole blood components. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8215300/),,0.88,189783,DB00495,Zidovudine
,8215300,free fraction,"The free fraction of zidovudine at a concentration of 500 ng/ml (1.7 microM) was 0.77 +/- 0.05 in plasma, 0.78 +/- 0.03 in serum, 0.88 +/- 0.03 in 4 g/dl albumin solution, and 1.0 in 100 mg/dl alpha 1-acid glycoprotein solution.",Intravascular distribution of zidovudine: role of plasma proteins and whole blood components. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8215300/),,1.0,189784,DB00495,Zidovudine
,8215300,free fraction,A free fraction of 0.72 +/- 0.10 was observed in plasma from HIV-infected patients with zidovudine concentrations ranging from 16 to 91 ng/ml.,Intravascular distribution of zidovudine: role of plasma proteins and whole blood components. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8215300/),,0.72,189785,DB00495,Zidovudine
,8215300,whole blood:plasma ratio,"After equilibrium was complete, the mean whole blood:plasma ratio was 0.86 +/- 0.02 and 0.80 +/- 0.04 (P = 0.20) and mean blood cell Partitioning ratio, [cell]/[plasma-free], was 0.85 +/- 0.06 and 0.66 +/- 0.14 (P = 0.25) for studies at 37 degrees C and 21 degrees C, respectively.",Intravascular distribution of zidovudine: role of plasma proteins and whole blood components. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8215300/),,0.86,189786,DB00495,Zidovudine
,8215300,whole blood:plasma ratio,"After equilibrium was complete, the mean whole blood:plasma ratio was 0.86 +/- 0.02 and 0.80 +/- 0.04 (P = 0.20) and mean blood cell Partitioning ratio, [cell]/[plasma-free], was 0.85 +/- 0.06 and 0.66 +/- 0.14 (P = 0.25) for studies at 37 degrees C and 21 degrees C, respectively.",Intravascular distribution of zidovudine: role of plasma proteins and whole blood components. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8215300/),,0.80,189787,DB00495,Zidovudine
,8215300,Partitioning ratio,"After equilibrium was complete, the mean whole blood:plasma ratio was 0.86 +/- 0.02 and 0.80 +/- 0.04 (P = 0.20) and mean blood cell Partitioning ratio, [cell]/[plasma-free], was 0.85 +/- 0.06 and 0.66 +/- 0.14 (P = 0.25) for studies at 37 degrees C and 21 degrees C, respectively.",Intravascular distribution of zidovudine: role of plasma proteins and whole blood components. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8215300/),-1·cell,0.85,189788,DB00495,Zidovudine
,8215300,Partitioning ratio,"After equilibrium was complete, the mean whole blood:plasma ratio was 0.86 +/- 0.02 and 0.80 +/- 0.04 (P = 0.20) and mean blood cell Partitioning ratio, [cell]/[plasma-free], was 0.85 +/- 0.06 and 0.66 +/- 0.14 (P = 0.25) for studies at 37 degrees C and 21 degrees C, respectively.",Intravascular distribution of zidovudine: role of plasma proteins and whole blood components. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8215300/),-1·cell,0.66,189789,DB00495,Zidovudine
,8726008,time at which the plasma concentration was maximal (Tmax),"Kinetics on days 13 and 16 demonstrated that RBT (300 or 450 mg) was readily absorbed, with the time at which the plasma concentration was maximal (Tmax) ranging between 2.6 and 2.9 h.",Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726008/),h,2.6 and 2.9,189944,DB00495,Zidovudine
,8726008,steady-state maximal plasma concentrations (Cmax),"At these two doses, the mean steady-state maximal plasma concentrations (Cmax) were 250 and 430 ng/ml on day 13 and 245 and 458 ng/ml on day 16, respectively.",Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726008/),[ng] / [ml],250,189945,DB00495,Zidovudine
,8726008,steady-state maximal plasma concentrations (Cmax),"At these two doses, the mean steady-state maximal plasma concentrations (Cmax) were 250 and 430 ng/ml on day 13 and 245 and 458 ng/ml on day 16, respectively.",Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726008/),[ng] / [ml],430,189946,DB00495,Zidovudine
,8726008,steady-state maximal plasma concentrations (Cmax),"At these two doses, the mean steady-state maximal plasma concentrations (Cmax) were 250 and 430 ng/ml on day 13 and 245 and 458 ng/ml on day 16, respectively.",Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726008/),[ng] / [ml],245,189947,DB00495,Zidovudine
,8726008,steady-state maximal plasma concentrations (Cmax),"At these two doses, the mean steady-state maximal plasma concentrations (Cmax) were 250 and 430 ng/ml on day 13 and 245 and 458 ng/ml on day 16, respectively.",Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726008/),[ng] / [ml],458,189948,DB00495,Zidovudine
,8726008,oral clearance (CLs/F),"No significant differences were apparent in the mean oral clearance (CLs/F) estimates (range, 1.60 to 1.77 liters/h/kg), which were dose independent and similar for the 2 assessment days, as was the urinary recovery of RBT and its 25-deacetyl metabolite.",Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726008/),[l] / [h·kg],1.60 to 1.77,189949,DB00495,Zidovudine
,8726008,AUC metabolite/parent ratio,Low urinary recovery of 25-deacetyl RBT and an AUC metabolite/parent ratio of 0.1 suggest that there is minimal metabolism of RBT via the deacetylation pathway.,Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726008/),,0.1,189950,DB00495,Zidovudine
,8852387,peak concentration (Cmax),Mean (+/- standard deviation) peak concentration (Cmax) was 0.135 +/- 0.06 mmol/L and mean trough level (Cmin) was 0.0085 +/- 0.003 mmol/L.,Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852387/),[mM] / [l],0.135,191032,DB00495,Zidovudine
,8852387,trough level (Cmin),Mean (+/- standard deviation) peak concentration (Cmax) was 0.135 +/- 0.06 mmol/L and mean trough level (Cmin) was 0.0085 +/- 0.003 mmol/L.,Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852387/),[mM] / [l],0.0085,191033,DB00495,Zidovudine
,8852387,concentration at steady state,Mean concentration at steady state was 0.045 +/- 0.006 mmol/L.,Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852387/),[mM] / [l],0.045,191034,DB00495,Zidovudine
,8852387,Apparent clearance (Cl/F),"Apparent clearance (Cl/F) was 0.18 +/- 0.005 L/hr/kg, and half-life (t1/2) was 2.5 +/- 0.5 hours.",Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852387/),[l] / [h·kg],0.18,191035,DB00495,Zidovudine
,8852387,half-life (t1/2),"Apparent clearance (Cl/F) was 0.18 +/- 0.005 L/hr/kg, and half-life (t1/2) was 2.5 +/- 0.5 hours.",Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852387/),h,2.5,191036,DB00495,Zidovudine
,8852387,tmax,"Hydroxyurea given orally to patients infected with HIV-1 was well absorbed from the gastrointestinal tract, with a tmax of 0.85 to 0.96 hours after ingestion.",Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852387/),h,0.85 to 0.96,191037,DB00495,Zidovudine
,1687578,Total,"Total and renal clearances for AZT, 0.482 +/- 0.058 and 0.326 +/- 0.075 L h-1 kg-1, respectively, and for ddI, 0.500 +/- 0.057 and 0.337 +/- 0.100 L h-1 kg-1, showed that these drugs were eliminated primarily by renal excretion rather than by liver metabolism as in man.",Pharmacokinetics of anti-HIV nucleosides in microswine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687578/),[l] / [h·kg],0.482,194562,DB00495,Zidovudine
,1687578,Total,"Total and renal clearances for AZT, 0.482 +/- 0.058 and 0.326 +/- 0.075 L h-1 kg-1, respectively, and for ddI, 0.500 +/- 0.057 and 0.337 +/- 0.100 L h-1 kg-1, showed that these drugs were eliminated primarily by renal excretion rather than by liver metabolism as in man.",Pharmacokinetics of anti-HIV nucleosides in microswine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687578/),[l] / [h·kg],0.500,194563,DB00495,Zidovudine
,1687578,renal clearances,"Total and renal clearances for AZT, 0.482 +/- 0.058 and 0.326 +/- 0.075 L h-1 kg-1, respectively, and for ddI, 0.500 +/- 0.057 and 0.337 +/- 0.100 L h-1 kg-1, showed that these drugs were eliminated primarily by renal excretion rather than by liver metabolism as in man.",Pharmacokinetics of anti-HIV nucleosides in microswine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687578/),[l] / [h·kg],0.326,194564,DB00495,Zidovudine
,1687578,renal clearances,"Total and renal clearances for AZT, 0.482 +/- 0.058 and 0.326 +/- 0.075 L h-1 kg-1, respectively, and for ddI, 0.500 +/- 0.057 and 0.337 +/- 0.100 L h-1 kg-1, showed that these drugs were eliminated primarily by renal excretion rather than by liver metabolism as in man.",Pharmacokinetics of anti-HIV nucleosides in microswine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687578/),[l] / [h·kg],0.337,194565,DB00495,Zidovudine
,1687578,Volume of distribution at steady state,"Volume of distribution at steady state values were 0.784 +/- 0.071, 1.192 +/- 0.288 and 0.886 +/- 0.199 L kg-1 for AZT, ddI and ddC, respectively.",Pharmacokinetics of anti-HIV nucleosides in microswine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687578/),[l] / [kg],0.784,194566,DB00495,Zidovudine
,1687578,Volume of distribution at steady state,"Volume of distribution at steady state values were 0.784 +/- 0.071, 1.192 +/- 0.288 and 0.886 +/- 0.199 L kg-1 for AZT, ddI and ddC, respectively.",Pharmacokinetics of anti-HIV nucleosides in microswine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687578/),[l] / [kg],1.192,194567,DB00495,Zidovudine
,1687578,Volume of distribution at steady state,"Volume of distribution at steady state values were 0.784 +/- 0.071, 1.192 +/- 0.288 and 0.886 +/- 0.199 L kg-1 for AZT, ddI and ddC, respectively.",Pharmacokinetics of anti-HIV nucleosides in microswine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687578/),[l] / [kg],0.886,194568,DB00495,Zidovudine
,1687578,Half-life,"Half-life values for AZT, ddI and ddC were 1.39 +/- 0.127, 2.585 +/- 0.243 and 1.832 +/- 0.380 h, respectively.",Pharmacokinetics of anti-HIV nucleosides in microswine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687578/),h,1.39,194569,DB00495,Zidovudine
,1687578,Half-life,"Half-life values for AZT, ddI and ddC were 1.39 +/- 0.127, 2.585 +/- 0.243 and 1.832 +/- 0.380 h, respectively.",Pharmacokinetics of anti-HIV nucleosides in microswine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687578/),h,2.585,194570,DB00495,Zidovudine
,1687578,Half-life,"Half-life values for AZT, ddI and ddC were 1.39 +/- 0.127, 2.585 +/- 0.243 and 1.832 +/- 0.380 h, respectively.",Pharmacokinetics of anti-HIV nucleosides in microswine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687578/),h,1.832,194571,DB00495,Zidovudine
,11505789,elimination half-life,HI-236 had an elimination half-life of 85.8 min after i.v. administration and 86.6 min after i.p. administration.,"In vivo toxicity, pharmacokinetic features and tissue distribution of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236), a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11505789/),min,85.8,198196,DB00495,Zidovudine
,11505789,elimination half-life,HI-236 had an elimination half-life of 85.8 min after i.v. administration and 86.6 min after i.p. administration.,"In vivo toxicity, pharmacokinetic features and tissue distribution of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236), a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11505789/),min,86.6,198197,DB00495,Zidovudine
,11505789,systemic clearance,"The systemic clearance of HI-236 was 4337 ml/h/kg after i.v. administration and 10,130 ml/h/kg after i.p. administration.","In vivo toxicity, pharmacokinetic features and tissue distribution of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236), a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11505789/),[ml] / [h·kg],4337,198198,DB00495,Zidovudine
,11505789,systemic clearance,"The systemic clearance of HI-236 was 4337 ml/h/kg after i.v. administration and 10,130 ml/h/kg after i.p. administration.","In vivo toxicity, pharmacokinetic features and tissue distribution of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236), a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11505789/),[ml] / [h·kg],"10,130",198199,DB00495,Zidovudine
,11505789,tmax,"Following i.p. injection, HI-236 was rapidly absorbed with a tmax values of 5.6 min and showed linear pharmacokinetics within the dose range of 10-80 mg/kg.","In vivo toxicity, pharmacokinetic features and tissue distribution of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236), a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11505789/),min,5.6,198200,DB00495,Zidovudine
,11505789,tmax,"Following oral administration, HI-236 was absorbed with a tmax of 5.8 min.","In vivo toxicity, pharmacokinetic features and tissue distribution of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236), a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11505789/),min,5.8,198201,DB00495,Zidovudine
,11505789,intraperitoneal bioavailability,"The intraperitoneal bioavailability was estimated at 42.9%, while the oral bioavailability was only 2.2%.","In vivo toxicity, pharmacokinetic features and tissue distribution of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236), a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11505789/),%,42.9,198202,DB00495,Zidovudine
,11505789,oral bioavailability,"The intraperitoneal bioavailability was estimated at 42.9%, while the oral bioavailability was only 2.2%.","In vivo toxicity, pharmacokinetic features and tissue distribution of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236), a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11505789/),%,2.2,198203,DB00495,Zidovudine
,16856617,Cmin,"Target level for lopinavir Cmin was 1.0 mg/l, based on in vitro IC50 data.",Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16856617/),[mg] / [l],1.0,199056,DB00495,Zidovudine
,16856617,AUC0-24,"The mean (standard deviation) AUC0-24, Cmax and Cmin of lopinavir were 149.8 +/- 58.8 h*mg/l, 10.77 +/- 2.90 mg/l and 2.88 +/- 3.74 mg/l respectively.",Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16856617/),[h·mg] / [l],149.8,199057,DB00495,Zidovudine
,16856617,Cmax,"The mean (standard deviation) AUC0-24, Cmax and Cmin of lopinavir were 149.8 +/- 58.8 h*mg/l, 10.77 +/- 2.90 mg/l and 2.88 +/- 3.74 mg/l respectively.",Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16856617/),[mg] / [l],10.77,199058,DB00495,Zidovudine
,16856617,Cmin,"The mean (standard deviation) AUC0-24, Cmax and Cmin of lopinavir were 149.8 +/- 58.8 h*mg/l, 10.77 +/- 2.90 mg/l and 2.88 +/- 3.74 mg/l respectively.",Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16856617/),[mg] / [l],2.88,199059,DB00495,Zidovudine
<,16856617,Cmin,In 10/19 (53%) children Cmin was considered to be too low (<1.0 mg/l).,Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16856617/),[mg] / [l],1.0,199060,DB00495,Zidovudine
>,11981362,trough concentrations (C(24h)),All patients maintained SQV trough concentrations (C(24h)) of >0.05 mg/L.,Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981362/),[mg] / [l],0.05,199637,DB00495,Zidovudine
,11981362,area under the plasma concentration-versus-time curve from 0 to 24 hours (AUC(0-24h)),"Median values for the area under the plasma concentration-versus-time curve from 0 to 24 hours (AUC(0-24h)), maximal concentration (C(max)), and C(24h) for SQV were 48.1 (h.mg)/L, 6.98 mg/L, and 0.17 mg/L, respectively.",Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981362/),[h·mg] / [l],48.1,199638,DB00495,Zidovudine
,11981362,maximal concentration (C(max)),"Median values for the area under the plasma concentration-versus-time curve from 0 to 24 hours (AUC(0-24h)), maximal concentration (C(max)), and C(24h) for SQV were 48.1 (h.mg)/L, 6.98 mg/L, and 0.17 mg/L, respectively.",Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981362/),[mg] / [l],6.98,199639,DB00495,Zidovudine
,11981362,C(24h),"Median values for the area under the plasma concentration-versus-time curve from 0 to 24 hours (AUC(0-24h)), maximal concentration (C(max)), and C(24h) for SQV were 48.1 (h.mg)/L, 6.98 mg/L, and 0.17 mg/L, respectively.",Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981362/),[mg] / [l],0.17,199640,DB00495,Zidovudine
,24736440,AUC0-12h,"Geometric mean zidovudine AUC0-12h was 3.0 h.mg/L, which is higher than previously observed in adults, and was independently higher in those receiving higher doses, younger and underweight children.",Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24736440/),[h·mg] / [l],3.0,200354,DB00495,Zidovudine
,19709321,peak,"In the following days, an increase in tacrolimus concentration was observed with a peak of 37 ng/mL.",Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19709321/),[ng] / [ml],37,200411,DB00495,Zidovudine
,19709321,half-life,Tacrolimus half-life was 6.5 days and tacrolimus maintenance dose was 0.5 mg every 4 days.,Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19709321/),d,6.5,200412,DB00495,Zidovudine
,21356294,systemic bioavailability,The IN administration of Poloxamer 407 and TDM based formulation showed a systemic bioavailability of 29.4% while exhibiting a 4 times slower absorption process (t(max) = 20 min) than control solution (t(max) = 5 min).,Poly(ethylene oxide/propylene oxide) copolymer thermo-reversible gelling system for the enhancement of intranasal zidovudine delivery to the brain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21356294/),%,29.4,203107,DB00495,Zidovudine
,21356294,t(max),The IN administration of Poloxamer 407 and TDM based formulation showed a systemic bioavailability of 29.4% while exhibiting a 4 times slower absorption process (t(max) = 20 min) than control solution (t(max) = 5 min).,Poly(ethylene oxide/propylene oxide) copolymer thermo-reversible gelling system for the enhancement of intranasal zidovudine delivery to the brain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21356294/),min,20,203108,DB00495,Zidovudine
,21356294,t(max),The IN administration of Poloxamer 407 and TDM based formulation showed a systemic bioavailability of 29.4% while exhibiting a 4 times slower absorption process (t(max) = 20 min) than control solution (t(max) = 5 min).,Poly(ethylene oxide/propylene oxide) copolymer thermo-reversible gelling system for the enhancement of intranasal zidovudine delivery to the brain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21356294/),min,5,203109,DB00495,Zidovudine
,7669489,area under the curve (AUC),"The area under the curve (AUC) was 14.2 +/- 4.9 and 15.8 +/- 7.2 mumol l-1 h and elimination half-life (t1/2, z) was 1.4 +/- 0.4 and 1.2 +/- 0.2 h in the absence and presence of ddI respectively.",Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669489/),[h·μM] / [l],14.2,204885,DB00495,Zidovudine
,7669489,area under the curve (AUC),"The area under the curve (AUC) was 14.2 +/- 4.9 and 15.8 +/- 7.2 mumol l-1 h and elimination half-life (t1/2, z) was 1.4 +/- 0.4 and 1.2 +/- 0.2 h in the absence and presence of ddI respectively.",Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669489/),[h·μM] / [l],15.8,204886,DB00495,Zidovudine
,7669489,"elimination half-life (t1/2, z)","The area under the curve (AUC) was 14.2 +/- 4.9 and 15.8 +/- 7.2 mumol l-1 h and elimination half-life (t1/2, z) was 1.4 +/- 0.4 and 1.2 +/- 0.2 h in the absence and presence of ddI respectively.",Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669489/),h,1.4,204887,DB00495,Zidovudine
,7669489,"elimination half-life (t1/2, z)","The area under the curve (AUC) was 14.2 +/- 4.9 and 15.8 +/- 7.2 mumol l-1 h and elimination half-life (t1/2, z) was 1.4 +/- 0.4 and 1.2 +/- 0.2 h in the absence and presence of ddI respectively.",Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669489/),h,1.2,204888,DB00495,Zidovudine
,2643914,half-lives,"Zidovudine disappearance following bolus administration was rapid and biexponential with half-lives of 9.6 and 92 minutes, and a total clearance of 705 +/- 330 mL/min.",The pharmacokinetics of zidovudine administered by continuous infusion in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2643914/),min,9.6,205262,DB00495,Zidovudine
,2643914,half-lives,"Zidovudine disappearance following bolus administration was rapid and biexponential with half-lives of 9.6 and 92 minutes, and a total clearance of 705 +/- 330 mL/min.",The pharmacokinetics of zidovudine administered by continuous infusion in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2643914/),min,92,205263,DB00495,Zidovudine
,2643914,total clearance,"Zidovudine disappearance following bolus administration was rapid and biexponential with half-lives of 9.6 and 92 minutes, and a total clearance of 705 +/- 330 mL/min.",The pharmacokinetics of zidovudine administered by continuous infusion in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2643914/),[ml] / [min],705,205264,DB00495,Zidovudine
above,2643914,concentrations (Css),"In contrast, with continuous infusion steady-state plasma zidovudine concentrations (Css) were maintained above 1 mumol/L continuously, even at the lowest infusion rate.",The pharmacokinetics of zidovudine administered by continuous infusion in children. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2643914/),[μM] / [l],1,205265,DB00495,Zidovudine
greater,2643914,Css,Six of eight had a Css greater than 3.0 mumol/L.,The pharmacokinetics of zidovudine administered by continuous infusion in children. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2643914/),[μM] / [l],3.0,205266,DB00495,Zidovudine
,8902065,maximum plasma concentration (Cmax),"There was a greater than threefold increase in maximum plasma concentration (Cmax) following 300 mg ZDV when compared with 100 mg ZDV (mean +/- SD, 2.59 +/- 0.52 versus 0.70 +/- 0.14 mumol/l).",The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902065/),[μM] / [l],2.59,206903,DB00495,Zidovudine
,8902065,maximum plasma concentration (Cmax),"There was a greater than threefold increase in maximum plasma concentration (Cmax) following 300 mg ZDV when compared with 100 mg ZDV (mean +/- SD, 2.59 +/- 0.52 versus 0.70 +/- 0.14 mumol/l).",The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902065/),[μM] / [l],0.70,206904,DB00495,Zidovudine
,8902065,area under the concentration time curve (AUC0-12 h),The area under the concentration time curve (AUC0-12 h) was also significantly increased (4.59 +/- 0.79 versus 1.42 +/- 0.51 mumol/l x h) following 300 mg ZDV dose.,The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902065/),[μM] / [h·l],4.59,206905,DB00495,Zidovudine
,8902065,area under the concentration time curve (AUC0-12 h),The area under the concentration time curve (AUC0-12 h) was also significantly increased (4.59 +/- 0.79 versus 1.42 +/- 0.51 mumol/l x h) following 300 mg ZDV dose.,The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902065/),[μM] / [h·l],1.42,206906,DB00495,Zidovudine
,8902065,AUC0-12 h,For total intracellular ZDV phosphate metabolites the AUC0-12 h was doubled (7.64 +/- 3.67 versus 3.71 +/- 1.83 pmol/10(6) cells x h) in patients taking 300 mg ZDV compared with 100 mg.,The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902065/),[pM] / [10(6)·cells·h],7.64,206907,DB00495,Zidovudine
,8902065,AUC0-12 h,For total intracellular ZDV phosphate metabolites the AUC0-12 h was doubled (7.64 +/- 3.67 versus 3.71 +/- 1.83 pmol/10(6) cells x h) in patients taking 300 mg ZDV compared with 100 mg.,The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902065/),[pM] / [10(6)·cells·h],3.71,206908,DB00495,Zidovudine
,8902065,AUC0-12 h,"The AUC0-12 h for ZDV-MP was significantly increased at the higher dose (6.47 +/- 3.14 versus 2.77 +/- 1.70 pmol/10(6) cells x h), whereas the active moiety ZDV-TP was variable and not significantly different (0.42 +/- 0.42 versus 0.61 +/- 0.81 pmol/10(6) cells x h) following 100 and 300 mg ZDV.",The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902065/),[pM] / [10(6)·cells·h],6.47,206909,DB00495,Zidovudine
,8902065,AUC0-12 h,"The AUC0-12 h for ZDV-MP was significantly increased at the higher dose (6.47 +/- 3.14 versus 2.77 +/- 1.70 pmol/10(6) cells x h), whereas the active moiety ZDV-TP was variable and not significantly different (0.42 +/- 0.42 versus 0.61 +/- 0.81 pmol/10(6) cells x h) following 100 and 300 mg ZDV.",The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902065/),[pM] / [10(6)·cells·h],2.77,206910,DB00495,Zidovudine
,8902065,AUC0-12 h,"The AUC0-12 h for ZDV-MP was significantly increased at the higher dose (6.47 +/- 3.14 versus 2.77 +/- 1.70 pmol/10(6) cells x h), whereas the active moiety ZDV-TP was variable and not significantly different (0.42 +/- 0.42 versus 0.61 +/- 0.81 pmol/10(6) cells x h) following 100 and 300 mg ZDV.",The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902065/),[pM] / [10(6],0.42,206911,DB00495,Zidovudine
,8902065,AUC0-12 h,"The AUC0-12 h for ZDV-MP was significantly increased at the higher dose (6.47 +/- 3.14 versus 2.77 +/- 1.70 pmol/10(6) cells x h), whereas the active moiety ZDV-TP was variable and not significantly different (0.42 +/- 0.42 versus 0.61 +/- 0.81 pmol/10(6) cells x h) following 100 and 300 mg ZDV.",The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902065/),cells·h,0.61,206912,DB00495,Zidovudine
,12669967,Renal excretion,"Renal excretion of unchanged prodrug (16.4 +/- 5.6% of the total dose administered intravenously), its conversion to AZT (12.1 +/- 5.4% of total dose administered intravenously), and its biliary excretion (54.3 +/- 4.9% of the total dose up to 4 h after intravenous administration) accounted for most of the elimination of NMe-Trp-AZT.",Disposition and oral bioavailability in rats of an antiviral and antitumor amino acid phosphoramidate prodrug of AZT-monophosphate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12669967/),%,16.4,207165,DB00495,Zidovudine
,12669967,biliary excretion,"Renal excretion of unchanged prodrug (16.4 +/- 5.6% of the total dose administered intravenously), its conversion to AZT (12.1 +/- 5.4% of total dose administered intravenously), and its biliary excretion (54.3 +/- 4.9% of the total dose up to 4 h after intravenous administration) accounted for most of the elimination of NMe-Trp-AZT.",Disposition and oral bioavailability in rats of an antiviral and antitumor amino acid phosphoramidate prodrug of AZT-monophosphate. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12669967/),%,54.3,207166,DB00495,Zidovudine
,11452705,concentration ratio,"At the time of delivery, the geometric mean cord/maternal concentration ratio was 1.24 for zidovudine and 1.12 for lamivudine, indicating free passage of each drug across the placenta.",Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452705/),,1.24,207259,DB00495,Zidovudine
,11452705,concentration ratio,"At the time of delivery, the geometric mean cord/maternal concentration ratio was 1.24 for zidovudine and 1.12 for lamivudine, indicating free passage of each drug across the placenta.",Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452705/),,1.12,207260,DB00495,Zidovudine
,9165546,steady-state plasma concentration (Css),"During the 24-week study, patients received oral zidovudine regimens that consisted of a standard fixed dose of 500 mg/day and a concentration-controlled regimen designed to maintain a steady-state plasma concentration (Css) of 0.187 +/- 0.04 mg/L (0.7 +/- 0.14 microM).",Pharmacokinetics and safety of concentration-controlled oral zidovudine therapy. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165546/),[mg] / [l],0.187,208773,DB00495,Zidovudine
,9165546,steady-state plasma concentration (Css),"During the 24-week study, patients received oral zidovudine regimens that consisted of a standard fixed dose of 500 mg/day and a concentration-controlled regimen designed to maintain a steady-state plasma concentration (Css) of 0.187 +/- 0.04 mg/L (0.7 +/- 0.14 microM).",Pharmacokinetics and safety of concentration-controlled oral zidovudine therapy. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165546/),μM,0.7,208774,DB00495,Zidovudine
,9165546,Css,The mean Css during standard therapy was 0.170 +/- 0.024 mg/L versus 0.205 +/- 0.021 mg/L with the concentration-controlled regimen (p = 0.025).,Pharmacokinetics and safety of concentration-controlled oral zidovudine therapy. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165546/),[mg] / [l],0.170,208775,DB00495,Zidovudine
,9165546,Css,The mean Css during standard therapy was 0.170 +/- 0.024 mg/L versus 0.205 +/- 0.021 mg/L with the concentration-controlled regimen (p = 0.025).,Pharmacokinetics and safety of concentration-controlled oral zidovudine therapy. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165546/),[mg] / [l],0.205,208776,DB00495,Zidovudine
,8597321,area under the plasma concentration curve,Mean increases in the area under the plasma concentration curve compared with the time curve over a 24-hour dosing interval were 82% (5442 +/- 2404 ng.h/mL compared with 3025 +/- 1117 ng.h/mL; P less than or equal to 0.05) for rifabutin and 216% (959 +/- 529 ng.h/mL compared with 244 +/- 141 ng.h/mL; P less than or equal to 0.05) for LM565.,Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8597321/),[h·ng] / [ml],5442,209039,DB00495,Zidovudine
,8597321,area under the plasma concentration curve,Mean increases in the area under the plasma concentration curve compared with the time curve over a 24-hour dosing interval were 82% (5442 +/- 2404 ng.h/mL compared with 3025 +/- 1117 ng.h/mL; P less than or equal to 0.05) for rifabutin and 216% (959 +/- 529 ng.h/mL compared with 244 +/- 141 ng.h/mL; P less than or equal to 0.05) for LM565.,Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8597321/),[h·ng] / [ml],3025,209040,DB00495,Zidovudine
,8597321,area under the plasma concentration curve,Mean increases in the area under the plasma concentration curve compared with the time curve over a 24-hour dosing interval were 82% (5442 +/- 2404 ng.h/mL compared with 3025 +/- 1117 ng.h/mL; P less than or equal to 0.05) for rifabutin and 216% (959 +/- 529 ng.h/mL compared with 244 +/- 141 ng.h/mL; P less than or equal to 0.05) for LM565.,Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8597321/),[h·ng] / [ml],959,209041,DB00495,Zidovudine
,8597321,area under the plasma concentration curve,Mean increases in the area under the plasma concentration curve compared with the time curve over a 24-hour dosing interval were 82% (5442 +/- 2404 ng.h/mL compared with 3025 +/- 1117 ng.h/mL; P less than or equal to 0.05) for rifabutin and 216% (959 +/- 529 ng.h/mL compared with 244 +/- 141 ng.h/mL; P less than or equal to 0.05) for LM565.,Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8597321/),[h·ng] / [ml],244,209042,DB00495,Zidovudine
,12917234,AUC(0-8),The AUC(0-8) was targeted between 15 and 30 mg h/L.,Changes in indinavir exposure over time: a case study in six HIV-1-infected children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12917234/),[h·mg] / [l],15 and 30,210003,DB00495,Zidovudine
,12917234,AUC(0-8),The geometric mean (GM) of the AUC(0-8) decreased from 25.3 mg h/L at the first PK-day to 19.1 mg h/L at the second PK-day [geometric mean ratio (GMR): 0.76 (95% C.I.: 0.48-1.20)].,Changes in indinavir exposure over time: a case study in six HIV-1-infected children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12917234/),[h·mg] / [l],25.3,210004,DB00495,Zidovudine
,12917234,AUC(0-8),The geometric mean (GM) of the AUC(0-8) decreased from 25.3 mg h/L at the first PK-day to 19.1 mg h/L at the second PK-day [geometric mean ratio (GMR): 0.76 (95% C.I.: 0.48-1.20)].,Changes in indinavir exposure over time: a case study in six HIV-1-infected children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12917234/),[h·mg] / [l],19.1,210005,DB00495,Zidovudine
,12917234,Cmax,The GM of Cmax decreased from 11.8 to 10.4 mg/L [GMR: 0.88 (95% C.I.: 0.59-1.32)].,Changes in indinavir exposure over time: a case study in six HIV-1-infected children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12917234/),[mg] / [l],11.8,210006,DB00495,Zidovudine
,12917234,Cmax,The GM of Cmax decreased from 11.8 to 10.4 mg/L [GMR: 0.88 (95% C.I.: 0.59-1.32)].,Changes in indinavir exposure over time: a case study in six HIV-1-infected children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12917234/),[mg] / [l],10.4,210007,DB00495,Zidovudine
above,12917234,AUC(0-8),All children had an AUC(0-8) above 15 mg h/L on the first PK-day; three had an AUC(0-8) below 15 mg h/L on the second PK-day.,Changes in indinavir exposure over time: a case study in six HIV-1-infected children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12917234/),[h·mg] / [l],15,210008,DB00495,Zidovudine
below,12917234,AUC(0-8),All children had an AUC(0-8) above 15 mg h/L on the first PK-day; three had an AUC(0-8) below 15 mg h/L on the second PK-day.,Changes in indinavir exposure over time: a case study in six HIV-1-infected children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12917234/),[h·mg] / [l],15,210009,DB00495,Zidovudine
,2764527,half-life,"Following intravenous bolus administration, AZT elimination was rapid, with a mean half-life of 1.2 h and a mean clearance of 318 ml/min per m2 (range, 200 to 441 ml/min per m2).",Pharmacokinetics of subcutaneous azidothymidine in rhesus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764527/),h,1.2,210536,DB00495,Zidovudine
,2764527,clearance,"Following intravenous bolus administration, AZT elimination was rapid, with a mean half-life of 1.2 h and a mean clearance of 318 ml/min per m2 (range, 200 to 441 ml/min per m2).",Pharmacokinetics of subcutaneous azidothymidine in rhesus monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764527/),[ml] / [m2·min],318,210537,DB00495,Zidovudine
,2764527,time to peak concentration,"The bolus subcutaneous dose was rapidly (time to peak concentration, 15 to 30 min) and nearly completely (fraction absorbed, 92%) absorbed without evidence of local tissue toxicity.",Pharmacokinetics of subcutaneous azidothymidine in rhesus monkeys. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764527/),min,15 to 30,210538,DB00495,Zidovudine
,2764527,fraction absorbed,"The bolus subcutaneous dose was rapidly (time to peak concentration, 15 to 30 min) and nearly completely (fraction absorbed, 92%) absorbed without evidence of local tissue toxicity.",Pharmacokinetics of subcutaneous azidothymidine in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764527/),%,92,210539,DB00495,Zidovudine
exceeded,2764527,steady-state concentrations,"With continuous subcutaneous infusion of AZT, the steady state was attained within 4 h and steady-state concentrations in plasma in the two animals exceeded 3.0 mumol/liter.",Pharmacokinetics of subcutaneous azidothymidine in rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764527/),[μM] / [l],3.0,210540,DB00495,Zidovudine
,2085892,maximum flux,"The maximum flux of 0.41 mumol/cm2/h was observed in excised human skin after application of a gel formulation including S-318, OA, MP and PG.",Enhanced transdermal delivery of zidovudine in rats and human skin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085892/),[μM] / [cm2·h],0.41,211983,DB00495,Zidovudine
,8593010,area under the curve (AUC),"The area under the curve (AUC) (1,670 +/- 192 ng.h/ml), maximum concentration of drug in serum (1,751 +/- 180 ng/ml), and half-life (2.04 +/- 0.38 h) of ZDV were increased, while the apparent oral clearance (1.57 +/- 0.31 liter/h/kg of body weight) was decreased; AUC (7,685 +/- 1,222 ng.h/ml) and maximum concentration of drug in serum (5,220 +/- 1,350 ng/ml) of GZDV and the AUC ratio of GZDV to ZDV (2.79 +/- 0.43) after oral administration were decreased.",Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593010/),[h·ng] / [ml],"1,670",212546,DB00495,Zidovudine
,8593010,maximum concentration of drug,"The area under the curve (AUC) (1,670 +/- 192 ng.h/ml), maximum concentration of drug in serum (1,751 +/- 180 ng/ml), and half-life (2.04 +/- 0.38 h) of ZDV were increased, while the apparent oral clearance (1.57 +/- 0.31 liter/h/kg of body weight) was decreased; AUC (7,685 +/- 1,222 ng.h/ml) and maximum concentration of drug in serum (5,220 +/- 1,350 ng/ml) of GZDV and the AUC ratio of GZDV to ZDV (2.79 +/- 0.43) after oral administration were decreased.",Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593010/),[ng] / [ml],"1,751",212547,DB00495,Zidovudine
,8593010,half-life,"The area under the curve (AUC) (1,670 +/- 192 ng.h/ml), maximum concentration of drug in serum (1,751 +/- 180 ng/ml), and half-life (2.04 +/- 0.38 h) of ZDV were increased, while the apparent oral clearance (1.57 +/- 0.31 liter/h/kg of body weight) was decreased; AUC (7,685 +/- 1,222 ng.h/ml) and maximum concentration of drug in serum (5,220 +/- 1,350 ng/ml) of GZDV and the AUC ratio of GZDV to ZDV (2.79 +/- 0.43) after oral administration were decreased.",Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593010/),h,2.04,212548,DB00495,Zidovudine
,8593010,apparent oral clearance,"The area under the curve (AUC) (1,670 +/- 192 ng.h/ml), maximum concentration of drug in serum (1,751 +/- 180 ng/ml), and half-life (2.04 +/- 0.38 h) of ZDV were increased, while the apparent oral clearance (1.57 +/- 0.31 liter/h/kg of body weight) was decreased; AUC (7,685 +/- 1,222 ng.h/ml) and maximum concentration of drug in serum (5,220 +/- 1,350 ng/ml) of GZDV and the AUC ratio of GZDV to ZDV (2.79 +/- 0.43) after oral administration were decreased.",Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593010/),[l] / [h·kg],1.57,212549,DB00495,Zidovudine
,8593010,AUC,"The area under the curve (AUC) (1,670 +/- 192 ng.h/ml), maximum concentration of drug in serum (1,751 +/- 180 ng/ml), and half-life (2.04 +/- 0.38 h) of ZDV were increased, while the apparent oral clearance (1.57 +/- 0.31 liter/h/kg of body weight) was decreased; AUC (7,685 +/- 1,222 ng.h/ml) and maximum concentration of drug in serum (5,220 +/- 1,350 ng/ml) of GZDV and the AUC ratio of GZDV to ZDV (2.79 +/- 0.43) after oral administration were decreased.",Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593010/),[h·ng] / [ml],"7,685",212550,DB00495,Zidovudine
,8593010,maximum concentration of drug,"The area under the curve (AUC) (1,670 +/- 192 ng.h/ml), maximum concentration of drug in serum (1,751 +/- 180 ng/ml), and half-life (2.04 +/- 0.38 h) of ZDV were increased, while the apparent oral clearance (1.57 +/- 0.31 liter/h/kg of body weight) was decreased; AUC (7,685 +/- 1,222 ng.h/ml) and maximum concentration of drug in serum (5,220 +/- 1,350 ng/ml) of GZDV and the AUC ratio of GZDV to ZDV (2.79 +/- 0.43) after oral administration were decreased.",Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593010/),[ng] / [ml],"5,220",212551,DB00495,Zidovudine
,8593010,AUC ratio,"The area under the curve (AUC) (1,670 +/- 192 ng.h/ml), maximum concentration of drug in serum (1,751 +/- 180 ng/ml), and half-life (2.04 +/- 0.38 h) of ZDV were increased, while the apparent oral clearance (1.57 +/- 0.31 liter/h/kg of body weight) was decreased; AUC (7,685 +/- 1,222 ng.h/ml) and maximum concentration of drug in serum (5,220 +/- 1,350 ng/ml) of GZDV and the AUC ratio of GZDV to ZDV (2.79 +/- 0.43) after oral administration were decreased.",Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062). ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593010/),,2.79,212552,DB00495,Zidovudine
,8593010,absolute bioavailability,ZDV absolute bioavailability was 0.75 +/- 0.15 in HIV-infected patients with hepatic disease.,Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593010/),,0.75,212553,DB00495,Zidovudine
,2350441,time to reach maximal serum concentration (Tmax),"In the absence of food, zidovudine is rapidly absorbed; the time to reach maximal serum concentration (Tmax) was 0.68 (+/- 0.25) h and the mean peak serum concentration (Cmax) achieved was 0.49 (+/- 0.3) micrograms/ml (dose normalized to 100 mg dose).",Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350441/),h,0.68,213465,DB00495,Zidovudine
,2350441,peak serum concentration (Cmax),"In the absence of food, zidovudine is rapidly absorbed; the time to reach maximal serum concentration (Tmax) was 0.68 (+/- 0.25) h and the mean peak serum concentration (Cmax) achieved was 0.49 (+/- 0.3) micrograms/ml (dose normalized to 100 mg dose).",Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350441/),[μg] / [ml],0.49,213466,DB00495,Zidovudine
,2350441,Tmax,"In the presence of a high-fat meal, Tmax was significantly prolonged [1.95 (+/- 0.69) h; P less than 0.05] and the Cmax reduced [0.245 (+/- 0.12) micrograms/ml; P less than 0.05].",Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350441/),h,1.95,213467,DB00495,Zidovudine
,2350441,Cmax,"In the presence of a high-fat meal, Tmax was significantly prolonged [1.95 (+/- 0.69) h; P less than 0.05] and the Cmax reduced [0.245 (+/- 0.12) micrograms/ml; P less than 0.05].",Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350441/),[μg] / [ml],0.245,213468,DB00495,Zidovudine
,8148221,elimination half-life,For patients with early bone marrow toxicity the elimination half-life of ZDV was 1.10 +/- 0.16 h with an oral clearance of 2752 +/- 1031 ml min-1 compared with values of 1.06 +/- 0.18 h and 2843 +/- 730 ml min-1 seen in the control group.,Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148221/),h,1.10,214380,DB00495,Zidovudine
,8148221,oral clearance,For patients with early bone marrow toxicity the elimination half-life of ZDV was 1.10 +/- 0.16 h with an oral clearance of 2752 +/- 1031 ml min-1 compared with values of 1.06 +/- 0.18 h and 2843 +/- 730 ml min-1 seen in the control group.,Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148221/),[ml] / [min],2752,214381,DB00495,Zidovudine
,8148221,oral clearance,For patients with early bone marrow toxicity the elimination half-life of ZDV was 1.10 +/- 0.16 h with an oral clearance of 2752 +/- 1031 ml min-1 compared with values of 1.06 +/- 0.18 h and 2843 +/- 730 ml min-1 seen in the control group.,Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148221/),h,1.06,214382,DB00495,Zidovudine
,8148221,oral clearance,For patients with early bone marrow toxicity the elimination half-life of ZDV was 1.10 +/- 0.16 h with an oral clearance of 2752 +/- 1031 ml min-1 compared with values of 1.06 +/- 0.18 h and 2843 +/- 730 ml min-1 seen in the control group.,Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148221/),[ml] / [min],2843,214383,DB00495,Zidovudine
,17485498,absorption rate constant,D-DOT was rapidly and almost completely absorbed (absorption rate constant = 2.7 h(-1); fraction of oral dose absorbed = 0.82 to 1.06).,Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17485498/),1/[h],2.7,215060,DB00495,Zidovudine
,17485498,fraction of oral dose absorbed,D-DOT was rapidly and almost completely absorbed (absorption rate constant = 2.7 h(-1); fraction of oral dose absorbed = 0.82 to 1.06).,Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17485498/),,0.82 to 1.06,215061,DB00495,Zidovudine
,17485498,serum beta half-life,The average serum beta half-life was 2.16 h.,Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17485498/),h,2.16,215062,DB00495,Zidovudine
,17485498,central,"The average central and steady-state volumes of distributions were 0.52 and 1.02 liter/kg of body weight, respectively, and the average systemic and renal clearance values were 0.36 liter/h/kg and 0.18 liter/h/kg.",Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17485498/),[l] / [kg],0.52,215063,DB00495,Zidovudine
,17485498,steady-state volumes of distributions,"The average central and steady-state volumes of distributions were 0.52 and 1.02 liter/kg of body weight, respectively, and the average systemic and renal clearance values were 0.36 liter/h/kg and 0.18 liter/h/kg.",Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17485498/),[l] / [kg],1.02,215064,DB00495,Zidovudine
,17485498,systemic,"The average central and steady-state volumes of distributions were 0.52 and 1.02 liter/kg of body weight, respectively, and the average systemic and renal clearance values were 0.36 liter/h/kg and 0.18 liter/h/kg.",Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17485498/),[l] / [h·kg],0.36,215065,DB00495,Zidovudine
,17485498,renal clearance,"The average central and steady-state volumes of distributions were 0.52 and 1.02 liter/kg of body weight, respectively, and the average systemic and renal clearance values were 0.36 liter/h/kg and 0.18 liter/h/kg.",Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17485498/),[l] / [h·kg],0.18,215066,DB00495,Zidovudine
,1974192,urinary,"The 0-24-hr urinary and fecal recoveries (mean +/- SD) of radioactive material were 78 +/- 14% and 20 +/- 9% of dose, respectively, indicating virtually complete recovery of the radioactive dose.",Tissue distribution and metabolic disposition of zidovudine in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974192/),%,78,215317,DB00495,Zidovudine
,1974192,fecal recoveries,"The 0-24-hr urinary and fecal recoveries (mean +/- SD) of radioactive material were 78 +/- 14% and 20 +/- 9% of dose, respectively, indicating virtually complete recovery of the radioactive dose.",Tissue distribution and metabolic disposition of zidovudine in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974192/),%,20,215318,DB00495,Zidovudine
,21110710,plasma half-life,The pro-drug provided a significant increase in the area under the plasma concentration time curve as compared to free drug and extended the plasma half-life from 1.06 h to 8.08 h.,Poly(HEMA-Zidovudine) conjugate: a macromolecular pro-drug for improvement in the biopharmaceutical properties of the drug. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110710/),h,1.06,215838,DB00495,Zidovudine
,21110710,plasma half-life,The pro-drug provided a significant increase in the area under the plasma concentration time curve as compared to free drug and extended the plasma half-life from 1.06 h to 8.08 h.,Poly(HEMA-Zidovudine) conjugate: a macromolecular pro-drug for improvement in the biopharmaceutical properties of the drug. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110710/),h,8.08,215839,DB00495,Zidovudine
,17914441,volume of seminal plasma,"The volume of seminal plasma decreased from 4.0 (1.2-5.1) ml (median with range) at 48 h after the baseline ejaculation to 0.72 (0.45-1.6) ml 1 h after a previous ejaculation, which was still adequate for drug concentration assessment.",Effect of semen sampling frequency on seminal antiretroviral drug concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17914441/),ml,4.0,216293,DB00495,Zidovudine
,17914441,volume of seminal plasma,"The volume of seminal plasma decreased from 4.0 (1.2-5.1) ml (median with range) at 48 h after the baseline ejaculation to 0.72 (0.45-1.6) ml 1 h after a previous ejaculation, which was still adequate for drug concentration assessment.",Effect of semen sampling frequency on seminal antiretroviral drug concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17914441/),ml,0.72,216294,DB00495,Zidovudine
,7518216,50,"The 50 and 90% effective concentrations for HIV-1 (HTLV-IIIB strain) replication in MT-4 cells were 15 and 98 nM, respectively.","Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7518216/),nM,15,216926,DB00495,Zidovudine
,7518216,50,"The 50 and 90% effective concentrations for HIV-1 (HTLV-IIIB strain) replication in MT-4 cells were 15 and 98 nM, respectively.","Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7518216/),nM,98,216927,DB00495,Zidovudine
,7518216,90%,"The 50 and 90% effective concentrations for HIV-1 (HTLV-IIIB strain) replication in MT-4 cells were 15 and 98 nM, respectively.","Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7518216/),nM,15,216928,DB00495,Zidovudine
,7518216,effective concentrations,"The 50 and 90% effective concentrations for HIV-1 (HTLV-IIIB strain) replication in MT-4 cells were 15 and 98 nM, respectively.","Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7518216/),nM,98,216929,DB00495,Zidovudine
,27006900,t 1/2,"AZT in plasma was eliminated rapidly with t 1/2 of 2.022 h, and AZT-MP, AZT-DP and AZT-TP were eliminated with t 1/2 of 13.428, 8.285 and 4.240 h, respectively.",Intracellular pharmacokinetic study of zidovudine and its phosphorylated metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27006900/),h,2.022,218284,DB00495,Zidovudine
,27006900,t 1/2,"AZT in plasma was eliminated rapidly with t 1/2 of 2.022 h, and AZT-MP, AZT-DP and AZT-TP were eliminated with t 1/2 of 13.428, 8.285 and 4.240 h, respectively.",Intracellular pharmacokinetic study of zidovudine and its phosphorylated metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27006900/),h,13.428,218285,DB00495,Zidovudine
,27006900,t 1/2,"AZT in plasma was eliminated rapidly with t 1/2 of 2.022 h, and AZT-MP, AZT-DP and AZT-TP were eliminated with t 1/2 of 13.428, 8.285 and 4.240 h, respectively.",Intracellular pharmacokinetic study of zidovudine and its phosphorylated metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27006900/),h,8.285,218286,DB00495,Zidovudine
,27006900,t 1/2,"AZT in plasma was eliminated rapidly with t 1/2 of 2.022 h, and AZT-MP, AZT-DP and AZT-TP were eliminated with t 1/2 of 13.428, 8.285 and 4.240 h, respectively.",Intracellular pharmacokinetic study of zidovudine and its phosphorylated metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27006900/),h,4.240,218287,DB00495,Zidovudine
,2334151,peak,"Initially, the mean peak ZDV concentration in plasma was 2,052 ng/ml with a range of 1,033 to 3,907 ng/ml, while during chronic dosing the peaks were 1,619 +/- 1,062 ng/ml and 1,711 +/- 786 ng/ml at weeks 6 and 12, respectively.",Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334151/),[ng] / [ml],"2,052",220286,DB00495,Zidovudine
,2334151,peaks,"Initially, the mean peak ZDV concentration in plasma was 2,052 ng/ml with a range of 1,033 to 3,907 ng/ml, while during chronic dosing the peaks were 1,619 +/- 1,062 ng/ml and 1,711 +/- 786 ng/ml at weeks 6 and 12, respectively.",Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334151/),[ng] / [ml],"1,619",220287,DB00495,Zidovudine
,2334151,peaks,"Initially, the mean peak ZDV concentration in plasma was 2,052 ng/ml with a range of 1,033 to 3,907 ng/ml, while during chronic dosing the peaks were 1,619 +/- 1,062 ng/ml and 1,711 +/- 786 ng/ml at weeks 6 and 12, respectively.",Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334151/),[ng] / [ml],"1,711",220288,DB00495,Zidovudine
,2334151,concentrations at,"ZDV concentrations at 4 h declined to 77 +/- 53 ng/ml, 110 +/- 43 ng/ml, and 101 +/- 49 ng/ml at weeks 1, 6, and 12, respectively.",Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334151/),[ng] / [ml],77,220289,DB00495,Zidovudine
,2334151,concentrations at,"ZDV concentrations at 4 h declined to 77 +/- 53 ng/ml, 110 +/- 43 ng/ml, and 101 +/- 49 ng/ml at weeks 1, 6, and 12, respectively.",Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334151/),[ng] / [ml],110,220290,DB00495,Zidovudine
,2334151,concentrations at,"ZDV concentrations at 4 h declined to 77 +/- 53 ng/ml, 110 +/- 43 ng/ml, and 101 +/- 49 ng/ml at weeks 1, 6, and 12, respectively.",Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334151/),[ng] / [ml],101,220291,DB00495,Zidovudine
,2334151,half-life (t1/2),"Initially, the plasma concentration-versus-time decay in three patients was linear, with a mean half-life (t1/2) of 1.3 +/- 0.5 h, while five patients had detectable concentrations in plasma after 4 h with an apparent delayed terminal-phase t1/2 of 4.8 +/- 2.8 h.",Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334151/),h,1.3,220292,DB00495,Zidovudine
,2334151,apparent delayed terminal-phase t1/2,"Initially, the plasma concentration-versus-time decay in three patients was linear, with a mean half-life (t1/2) of 1.3 +/- 0.5 h, while five patients had detectable concentrations in plasma after 4 h with an apparent delayed terminal-phase t1/2 of 4.8 +/- 2.8 h.",Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334151/),h,4.8,220293,DB00495,Zidovudine
,2334151,terminal t1/2,At week 6 the prolonged elimination pattern was noted in all patients (terminal t1/2 = 4.1 +/- 2.0 h).,Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334151/),h,4.1,220294,DB00495,Zidovudine
,15551216,terminal plasma half-life [T1/2],"Mean maternal antenatal d4T pharmacokinetics (terminal plasma half-life [T1/2], 83.5+/-16.8 min; area under the plasma-concentration time curve [AUC0-infinity), 81.6+/-22.0 microg.min/mL; n=6) were not significantly different from those during labor (T(1/2), 87.3+/-24.7 min; AUC0-infinity, 88.1+/-16.6 microg.min/mL; n=6).",Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15551216/),min,83.5,222302,DB00495,Zidovudine
,15551216,area under the plasma-concentration time curve [AUC0-infinity),"Mean maternal antenatal d4T pharmacokinetics (terminal plasma half-life [T1/2], 83.5+/-16.8 min; area under the plasma-concentration time curve [AUC0-infinity), 81.6+/-22.0 microg.min/mL; n=6) were not significantly different from those during labor (T(1/2), 87.3+/-24.7 min; AUC0-infinity, 88.1+/-16.6 microg.min/mL; n=6).",Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15551216/),[min·μg] / [ml],81.6,222303,DB00495,Zidovudine
,15551216,T(1/2),"Mean maternal antenatal d4T pharmacokinetics (terminal plasma half-life [T1/2], 83.5+/-16.8 min; area under the plasma-concentration time curve [AUC0-infinity), 81.6+/-22.0 microg.min/mL; n=6) were not significantly different from those during labor (T(1/2), 87.3+/-24.7 min; AUC0-infinity, 88.1+/-16.6 microg.min/mL; n=6).",Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15551216/),min,87.3,222304,DB00495,Zidovudine
,15551216,AUC0-infinity,"Mean maternal antenatal d4T pharmacokinetics (terminal plasma half-life [T1/2], 83.5+/-16.8 min; area under the plasma-concentration time curve [AUC0-infinity), 81.6+/-22.0 microg.min/mL; n=6) were not significantly different from those during labor (T(1/2), 87.3+/-24.7 min; AUC0-infinity, 88.1+/-16.6 microg.min/mL; n=6).",Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15551216/),[min·μg] / [ml],88.1,222305,DB00495,Zidovudine
,15551216,oral clearance,The oral clearance of d4T in infants was significantly greater at week 6 versus week 1 (6.8+/-1.0 vs. 5.6+/-1.2 mL/min/kg).,Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15551216/),[ml] / [kg·min],6.8,222306,DB00495,Zidovudine
,15551216,oral clearance,The oral clearance of d4T in infants was significantly greater at week 6 versus week 1 (6.8+/-1.0 vs. 5.6+/-1.2 mL/min/kg).,Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15551216/),[ml] / [kg·min],5.6,222307,DB00495,Zidovudine
,11089617,protein binding,"Overall indinavir protein binding was 61+/-6%, with a range among the profiles of 54 to 70%.",Indinavir plasma protein binding in HIV-1-infected adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11089617/),%,61,222961,DB00495,Zidovudine
,11089617,binding,"Indinavir binding was higher at the 8 h post-dose concentration compared with the 1 h post-dose concentration (66 versus 57%, P = 0.0006).",Indinavir plasma protein binding in HIV-1-infected adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11089617/),,66,222962,DB00495,Zidovudine
,11089617,binding,"Indinavir binding was higher at the 8 h post-dose concentration compared with the 1 h post-dose concentration (66 versus 57%, P = 0.0006).",Indinavir plasma protein binding in HIV-1-infected adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11089617/),,57,222963,DB00495,Zidovudine
,11089617,protein binding,The mean 61% protein binding for indinavir in these HIV-infected persons is similar to the in vitro report of 60%.,Indinavir plasma protein binding in HIV-1-infected adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11089617/),%,61,222964,DB00495,Zidovudine
,11089617,protein binding,The mean 61% protein binding for indinavir in these HIV-infected persons is similar to the in vitro report of 60%.,Indinavir plasma protein binding in HIV-1-infected adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11089617/),%,60,222965,DB00495,Zidovudine
,8359192,peak plasma concentration,"The peak plasma concentration and AUC after a single oral dose of 200 mg, were the same as those reported in 6 healthy male volunteers (3.1 vs 4.0 mumol.l-1 and 7.2 vs 5.2 mumol.h.l-1, respectively).",Absorption of zidovudine in patients with diarrhoea. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359192/),[μM] / [l],3.1,223628,DB00495,Zidovudine
,8359192,peak plasma concentration,"The peak plasma concentration and AUC after a single oral dose of 200 mg, were the same as those reported in 6 healthy male volunteers (3.1 vs 4.0 mumol.l-1 and 7.2 vs 5.2 mumol.h.l-1, respectively).",Absorption of zidovudine in patients with diarrhoea. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359192/),[μM] / [l],4.0,223629,DB00495,Zidovudine
,8359192,AUC,"The peak plasma concentration and AUC after a single oral dose of 200 mg, were the same as those reported in 6 healthy male volunteers (3.1 vs 4.0 mumol.l-1 and 7.2 vs 5.2 mumol.h.l-1, respectively).",Absorption of zidovudine in patients with diarrhoea. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359192/),[h·μM] / [l],7.2,223630,DB00495,Zidovudine
,8359192,AUC,"The peak plasma concentration and AUC after a single oral dose of 200 mg, were the same as those reported in 6 healthy male volunteers (3.1 vs 4.0 mumol.l-1 and 7.2 vs 5.2 mumol.h.l-1, respectively).",Absorption of zidovudine in patients with diarrhoea. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359192/),[h·μM] / [l],5.2,223631,DB00495,Zidovudine
,15883177,AUC,"On 600 mg of indinavir, median indinavir AUC, C(max), and C(min) were 39.3 mg.h/L (20.6-50.5), 6.2 mg/L (3.7-9.0) and 0.41 mg/L (0.12-0.77), respectively, and on indinavir 400 mg, 18.3 mg.h/L (11.1-33.0), 3.8 mg/L (2.2-7.8) and 0.17 mg/L (0.10-0.39), respectively.","Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883177/),[h·mg] / [l],39.3,223656,DB00495,Zidovudine
,15883177,C(max),"On 600 mg of indinavir, median indinavir AUC, C(max), and C(min) were 39.3 mg.h/L (20.6-50.5), 6.2 mg/L (3.7-9.0) and 0.41 mg/L (0.12-0.77), respectively, and on indinavir 400 mg, 18.3 mg.h/L (11.1-33.0), 3.8 mg/L (2.2-7.8) and 0.17 mg/L (0.10-0.39), respectively.","Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883177/),[mg] / [l],6.2,223657,DB00495,Zidovudine
,15883177,C(min),"On 600 mg of indinavir, median indinavir AUC, C(max), and C(min) were 39.3 mg.h/L (20.6-50.5), 6.2 mg/L (3.7-9.0) and 0.41 mg/L (0.12-0.77), respectively, and on indinavir 400 mg, 18.3 mg.h/L (11.1-33.0), 3.8 mg/L (2.2-7.8) and 0.17 mg/L (0.10-0.39), respectively.","Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15883177/),[mg] / [l],0.41,223658,DB00495,Zidovudine
,20632458,detection limit,"Lopinavir and ritonavir were measured by reverse-phase high-performance liquid chromatography (detection limit, 0.09 mcg/mL).",Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20632458/),[mcg] / [ml],0.09,223752,DB00495,Zidovudine
,20632458,AUC,"Median lopinavir AUC for the second trimester (n = 11), third trimester (n = 33), and postpartum (n = 27) were 72, 96, and 133 mcg x hr/mL, respectively.",Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20632458/),[h·mcg] / [ml],72,223753,DB00495,Zidovudine
,20632458,AUC,"Median lopinavir AUC for the second trimester (n = 11), third trimester (n = 33), and postpartum (n = 27) were 72, 96, and 133 mcg x hr/mL, respectively.",Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20632458/),[h·mcg] / [ml],96,223754,DB00495,Zidovudine
,20632458,AUC,"Median lopinavir AUC for the second trimester (n = 11), third trimester (n = 33), and postpartum (n = 27) were 72, 96, and 133 mcg x hr/mL, respectively.",Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20632458/),[h·mcg] / [ml],133,223755,DB00495,Zidovudine
,20632458,minimum lopinavir concentrations,"Median minimum lopinavir concentrations were 3.4, 4.9, and 6.9 mcg/mL.",Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20632458/),[mcg] / [ml],3.4,223756,DB00495,Zidovudine
,20632458,minimum lopinavir concentrations,"Median minimum lopinavir concentrations were 3.4, 4.9, and 6.9 mcg/mL.",Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20632458/),[mcg] / [ml],4.9,223757,DB00495,Zidovudine
,20632458,minimum lopinavir concentrations,"Median minimum lopinavir concentrations were 3.4, 4.9, and 6.9 mcg/mL.",Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20632458/),[mcg] / [ml],6.9,223758,DB00495,Zidovudine
,20632458,AUC,The higher lopinavir/ritonavir tablet dose (600 mg/150 mg) provided exposure during the third trimester similar to the average AUC (98 mcg x hr x mL(-1) in nonpregnant adults taking 400 mg/100 mg twice daily.,Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20632458/),[h·mcg] / [ml],98,223759,DB00495,Zidovudine
,2060570,half-life,In both conditions the mean half-life was about 1.5 h and the period of plasma zidovudine concentrations greater than 1 mumol.l-1 was 2 h (NS).,Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060570/),h,1.5,224211,DB00495,Zidovudine
,2060570,half-life,In both conditions the mean half-life was about 1.5 h and the period of plasma zidovudine concentrations greater than 1 mumol.l-1 was 2 h (NS).,Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060570/),h,2,224212,DB00495,Zidovudine
,22884056,half-life,"The half-life of AZT, analyzed by the non-compartment model (P = 0.02), in male patients ((1.02 ± 0.22) hours) was shorter than that of AZT in female patients ((1.55 ± 0.29) hours).",Steady-state pharmacokinetics of zidovudine in Chinese HIV-infected patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884056/),h,1.02,224239,DB00495,Zidovudine
,22884056,half-life,"The half-life of AZT, analyzed by the non-compartment model (P = 0.02), in male patients ((1.02 ± 0.22) hours) was shorter than that of AZT in female patients ((1.55 ± 0.29) hours).",Steady-state pharmacokinetics of zidovudine in Chinese HIV-infected patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884056/),h,1.55,224240,DB00495,Zidovudine
,22884056,clearance,"The AZT clearance, analyzed by the one-compartment model (P = 0.045), in male patients ((262.60 ± 28.13) L/h) was higher than that in female patients ((195.85 ± 60.51) L/h).",Steady-state pharmacokinetics of zidovudine in Chinese HIV-infected patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884056/),[l] / [h],262.60,224241,DB00495,Zidovudine
,22884056,clearance,"The AZT clearance, analyzed by the one-compartment model (P = 0.045), in male patients ((262.60 ± 28.13) L/h) was higher than that in female patients ((195.85 ± 60.51) L/h).",Steady-state pharmacokinetics of zidovudine in Chinese HIV-infected patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884056/),[l] / [h],195.85,224242,DB00495,Zidovudine
,23877688,absorption rate,"The mean population parameter estimates were as follows: absorption rate, 2.86 h(-1); apparent elimination clearance, 89.7 liters · h(-1) (between-subject variability, 0.701 liters · h(-1)); apparent volume of distribution, 229 liters (between-subject variability, 0.807 liters); metabolic formation rate constant, 12.6 h(-1) (between-subject variability, 0.352 h(-1)); and elimination rate constant of G-ZDV, 2.27 h(-1).",Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23877688/),1/[h],2.86,224281,DB00495,Zidovudine
,23877688,apparent elimination clearance,"The mean population parameter estimates were as follows: absorption rate, 2.86 h(-1); apparent elimination clearance, 89.7 liters · h(-1) (between-subject variability, 0.701 liters · h(-1)); apparent volume of distribution, 229 liters (between-subject variability, 0.807 liters); metabolic formation rate constant, 12.6 h(-1) (between-subject variability, 0.352 h(-1)); and elimination rate constant of G-ZDV, 2.27 h(-1).",Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23877688/),[l] / [h],89.7,224282,DB00495,Zidovudine
,23877688,apparent volume of distribution,"The mean population parameter estimates were as follows: absorption rate, 2.86 h(-1); apparent elimination clearance, 89.7 liters · h(-1) (between-subject variability, 0.701 liters · h(-1)); apparent volume of distribution, 229 liters (between-subject variability, 0.807 liters); metabolic formation rate constant, 12.6 h(-1) (between-subject variability, 0.352 h(-1)); and elimination rate constant of G-ZDV, 2.27 h(-1).",Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23877688/),l,229,224283,DB00495,Zidovudine
,23877688,metabolic formation rate constant,"The mean population parameter estimates were as follows: absorption rate, 2.86 h(-1); apparent elimination clearance, 89.7 liters · h(-1) (between-subject variability, 0.701 liters · h(-1)); apparent volume of distribution, 229 liters (between-subject variability, 0.807 liters); metabolic formation rate constant, 12.6 h(-1) (between-subject variability, 0.352 h(-1)); and elimination rate constant of G-ZDV, 2.27 h(-1).",Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children. ,Km-Q52,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23877688/),1/[h],12.6,224284,DB00495,Zidovudine
,23877688,elimination rate constant,"The mean population parameter estimates were as follows: absorption rate, 2.86 h(-1); apparent elimination clearance, 89.7 liters · h(-1) (between-subject variability, 0.701 liters · h(-1)); apparent volume of distribution, 229 liters (between-subject variability, 0.807 liters); metabolic formation rate constant, 12.6 h(-1) (between-subject variability, 0.352 h(-1)); and elimination rate constant of G-ZDV, 2.27 h(-1).",Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23877688/),1/[h],2.27,224285,DB00495,Zidovudine
,8494380,ratios,"At 75 min after infusion of AZT, DPAZT, and IAZT, the CSF plasma AZT ratios were 0.23, 0.30, and 0.25, while the brain/CSF AZT ratios were 0.32, 0.63, and 0.64, respectively.",Comparative pharmacokinetics of two prodrugs of zidovudine in rabbits: enhanced levels of zidovudine in brain tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494380/),,0.23,227352,DB00495,Zidovudine
,8494380,ratios,"At 75 min after infusion of AZT, DPAZT, and IAZT, the CSF plasma AZT ratios were 0.23, 0.30, and 0.25, while the brain/CSF AZT ratios were 0.32, 0.63, and 0.64, respectively.",Comparative pharmacokinetics of two prodrugs of zidovudine in rabbits: enhanced levels of zidovudine in brain tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494380/),,0.30,227353,DB00495,Zidovudine
,8494380,ratios,"At 75 min after infusion of AZT, DPAZT, and IAZT, the CSF plasma AZT ratios were 0.23, 0.30, and 0.25, while the brain/CSF AZT ratios were 0.32, 0.63, and 0.64, respectively.",Comparative pharmacokinetics of two prodrugs of zidovudine in rabbits: enhanced levels of zidovudine in brain tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494380/),,0.25,227354,DB00495,Zidovudine
,8494380,ratios,"At 75 min after infusion of AZT, DPAZT, and IAZT, the CSF plasma AZT ratios were 0.23, 0.30, and 0.25, while the brain/CSF AZT ratios were 0.32, 0.63, and 0.64, respectively.",Comparative pharmacokinetics of two prodrugs of zidovudine in rabbits: enhanced levels of zidovudine in brain tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494380/),,0.32,227355,DB00495,Zidovudine
,8494380,ratios,"At 75 min after infusion of AZT, DPAZT, and IAZT, the CSF plasma AZT ratios were 0.23, 0.30, and 0.25, while the brain/CSF AZT ratios were 0.32, 0.63, and 0.64, respectively.",Comparative pharmacokinetics of two prodrugs of zidovudine in rabbits: enhanced levels of zidovudine in brain tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494380/),,0.63,227356,DB00495,Zidovudine
,8494380,ratios,"At 75 min after infusion of AZT, DPAZT, and IAZT, the CSF plasma AZT ratios were 0.23, 0.30, and 0.25, while the brain/CSF AZT ratios were 0.32, 0.63, and 0.64, respectively.",Comparative pharmacokinetics of two prodrugs of zidovudine in rabbits: enhanced levels of zidovudine in brain tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494380/),,0.64,227357,DB00495,Zidovudine
,8460920,absolute neutrophil count,"Of 11 patients, 7 (1.0 micrograms/kg, n = 5; 0.3 micrograms/kg, n = 2) had a pharmacologic response to GM-CSF with an increase to a mean absolute neutrophil count of 3,189 cells per mm3 at 4 weeks (P < 0.05).",Pharmacokinetics and pharmacodynamics of granulocyte-macrophage colony-stimulating factor and zidovudine in patients with AIDS and severe AIDS-related complex. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8460920/),,"3,",227835,DB00495,Zidovudine
,8460920,peak concentration,"The peak concentration of GM-CSF in plasma ranged from 11.5 to 84.4 pg/ml, and the time to peak ranged from 1 to 3 h.",Pharmacokinetics and pharmacodynamics of granulocyte-macrophage colony-stimulating factor and zidovudine in patients with AIDS and severe AIDS-related complex. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8460920/),[pg] / [ml],11.5 to 84.4,227836,DB00495,Zidovudine
,8460920,time to peak,"The peak concentration of GM-CSF in plasma ranged from 11.5 to 84.4 pg/ml, and the time to peak ranged from 1 to 3 h.",Pharmacokinetics and pharmacodynamics of granulocyte-macrophage colony-stimulating factor and zidovudine in patients with AIDS and severe AIDS-related complex. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8460920/),h,1 to 3,227837,DB00495,Zidovudine
,8098905,total body clearance,"The total body clearance (26.3 +/- 10.1 ml/min/kg), mean terminal elimination phase zidovudine half-life (1.3 +/- 0.2 hours), and urinary zidovudine recovery were similar to values in nonpregnant adults.",The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8098905/),[ml] / [kg·min],26.3,228103,DB00495,Zidovudine
,8098905,terminal elimination phase zido,"The total body clearance (26.3 +/- 10.1 ml/min/kg), mean terminal elimination phase zidovudine half-life (1.3 +/- 0.2 hours), and urinary zidovudine recovery were similar to values in nonpregnant adults.",The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8098905/),h,1.3,228104,DB00495,Zidovudine
,17446146,flow rate,"The mobile phase consisted of methanol (85%, v/v) and diethyl ether (15%, v/v) at a flow rate of 1.0 mL/min.",Investigation of the pharmacokinetics and determination of cholesteryl carbonate zidovudine in rat plasma by non-aqueous reversed-phase high performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17446146/),[ml] / [min],1.0,228701,DB00495,Zidovudine
higher,17446146,extraction recoveries,The extraction recoveries of AZTC at the three concentrations examined were all higher than 80%.,Investigation of the pharmacokinetics and determination of cholesteryl carbonate zidovudine in rat plasma by non-aqueous reversed-phase high performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17446146/),%,80,228702,DB00495,Zidovudine
,17446146,elimination half-life (t1/2),The mean elimination half-life (t1/2) was 292.4 min.,Investigation of the pharmacokinetics and determination of cholesteryl carbonate zidovudine in rat plasma by non-aqueous reversed-phase high performance liquid chromatography with UV detection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17446146/),min,292.4,228703,DB00495,Zidovudine
,20936623,absorption half-life (t1/2ka),"Compared to free AZT, the absorption half-life (t1/2ka) and elimination half life (t1/2ß) of AZT released from the conjugate were both extended to 0.51±0.03 h (p <0.01) and 2.94±0.24 h (p <0.01), respectively.","Synthesis, in vitro and in vivo release kinetics, and anti-HIV activity of a sustained-release prodrug (mPEG-AZT) of 3'-azido-3'-deoxythymidine (AZT, Zidovudine). ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20936623/),h,0.51,230486,DB00495,Zidovudine
,20936623,elimination half life (t1/2ß),"Compared to free AZT, the absorption half-life (t1/2ka) and elimination half life (t1/2ß) of AZT released from the conjugate were both extended to 0.51±0.03 h (p <0.01) and 2.94±0.24 h (p <0.01), respectively.","Synthesis, in vitro and in vivo release kinetics, and anti-HIV activity of a sustained-release prodrug (mPEG-AZT) of 3'-azido-3'-deoxythymidine (AZT, Zidovudine). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20936623/),h,2.94,230487,DB00495,Zidovudine
,20936623,EC(50),"Evaluation of the in vitro anti-HIV activities showed mPEG-AZT exhibited good inhibition of HIV-1, with an EC(50) value of 0.0634 μM, but it is lower than that of free AZT.","Synthesis, in vitro and in vivo release kinetics, and anti-HIV activity of a sustained-release prodrug (mPEG-AZT) of 3'-azido-3'-deoxythymidine (AZT, Zidovudine). ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20936623/),μM,0.0634,230488,DB00495,Zidovudine
,9661022,maximum concentration in (Cmax),"The maximum concentration in (Cmax) of ZDV plasma decreased from 748 +/- 375 (mean +/- standard deviation) to 546 +/- 296, and area under the concentration-time curve from 0 to 24 h (AUC0-24) decreased from 3,052 +/- 1,007 to 2,261 +/- 715 when coadministered with ritonavir.",Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661022/),,748,230983,DB00495,Zidovudine
,9661022,maximum concentration in (Cmax),"The maximum concentration in (Cmax) of ZDV plasma decreased from 748 +/- 375 (mean +/- standard deviation) to 546 +/- 296, and area under the concentration-time curve from 0 to 24 h (AUC0-24) decreased from 3,052 +/- 1,007 to 2,261 +/- 715 when coadministered with ritonavir.",Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661022/),,546,230984,DB00495,Zidovudine
,9661022,area under the concentration-time curve from 0 to 24 h (AUC0-24),"The maximum concentration in (Cmax) of ZDV plasma decreased from 748 +/- 375 (mean +/- standard deviation) to 546 +/- 296, and area under the concentration-time curve from 0 to 24 h (AUC0-24) decreased from 3,052 +/- 1,007 to 2,261 +/- 715 when coadministered with ritonavir.",Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661022/),,"3,052",230985,DB00495,Zidovudine
,9661022,area under the concentration-time curve from 0 to 24 h (AUC0-24),"The maximum concentration in (Cmax) of ZDV plasma decreased from 748 +/- 375 (mean +/- standard deviation) to 546 +/- 296, and area under the concentration-time curve from 0 to 24 h (AUC0-24) decreased from 3,052 +/- 1,007 to 2,261 +/- 715 when coadministered with ritonavir.",Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661022/),,"2,261",230986,DB00495,Zidovudine
,1895207,area under the curve (AUC),"In those with normal hepatic function, the following parameters were described: AZT, area under the curve (AUC) +/- SD, 9.9 +/- 5.7 microM.h, maximum concentration (Cmax) +/- SD, 7.3 +/- 4.7 microM; time to maximum concentration (Tmax) +/- SD, 0.93 +/- 0.42 h, and half-life (t1/2) +/- SD, 1.0 +/- 0.8 h.",Canadian multicenter azidothymidine trial: AZT pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1895207/),h·μM,9.9,231322,DB00495,Zidovudine
,1895207,maximum concentration (Cmax),"In those with normal hepatic function, the following parameters were described: AZT, area under the curve (AUC) +/- SD, 9.9 +/- 5.7 microM.h, maximum concentration (Cmax) +/- SD, 7.3 +/- 4.7 microM; time to maximum concentration (Tmax) +/- SD, 0.93 +/- 0.42 h, and half-life (t1/2) +/- SD, 1.0 +/- 0.8 h.",Canadian multicenter azidothymidine trial: AZT pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1895207/),μM,7.3,231323,DB00495,Zidovudine
,1895207,time to maximum concentration (Tmax),"In those with normal hepatic function, the following parameters were described: AZT, area under the curve (AUC) +/- SD, 9.9 +/- 5.7 microM.h, maximum concentration (Cmax) +/- SD, 7.3 +/- 4.7 microM; time to maximum concentration (Tmax) +/- SD, 0.93 +/- 0.42 h, and half-life (t1/2) +/- SD, 1.0 +/- 0.8 h.",Canadian multicenter azidothymidine trial: AZT pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1895207/),h,0.93,231324,DB00495,Zidovudine
,1895207,half-life (t1/2),"In those with normal hepatic function, the following parameters were described: AZT, area under the curve (AUC) +/- SD, 9.9 +/- 5.7 microM.h, maximum concentration (Cmax) +/- SD, 7.3 +/- 4.7 microM; time to maximum concentration (Tmax) +/- SD, 0.93 +/- 0.42 h, and half-life (t1/2) +/- SD, 1.0 +/- 0.8 h.",Canadian multicenter azidothymidine trial: AZT pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1895207/),h,1.0,231325,DB00495,Zidovudine
,1895207,AUC,"Corresponding values for GAZT were: AUC +/- SD 35.7 +/- 10.3 microM.h, Cmax +/- SD 21.3 +/- 7.3 microM, Tmax +/- SD 1.2 +/- 0.50 h, t1/2 +/- SD 0.98 +/- 0.62 h, No significant differences were found in comparisons of study site, CDC classification of disease, smokers versus nonsmokers, and in patients with hepatic dysfunction, although a higher AUC and earlier Cmax for AZT was noted in the latter group.",Canadian multicenter azidothymidine trial: AZT pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1895207/),h·μM,35.7,231326,DB00495,Zidovudine
,1895207,Cmax,"Corresponding values for GAZT were: AUC +/- SD 35.7 +/- 10.3 microM.h, Cmax +/- SD 21.3 +/- 7.3 microM, Tmax +/- SD 1.2 +/- 0.50 h, t1/2 +/- SD 0.98 +/- 0.62 h, No significant differences were found in comparisons of study site, CDC classification of disease, smokers versus nonsmokers, and in patients with hepatic dysfunction, although a higher AUC and earlier Cmax for AZT was noted in the latter group.",Canadian multicenter azidothymidine trial: AZT pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1895207/),μM,21.3,231327,DB00495,Zidovudine
,1895207,Tmax,"Corresponding values for GAZT were: AUC +/- SD 35.7 +/- 10.3 microM.h, Cmax +/- SD 21.3 +/- 7.3 microM, Tmax +/- SD 1.2 +/- 0.50 h, t1/2 +/- SD 0.98 +/- 0.62 h, No significant differences were found in comparisons of study site, CDC classification of disease, smokers versus nonsmokers, and in patients with hepatic dysfunction, although a higher AUC and earlier Cmax for AZT was noted in the latter group.",Canadian multicenter azidothymidine trial: AZT pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1895207/),h,1.2,231328,DB00495,Zidovudine
,1895207,t1/2,"Corresponding values for GAZT were: AUC +/- SD 35.7 +/- 10.3 microM.h, Cmax +/- SD 21.3 +/- 7.3 microM, Tmax +/- SD 1.2 +/- 0.50 h, t1/2 +/- SD 0.98 +/- 0.62 h, No significant differences were found in comparisons of study site, CDC classification of disease, smokers versus nonsmokers, and in patients with hepatic dysfunction, although a higher AUC and earlier Cmax for AZT was noted in the latter group.",Canadian multicenter azidothymidine trial: AZT pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1895207/),h,0.98,231329,DB00495,Zidovudine
,8361863,peak plasma concentrations,"The drug's mean peak plasma concentrations (range 233-808 ng/ml) were 556 +/- 145, 385 +/- 132, and 495 +/- 143 ng/ml during the menstrual, late follicular-ovulatory, and luteal phases, respectively.",Zidovudine pharmacokinetics in HIV-positive women during different phases of the menstrual cycle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8361863/),[ng] / [ml],233-808,232081,DB00495,Zidovudine
,8361863,peak plasma concentrations,"The drug's mean peak plasma concentrations (range 233-808 ng/ml) were 556 +/- 145, 385 +/- 132, and 495 +/- 143 ng/ml during the menstrual, late follicular-ovulatory, and luteal phases, respectively.",Zidovudine pharmacokinetics in HIV-positive women during different phases of the menstrual cycle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8361863/),[ng] / [ml],556,232082,DB00495,Zidovudine
,8361863,peak plasma concentrations,"The drug's mean peak plasma concentrations (range 233-808 ng/ml) were 556 +/- 145, 385 +/- 132, and 495 +/- 143 ng/ml during the menstrual, late follicular-ovulatory, and luteal phases, respectively.",Zidovudine pharmacokinetics in HIV-positive women during different phases of the menstrual cycle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8361863/),[ng] / [ml],385,232083,DB00495,Zidovudine
,8361863,peak plasma concentrations,"The drug's mean peak plasma concentrations (range 233-808 ng/ml) were 556 +/- 145, 385 +/- 132, and 495 +/- 143 ng/ml during the menstrual, late follicular-ovulatory, and luteal phases, respectively.",Zidovudine pharmacokinetics in HIV-positive women during different phases of the menstrual cycle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8361863/),[ng] / [ml],495,232084,DB00495,Zidovudine
,8361863,area under the curve,"The mean zidovudine area under the curve was 886 +/- 156, 845 +/- 268, and 775 +/- 167 ng.hour/ml.",Zidovudine pharmacokinetics in HIV-positive women during different phases of the menstrual cycle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8361863/),[h·ng] / [ml],886,232085,DB00495,Zidovudine
,8361863,area under the curve,"The mean zidovudine area under the curve was 886 +/- 156, 845 +/- 268, and 775 +/- 167 ng.hour/ml.",Zidovudine pharmacokinetics in HIV-positive women during different phases of the menstrual cycle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8361863/),[h·ng] / [ml],845,232086,DB00495,Zidovudine
,8361863,area under the curve,"The mean zidovudine area under the curve was 886 +/- 156, 845 +/- 268, and 775 +/- 167 ng.hour/ml.",Zidovudine pharmacokinetics in HIV-positive women during different phases of the menstrual cycle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8361863/),[h·ng] / [ml],775,232087,DB00495,Zidovudine
,8361863,percentage of dose recovered,"The mean percentage of dose recovered was 44.2 +/- 26.0, 56.9 +/- 19.1, and 42.2 +/- 16.6, respectively.",Zidovudine pharmacokinetics in HIV-positive women during different phases of the menstrual cycle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8361863/),,44.2,232088,DB00495,Zidovudine
,8361863,percentage of dose recovered,"The mean percentage of dose recovered was 44.2 +/- 26.0, 56.9 +/- 19.1, and 42.2 +/- 16.6, respectively.",Zidovudine pharmacokinetics in HIV-positive women during different phases of the menstrual cycle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8361863/),,56.9,232089,DB00495,Zidovudine
,8361863,percentage of dose recovered,"The mean percentage of dose recovered was 44.2 +/- 26.0, 56.9 +/- 19.1, and 42.2 +/- 16.6, respectively.",Zidovudine pharmacokinetics in HIV-positive women during different phases of the menstrual cycle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8361863/),,42.2,232090,DB00495,Zidovudine
,9371345,clearance [CL]/bioavailability [F],"The mean values of the pharmacokinetic parameters of zidovudine (clearance [CL]/bioavailability [F], 168 liters/h; volume of distribution [V]/F, 185 liters; half-life, 0.76 h) and zalcitabine (CL/F, 25 liters/h; V/F, 92.2 liters; half-life, 2.7 h) were similar to those reported previously.","Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9371345/),[l] / [h],168,232309,DB00495,Zidovudine
,9371345,volume of distribution [V]/F,"The mean values of the pharmacokinetic parameters of zidovudine (clearance [CL]/bioavailability [F], 168 liters/h; volume of distribution [V]/F, 185 liters; half-life, 0.76 h) and zalcitabine (CL/F, 25 liters/h; V/F, 92.2 liters; half-life, 2.7 h) were similar to those reported previously.","Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9371345/),l,185,232310,DB00495,Zidovudine
,9371345,half-life,"The mean values of the pharmacokinetic parameters of zidovudine (clearance [CL]/bioavailability [F], 168 liters/h; volume of distribution [V]/F, 185 liters; half-life, 0.76 h) and zalcitabine (CL/F, 25 liters/h; V/F, 92.2 liters; half-life, 2.7 h) were similar to those reported previously.","Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9371345/),h,0.76,232311,DB00495,Zidovudine
,9371345,CL/F,"The mean values of the pharmacokinetic parameters of zidovudine (clearance [CL]/bioavailability [F], 168 liters/h; volume of distribution [V]/F, 185 liters; half-life, 0.76 h) and zalcitabine (CL/F, 25 liters/h; V/F, 92.2 liters; half-life, 2.7 h) were similar to those reported previously.","Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9371345/),[l] / [h],25,232312,DB00495,Zidovudine
,9371345,V/F,"The mean values of the pharmacokinetic parameters of zidovudine (clearance [CL]/bioavailability [F], 168 liters/h; volume of distribution [V]/F, 185 liters; half-life, 0.76 h) and zalcitabine (CL/F, 25 liters/h; V/F, 92.2 liters; half-life, 2.7 h) were similar to those reported previously.","Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9371345/),l,92.2,232313,DB00495,Zidovudine
,9371345,half-life,"The mean values of the pharmacokinetic parameters of zidovudine (clearance [CL]/bioavailability [F], 168 liters/h; volume of distribution [V]/F, 185 liters; half-life, 0.76 h) and zalcitabine (CL/F, 25 liters/h; V/F, 92.2 liters; half-life, 2.7 h) were similar to those reported previously.","Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9371345/),h,2.7,232314,DB00495,Zidovudine
,9371345,maximum concentration of drug in serum [Cmax],"For saquinavir, the mean pharmacokinetic parameter estimates using parametric methods were as follows: maximum concentration of drug in serum [Cmax], 70.8 ng/ml; time to Cmax, 3.11 h; area under the curve, 809 ng x h/ml; CL/F, 989 liters/h; V/F, 1,503 liters; half-life, 1.38 h.","Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9371345/),[ng] / [ml],70.8,232315,DB00495,Zidovudine
,9371345,time to Cmax,"For saquinavir, the mean pharmacokinetic parameter estimates using parametric methods were as follows: maximum concentration of drug in serum [Cmax], 70.8 ng/ml; time to Cmax, 3.11 h; area under the curve, 809 ng x h/ml; CL/F, 989 liters/h; V/F, 1,503 liters; half-life, 1.38 h.","Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9371345/),h,3.11,232316,DB00495,Zidovudine
,9371345,area under the curve,"For saquinavir, the mean pharmacokinetic parameter estimates using parametric methods were as follows: maximum concentration of drug in serum [Cmax], 70.8 ng/ml; time to Cmax, 3.11 h; area under the curve, 809 ng x h/ml; CL/F, 989 liters/h; V/F, 1,503 liters; half-life, 1.38 h.","Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9371345/),[h·ng] / [ml],809,232317,DB00495,Zidovudine
,9371345,CL/F,"For saquinavir, the mean pharmacokinetic parameter estimates using parametric methods were as follows: maximum concentration of drug in serum [Cmax], 70.8 ng/ml; time to Cmax, 3.11 h; area under the curve, 809 ng x h/ml; CL/F, 989 liters/h; V/F, 1,503 liters; half-life, 1.38 h.","Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9371345/),[l] / [h],989,232318,DB00495,Zidovudine
,9371345,V/F,"For saquinavir, the mean pharmacokinetic parameter estimates using parametric methods were as follows: maximum concentration of drug in serum [Cmax], 70.8 ng/ml; time to Cmax, 3.11 h; area under the curve, 809 ng x h/ml; CL/F, 989 liters/h; V/F, 1,503 liters; half-life, 1.38 h.","Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9371345/),l,"1,503",232319,DB00495,Zidovudine
,9371345,half-life,"For saquinavir, the mean pharmacokinetic parameter estimates using parametric methods were as follows: maximum concentration of drug in serum [Cmax], 70.8 ng/ml; time to Cmax, 3.11 h; area under the curve, 809 ng x h/ml; CL/F, 989 liters/h; V/F, 1,503 liters; half-life, 1.38 h.","Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9371345/),h,1.38,232320,DB00495,Zidovudine
,11741217,CL/F,Estimates of the apparent clearance for nevirapine (CL/F = 3.3 L/hour; 95% confidence interval [CI] 2.9 to 3.7 L/hour) and lamivudine (CL/F 27.6 L/hour; 95% CI 22 to 33.2 L/hour) were consistent with the values reported in earlier trials.,Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11741217/),[l] / [h],3.3,233677,DB00495,Zidovudine
,11741217,CL/F,Estimates of the apparent clearance for nevirapine (CL/F = 3.3 L/hour; 95% confidence interval [CI] 2.9 to 3.7 L/hour) and lamivudine (CL/F 27.6 L/hour; 95% CI 22 to 33.2 L/hour) were consistent with the values reported in earlier trials.,Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11741217/),[l] / [h],27.6,233678,DB00495,Zidovudine
,1482146,peak plasma SCH-39304 concentrations,"Absorption appeared to be slow, with mean day 1 peak plasma SCH-39304 concentrations of 1.2 micrograms/ml at 2.1 h (50 mg) and 3.9 micrograms/ml at 4.0 h (200 mg) after drug administration.",Pharmacokinetics of SCH-39304 in human immunodeficiency virus-infected patients following chronic oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482146/),[μg] / [ml],1.2,234173,DB00495,Zidovudine
,1482146,peak plasma SCH-39304 concentrations,"Absorption appeared to be slow, with mean day 1 peak plasma SCH-39304 concentrations of 1.2 micrograms/ml at 2.1 h (50 mg) and 3.9 micrograms/ml at 4.0 h (200 mg) after drug administration.",Pharmacokinetics of SCH-39304 in human immunodeficiency virus-infected patients following chronic oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482146/),[μg] / [ml],3.9,234174,DB00495,Zidovudine
,1482146,peak plasma SCH-39304 concentrations,Mean peak plasma SCH-39304 concentrations on day 16 were 7.6 micrograms/ml at 4.3 h (50 mg) and 17.2 micrograms/ml at 3.2 h (200 mg) after drug administration.,Pharmacokinetics of SCH-39304 in human immunodeficiency virus-infected patients following chronic oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482146/),[μg] / [ml],7.6,234175,DB00495,Zidovudine
,1482146,peak plasma SCH-39304 concentrations,Mean peak plasma SCH-39304 concentrations on day 16 were 7.6 micrograms/ml at 4.3 h (50 mg) and 17.2 micrograms/ml at 3.2 h (200 mg) after drug administration.,Pharmacokinetics of SCH-39304 in human immunodeficiency virus-infected patients following chronic oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482146/),[μg] / [ml],17.2,234176,DB00495,Zidovudine
,1482146,elimination half-lives,"Mean elimination half-lives on day 16 for the 50- and 200-mg daily dosages were 100 and 89 h, respectively.",Pharmacokinetics of SCH-39304 in human immunodeficiency virus-infected patients following chronic oral dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482146/),h,100,234177,DB00495,Zidovudine
,1482146,elimination half-lives,"Mean elimination half-lives on day 16 for the 50- and 200-mg daily dosages were 100 and 89 h, respectively.",Pharmacokinetics of SCH-39304 in human immunodeficiency virus-infected patients following chronic oral dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482146/),h,89,234178,DB00495,Zidovudine
,1482146,areas under the plasma concentration-versus-time curve (from 0 to 24 h),"Mean areas under the plasma concentration-versus-time curve (from 0 to 24 h) on day 16 reflect a lower than expected increase with the 200-mg/day regimen (314.5 microgram.h/ml) compared with that for the 50-mg/day regimen (139.9 microgram.h/ml), suggesting the potential for reduced bioavailability at higher dosages.",Pharmacokinetics of SCH-39304 in human immunodeficiency virus-infected patients following chronic oral dosing. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482146/),[h·μg] / [ml],314.5,234179,DB00495,Zidovudine
,1482146,areas under the plasma concentration-versus-time curve (from 0 to 24 h),"Mean areas under the plasma concentration-versus-time curve (from 0 to 24 h) on day 16 reflect a lower than expected increase with the 200-mg/day regimen (314.5 microgram.h/ml) compared with that for the 50-mg/day regimen (139.9 microgram.h/ml), suggesting the potential for reduced bioavailability at higher dosages.",Pharmacokinetics of SCH-39304 in human immunodeficiency virus-infected patients following chronic oral dosing. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482146/),[h·μg] / [ml],139.9,234180,DB00495,Zidovudine
,9612607,clearance,The antipyrine clearance was significantly reduced in the group of AIDS patients (43.1 +/- 7.2 ml/min compared to 56.4 +/- 8.7 ml/min).,Effect of zidovudine therapy in patients with HIV infection on endogenous interferon plasma levels and the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9612607/),[ml] / [min],43.1,235139,DB00495,Zidovudine
,9612607,clearance,The antipyrine clearance was significantly reduced in the group of AIDS patients (43.1 +/- 7.2 ml/min compared to 56.4 +/- 8.7 ml/min).,Effect of zidovudine therapy in patients with HIV infection on endogenous interferon plasma levels and the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9612607/),[ml] / [min],56.4,235140,DB00495,Zidovudine
,9612607,clearance,"In contrast to these results, we found a significant decrease in IFN-alpha and IFN-gamma (19.8 +/- 3.6 U/ml, 4.6 +/- 1.5 U/ml before; 7.9 +/- 2.6 U/ml, 1.9 +/- 1.3 U/ml after administration of ZDV), a decrease in antipyrine half-life, an elevation of the antipyrine clearance (49.8 +/- 15.7 ml/min, 57.3 +/- 13.7 ml/min) and an elevation of the clearances to metabolite.",Effect of zidovudine therapy in patients with HIV infection on endogenous interferon plasma levels and the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9612607/),[ml] / [min],49.8,235141,DB00495,Zidovudine
,9612607,clearance,"In contrast to these results, we found a significant decrease in IFN-alpha and IFN-gamma (19.8 +/- 3.6 U/ml, 4.6 +/- 1.5 U/ml before; 7.9 +/- 2.6 U/ml, 1.9 +/- 1.3 U/ml after administration of ZDV), a decrease in antipyrine half-life, an elevation of the antipyrine clearance (49.8 +/- 15.7 ml/min, 57.3 +/- 13.7 ml/min) and an elevation of the clearances to metabolite.",Effect of zidovudine therapy in patients with HIV infection on endogenous interferon plasma levels and the hepatic cytochrome P450 enzyme system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9612607/),[ml] / [min],57.3,235142,DB00495,Zidovudine
,18052620,retention time,"Chromatography was performed on a C-18 analytical columns and the retention time ranged from 6.8 to 8.0 min for stavudine, 7.5 to 9.0 min for lamivudine, 11.2 to 11.9 min for zidovudine and indinavir.","Validation of high-performance liquid chromatography methods for determination of zidovudine, stavudine, lamivudine and indinavir in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18052620/),min,6.8 to 8.0,236254,DB00495,Zidovudine
,18052620,retention time,"Chromatography was performed on a C-18 analytical columns and the retention time ranged from 6.8 to 8.0 min for stavudine, 7.5 to 9.0 min for lamivudine, 11.2 to 11.9 min for zidovudine and indinavir.","Validation of high-performance liquid chromatography methods for determination of zidovudine, stavudine, lamivudine and indinavir in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18052620/),min,7.5 to 9.0,236255,DB00495,Zidovudine
,18052620,retention time,"Chromatography was performed on a C-18 analytical columns and the retention time ranged from 6.8 to 8.0 min for stavudine, 7.5 to 9.0 min for lamivudine, 11.2 to 11.9 min for zidovudine and indinavir.","Validation of high-performance liquid chromatography methods for determination of zidovudine, stavudine, lamivudine and indinavir in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18052620/),min,11.2 to 11.9,236256,DB00495,Zidovudine
,18052620,curve,"Analytical curve ranged from 10-1600 ng/ml for stavudine, 50-3200 ng/ml for lamivudine, 0.05-5.0 microg/ml for zidovudine and 0.1-10.0 microg/ml for indinavir.","Validation of high-performance liquid chromatography methods for determination of zidovudine, stavudine, lamivudine and indinavir in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18052620/),[ng] / [ml],10-1600,236257,DB00495,Zidovudine
,18052620,curve,"Analytical curve ranged from 10-1600 ng/ml for stavudine, 50-3200 ng/ml for lamivudine, 0.05-5.0 microg/ml for zidovudine and 0.1-10.0 microg/ml for indinavir.","Validation of high-performance liquid chromatography methods for determination of zidovudine, stavudine, lamivudine and indinavir in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18052620/),[ng] / [ml],50-3200,236258,DB00495,Zidovudine
,18052620,curve,"Analytical curve ranged from 10-1600 ng/ml for stavudine, 50-3200 ng/ml for lamivudine, 0.05-5.0 microg/ml for zidovudine and 0.1-10.0 microg/ml for indinavir.","Validation of high-performance liquid chromatography methods for determination of zidovudine, stavudine, lamivudine and indinavir in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18052620/),[μg] / [ml],0.05-5.0,236259,DB00495,Zidovudine
,18052620,curve,"Analytical curve ranged from 10-1600 ng/ml for stavudine, 50-3200 ng/ml for lamivudine, 0.05-5.0 microg/ml for zidovudine and 0.1-10.0 microg/ml for indinavir.","Validation of high-performance liquid chromatography methods for determination of zidovudine, stavudine, lamivudine and indinavir in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18052620/),[μg] / [ml],0.1-10.0,236260,DB00495,Zidovudine
higher,18052620,Extraction recoveries,Extraction recoveries are higher than 89% for all formulations.,"Validation of high-performance liquid chromatography methods for determination of zidovudine, stavudine, lamivudine and indinavir in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18052620/),%,89,236261,DB00495,Zidovudine
,8722550,Cmax,Zidovudine was rapidly absorbed with large peak variation (Cmax: 1.10 +/- 0.43 mg/L).,Zidovudine absorption and small intestinal function in HIV seropositive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722550/),[mg] / [l],1.10,238907,DB00495,Zidovudine
,8722550,AUC,Mean diarrhoea AUC (mg/L.h) was 1.13 +/- 0.30 and 1.07 +/- 0.36 in non-diarrhoeal patients.,Zidovudine absorption and small intestinal function in HIV seropositive patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722550/),[mg] / [h·l],1.13,238908,DB00495,Zidovudine
,8722550,AUC,Mean diarrhoea AUC (mg/L.h) was 1.13 +/- 0.30 and 1.07 +/- 0.36 in non-diarrhoeal patients.,Zidovudine absorption and small intestinal function in HIV seropositive patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722550/),[mg] / [h·l],1.07,238909,DB00495,Zidovudine
,8021765,AUC,The mean AUC for zidovudine ranged from 4.8 mumol.,Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8021765/),μM,4.8,239546,DB00495,Zidovudine
,8021765,AUC,The mean AUC for didanosine ranged from 2.8 mumol.,Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8021765/),μM,2.8,239547,DB00495,Zidovudine
,8680886,rates of CD4 change (ACD4),"Among ZDV-treated patients, the median rates of CD4 change (ACD4) in the initial 16 weeks were - 121 and - 120 cells per year in the placebo and acemannan groups, respectively ( p = 0.45), ACD4 from week 16 to 48 was 0 and - 61 cells per year in the acemannan and placebo groups (p = .11), respectively.",Double-blind placebo-controlled pilot trial of acemannan in advanced human immunodeficiency virus disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8680886/),[cells] / [year],121,241678,DB00495,Zidovudine
,8680886,ACD4,"Among ZDV-treated patients, the median rates of CD4 change (ACD4) in the initial 16 weeks were - 121 and - 120 cells per year in the placebo and acemannan groups, respectively ( p = 0.45), ACD4 from week 16 to 48 was 0 and - 61 cells per year in the acemannan and placebo groups (p = .11), respectively.",Double-blind placebo-controlled pilot trial of acemannan in advanced human immunodeficiency virus disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8680886/),[cells] / [year],0,241679,DB00495,Zidovudine
,8680886,ACD4,"Among ZDV-treated patients, the median rates of CD4 change (ACD4) in the initial 16 weeks were - 121 and - 120 cells per year in the placebo and acemannan groups, respectively ( p = 0.45), ACD4 from week 16 to 48 was 0 and - 61 cells per year in the acemannan and placebo groups (p = .11), respectively.",Double-blind placebo-controlled pilot trial of acemannan in advanced human immunodeficiency virus disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8680886/),[cells] / [year],-,241680,DB00495,Zidovudine
,8680886,ACD4,"Among ZDV-treated patients, the median rates of CD4 change (ACD4) in the initial 16 weeks were - 121 and - 120 cells per year in the placebo and acemannan groups, respectively ( p = 0.45), ACD4 from week 16 to 48 was 0 and - 61 cells per year in the acemannan and placebo groups (p = .11), respectively.",Double-blind placebo-controlled pilot trial of acemannan in advanced human immunodeficiency virus disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8680886/),[cells] / [year],61,241681,DB00495,Zidovudine
,18611830,AUC,"The AUC for ZDV-TP was 0.53 and 0.52 pmol x h/10(6) PBMC in the absence and presence of D4T, respectively.",Pharmacokinetics of intracellular zidovudine and its phosphorylated anabolites in the absence and presence of stavudine using an in vitro human peripheral blood mononuclear cell (PBMC) model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611830/),[h·pM] / [10(6],0.53,241836,DB00495,Zidovudine
,18611830,AUC,"The AUC for ZDV-TP was 0.53 and 0.52 pmol x h/10(6) PBMC in the absence and presence of D4T, respectively.",Pharmacokinetics of intracellular zidovudine and its phosphorylated anabolites in the absence and presence of stavudine using an in vitro human peripheral blood mononuclear cell (PBMC) model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611830/),[h·pM] / [10(6],0.52,241837,DB00495,Zidovudine
,18611830,AUC,The AUC for ZDV monophosphate was 157.45 and 172.44 pmol x h/10(6) PBMC pre and post D4T.,Pharmacokinetics of intracellular zidovudine and its phosphorylated anabolites in the absence and presence of stavudine using an in vitro human peripheral blood mononuclear cell (PBMC) model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611830/),[h·pM] / [10(6],157.45,241838,DB00495,Zidovudine
,18611830,AUC,The AUC for ZDV monophosphate was 157.45 and 172.44 pmol x h/10(6) PBMC pre and post D4T.,Pharmacokinetics of intracellular zidovudine and its phosphorylated anabolites in the absence and presence of stavudine using an in vitro human peripheral blood mononuclear cell (PBMC) model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611830/),[h·pM] / [10(6],172.44,241839,DB00495,Zidovudine
above,19118970,relative,The relative and absolute recovery was above 72% and no matrix effects were observed for all the analytes.,Quantitative determination of zidovudine diaryl phosphate triester pro-drugs in rat plasma by high-performance liquid chromatography-electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19118970/),%,72,244771,DB00495,Zidovudine
above,19118970,absolute recovery,The relative and absolute recovery was above 72% and no matrix effects were observed for all the analytes.,Quantitative determination of zidovudine diaryl phosphate triester pro-drugs in rat plasma by high-performance liquid chromatography-electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19118970/),%,72,244772,DB00495,Zidovudine
,11959574,intracellular half-life,"DPC 817 combines this favorable resistance profile with rapid uptake and conversion to the active metabolite DPC 817-triphosphate, which has an intracellular half-life of 13 to 17 h.",DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11959574/),h,13 to 17,245697,DB00495,Zidovudine
less,2328158,bioavailability,"However, bioavailability of both nucleosides was markedly lower (less than 50%) after 200 mg/kg, possibly indicating the involvement of a saturable absorption mechanism.","3'-Azido-2',3'-dideoxyuridine (AzddU): comparative pharmacokinetics with 3'-azido-3'-deoxythymidine (AZT) in monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328158/),%,50,246185,DB00495,Zidovudine
,2328158,concentration ratios in CSF:serum,AzddU and AZT penetrated the cerebrospinal fluid (CSF) with concentration ratios in CSF:serum ranging from 0.05 to 0.25 one hour after drug administration.,"3'-Azido-2',3'-dideoxyuridine (AzddU): comparative pharmacokinetics with 3'-azido-3'-deoxythymidine (AZT) in monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328158/),,0.05 to 0.25,246186,DB00495,Zidovudine
,22155910,area under the curve (AUC),"With the FDC tablet, the geometric mean (90% CI) area under the curve (AUC) for ZDV, 3TC and NVP was 1.58 (1.49-1.68), 7.78 (7.38-8.19) and 68.88 (62.13-76.36) μg•h/ml, respectively.",Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155910/),[h·μg] / [ml],1.58,247164,DB00495,Zidovudine
,22155910,area under the curve (AUC),"With the FDC tablet, the geometric mean (90% CI) area under the curve (AUC) for ZDV, 3TC and NVP was 1.58 (1.49-1.68), 7.78 (7.38-8.19) and 68.88 (62.13-76.36) μg•h/ml, respectively.",Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155910/),[h·μg] / [ml],7.78,247165,DB00495,Zidovudine
,22155910,area under the curve (AUC),"With the FDC tablet, the geometric mean (90% CI) area under the curve (AUC) for ZDV, 3TC and NVP was 1.58 (1.49-1.68), 7.78 (7.38-8.19) and 68.88 (62.13-76.36) μg•h/ml, respectively.",Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155910/),[h·μg] / [ml],68.88,247166,DB00495,Zidovudine
,22155910,AUC,"While receiving the tablet, NVP AUC in children with CYP2B 516 GG (45%), GT (45%) and TT (10%) genotypes were 67.0, 74.5 and 106.4 μg•h/ml, respectively (P=0.04).",Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155910/),[h·μg] / [ml],45,247167,DB00495,Zidovudine
,22155910,AUC,"While receiving the tablet, NVP AUC in children with CYP2B 516 GG (45%), GT (45%) and TT (10%) genotypes were 67.0, 74.5 and 106.4 μg•h/ml, respectively (P=0.04).",Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155910/),[h·μg] / [ml],10,247168,DB00495,Zidovudine
,22155910,AUC,"While receiving the tablet, NVP AUC in children with CYP2B 516 GG (45%), GT (45%) and TT (10%) genotypes were 67.0, 74.5 and 106.4 μg•h/ml, respectively (P=0.04).",Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155910/),[h·μg] / [ml],67.0,247169,DB00495,Zidovudine
,22155910,AUC,"While receiving the tablet, NVP AUC in children with CYP2B 516 GG (45%), GT (45%) and TT (10%) genotypes were 67.0, 74.5 and 106.4 μg•h/ml, respectively (P=0.04).",Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155910/),[h·μg] / [ml],74.5,247170,DB00495,Zidovudine
,22155910,AUC,"While receiving the tablet, NVP AUC in children with CYP2B 516 GG (45%), GT (45%) and TT (10%) genotypes were 67.0, 74.5 and 106.4 μg•h/ml, respectively (P=0.04).",Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155910/),[h·μg] / [ml],106.4,247171,DB00495,Zidovudine
,8632406,K(i),"The (5R,6R)- and (5S,6S)-5-X-6-OMe-5,6-dihydro-AZT diastereomers demonstrated a high affinity (K(i) = 0.2-0.5 mM) for the transporter relative to AZT (K(i) = 1.3 mM), with the exception of (5S,6R)-5-chloro-6-methoxy-5,6-dihydro-3'-azido-3'-deoxythymidine (CMAZT) which has a K(i) value larger than 1.5 mM. [2-(14)C]-Labeled (5R,6R)- and (5S,6S)-5-bromo-6-methoxy(or ethoxy)- 5,6-dihydro-3'-azido-3'-deoxythymidines were synthesized by the regiospecific addition of methyl hypobromite or ethyl hypobromite to the 5,6-olefinic bond of [2-(14)C]-AZT in high radiochemical yield [(5R,6R)-BMAZT, 48%, and (5S,6S)-BMAZT, 33%; (5R,6R)-BEAZT, 61%, and (5S,6S)-BEAZT, 15%), high radiochemical purity (>98%), and high specific activity (56mCi/mmol)].","In vivo biodistribution, pharmacokinetic parameters, and brain uptake of 5-halo-y-methoxy(or ethoxy)-5,6-dihydro-3'-azido-3'-deoxythymidine diastereomers as potential prodrugs of 3'-azido-3'-deoxythymidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632406/),mM,0.2-0.5,247987,DB00495,Zidovudine
,8632406,K(i),"The (5R,6R)- and (5S,6S)-5-X-6-OMe-5,6-dihydro-AZT diastereomers demonstrated a high affinity (K(i) = 0.2-0.5 mM) for the transporter relative to AZT (K(i) = 1.3 mM), with the exception of (5S,6R)-5-chloro-6-methoxy-5,6-dihydro-3'-azido-3'-deoxythymidine (CMAZT) which has a K(i) value larger than 1.5 mM. [2-(14)C]-Labeled (5R,6R)- and (5S,6S)-5-bromo-6-methoxy(or ethoxy)- 5,6-dihydro-3'-azido-3'-deoxythymidines were synthesized by the regiospecific addition of methyl hypobromite or ethyl hypobromite to the 5,6-olefinic bond of [2-(14)C]-AZT in high radiochemical yield [(5R,6R)-BMAZT, 48%, and (5S,6S)-BMAZT, 33%; (5R,6R)-BEAZT, 61%, and (5S,6S)-BEAZT, 15%), high radiochemical purity (>98%), and high specific activity (56mCi/mmol)].","In vivo biodistribution, pharmacokinetic parameters, and brain uptake of 5-halo-y-methoxy(or ethoxy)-5,6-dihydro-3'-azido-3'-deoxythymidine diastereomers as potential prodrugs of 3'-azido-3'-deoxythymidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632406/),mM,1.3,247988,DB00495,Zidovudine
larger,8632406,K(i),"The (5R,6R)- and (5S,6S)-5-X-6-OMe-5,6-dihydro-AZT diastereomers demonstrated a high affinity (K(i) = 0.2-0.5 mM) for the transporter relative to AZT (K(i) = 1.3 mM), with the exception of (5S,6R)-5-chloro-6-methoxy-5,6-dihydro-3'-azido-3'-deoxythymidine (CMAZT) which has a K(i) value larger than 1.5 mM. [2-(14)C]-Labeled (5R,6R)- and (5S,6S)-5-bromo-6-methoxy(or ethoxy)- 5,6-dihydro-3'-azido-3'-deoxythymidines were synthesized by the regiospecific addition of methyl hypobromite or ethyl hypobromite to the 5,6-olefinic bond of [2-(14)C]-AZT in high radiochemical yield [(5R,6R)-BMAZT, 48%, and (5S,6S)-BMAZT, 33%; (5R,6R)-BEAZT, 61%, and (5S,6S)-BEAZT, 15%), high radiochemical purity (>98%), and high specific activity (56mCi/mmol)].","In vivo biodistribution, pharmacokinetic parameters, and brain uptake of 5-halo-y-methoxy(or ethoxy)-5,6-dihydro-3'-azido-3'-deoxythymidine diastereomers as potential prodrugs of 3'-azido-3'-deoxythymidine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8632406/),mM,1.5,247989,DB00495,Zidovudine
,8165194,steady-state CSF/plasma concentration ratios,"When ZDV and ddI were administered alone, the steady-state CSF/plasma concentration ratios were significantly different from unity (ZDV, 0.20 +/- 0.08; ddI, 0.09 +/- 0.04) and were independent of the plasma concentration (P > 0.05).","Efflux of zidovudine and 2',3'-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165194/),,unity,249699,DB00495,Zidovudine
,8165194,steady-state CSF/plasma concentration ratios,"When ZDV and ddI were administered alone, the steady-state CSF/plasma concentration ratios were significantly different from unity (ZDV, 0.20 +/- 0.08; ddI, 0.09 +/- 0.04) and were independent of the plasma concentration (P > 0.05).","Efflux of zidovudine and 2',3'-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165194/),,0.20,249700,DB00495,Zidovudine
,8165194,steady-state CSF/plasma concentration ratios,"When ZDV and ddI were administered alone, the steady-state CSF/plasma concentration ratios were significantly different from unity (ZDV, 0.20 +/- 0.08; ddI, 0.09 +/- 0.04) and were independent of the plasma concentration (P > 0.05).","Efflux of zidovudine and 2',3'-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165194/),,0.09,249701,DB00495,Zidovudine
,8165194,CSF/plasma concentration ratio,"In contrast, the CSF/plasma concentration ratio of antipyrine (0.82 +/- 0.19) was close but significantly smaller than unity (P > 0.05).","Efflux of zidovudine and 2',3'-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165194/),,0.82,249702,DB00495,Zidovudine
,31034939,UBTs,"Reciprocal UBTs for the different colistin concentrations obtained in urine ranged from 1-128 and 0-2 for colistin-susceptible and colistin-resistant isolates, respectively.",Urinary bactericidal activity of colistin and azidothymidine combinations against mcr-1-positive colistin-resistant Escherichia coli. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31034939/),,1-128,255077,DB00495,Zidovudine
,31034939,UBTs,"Reciprocal UBTs for the different colistin concentrations obtained in urine ranged from 1-128 and 0-2 for colistin-susceptible and colistin-resistant isolates, respectively.",Urinary bactericidal activity of colistin and azidothymidine combinations against mcr-1-positive colistin-resistant Escherichia coli. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31034939/),,0-2,255078,DB00495,Zidovudine
,8931785,Cmax,"In patients with SID, Cmax ZDV was reduced (6.39 +/- 3.39 versus 11.51 +/- 5.01 mumol/l; P < 0.05) and Tmax ZDV prolonged (0.81 +/- 0.51 versus 0.40 +/- 0.14 h; P < 0.05) but AUC0-6 h ZDV was no different from the non-SID group (8.03 +/- 2.73 versus 14.56 +/- 9.0 mumol/l-1xh; P = 0.06).",Impaired absorption of zidovudine in patients with AIDS-related small intestinal disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8931785/),[μM] / [l],6.39,255822,DB00495,Zidovudine
,8931785,Cmax,"In patients with SID, Cmax ZDV was reduced (6.39 +/- 3.39 versus 11.51 +/- 5.01 mumol/l; P < 0.05) and Tmax ZDV prolonged (0.81 +/- 0.51 versus 0.40 +/- 0.14 h; P < 0.05) but AUC0-6 h ZDV was no different from the non-SID group (8.03 +/- 2.73 versus 14.56 +/- 9.0 mumol/l-1xh; P = 0.06).",Impaired absorption of zidovudine in patients with AIDS-related small intestinal disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8931785/),[μM] / [l],11.51,255823,DB00495,Zidovudine
,8931785,Tmax,"In patients with SID, Cmax ZDV was reduced (6.39 +/- 3.39 versus 11.51 +/- 5.01 mumol/l; P < 0.05) and Tmax ZDV prolonged (0.81 +/- 0.51 versus 0.40 +/- 0.14 h; P < 0.05) but AUC0-6 h ZDV was no different from the non-SID group (8.03 +/- 2.73 versus 14.56 +/- 9.0 mumol/l-1xh; P = 0.06).",Impaired absorption of zidovudine in patients with AIDS-related small intestinal disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8931785/),h,0.81,255824,DB00495,Zidovudine
,8931785,Tmax,"In patients with SID, Cmax ZDV was reduced (6.39 +/- 3.39 versus 11.51 +/- 5.01 mumol/l; P < 0.05) and Tmax ZDV prolonged (0.81 +/- 0.51 versus 0.40 +/- 0.14 h; P < 0.05) but AUC0-6 h ZDV was no different from the non-SID group (8.03 +/- 2.73 versus 14.56 +/- 9.0 mumol/l-1xh; P = 0.06).",Impaired absorption of zidovudine in patients with AIDS-related small intestinal disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8931785/),h,0.40,255825,DB00495,Zidovudine
,8931785,AUC0-6 h,"In patients with SID, Cmax ZDV was reduced (6.39 +/- 3.39 versus 11.51 +/- 5.01 mumol/l; P < 0.05) and Tmax ZDV prolonged (0.81 +/- 0.51 versus 0.40 +/- 0.14 h; P < 0.05) but AUC0-6 h ZDV was no different from the non-SID group (8.03 +/- 2.73 versus 14.56 +/- 9.0 mumol/l-1xh; P = 0.06).",Impaired absorption of zidovudine in patients with AIDS-related small intestinal disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8931785/),[μM] / [l],8.03,255826,DB00495,Zidovudine
,8931785,AUC0-6 h,"In patients with SID, Cmax ZDV was reduced (6.39 +/- 3.39 versus 11.51 +/- 5.01 mumol/l; P < 0.05) and Tmax ZDV prolonged (0.81 +/- 0.51 versus 0.40 +/- 0.14 h; P < 0.05) but AUC0-6 h ZDV was no different from the non-SID group (8.03 +/- 2.73 versus 14.56 +/- 9.0 mumol/l-1xh; P = 0.06).",Impaired absorption of zidovudine in patients with AIDS-related small intestinal disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8931785/),[μM] / [l],14.56,255827,DB00495,Zidovudine
,8931785,t 1/2,"There were no differences in t 1/2 ZDV (1.22 +/- 0.20 versus 1.13 +/- 0.30 h) or CL0 ZDV (3017 +/- 1158 versus 1700 +/- 889 ml/min; P > 0.05) between SID and non-SID groups, respectively, and GZDV values were comparable between the two groups.",Impaired absorption of zidovudine in patients with AIDS-related small intestinal disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8931785/),h,1.22,255828,DB00495,Zidovudine
,8931785,t 1/2,"There were no differences in t 1/2 ZDV (1.22 +/- 0.20 versus 1.13 +/- 0.30 h) or CL0 ZDV (3017 +/- 1158 versus 1700 +/- 889 ml/min; P > 0.05) between SID and non-SID groups, respectively, and GZDV values were comparable between the two groups.",Impaired absorption of zidovudine in patients with AIDS-related small intestinal disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8931785/),h,1.13,255829,DB00495,Zidovudine
,8931785,CL0,"There were no differences in t 1/2 ZDV (1.22 +/- 0.20 versus 1.13 +/- 0.30 h) or CL0 ZDV (3017 +/- 1158 versus 1700 +/- 889 ml/min; P > 0.05) between SID and non-SID groups, respectively, and GZDV values were comparable between the two groups.",Impaired absorption of zidovudine in patients with AIDS-related small intestinal disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8931785/),[ml] / [min],3017,255830,DB00495,Zidovudine
,8931785,CL0,"There were no differences in t 1/2 ZDV (1.22 +/- 0.20 versus 1.13 +/- 0.30 h) or CL0 ZDV (3017 +/- 1158 versus 1700 +/- 889 ml/min; P > 0.05) between SID and non-SID groups, respectively, and GZDV values were comparable between the two groups.",Impaired absorption of zidovudine in patients with AIDS-related small intestinal disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8931785/),[ml] / [min],1700,255831,DB00495,Zidovudine
,23183881,ABC levels,Median ABC levels in breast milk were 85% of those in plasma (0.057 μg/ml versus 0.067 μg/ml).,"Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23183881/),[μg] / [ml],0.057,256402,DB00495,Zidovudine
,23183881,ABC levels,Median ABC levels in breast milk were 85% of those in plasma (0.057 μg/ml versus 0.067 μg/ml).,"Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23183881/),[μg] / [ml],0.067,256403,DB00495,Zidovudine
,8726001,area under the 24-h concentration-time curve,"Population pharmacokinetic analysis assuming a one-compartment model yielded the following estimates: area under the 24-h concentration-time curve, 42.7 +/- 12.3 micrograms.h/ml; halflife, 139 +/- 34 h; clearance, 1.28 +/- 0.41 liters/h; volume of distribution, 246 +/- 641; and absorption rate constant, 1.5 +/- 1.3 liters/h.",Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726001/),[h·μg] / [ml],42.7,256619,DB00495,Zidovudine
,8726001,halflife,"Population pharmacokinetic analysis assuming a one-compartment model yielded the following estimates: area under the 24-h concentration-time curve, 42.7 +/- 12.3 micrograms.h/ml; halflife, 139 +/- 34 h; clearance, 1.28 +/- 0.41 liters/h; volume of distribution, 246 +/- 641; and absorption rate constant, 1.5 +/- 1.3 liters/h.",Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726001/),h,139,256620,DB00495,Zidovudine
,8726001,clearance,"Population pharmacokinetic analysis assuming a one-compartment model yielded the following estimates: area under the 24-h concentration-time curve, 42.7 +/- 12.3 micrograms.h/ml; halflife, 139 +/- 34 h; clearance, 1.28 +/- 0.41 liters/h; volume of distribution, 246 +/- 641; and absorption rate constant, 1.5 +/- 1.3 liters/h.",Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726001/),[l] / [h],1.28,256621,DB00495,Zidovudine
,8726001,volume of distribution,"Population pharmacokinetic analysis assuming a one-compartment model yielded the following estimates: area under the 24-h concentration-time curve, 42.7 +/- 12.3 micrograms.h/ml; halflife, 139 +/- 34 h; clearance, 1.28 +/- 0.41 liters/h; volume of distribution, 246 +/- 641; and absorption rate constant, 1.5 +/- 1.3 liters/h.",Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726001/),,246,256622,DB00495,Zidovudine
,8726001,absorption rate constant,"Population pharmacokinetic analysis assuming a one-compartment model yielded the following estimates: area under the 24-h concentration-time curve, 42.7 +/- 12.3 micrograms.h/ml; halflife, 139 +/- 34 h; clearance, 1.28 +/- 0.41 liters/h; volume of distribution, 246 +/- 641; and absorption rate constant, 1.5 +/- 1.3 liters/h.",Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726001/),[l] / [h],1.5,256623,DB00495,Zidovudine
,14624060,peak concentrations,"The mean peak concentrations (microg/ml) were 0.69 for abacavir and 0.57 for zidovudine; the mean peak/trough concentrations (microg/ml) were 2.07/1.32 for efavirenz, 2.43/2.23 for nevirapine, 5.48/1.08 for indinavir, 4.69/3.51 for lopinavir, and 3.54/1.45 for nelfinavir.","Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624060/),[μg] / [ml],0.69,257030,DB00495,Zidovudine
,14624060,peak concentrations,"The mean peak concentrations (microg/ml) were 0.69 for abacavir and 0.57 for zidovudine; the mean peak/trough concentrations (microg/ml) were 2.07/1.32 for efavirenz, 2.43/2.23 for nevirapine, 5.48/1.08 for indinavir, 4.69/3.51 for lopinavir, and 3.54/1.45 for nelfinavir.","Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624060/),[μg] / [ml],0.57,257031,DB00495,Zidovudine
,14624060,peak/trough concentrations,"The mean peak concentrations (microg/ml) were 0.69 for abacavir and 0.57 for zidovudine; the mean peak/trough concentrations (microg/ml) were 2.07/1.32 for efavirenz, 2.43/2.23 for nevirapine, 5.48/1.08 for indinavir, 4.69/3.51 for lopinavir, and 3.54/1.45 for nelfinavir.","Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624060/),[μg] / [ml],2.07,257032,DB00495,Zidovudine
,14624060,peak/trough concentrations,"The mean peak concentrations (microg/ml) were 0.69 for abacavir and 0.57 for zidovudine; the mean peak/trough concentrations (microg/ml) were 2.07/1.32 for efavirenz, 2.43/2.23 for nevirapine, 5.48/1.08 for indinavir, 4.69/3.51 for lopinavir, and 3.54/1.45 for nelfinavir.","Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624060/),[μg] / [ml],1.32,257033,DB00495,Zidovudine
,14624060,peak/trough concentrations,"The mean peak concentrations (microg/ml) were 0.69 for abacavir and 0.57 for zidovudine; the mean peak/trough concentrations (microg/ml) were 2.07/1.32 for efavirenz, 2.43/2.23 for nevirapine, 5.48/1.08 for indinavir, 4.69/3.51 for lopinavir, and 3.54/1.45 for nelfinavir.","Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624060/),-1,2.43,257034,DB00495,Zidovudine
,14624060,peak/trough concentrations,"The mean peak concentrations (microg/ml) were 0.69 for abacavir and 0.57 for zidovudine; the mean peak/trough concentrations (microg/ml) were 2.07/1.32 for efavirenz, 2.43/2.23 for nevirapine, 5.48/1.08 for indinavir, 4.69/3.51 for lopinavir, and 3.54/1.45 for nelfinavir.","Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624060/),-1,2.23,257035,DB00495,Zidovudine
,14624060,peak/trough concentrations,"The mean peak concentrations (microg/ml) were 0.69 for abacavir and 0.57 for zidovudine; the mean peak/trough concentrations (microg/ml) were 2.07/1.32 for efavirenz, 2.43/2.23 for nevirapine, 5.48/1.08 for indinavir, 4.69/3.51 for lopinavir, and 3.54/1.45 for nelfinavir.","Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624060/),-1,5.48,257036,DB00495,Zidovudine
,14624060,peak/trough concentrations,"The mean peak concentrations (microg/ml) were 0.69 for abacavir and 0.57 for zidovudine; the mean peak/trough concentrations (microg/ml) were 2.07/1.32 for efavirenz, 2.43/2.23 for nevirapine, 5.48/1.08 for indinavir, 4.69/3.51 for lopinavir, and 3.54/1.45 for nelfinavir.","Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624060/),-1,1.08,257037,DB00495,Zidovudine
,14624060,peak/trough concentrations,"The mean peak concentrations (microg/ml) were 0.69 for abacavir and 0.57 for zidovudine; the mean peak/trough concentrations (microg/ml) were 2.07/1.32 for efavirenz, 2.43/2.23 for nevirapine, 5.48/1.08 for indinavir, 4.69/3.51 for lopinavir, and 3.54/1.45 for nelfinavir.","Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624060/),-1,4.69,257038,DB00495,Zidovudine
,14624060,peak/trough concentrations,"The mean peak concentrations (microg/ml) were 0.69 for abacavir and 0.57 for zidovudine; the mean peak/trough concentrations (microg/ml) were 2.07/1.32 for efavirenz, 2.43/2.23 for nevirapine, 5.48/1.08 for indinavir, 4.69/3.51 for lopinavir, and 3.54/1.45 for nelfinavir.","Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624060/),-1,3.51,257039,DB00495,Zidovudine
,14624060,peak/trough concentrations,"The mean peak concentrations (microg/ml) were 0.69 for abacavir and 0.57 for zidovudine; the mean peak/trough concentrations (microg/ml) were 2.07/1.32 for efavirenz, 2.43/2.23 for nevirapine, 5.48/1.08 for indinavir, 4.69/3.51 for lopinavir, and 3.54/1.45 for nelfinavir.","Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624060/),-1,3.54,257040,DB00495,Zidovudine
,17949768,maximum serum concentrations (Cmax),"Average maximum serum concentrations (Cmax) for AZT and 3TC were 2.35 and 2.65 microg/ml, respectively, and were observed at 0.83 h (Tmax).",Metabolism and pharmacokinetics of the combination Zidovudine plus Lamivudine in the adult Erythrocebus patas monkey determined by liquid chromatography-tandem mass spectrometric analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17949768/),[μg] / [ml],2.35,257537,DB00495,Zidovudine
,17949768,maximum serum concentrations (Cmax),"Average maximum serum concentrations (Cmax) for AZT and 3TC were 2.35 and 2.65 microg/ml, respectively, and were observed at 0.83 h (Tmax).",Metabolism and pharmacokinetics of the combination Zidovudine plus Lamivudine in the adult Erythrocebus patas monkey determined by liquid chromatography-tandem mass spectrometric analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17949768/),[μg] / [ml],2.65,257538,DB00495,Zidovudine
,17949768,Tmax,"Average maximum serum concentrations (Cmax) for AZT and 3TC were 2.35 and 2.65 microg/ml, respectively, and were observed at 0.83 h (Tmax).",Metabolism and pharmacokinetics of the combination Zidovudine plus Lamivudine in the adult Erythrocebus patas monkey determined by liquid chromatography-tandem mass spectrometric analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17949768/),h,0.83,257539,DB00495,Zidovudine
,17949768,Cmax,"Cmax was 13.34 microg/ml for the AZT-glucuronide (AZT-G) and was 0.023 microg/ml for the potentially toxic minor metabolite 3'-amino-3'-deoxythymidine (AMT), both occurring at about 1 h after dosing.",Metabolism and pharmacokinetics of the combination Zidovudine plus Lamivudine in the adult Erythrocebus patas monkey determined by liquid chromatography-tandem mass spectrometric analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17949768/),[μg] / [ml],13.34,257540,DB00495,Zidovudine
,17949768,Cmax,"Cmax was 13.34 microg/ml for the AZT-glucuronide (AZT-G) and was 0.023 microg/ml for the potentially toxic minor metabolite 3'-amino-3'-deoxythymidine (AMT), both occurring at about 1 h after dosing.",Metabolism and pharmacokinetics of the combination Zidovudine plus Lamivudine in the adult Erythrocebus patas monkey determined by liquid chromatography-tandem mass spectrometric analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17949768/),[μg] / [ml],0.023,257541,DB00495,Zidovudine
,17949768,elimination half-times,"Similar elimination half-times, 0.70 and 0.68 h(-1), were found for AZT and AZT-G, respectively, while 3TC was eliminated about half as fast (0.33 h(-1)) resulting in AUC(0-infinity) values of 6.97 microg/ml h for 3TC, 2.99 microg/ml h for AZT, 20.5 microg/ml h for AZT-G and 0.002 for AMT 6.97 microg/ml h.",Metabolism and pharmacokinetics of the combination Zidovudine plus Lamivudine in the adult Erythrocebus patas monkey determined by liquid chromatography-tandem mass spectrometric analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17949768/),1/[h],0.70,257542,DB00495,Zidovudine
,17949768,elimination half-times,"Similar elimination half-times, 0.70 and 0.68 h(-1), were found for AZT and AZT-G, respectively, while 3TC was eliminated about half as fast (0.33 h(-1)) resulting in AUC(0-infinity) values of 6.97 microg/ml h for 3TC, 2.99 microg/ml h for AZT, 20.5 microg/ml h for AZT-G and 0.002 for AMT 6.97 microg/ml h.",Metabolism and pharmacokinetics of the combination Zidovudine plus Lamivudine in the adult Erythrocebus patas monkey determined by liquid chromatography-tandem mass spectrometric analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17949768/),1/[h],0.68,257543,DB00495,Zidovudine
,17949768,AUC(0-infinity),"Similar elimination half-times, 0.70 and 0.68 h(-1), were found for AZT and AZT-G, respectively, while 3TC was eliminated about half as fast (0.33 h(-1)) resulting in AUC(0-infinity) values of 6.97 microg/ml h for 3TC, 2.99 microg/ml h for AZT, 20.5 microg/ml h for AZT-G and 0.002 for AMT 6.97 microg/ml h.",Metabolism and pharmacokinetics of the combination Zidovudine plus Lamivudine in the adult Erythrocebus patas monkey determined by liquid chromatography-tandem mass spectrometric analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17949768/),[μg] / [h·ml],6.97,257544,DB00495,Zidovudine
,17949768,AUC(0-infinity),"Similar elimination half-times, 0.70 and 0.68 h(-1), were found for AZT and AZT-G, respectively, while 3TC was eliminated about half as fast (0.33 h(-1)) resulting in AUC(0-infinity) values of 6.97 microg/ml h for 3TC, 2.99 microg/ml h for AZT, 20.5 microg/ml h for AZT-G and 0.002 for AMT 6.97 microg/ml h.",Metabolism and pharmacokinetics of the combination Zidovudine plus Lamivudine in the adult Erythrocebus patas monkey determined by liquid chromatography-tandem mass spectrometric analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17949768/),[μg] / [h·ml],2.99,257545,DB00495,Zidovudine
,17949768,AUC(0-infinity),"Similar elimination half-times, 0.70 and 0.68 h(-1), were found for AZT and AZT-G, respectively, while 3TC was eliminated about half as fast (0.33 h(-1)) resulting in AUC(0-infinity) values of 6.97 microg/ml h for 3TC, 2.99 microg/ml h for AZT, 20.5 microg/ml h for AZT-G and 0.002 for AMT 6.97 microg/ml h.",Metabolism and pharmacokinetics of the combination Zidovudine plus Lamivudine in the adult Erythrocebus patas monkey determined by liquid chromatography-tandem mass spectrometric analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17949768/),[μg] / [h·ml],20.5,257546,DB00495,Zidovudine
,17949768,AUC(0-infinity),"Similar elimination half-times, 0.70 and 0.68 h(-1), were found for AZT and AZT-G, respectively, while 3TC was eliminated about half as fast (0.33 h(-1)) resulting in AUC(0-infinity) values of 6.97 microg/ml h for 3TC, 2.99 microg/ml h for AZT, 20.5 microg/ml h for AZT-G and 0.002 for AMT 6.97 microg/ml h.",Metabolism and pharmacokinetics of the combination Zidovudine plus Lamivudine in the adult Erythrocebus patas monkey determined by liquid chromatography-tandem mass spectrometric analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17949768/),[μg] / [h·ml],0.002,257547,DB00495,Zidovudine
,29339228,plasmatic half-life (t1/2,"In particular, its short plasmatic half-life (t1/2 ~ 1 h) is related to its low bound fraction to whole plasmatic proteins and in particular to human serum albumin (HSA).",Stability and plasmatic protein binding of novel zidovudine prodrugs: Targeting site ii of human serum albumin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29339228/),h,1,259351,DB00495,Zidovudine
,29339228,t1/2,"Prodrugs 4-6 were found to be relatively stable at pH 7.4 (t1/2 between 4.1 and 57.8 h), while also demonstrated adequate stabilities in human plasma at 37 °C (t1/2 between 1.0 and 2.1 h).",Stability and plasmatic protein binding of novel zidovudine prodrugs: Targeting site ii of human serum albumin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29339228/),h,4.1 and 57.8,259352,DB00495,Zidovudine
,29339228,t1/2,"Prodrugs 4-6 were found to be relatively stable at pH 7.4 (t1/2 between 4.1 and 57.8 h), while also demonstrated adequate stabilities in human plasma at 37 °C (t1/2 between 1.0 and 2.1 h).",Stability and plasmatic protein binding of novel zidovudine prodrugs: Targeting site ii of human serum albumin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29339228/),h,1.0 and 2.1,259353,DB00495,Zidovudine
,17694300,oral volume of distribution (V/F),"Mean parameters [interpatient variability in coefficient of variation (CV%)] of LMV, STV and ZDV were: oral volume of distribution (V/F) 145 l (52%), 24 l (81%) and 248 l (80%), oral clearance (Cl/F) 32 l/h, 16 l/h (74%) and 124 l/h (51%), respectively.","Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694300/),l,145,259435,DB00495,Zidovudine
,17694300,oral volume of distribution (V/F),"Mean parameters [interpatient variability in coefficient of variation (CV%)] of LMV, STV and ZDV were: oral volume of distribution (V/F) 145 l (52%), 24 l (81%) and 248 l (80%), oral clearance (Cl/F) 32 l/h, 16 l/h (74%) and 124 l/h (51%), respectively.","Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694300/),l,24,259436,DB00495,Zidovudine
,17694300,oral volume of distribution (V/F),"Mean parameters [interpatient variability in coefficient of variation (CV%)] of LMV, STV and ZDV were: oral volume of distribution (V/F) 145 l (52%), 24 l (81%) and 248 l (80%), oral clearance (Cl/F) 32 l/h, 16 l/h (74%) and 124 l/h (51%), respectively.","Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694300/),l,248,259437,DB00495,Zidovudine
,17694300,oral clearance (Cl/F),"Mean parameters [interpatient variability in coefficient of variation (CV%)] of LMV, STV and ZDV were: oral volume of distribution (V/F) 145 l (52%), 24 l (81%) and 248 l (80%), oral clearance (Cl/F) 32 l/h, 16 l/h (74%) and 124 l/h (51%), respectively.","Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694300/),[l] / [h],32,259438,DB00495,Zidovudine
,17694300,oral clearance (Cl/F),"Mean parameters [interpatient variability in coefficient of variation (CV%)] of LMV, STV and ZDV were: oral volume of distribution (V/F) 145 l (52%), 24 l (81%) and 248 l (80%), oral clearance (Cl/F) 32 l/h, 16 l/h (74%) and 124 l/h (51%), respectively.","Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694300/),[l] / [h],16,259439,DB00495,Zidovudine
,17694300,oral clearance (Cl/F),"Mean parameters [interpatient variability in coefficient of variation (CV%)] of LMV, STV and ZDV were: oral volume of distribution (V/F) 145 l (52%), 24 l (81%) and 248 l (80%), oral clearance (Cl/F) 32 l/h, 16 l/h (74%) and 124 l/h (51%), respectively.","Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694300/),[l] / [h],124,259440,DB00495,Zidovudine
,17694300,absorption duration (Ta),"For LMV, absorption duration (Ta) was 1.46 h (64%).","Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694300/),h,1.46,259441,DB00495,Zidovudine
,17694300,ka,"For STV and ZDV, ka was 0.46 h(-1) and 2.9 h(-1), respectively.","Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694300/),1/[h],0.46,259442,DB00495,Zidovudine
,17694300,ka,"For STV and ZDV, ka was 0.46 h(-1) and 2.9 h(-1), respectively.","Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694300/),1/[h],2.9,259443,DB00495,Zidovudine
,20956588,absorption rate constants,"A one-compartment model was used for mothers and neonates; the absorption rate constants for mothers and neonates were 0.95 h(-1) (intersubject variability, 111%) and 0.39 h(-1), respectively; the apparent elimination clearances were 1.42 liter·h(-1) (intersubject variability, 22%) and 0.035 liter·h(-1), respectively; and apparent volumes of distribution were 87.3 liters (intersubject variability, 25%) and 5.65 liters, respectively.",Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20956588/),1/[h],0.95,260499,DB00495,Zidovudine
,20956588,absorption rate constants,"A one-compartment model was used for mothers and neonates; the absorption rate constants for mothers and neonates were 0.95 h(-1) (intersubject variability, 111%) and 0.39 h(-1), respectively; the apparent elimination clearances were 1.42 liter·h(-1) (intersubject variability, 22%) and 0.035 liter·h(-1), respectively; and apparent volumes of distribution were 87.3 liters (intersubject variability, 25%) and 5.65 liters, respectively.",Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20956588/),1/[h],0.39,260500,DB00495,Zidovudine
,20956588,apparent elimination clearances,"A one-compartment model was used for mothers and neonates; the absorption rate constants for mothers and neonates were 0.95 h(-1) (intersubject variability, 111%) and 0.39 h(-1), respectively; the apparent elimination clearances were 1.42 liter·h(-1) (intersubject variability, 22%) and 0.035 liter·h(-1), respectively; and apparent volumes of distribution were 87.3 liters (intersubject variability, 25%) and 5.65 liters, respectively.",Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20956588/),[l] / [h],1.42,260501,DB00495,Zidovudine
,20956588,apparent elimination clearances,"A one-compartment model was used for mothers and neonates; the absorption rate constants for mothers and neonates were 0.95 h(-1) (intersubject variability, 111%) and 0.39 h(-1), respectively; the apparent elimination clearances were 1.42 liter·h(-1) (intersubject variability, 22%) and 0.035 liter·h(-1), respectively; and apparent volumes of distribution were 87.3 liters (intersubject variability, 25%) and 5.65 liters, respectively.",Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20956588/),[l] / [h],0.035,260502,DB00495,Zidovudine
,20956588,apparent volumes of distribution,"A one-compartment model was used for mothers and neonates; the absorption rate constants for mothers and neonates were 0.95 h(-1) (intersubject variability, 111%) and 0.39 h(-1), respectively; the apparent elimination clearances were 1.42 liter·h(-1) (intersubject variability, 22%) and 0.035 liter·h(-1), respectively; and apparent volumes of distribution were 87.3 liters (intersubject variability, 25%) and 5.65 liters, respectively.",Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20956588/),l,87.3,260503,DB00495,Zidovudine
,20956588,apparent volumes of distribution,"A one-compartment model was used for mothers and neonates; the absorption rate constants for mothers and neonates were 0.95 h(-1) (intersubject variability, 111%) and 0.39 h(-1), respectively; the apparent elimination clearances were 1.42 liter·h(-1) (intersubject variability, 22%) and 0.035 liter·h(-1), respectively; and apparent volumes of distribution were 87.3 liters (intersubject variability, 25%) and 5.65 liters, respectively.",Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20956588/),l,5.65,260504,DB00495,Zidovudine
,20956588,rate constants,"An effect compartment was linked to maternal circulation by mother-to-cord and cord-to-mother rate constants of 1.10 h(-1) and 1.43 h(-1), respectively.",Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20956588/),1/[h],1.10,260505,DB00495,Zidovudine
,20956588,rate constants,"An effect compartment was linked to maternal circulation by mother-to-cord and cord-to-mother rate constants of 1.10 h(-1) and 1.43 h(-1), respectively.",Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20956588/),1/[h],1.43,260506,DB00495,Zidovudine
,20956588,half-lives,Neonates had a very long half-lives (110 h) compared to adults.,Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20956588/),h,110,260507,DB00495,Zidovudine
,20956588,half-maximal inhibitory concentration (IC(50)),"In the 38 mothers, the simulated median individual predicted time during which the NVP concentration remained above the half-maximal inhibitory concentration (IC(50)) was 13.2 days (range, 12 to 19.2 days).",Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20956588/),d,13.2,260508,DB00495,Zidovudine
,9757985,trough,Twelve placental perfusion studies were performed at trough (1-2 microg/mL) and peak (approximately 20 microg/mL) combinations of ritonavir and zidovudine.,Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757985/),[μg] / [ml],1-2,261057,DB00495,Zidovudine
,9757985,trough,Twelve placental perfusion studies were performed at trough (1-2 microg/mL) and peak (approximately 20 microg/mL) combinations of ritonavir and zidovudine.,Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757985/),[μg] / [ml],20,261058,DB00495,Zidovudine
<,9757985,trough concentrations,Transfer of ritonavir at trough concentrations was undetectable (<0.025 microg/mL).,Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757985/),[μg] / [ml],0.025,261059,DB00495,Zidovudine
,9757985,clearance index,The clearance index of ritonavir at peak concentration was 0.085 +/- 0.05 and was unaffected by zidovudine.,Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757985/),,0.085,261060,DB00495,Zidovudine
,10894283,trough concentration,Addition of RTV increased the median IDV trough concentration in serum from 65 to 336 ng/ml (P = 0.005).,Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10894283/),[ng] / [ml],65 to 336,261419,DB00495,Zidovudine
,10894283,concentration,Median IDV concentration in seminal plasma increased from 141 to 1634 ng/ml (P = 0.002) (n = 9) and in cerebrospinal fluid from 39 (n = 12) to 104 (n = 7) ng/ml (P < 0.001).,Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10894283/),,39,261420,DB00495,Zidovudine
,10894283,concentration,Median IDV concentration in seminal plasma increased from 141 to 1634 ng/ml (P = 0.002) (n = 9) and in cerebrospinal fluid from 39 (n = 12) to 104 (n = 7) ng/ml (P < 0.001).,Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10894283/),,104,261421,DB00495,Zidovudine
,8239589,plasma elimination half-life,"Thymine and X exhibited kinetic profiles similar to that of D4T, with plasma elimination half-life of 2 to 3 h, whereas BAIBA levels remained constant for extended periods and declined slowly; this metabolite could be detected 24 h after intravenous drug administration.","In vitro and in vivo disposition and metabolism of 3'-deoxy-2',3'-didehydrothymidine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8239589/),h,2 to 3,262263,DB00495,Zidovudine
,8239589,oral bioavailability,Mean oral bioavailability of D4T was high at approximately 70%.,"In vitro and in vivo disposition and metabolism of 3'-deoxy-2',3'-didehydrothymidine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8239589/),%,70,262264,DB00495,Zidovudine
,20058328,total run time,"Chromatographic separation was achieved on a Shiseido C(8) column (150 x 2.0 mm, 5 microm) with a total run time of 6 min.","Simultaneous determination of lamivudine, stavudine and nevirapine in human plasma by LC-MS/MS and its application to pharmacokinetic study in clinic. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20058328/),min,6,263752,DB00495,Zidovudine
,8786245,plasma clearance,"After intravenous dosing, zidovudine plasma clearance for placebo and rHu GM-CSF averaged 1.4 +/- 0.2 and 1.3 +/- 0.2 L/hr/kg, respectively (P = 0.017), mean residence time averaged 1.5 +/- 0.5 and 1.9 +/- 0.6 hours, respectively (P = 0.012), and the steady-state volume of distribution was 2.0 +/- 0.7 and 2.3 +/- 0.7 L/kg, respectively (P = 0.027) for the two treatment arms.",Oral and intravenous zidovudine pharmacokinetics: the effect of granulocyte-macrophage colony stimulating factor. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786245/),[l] / [h·kg],1.4,263851,DB00495,Zidovudine
,8786245,plasma clearance,"After intravenous dosing, zidovudine plasma clearance for placebo and rHu GM-CSF averaged 1.4 +/- 0.2 and 1.3 +/- 0.2 L/hr/kg, respectively (P = 0.017), mean residence time averaged 1.5 +/- 0.5 and 1.9 +/- 0.6 hours, respectively (P = 0.012), and the steady-state volume of distribution was 2.0 +/- 0.7 and 2.3 +/- 0.7 L/kg, respectively (P = 0.027) for the two treatment arms.",Oral and intravenous zidovudine pharmacokinetics: the effect of granulocyte-macrophage colony stimulating factor. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786245/),[l] / [h·kg],1.3,263852,DB00495,Zidovudine
,8786245,mean residence time,"After intravenous dosing, zidovudine plasma clearance for placebo and rHu GM-CSF averaged 1.4 +/- 0.2 and 1.3 +/- 0.2 L/hr/kg, respectively (P = 0.017), mean residence time averaged 1.5 +/- 0.5 and 1.9 +/- 0.6 hours, respectively (P = 0.012), and the steady-state volume of distribution was 2.0 +/- 0.7 and 2.3 +/- 0.7 L/kg, respectively (P = 0.027) for the two treatment arms.",Oral and intravenous zidovudine pharmacokinetics: the effect of granulocyte-macrophage colony stimulating factor. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786245/),h,1.5,263853,DB00495,Zidovudine
,8786245,mean residence time,"After intravenous dosing, zidovudine plasma clearance for placebo and rHu GM-CSF averaged 1.4 +/- 0.2 and 1.3 +/- 0.2 L/hr/kg, respectively (P = 0.017), mean residence time averaged 1.5 +/- 0.5 and 1.9 +/- 0.6 hours, respectively (P = 0.012), and the steady-state volume of distribution was 2.0 +/- 0.7 and 2.3 +/- 0.7 L/kg, respectively (P = 0.027) for the two treatment arms.",Oral and intravenous zidovudine pharmacokinetics: the effect of granulocyte-macrophage colony stimulating factor. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786245/),h,1.9,263854,DB00495,Zidovudine
,8786245,steady-state volume of distribution,"After intravenous dosing, zidovudine plasma clearance for placebo and rHu GM-CSF averaged 1.4 +/- 0.2 and 1.3 +/- 0.2 L/hr/kg, respectively (P = 0.017), mean residence time averaged 1.5 +/- 0.5 and 1.9 +/- 0.6 hours, respectively (P = 0.012), and the steady-state volume of distribution was 2.0 +/- 0.7 and 2.3 +/- 0.7 L/kg, respectively (P = 0.027) for the two treatment arms.",Oral and intravenous zidovudine pharmacokinetics: the effect of granulocyte-macrophage colony stimulating factor. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786245/),[l] / [kg],2.0,263855,DB00495,Zidovudine
,8786245,steady-state volume of distribution,"After intravenous dosing, zidovudine plasma clearance for placebo and rHu GM-CSF averaged 1.4 +/- 0.2 and 1.3 +/- 0.2 L/hr/kg, respectively (P = 0.017), mean residence time averaged 1.5 +/- 0.5 and 1.9 +/- 0.6 hours, respectively (P = 0.012), and the steady-state volume of distribution was 2.0 +/- 0.7 and 2.3 +/- 0.7 L/kg, respectively (P = 0.027) for the two treatment arms.",Oral and intravenous zidovudine pharmacokinetics: the effect of granulocyte-macrophage colony stimulating factor. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786245/),[l] / [kg],2.3,263856,DB00495,Zidovudine
,1549540,Peak serum concentrations,Peak serum concentrations ranged from 0.3-47.8 microns and area under the curve from 0.5-26.1 mg x hour/L.,Zidovudine pharmacokinetics in five HIV seronegative patients undergoing continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1549540/),μns,0.3-47.8,264682,DB00495,Zidovudine
,1549540,area under the curve,Peak serum concentrations ranged from 0.3-47.8 microns and area under the curve from 0.5-26.1 mg x hour/L.,Zidovudine pharmacokinetics in five HIV seronegative patients undergoing continuous ambulatory peritoneal dialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1549540/),[h·mg] / [l],0.5-26.1,264683,DB00495,Zidovudine
,1549540,clearance,These differences resulted in corresponding differences in clearance (range 66-3176 ml/min/1.73 m2) and volume of distribution (range 16-825 L).,Zidovudine pharmacokinetics in five HIV seronegative patients undergoing continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1549540/),[ml] / [1.73·m2·min],66-3176,264684,DB00495,Zidovudine
,1549540,volume of distribution,These differences resulted in corresponding differences in clearance (range 66-3176 ml/min/1.73 m2) and volume of distribution (range 16-825 L).,Zidovudine pharmacokinetics in five HIV seronegative patients undergoing continuous ambulatory peritoneal dialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1549540/),l,16-825,264685,DB00495,Zidovudine
,1549540,Net peritoneal dialysis clearance,Net peritoneal dialysis clearance of AZT was 5 ml/minute.,Zidovudine pharmacokinetics in five HIV seronegative patients undergoing continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1549540/),[ml] / [min],5,264686,DB00495,Zidovudine
,10821415,extraction recoveries,"The average extraction recoveries of AZTMP and AZT in plasma were approximately 85% and 97% over their linear ranges of 0.05-5 microg/ml and 0.125-25 microg/ml, respectively.",Simultaneous determination of zidovudine and its monophosphate in mouse plasma and peripheral red blood cells by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10821415/),%,85,265805,DB00495,Zidovudine
,10821415,extraction recoveries,"The average extraction recoveries of AZTMP and AZT in plasma were approximately 85% and 97% over their linear ranges of 0.05-5 microg/ml and 0.125-25 microg/ml, respectively.",Simultaneous determination of zidovudine and its monophosphate in mouse plasma and peripheral red blood cells by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10821415/),%,97,265806,DB00495,Zidovudine
,10821415,Extraction recoveries,"Extraction recoveries of AZTMP and AZT from peripheral red blood cells averaged 56 and 69% over their linear ranges of 0.125-5 microg/ml and 0.125-25 microg/ml, respectively.",Simultaneous determination of zidovudine and its monophosphate in mouse plasma and peripheral red blood cells by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10821415/),%,56,265807,DB00495,Zidovudine
,10821415,Extraction recoveries,"Extraction recoveries of AZTMP and AZT from peripheral red blood cells averaged 56 and 69% over their linear ranges of 0.125-5 microg/ml and 0.125-25 microg/ml, respectively.",Simultaneous determination of zidovudine and its monophosphate in mouse plasma and peripheral red blood cells by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10821415/),%,69,265808,DB00495,Zidovudine
,9423165,maximum transport capacity,"The estimated maximum transport capacity and dissociation constant were 3.5 micrograms/min kg and 127 micrograms/mL, respectively.",Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9423165/),[μg] / [kg·min],3.5,268098,DB00495,Zidovudine
,9423165,dissociation constant,"The estimated maximum transport capacity and dissociation constant were 3.5 micrograms/min kg and 127 micrograms/mL, respectively.",Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9423165/),[μg] / [ml],127,268099,DB00495,Zidovudine
,9423165,total linear elimination clearance from CSF,The total linear elimination clearance from CSF was 0.0073 mL/min kg.,Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9423165/),[ml] / [kg·min],0.0073,268100,DB00495,Zidovudine
,9423165,brain to plasma efflux rate constant,This analysis yielded a brain to plasma efflux rate constant of 0.040/min.,Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9423165/),1/[min],0.040,268101,DB00495,Zidovudine
less,2589846,time to peak concentration,The lower relative maximum peak concentration in serum (approximately 81%) and small delays in time to peak concentration (less than 30 min) of the capsule formulation as compared with the liquid formulations are thought to be due to the additional processes of disintegration and dissolution associated with capsule administration.,"Bioequivalence assessment of zidovudine (Retrovir) syrup, solution, and capsule formulations in patients infected with human immunodeficiency virus. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589846/),min,30,268692,DB00495,Zidovudine
,10939552,area under the curve ratio (,The median area under the curve ratio (semen AUC0-48:serum AUC0-infinity) was 3.31 for zidovudine and 15.04 for zidovudine-glucuronide.,Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10939552/),,3.31,268895,DB00495,Zidovudine
,10939552,area under the curve ratio (,The median area under the curve ratio (semen AUC0-48:serum AUC0-infinity) was 3.31 for zidovudine and 15.04 for zidovudine-glucuronide.,Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10939552/),,15.04,268896,DB00495,Zidovudine
,19940337,flow rate,The mobile phase consisted of HPLC Grade Acetonitrile: 2 mM Ammonium acetate (90 : 10 v / v) at a flow rate of 0.5 mL min(-1).,High performance liquid chromatography/negative ion electrospray tandem mass spectrometry method for the measurement of hydrochlorothiazide in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940337/),[ml] / [min],0.5,270599,DB00495,Zidovudine
,19940337,total chromatographic runtime,The total chromatographic runtime was 2.5 minutes.,High performance liquid chromatography/negative ion electrospray tandem mass spectrometry method for the measurement of hydrochlorothiazide in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940337/),min,2.5,270600,DB00495,Zidovudine
,19940337,m/z,The mass transition ion pair has been followed as m/z 296.10/205.00 for HCTZ and 266.10/223.10 for Zidovudine.,High performance liquid chromatography/negative ion electrospray tandem mass spectrometry method for the measurement of hydrochlorothiazide in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940337/),,296.10,270601,DB00495,Zidovudine
,19940337,m/z,The mass transition ion pair has been followed as m/z 296.10/205.00 for HCTZ and 266.10/223.10 for Zidovudine.,High performance liquid chromatography/negative ion electrospray tandem mass spectrometry method for the measurement of hydrochlorothiazide in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940337/),,205.00,270602,DB00495,Zidovudine
,19940337,m/z,The mass transition ion pair has been followed as m/z 296.10/205.00 for HCTZ and 266.10/223.10 for Zidovudine.,High performance liquid chromatography/negative ion electrospray tandem mass spectrometry method for the measurement of hydrochlorothiazide in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940337/),,266.10,270603,DB00495,Zidovudine
,19940337,m/z,The mass transition ion pair has been followed as m/z 296.10/205.00 for HCTZ and 266.10/223.10 for Zidovudine.,High performance liquid chromatography/negative ion electrospray tandem mass spectrometry method for the measurement of hydrochlorothiazide in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940337/),,223.10,270604,DB00495,Zidovudine
,19940337,overall recovery,The mean overall recovery of HCTZ was 66.40% with a precision of 2.44%.,High performance liquid chromatography/negative ion electrospray tandem mass spectrometry method for the measurement of hydrochlorothiazide in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940337/),%,66.40,270605,DB00495,Zidovudine
,19940337,recovery,The mean recovery of internal standard (Zidovudine) was 63.62% with a precision ranging from 2.06% to 5.40%.,High performance liquid chromatography/negative ion electrospray tandem mass spectrometry method for the measurement of hydrochlorothiazide in human plasma: application to a comparative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19940337/),%,63.62,270606,DB00495,Zidovudine
,10390227,AUC0-infinity,"Coadministration of abacavir with ZDV (with or without 3TC) decreased the mean Cmax of ZDV by approximately 20% (from 1.5 to 1.2 microg/ml), delayed the median Tmax for ZDV by 0.5 h, increased the mean AUC0-infinity for GZDV by up to 40% (from 11.8 to 16.5 microg.","Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390227/),μg,11.8,271623,DB00495,Zidovudine
,10390227,AUC0-infinity,"Coadministration of abacavir with ZDV (with or without 3TC) decreased the mean Cmax of ZDV by approximately 20% (from 1.5 to 1.2 microg/ml), delayed the median Tmax for ZDV by 0.5 h, increased the mean AUC0-infinity for GZDV by up to 40% (from 11.8 to 16.5 microg.","Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390227/),μg,16.5,271624,DB00495,Zidovudine
,10390227,AUC0-infinity,Coadministration of abacavir with 3TC (with or without ZDV) decreased the mean AUC0-infinity for 3TC by approximately 15% (from 5.1 to 4.3 microg.,"Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390227/),μg,5.1,271625,DB00495,Zidovudine
,10390227,AUC0-infinity,Coadministration of abacavir with 3TC (with or without ZDV) decreased the mean AUC0-infinity for 3TC by approximately 15% (from 5.1 to 4.3 microg.,"Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390227/),μg,4.3,271626,DB00495,Zidovudine
,10390227,Cmax,"h/ml), decreased the mean Cmax by approximately 35% (from 1.4 to 0.9 microg/ml), and delayed the median Tmax by approximately 1 h.","Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390227/),[μg] / [ml],1.4,271627,DB00495,Zidovudine
,10390227,Cmax,"h/ml), decreased the mean Cmax by approximately 35% (from 1.4 to 0.9 microg/ml), and delayed the median Tmax by approximately 1 h.","Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390227/),[μg] / [ml],0.9,271628,DB00495,Zidovudine
,8429708,maximum concentration (Cmax),The maximum concentration (Cmax) of ZDV was 0.81 +/- 0.38 microgram/ml demonstrating high interindividual variability with values between 0.35 microgram/ml and 1.45 microgram/ml.,[Pharmacokinetic study of zidovudine in parenteral drug addicts with human immunodeficiency virus infection]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429708/),[μg] / [ml],0.81,271858,DB00495,Zidovudine
,8429708,maximum concentration (Cmax),The maximum concentration (Cmax) of ZDV was 0.81 +/- 0.38 microgram/ml demonstrating high interindividual variability with values between 0.35 microgram/ml and 1.45 microgram/ml.,[Pharmacokinetic study of zidovudine in parenteral drug addicts with human immunodeficiency virus infection]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429708/),[μg] / [ml],0.35,271859,DB00495,Zidovudine
,8429708,maximum concentration (Cmax),The maximum concentration (Cmax) of ZDV was 0.81 +/- 0.38 microgram/ml demonstrating high interindividual variability with values between 0.35 microgram/ml and 1.45 microgram/ml.,[Pharmacokinetic study of zidovudine in parenteral drug addicts with human immunodeficiency virus infection]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429708/),[μg] / [ml],1.45,271860,DB00495,Zidovudine
,8429708,Cmax,The mean Cmax of G-ZDV was 1.44 +/- 0.64 microgram/ml.,[Pharmacokinetic study of zidovudine in parenteral drug addicts with human immunodeficiency virus infection]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429708/),[μg] / [ml],1.44,271861,DB00495,Zidovudine
,8429708,t1/2,"The mean t1/2 of ZDV and G-ZDV was 1.63 +/- 0.75 hours and 1.12 +/- 0.32 hours, respectively, with values oscillating between 0.99 and 3.14 h in the case of ZDV.",[Pharmacokinetic study of zidovudine in parenteral drug addicts with human immunodeficiency virus infection]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429708/),h,1.63,271862,DB00495,Zidovudine
,8429708,t1/2,"The mean t1/2 of ZDV and G-ZDV was 1.63 +/- 0.75 hours and 1.12 +/- 0.32 hours, respectively, with values oscillating between 0.99 and 3.14 h in the case of ZDV.",[Pharmacokinetic study of zidovudine in parenteral drug addicts with human immunodeficiency virus infection]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429708/),h,1.12,271863,DB00495,Zidovudine
,8429708,t1/2,"The mean t1/2 of ZDV and G-ZDV was 1.63 +/- 0.75 hours and 1.12 +/- 0.32 hours, respectively, with values oscillating between 0.99 and 3.14 h in the case of ZDV.",[Pharmacokinetic study of zidovudine in parenteral drug addicts with human immunodeficiency virus infection]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429708/),h,0.99 and 3.14,271864,DB00495,Zidovudine
,8429708,area below the curve concentration/time (AUC),The area below the curve concentration/time (AUC) of ZDV was 1.43 +/- 0.34 microgram-h/ml and in the case of G-ZDV the AUC was 2.73 +/- 0.91 microgram-h/ml.,[Pharmacokinetic study of zidovudine in parenteral drug addicts with human immunodeficiency virus infection]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429708/),[μgram-h] / [ml],1.43,271865,DB00495,Zidovudine
,8429708,AUC,The area below the curve concentration/time (AUC) of ZDV was 1.43 +/- 0.34 microgram-h/ml and in the case of G-ZDV the AUC was 2.73 +/- 0.91 microgram-h/ml.,[Pharmacokinetic study of zidovudine in parenteral drug addicts with human immunodeficiency virus infection]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429708/),[μgram-h] / [ml],2.73,271866,DB00495,Zidovudine
,8429708,Total body clearance (Clb),Total body clearance (Clb) of ZDV was 2.11 +/- 0.64 l/kg/h and the volume of distribution (Vd) of ZDV was 5.6 +/- 1.73 l/kg.,[Pharmacokinetic study of zidovudine in parenteral drug addicts with human immunodeficiency virus infection]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429708/),[l] / [h·kg],2.11,271867,DB00495,Zidovudine
,8429708,volume of distribution (Vd),Total body clearance (Clb) of ZDV was 2.11 +/- 0.64 l/kg/h and the volume of distribution (Vd) of ZDV was 5.6 +/- 1.73 l/kg.,[Pharmacokinetic study of zidovudine in parenteral drug addicts with human immunodeficiency virus infection]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429708/),[l] / [kg],5.6,271868,DB00495,Zidovudine
,11742433,AUC (AUC(8)),The SQV targeted exposure was an 8-hour AUC (AUC(8)) of 3000 ng.,Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11742433/),h,8,272400,DB00495,Zidovudine
,11742433,AUC (AUC(8)),The SQV targeted exposure was an 8-hour AUC (AUC(8)) of 3000 ng.,Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11742433/),ng,3000,272401,DB00495,Zidovudine
,11742433,AUC(8),"Median (range) AUC(8) and trough (C8H) were 1672 (738-2614) ng. h/mL and 60 (<15-332) ng/mL, respectively.",Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11742433/),[h·ng] / [ml],1672,272402,DB00495,Zidovudine
,11742433,trough (C8H),"Median (range) AUC(8) and trough (C8H) were 1672 (738-2614) ng. h/mL and 60 (<15-332) ng/mL, respectively.",Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11742433/),[ng] / [ml],60,272403,DB00495,Zidovudine
,11742433,Oral clearance (CL/F),Oral clearance (CL/F) was 9.3 (5.1-16.6) L/h/kg and C(max) was 599 (177-953) ng/mL.,Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11742433/),[l] / [h·kg],9.3,272404,DB00495,Zidovudine
,11742433,C(max),Oral clearance (CL/F) was 9.3 (5.1-16.6) L/h/kg and C(max) was 599 (177-953) ng/mL.,Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11742433/),[ng] / [ml],599,272405,DB00495,Zidovudine
,10417493,AUC ratios,"Over the three periods AMT plasma levels were <18 ng ml-1 (n=6) and <40 ng ml-1 (n=2), and molar AMT/zidovudine AUC ratios ranged from 1.7% to 4.5%.",Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10417493/),%,1.7,272831,DB00495,Zidovudine
,10417493,AUC ratios,"Over the three periods AMT plasma levels were <18 ng ml-1 (n=6) and <40 ng ml-1 (n=2), and molar AMT/zidovudine AUC ratios ranged from 1.7% to 4.5%.",Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10417493/),%,4.5,272832,DB00495,Zidovudine
,10582890,limit of detection (LOD),The limit of detection (LOD) by these methods ranged from 20 to 200 fmol/10(6) cells.,Determination of zidovudine triphosphate intracellular concentrations in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals by tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582890/),[fmol] / [10(6)·cells],20 to 200,273059,DB00495,Zidovudine
,10582890,LOD,"The LOD by this method is 4.0 fmol/10(6) cells with a linear concentration range of at least 4 orders of magnitude from 4. 0 to 10,000 fmol/10(6) cells.",Determination of zidovudine triphosphate intracellular concentrations in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals by tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582890/),[fmol] / [10(6)·cells],4.0,273060,DB00495,Zidovudine
,9068926,peak drug plasma concentration (Cmax),"Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],2.8,273446,DB00495,Zidovudine
,9068926,peak drug plasma concentration (Cmax),"Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],5.2,273447,DB00495,Zidovudine
,9068926,bioavailability,The bioavailability of oral levofloxacin approaches 100% and is little affected by the administration with food.,The clinical pharmacokinetics of levofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),%,100,273448,DB00495,Zidovudine
,9068926,Cmax,"Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg.h/L, respectively, both increasing linearly in a dose-proportional fashion.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],0.6 to 9.4,273449,DB00495,Zidovudine
,9068926,area under the concentration-time curve (AUC),"Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg.h/L, respectively, both increasing linearly in a dose-proportional fashion.",The clinical pharmacokinetics of levofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[h·mg] / [l],4.7 to 108,273450,DB00495,Zidovudine
,9068926,volume of distribution,"Levofloxacin is widely distributed throughout the body, with a mean volume of distribution of 1.1 L/kg, and penetrates well into most body tissues and fluids.",The clinical pharmacokinetics of levofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[l] / [kg],1.1,273451,DB00495,Zidovudine
,9068926,plasma elimination half-life (t1/2 beta),The plasma elimination half-life (t1/2 beta) ranges from 6 to 8 hours in individuals with normal renal function.,The clinical pharmacokinetics of levofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),h,6 to 8,273452,DB00495,Zidovudine
,18333866,renal clearance,Mean values for renal clearance ranged from 8.2 l h(-1) (cohort 1) to 13.2 l h(-1) (cohort 4).,A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333866/),[l] / [h],8.2,273885,DB00495,Zidovudine
,18333866,renal clearance,Mean values for renal clearance ranged from 8.2 l h(-1) (cohort 1) to 13.2 l h(-1) (cohort 4).,A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333866/),[l] / [h],13.2,273886,DB00495,Zidovudine
